<SEC-DOCUMENT>0001144204-12-017767.txt : 20120328
<SEC-HEADER>0001144204-12-017767.hdr.sgml : 20120328
<ACCEPTANCE-DATETIME>20120328171321
ACCESSION NUMBER:		0001144204-12-017767
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20111231
FILED AS OF DATE:		20120328
DATE AS OF CHANGE:		20120328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DERMA SCIENCES, INC.
		CENTRAL INDEX KEY:			0000892160
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				232328753
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13070
		FILM NUMBER:		12721340

	BUSINESS ADDRESS:	
		STREET 1:		214 CARNEGIE CENTER, SUITE 300
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		6095144744

	MAIL ADDRESS:	
		STREET 1:		214 CARNEGIE CENTER, SUITE 300
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DERMA SCIENCES INC
		DATE OF NAME CHANGE:	19940513
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v305353_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; color: Red"></P>

<P STYLE="margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the fiscal year ended December 31, 2011</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 for the transition period from _____ to _____</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commission file number: 1-31070</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DERMA SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Issuer in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding: 0; text-align: center; border-bottom: Black 1pt solid">Pennsylvania</TD>
    <TD STYLE="width: 40%; padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 25%; padding: 0; text-align: center; border-bottom: Black 1pt solid">23-2328753</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center">(State or other jurisdiction of</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center">incorporation or organization)</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; padding: 0; text-align: center; text-decoration: none; border-bottom: Black 1pt solid">214 Carnegie Center, Suite 300, Princeton, New Jersey</TD>
    <TD STYLE="width: 28%; padding: 0; text-align: center"></TD>
    <TD STYLE="width: 25%; padding: 0; text-align: center; text-decoration: none; border-bottom: Black 1pt solid">08540</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;(Zip code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Registrant's telephone number: (609) 514-4744</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered under Section 12(b)
of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: center">Title of each class</TD>
    <TD STYLE="width: 50%; padding: 0; text-align: center">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center">Common Stock, $.01 par value</TD>
    <TD STYLE="padding: 0; text-align: center">The NASDAQ Stock Market LLC</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered under Section 12(g)
of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Indicate by check mark
if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">No <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Indicate by check mark
if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">No <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Indicate by checkmark
whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Yes <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">No <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Indicate by check mark
whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the Registrant was required to submit and post such files).</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Yes <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">No <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Indicate by checkmark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to
the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Indicate by check mark
whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding: 0; text-align: left; text-indent: 0">Large accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 40%; padding: 0; text-align: left; text-indent: 0">Accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Non-accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT>
    (Do not check if a smaller reporting     company)</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Smaller reporting company <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">No <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate market
value of the common equity stock held by non-affiliates, computed by reference to the average bid and asked prices of such stock
as of June 30, 2011, was approximately $55,127,459.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
outstanding of the issuer's common equity as of March 26, 2012 was 10,630,865.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Documents Incorporated by Reference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Portions of the Registrant&rsquo;s
definitive proxy statement for its 2012 annual meeting of shareholders are incorporated by reference in Part III of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; border-top: Black 1pt solid; border-bottom: Black 1pt solid"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 78%; padding: 0; text-align: left; text-indent: 0">PART&nbsp;I</TD>
    <TD STYLE="width: 2%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 8%; padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item&nbsp;1.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Business</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item&nbsp;1A.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Risk Factors</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 1B.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Unresolved Staff Comments</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 2.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Properties</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 3.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Legal Proceedings</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 4.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Mine Safety Disclosures</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">PART&nbsp;II</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 5.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Market For Registrant&rsquo;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 6.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Selected Financial Data</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 7.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 7A.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 8.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Financial Statements and Supplementary Data</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 9.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 9A.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Controls and Procedures</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 9B.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Other Information</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">PART&nbsp;III</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 10.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Directors, Executive Officers and Corporate Governance</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 11.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Executive Compensation</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 12.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 13.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Certain Relationships and Related Transactions, Director Independence</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 14.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Principal Accounting Fees and Services</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">PART&nbsp;IV&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Item 15.</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Exhibits, Financial Statement Schedules</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center">50</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Part I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1. Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Overview</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derma Sciences,
Inc. (&ldquo;Derma Sciences&rdquo;) and its subsidiaries Sunshine Products, Inc., Derma Sciences Canada Inc., Derma First Aid
Products, Inc. and Derma Sciences Europe LTD are referred to collectively as &ldquo;we,&rdquo; &ldquo;our,&rdquo;
&ldquo;us&rdquo; and the &ldquo;Company.&rdquo; Our executive offices are located at 214 Carnegie Center, Suite 300,
Princeton, New Jersey 08540. Derma Sciences was incorporated under the laws of Colorado on September 10, 1984 and, on June 3,
1996, changed its state of domicile to Pennsylvania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derma Sciences is
a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced
wound care and traditional wound care products. The Company has one pharmaceutical wound care product candidate that has
completed a Phase 2 study and is working towards initiation of a Phase 3 study in 2012. The Company maintains manufacturing
facilities in Toronto, Canada and Nantong, China and a well-established network of third party suppliers for its products.
The majority of our products are sold through distributors to various health care providers such as wound care centers,
extended care facilities, acute care facilities, home health care agencies and physicians&rsquo; offices. Some of our
products are sold through retail channels. The Company markets its products principally through direct sales representatives
in the United States (the &ldquo;U.S.&rdquo;), Canada and the United Kingdom (the &ldquo;U.K.&rdquo;), and through
independent distributors within other select international markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Products</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Advanced Wound Care</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our advanced wound
care products include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>MEDIHONEY</I> is
a line of novel, patented dressings, comprised of a high percentage of Active <I>Leptospermum</I> Honey. This unique type of honey
has been shown to result in durable antimicrobial, anti-inflammatory and immunomodulatory activities. <I>Medihoney</I> dressings
are ideal for the management of non-chronic and hard-to-heal wounds including chronic ulcers, burns and post-operative wounds.
The dressings are non-toxic and have been shown in a large scale, randomized controlled study to promote healing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>BIOGUARD</I> is
a line of novel, patented barrier dressings that contain an active antimicrobial compound. This compound, a cationic biocide, is
intrinsically bound to the dressing through a proprietary process resulting in the inability for the compound to separate from
the dressing. These dressings are ideal for prophylactic use in the prevention of hospital or community acquired infections through
wound sites. The dressings have been shown to kill 99.9% of virulent bacteria such as methicillin resistant <I>staphylococcus aureus</I>
(MRSA) in less than 1 minute, and 99.999% of MRSA in less than 1 hour.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>ALGICELL AG</I>
is a proprietary antimicrobial dressing utilizing ionic silver as its active ingredient. The dressing can absorb up to 20 times
its weight in wound fluid. These dressings compare favorably to the market leading dressings at a cost-effective price point.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>XTRASORB</I> is
a novel, proprietary line of dressings that utilizes super absorbent polymer technologies. While other absorbing dressings currently
on the market use open cell structures to capture fluid, <I>Xtrasorb</I> dressings convert fluid within the dressings to a gel,
thus locking the exudates into the dressings. <I>Xtrasorb</I> dressings have a distinct advantage over competitive dressings in
that they absorb more fluid and hold the fluid away from the wound, thus avoiding further deterioration of the wound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>TCC-EZ</I> is a
novel, patented advanced dressing system for the management of diabetic foot ulcers. It is considered a &ldquo;next generation&rdquo;
total contact casting (TCC) system. TCC has been shown in multiple randomized controlled studies to achieve 89% heal rates. However,
traditional TCC is utilized in less than 2% of otherwise indicated cases due to various factors such as long application times,
frequency of application error and patient dissatisfaction as a result of the heavy nature of the cast. <I>TCC-EZ</I> virtually
eliminates these issues as it can be applied in less than one third the time of a traditional TCC. <I>TCC-EZ</I> is a one-step
process, so application errors are uncommon, and the cast itself is significantly lighter, due to its open weave pattern, than
a traditional TCC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other advanced wound
care products include a range of moist, occlusive dressings such as hydrocolloids, foams, hydrogels, alginates, additional silver
antimicrobial dressings, cleansers and our proprietary <I>Dermagran</I> products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to evaluate
certain products and technologies within the advanced wound care market. Once products and technologies are identified, we may
enter into licensing agreements or joint venture relationships with owners of the products and technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 27, 2012, the Company entered into a definitive Agreement
and Plan of Merger (the &ldquo;Agreement&rdquo;) to acquire the stock of Medefficiency, Inc. (&ldquo;Medefficiency&rdquo;), a company
engaged in the development, manufacturing and marketing of medical devices for treating chronic wounds and lower extremity injuries.
Medefficiency specializes in total contact casting (&ldquo;TCC&rdquo;) products. The TCC-EZ total contact cast system is Medefficiency&rsquo;s
lead product, in addition to a line of traditional and specialized contact casts and related equipment. TCC-EZ represents the next
generation of total contact casting and was developed to provide equivalent off-loading to a traditional total contact cast: yet
it is much faster and easier to apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has distributed Medefficiency&rsquo;s products since
2008 under an exclusive distribution agreement. Having the rights to these products and integrating them into our existing advanced
wound care marketing and sales infrastructure will allow the Company to realize the benefit of these product&rsquo;s significant
growth potential and higher margins. The growing body of clinical evidence of TCC-EZ&rsquo;s efficacy fits well with the Company&rsquo;s
evidenced-based sales approach. The acquisition is subject to customary closing conditions and is anticipated to be completed by
April 30, 2012.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Traditional Wound Care</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our traditional wound
care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other
compression devices. We also manufacture and market a broad line of adhesive bandages and related first aid products for the medical,
industrial, private label and retail markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We manufacture private
label wound care and adhesive bandages for a number of United States and international customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We market a line of
wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and
other institutions. Our specialty securement and closure device products incorporate our proprietary polyamide fabrics in combination
with a pressure sensitive skin-friendly adhesive. These product combinations result in an ideal balance between elasticity and
adherence, making the products unique in their ability to safely hold devices in place on the skin while assisting with the closure
of sensitive areas of the skin where a good cosmetic outcome is a priority. We also market a line of traditional rigid wound closure
strips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We market general purpose
and specialized skin care products to nursing homes, hospitals, home healthcare agencies and other institutions. These products
include barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath
additives, body oils and moisturizers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pharmaceutical Wound Care</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing
DSC127, an angiotensin analog licensed from the University of Southern California in November 2007, for use in wound healing and
scar reduction. The compound has shown activity in these areas in pre-clinical animal model testing. The compound has successfully
completed a Phase 1 study on healthy patients and a Phase 2 study on patients with diabetic foot ulcers. Topline results of this
study were reported in February and May 2011. Full results of the study are currently under peer review at a major international
advanced wound care journal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DSC127 is a patented,
topically applied novel angiotensin analog that targets receptors that are up-regulated upon injury to tissue. The drug has been
shown to improve epithelialization, granulation and vascularization, accelerating wound healing in a variety of normal and diabetic
animal models. This finding suggests that DSC127 produces different actions at the wound site during various stages of healing.
There were no safety concerns observed in the preclinical and Phase 1 and Phase 2 trials of DSC127.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The potential markets
for DSC127 include: (1) the $10 billion chronic wound market; (2) the $8 billion scar prevention/reduction market; (3) the $6 billion
burn market; and (4) the $6 billion radiation and other wound markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June of 2011,
we raised approximately $26.3 million in order to fund the Phase 3 pivotal studies and associated activities. Since that
time, we have put together a consulting team comprised of senior regulatory, medical, clinical, chemistry, manufacturing and
control, bioanalytical and non-clinical executives. We have had one meeting with the FDA to discuss the results of our Phase
2 study and the design of our Phase 3 study. The Company intends to hold another meeting with the FDA to discuss the Phase 3
protocols for the pivotal studies, and a separate meeting to discuss the Chemistry, Manufacturing and Control
(&ldquo;CMC&rdquo;) portion of the program. The Company is intending to initiate the Phase 3 pivotal studies in the second
half of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Sales and Marketing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2011, the United
States accounted for 66%, Canada for 25% and the rest of the world for 9% of our total sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<I>United States</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
we employ a direct sales force and have relationships with a number of national, regional and local distributors (with their own
sales forces) to sell our products. The majority of our sales are made to distributors and large institutional customers who sell
the products to end users. Direct sales to end users are not a significant part of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our direct sales force
consists of an executive vice president&mdash;sales, a vice president of advanced wound care&ndash;sales, a vice president of advanced
wound care&mdash;corporate accounts, four regional managers, 38 direct territory representatives, a sales administrator and four
clinical resource specialists. We also employ a vice president of distribution&mdash;sales whose primary responsibility is to support
our traditional wound care business. Our sales employees receive a base salary together with commissions based upon sales achievement
within their area of responsibility.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Canada</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Canada, we employ
a sales manager and three direct sales representatives and one manufacturer&rsquo;s representative covering the major population
centers. Our direct sales representatives receive a base salary together with commissions based upon territory sales. Our manufacturer&rsquo;s
representative is paid commission based upon territory sales achievement and is reimbursed for expenses. The majority of our Canadian
sales are to hospitals pursuant to tender contracts with national, provincial and local buying groups. These institutional contracts
are generally exclusive in nature and are awarded for a term of one to five years. Nursing home, home healthcare, physician office
and retail sales are for the most part made through local dealers and government sponsored Community Care Access Centres (CCAC)
agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2005, we entered
into an agreement with a Canadian company, our only customer in Canada, to serve as the exclusive distributor of our products in
Canada. The distribution agreement has been amended from time to time, the latest being January 2011. The amended agreement expires
in April 2016. The distributor maintains strategically located distribution centers and over 50 sales representatives throughout
Canada. We believe the agreement provides us with the means to supplement our direct sales force and better serve our customers
throughout Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years
ended December 31, 2011 and 2010, our  Canadian  distributor accounted for 24% and 25% of  the Company&rsquo;s consolidated
net sales, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Foreign Markets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">We have a direct selling
organization in the United Kingdom consisting of five sales representatives and a sales administrator. This staff is managed by
the general manager of this business unit. The general manager is also responsible for managing distributor relationships within
the rest of the European Union, the Middle East and Africa. Throughout the rest of the world, we sell our products under various
licensing and distribution agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Competition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
our traditional wound care products compete in a commodity oriented marketplace with Covidien, Medline, Medical Action and a number
of others. In the advanced wound care products marketplace, we compete principally with Convatec, Smith &amp; Nephew, Molnlycke
and Systagenix. Our adhesive bandage and related first aid products compete with Medline, ASO and Dynerex in the medical market,
Medline and ASO in the industrial market, ASO, Medline and Liberty in the private label market and Johnson &amp; Johnson, 3M and
Medline in the retail market. The market for wound closure strips and catheter fasteners is characterized by a wide range of generic
competition. The most dominant competitor in the suture strip market is 3M. Our skin care products compete in a commodity oriented
marketplace with Medline, Provon and a number of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Canada, our traditional
wound care products compete in a commodity-oriented marketplace with Covidien, Medicom, Medical Mart and a number of others. In
the advanced wound care products marketplace, we compete principally with the same competitors as we compete with in the United
States, together with a number of domestic generic companies. Internationally, we compete with global and local multinationals
and domestic advanced wound care companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our ability
to remain competitive is based on our ability to provide our customers with a broad range of quality products at a competitive
price with superior customer service. The prospective ability to develop products cost effectively and/or acquire and commercialize
new products that provide superior value is an integral component of our ability to stay competitive. We believe that the breadth
and quality of our existing product lines, the infrastructure in place to cost effectively source and market our products and
the skill and dedication of our employees will allow us to successfully compete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Product Sourcing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease manufacturing
and warehousing facilities in Toronto, Canada, and Nantong, China, and employ contract manufacturers in Mexico and China. Approximately
60% of our products are manufactured at these four locations. The remaining 40% of our products are manufactured by third party
manufacturers in the United States, China and other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing facilities
and the two contract manufacturers are monitored by our management and quality control teams who oversee production activity. Most
of the equipment in these facilities is owned and used exclusively by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our Toronto facility,
we manufacture advanced and traditional wound care products. This facility has the capability of liquid packaging, blister/vacuum
packaging, impregnation, die-cutting and steam sterilization. We also have a research and development laboratory on site. The Toronto
facility is ISO 13485:2003, ISO 9001:2008, and Directive 93/42/EEC certified and SGS registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our Nantong facility,
we manufacture principally traditional and some advanced wound care products. This facility is primarily designed for production
of low volume and specialty products. The quality control team at Nantong has the responsibility to oversee and inspect all products
produced in China (including third party suppliers) for us. The Nantong facility is ISO 9001:2008 certified and TUV registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In both our Mexico
and China contract manufacturing facilities we have adhesive bandages and related first aid products manufactured on our behalf.
The Mexico facility is ISO 9001:2008 and ISO 13485:2004 certified and Aenor IQNET registered. The China facility is ISO 13485:2003
certified and NQA registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of traditional and
advanced wound care products are sourced in semi-finished and finished form directly from suppliers. Derma Canada also serves in
a distributor capacity (sourcing finished products directly from suppliers) for a number of medical device products in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a long-standing
network of suppliers for our outsourced products. The majority of our outsourced products utilize readily available components.
Accordingly, there are numerous companies capable of manufacturing these products to applicable regulatory standards. Given the
availability of other suppliers, as well as our policy regarding maintenance of adequate safety stock levels, we do not believe
that a temporary interruption in supply or loss of one or more of our suppliers would have a long-term detrimental impact on our
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require that all
of our suppliers conform to the standards set forth in the Good Manufacturing Practice (&ldquo;GMP&rdquo;) regulations promulgated
by the United States FDA and local health agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Patents, Trademarks, Proprietary and
Non-Proprietary Technology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own or license a
number of trademarks covering the Company and its products. In addition, we own or license over 50 United States patents, corresponding
foreign patents and patent applications. Most of our patents relating to our DSC127 technology are held under license agreements
of indefinite duration. The license agreement relative to our <I>Bioguard</I> technology expires in June 2014. In 2010, we entered
into an agreement extending our <I>Medihoney</I> license in perpetuity. Subject to meeting minimum royalty and other specified
conditions, we expect to maintain these licenses indefinitely. We also have a number of non-patented formulations and process technologies
that, together with the aforementioned patents, provide competitive advantages in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our patents,
proprietary and non-proprietary technology, afford us reasonable protection against the unauthorized copying of the technology
embodied in the subject products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Government Regulation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>United States&nbsp;&mdash;&nbsp;Scope
of Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture, distribution
and advertising of our products are subject to regulation by numerous federal and state governmental agencies in the United States.
The FDA is responsible for enforcement of the Federal Food, Drug and Cosmetic Act, as amended, (&ldquo;FDC Act&rdquo;) which regulates
drugs and devices manufactured and distributed in interstate commerce. Many of our products are classified either as over-the-counter
drugs or medical devices pursuant to the FDC Act. The Federal Trade Commission (&ldquo;FTC&rdquo;) administers the Federal Trade
Commission Act (&ldquo;FTC Act&rdquo;) which regulates the advertising of products including over-the-counter drugs and devices.
All states have individual laws analogous to the FDC Act and the FTC Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Canada&nbsp;&mdash;&nbsp;Scope of Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medical Devices
Regulations have been established under the authority of the Food and Drugs Act and apply to all medical devices imported and sold
in Canada. The Medical Devices Bureau of the Therapeutic Products Directorate is the national authority that monitors and evaluates
the safety, effectiveness and quality of diagnostic and therapeutic medical devices sold in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Health Products
and Food Branch Inspectorate of Health Canada regulates drugs and the processes used to manufacture drugs. A Drug Establishment
License is required for activities such as fabrication, packaging/labeling, importation, distribution, wholesale and testing. Derma
Canada last underwent an inspection by the Health Products and Food Branch Inspectorate in September 2011, which occasioned the
renewal and subsequent annual renewal of its Drug Establishment License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Foreign Regulatory Authorities
&ndash; Scope of Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not FDA
approval has been obtained, approval of medical drugs and devices by regulatory authorities in foreign countries must be obtained
prior to marketing drugs and devices in such countries. The requirements governing the conduct of clinical trials and product approval
vary widely from country to country and the time required for approval may be longer or shorter than that required for FDA approval.
Although there are procedures for unified filings for certain European countries, most countries currently maintain their own product
approval procedures and requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Regulatory
Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
regulatory framework for product approvals, we are subject to regulation under state and federal law, including requirements regarding
occupational safety, laboratory practices, environmental protection and hazardous substance control, and may be subject to other
present and future local, state, federal and foreign regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject
to federal, state and foreign laws and regulations adopted for the protection of the environment and the health and safety of employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
Company is in compliance with all such laws, regulations and standards currently in effect and that the cost of continued compliance
with such laws, regulations and standards will not have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Third Party Reimbursement in the United
States</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
we sell our wound care products to nursing homes, hospitals, home healthcare agencies, retail and &ldquo;closed door&rdquo; pharmacies
and similar institutions. The patients at these institutions for whose care our products are purchased often are covered by medical
insurance. Accordingly, our customers routinely seek reimbursement for the cost of our wound care products from third party payors
such as Medicare, Medicaid, health maintenance organizations and private insurers. The availability of reimbursement from such
third party payors is a factor in our sales of wound care products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Federal and state governments,
as well as private insurers, will continue their pursuit of programs designed to control or reduce the cost of health care. These
cost cutting measures may include reductions in reimbursements and/or increases in mandatory rebates for wound care products. As
such, there is uncertainty as to whether, and to what extent, reimbursements for our products will continue to be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We had 212
full-time and two part-time employees at December 31, 2011. Of these employees, 92 are located in the United States, 76 in
Canada, 40 in China and 6 in Europe. We consider our employee relations to be satisfactory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 1A. Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We have a history of losses and can
offer no assurance of future profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">We incurred losses of
$4,340,411 in 2011 and $2,448,864 in 2010, and additional losses in previous years. At December 31, 2011, we had an accumulated
deficit of $28,136,327. We cannot offer any assurance that we will be able to generate sustained or significant future earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our liquidity may be dependent upon
amounts available through additional debt or equity financings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">We have a history of
operating losses and negative cash flow from operating activities. As such, we have utilized funds from offerings of our equity
securities and line of credit to fund our operations. We have taken steps to improve our overall liquidity and believe we have
sufficient liquidity to meet our needs for the next twelve months. However, in the event our cash flow from operating activities
is insufficient to meet our requirements, we may be forced either to secure a line of credit or seek additional equity financing.
The sale of additional securities could result in additional dilution to our shareholders. The incurrence of indebtedness would
result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations.
There can be no assurance that such financing would be available or, if available, that such financing could be obtained upon terms
acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our foreign operations are essential
to our economic success and are subject to various unique risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">Our future operations
and earnings will depend to a large extent on the results of our international operations and our ability to maintain a continuous
supply of basic wound care products from our operations in China and suppliers in China and Mexico. While we do not envision any
adverse change to our international operations or suppliers, adverse changes to these operations, as a result of political, governmental,
regulatory, economic, exchange rate, labor, logistical or other factors, could have a material adverse effect on our future operating
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The rate of reimbursement for the purchase
of our products by government and private insurance is subject to change.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Sales of several of our
wound care products depend partly on the ability of our customers to obtain reimbursement for the cost of our products from government
health administration agencies such as Medicare and Medicaid. Both government health administration agencies and private insurance
firms continuously seek to reduce healthcare costs. Our ability to commercialize our products successfully will depend in part
on the extent to which reimbursement for the costs of such products and related treatments will be available from government health
administration authorities, private health insurers and other third-party payors. Significant uncertainty exists as to the reimbursement
status of newly approved medical products. The continuing efforts of the government, insurance companies, managed care organizations
and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Our ability to set a price
we believe is fair for our products;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Our ability to generate
revenues or achieve or maintain profitability; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">The availability to us
of capital.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement, particularly
for new therapeutic products or where payors perceive that the target indication of the new product is well served by existing
drugs or other treatments. Accordingly, even if coverage and reimbursement are provided, market acceptance of our products would
be adversely affected if the amount of coverage and/or reimbursement available for the use of our products proved to be unprofitable
for healthcare providers or less profitable than alternative treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">There
have been federal and state legislation changes which has subjected the pricing of healthcare goods and services to government
control and made other changes to the United States healthcare system. While we cannot predict the outcome of current or future
legislation, we anticipate, particularly given the recent enactment of healthcare reform legislation that Congress and state legislatures
will continue to introduce initiatives directed at lowering the total cost of healthcare. In addition, in certain foreign markets
the pricing of drugs is subject to government control and reimbursement may in some cases be unavailable or insufficient. It is
uncertain if future legislation, whether domestic or abroad, will be adopted that might affect our products. It is also uncertain
what actions federal, state or private payors for healthcare treatment and services may take in response to any such healthcare
reform proposals or legislation. Any such healthcare reforms could have a material and adverse effect on the marketability of
any products for which we ultimately receive FDA or other regulatory agency approval or for which we receive government sponsored
reimbursements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Medical excise tax enacted into law
becomes effective in 2013.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">President Obama has signed
into law the Patient Protection and Affordable Care Act which imposes, among other things, an annual excise tax of 2.3% on any
entity that manufactures or imports medical devices offered for sale in the United States beginning in 2013. Under these provisions,
the Congressional Research Service predicts that the total cost to the medical device industry may be up to $20 billion over the
next decade. We expect to be subject to this excise tax in the future on our sales of certain medical devices we manufacture, produce
or import. We anticipate that all of our sales of medical devices in the United States will be subject to this 2.3% excise tax.
The financial impact of this tax on our business is unclear and there can be no assurance that our business will not be materially
adversely affected by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our success may depend upon our ability
to protect our patents and proprietary technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">We own patents, both
in the United States and abroad, for several of our products, and rely upon the protection afforded by our patents and trade secrets
to protect our technology. Our future success may depend upon our ability to protect our intellectual property. However, the enforcement
of intellectual property rights can be both expensive and time consuming. Therefore, we may not be able to devote the resources
necessary to prevent infringement of our intellectual property. Also, our competitors may develop or acquire substantially similar
technologies without infringing our patents or trade secrets. For these reasons, we cannot be certain that our patents and proprietary
technology will provide us with a competitive advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Government regulation plays a significant
role in our ability to acquire and market products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Government regulation
by the United States Food and Drug Administration and similar agencies in other countries is a significant factor in the development,
manufacturing and marketing of many of our products and in our acquisition or licensing of new products. Complying with government
regulations is often time consuming and expensive and may involve delays or actions adversely impacting the marketing and sale
of our current or future products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Approximately 40 percent of our products
are sourced from third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Approximately 40 percent
of our products are sourced in raw, semi-finished and finished form directly from third party suppliers. None of these suppliers
presently account for more than 10 percent of our sales. We maintain good relations with our third party suppliers. There are several
third party suppliers available for each of our products. If a current supplier were unable or unwilling to continue to supply
our products, sale of the affected products could be delayed for the period necessary to secure a replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The technology utilized in many of our
advanced wound care products is licensed from third parties and could become unavailable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Approximately
68 percent of our advanced wound care products utilize technology that we license on an exclusive basis from third
parties. These products include <I>Medihoney</I> dressings, <I>Bioguard</I> dressings and MedEfficiency <SUP>TM</SUP> total
contact casts. The licensing agreements that we have with the owners of these technologies are of limited duration (with
the exception of <I>Medihoney, </I>which is in perpetuity) and renewals of the agreements are in the discretion of the
licensors. In addition, the maintenance of the license agreements requires that we meet various minimum sales and/or minimum
royalty requirements. If we fail to meet the minimum sales or minimum royalty requirements of a given license agreement,
there is a possibility that the agreement will be cancelled or not renewed or that our exclusivity under the license
agreement will be withdrawn. If any of these events were to occur, our ability to sell the products utilizing the licensed
technology could be lost or compromised and our revenues and potential profits could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Competitors could invent products superior
to ours and cause our products and technology to become obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">The wound and skin care
sectors of the medical products industry are characterized by rapidly evolving technology and intense competition. Our competitors&nbsp;currently
manufacture and distribute a variety of products that are in many respects comparable to our products. Many suppliers of competing
products are considerably larger and have much greater resources than we do. In addition, many specialized products companies have
formed collaborations with large, established companies to support research, development and commercialization of wound and skin
care products which may be competitive with ours. Academic institutions, government agencies and other public and private research
organizations are also conducting research activities and may commercialize wound and skin care products on their own or through
joint ventures. While we have no specific knowledge of products under development by our competitors, it is possible that these
competitors may develop technologies and products that are more effective than any we currently have. If this occurs, any of our
products and technology affected by these developments could become obsolete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Although we are insured, any material
product liability claims could adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">We sell over-the-counter
products and medical devices and are exposed to the risk of lawsuits claiming alleged injury caused by our products. Among the
grounds for potential claims against us are injuries due to alleged product inefficacy and injuries resulting from infection due
to allegedly non-sterile products. Although we carry product liability insurance with limits of $1.0 million per occurrence and
$2.0 million aggregate with $10.0 million in umbrella coverage, this insurance may not be adequate to reimburse us for all damages
that we could suffer as a result of successful product liability claims. Also, defending against a claim could be time consuming
and costly. No material product liability claim has ever been made against us and we are not aware of any pending product liability
claims. However, a successful material product liability suit could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The potential increase in common shares
due to the conversion, exercise or vesting of outstanding dilutive securities may have a depressive effect upon the market value
of our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Up to 4,773,217 shares
of our common stock were potentially issuable at December 31, 2011 upon the conversion, exercise or vesting of outstanding convertible
preferred stock, warrants, options and restricted stock units (&ldquo;dilutive securities&rdquo;). The shares of common stock potentially
issuable upon conversion, exercise or vesting of dilutive securities are substantial compared to the 10,577,632 shares of common
stock outstanding at December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Earnings per share of
common stock may be substantially diluted by the existence of these dilutive securities regardless of whether they are converted,
exercised or issued. This dilution of earnings per share could have a depressive effect upon the market value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our stock price has been volatile and
this volatility is likely to continue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Historically, the market
price of our common stock has been volatile. The high and low stock prices for the years 2007 through 2011 are set forth in the
table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.65pt; text-align: center"><I>Derma Sciences, Inc.<BR>
Trading Range&nbsp;&ndash;&nbsp;Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 50%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Year</U></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify">2007</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4.64</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11.20</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">2008</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.60</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">10.80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">2009</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.92</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.40</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Events
that may affect our common stock price include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Outcome of DSC 127 development;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Quarter to quarter variations
in our operating results;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Changes in earnings estimates
by securities analysts;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Changes in interest rates
or other general economic conditions;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Changes in market conditions
in the wound care industry;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Fluctuations in stock
market prices and trading volumes of similar companies;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Discussion of us or our
stock price by the financial and scientific press and in online investor&nbsp;</FONT>communities;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Additions or departures
of key personnel;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Changes in third party
reimbursement policies;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">The introduction of new
products either by us or by our competitors; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD><FONT STYLE="font-size: 10pt">The loss of a major customer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Although publicly traded
securities are subject to price and volume fluctuations, it is likely that our common stock will experience these fluctuations
to a greater degree than the securities of more established and better capitalized organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We have not paid, and we are unlikely
to pay in the near future, cash dividends on our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">We have never paid any
cash dividends on our common or preferred stock and do not anticipate paying cash dividends in the foreseeable future. The payment
of dividends by us will depend on our future earnings, financial condition and such other business and economic factors as our
management may consider relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If members of our management and
their affiliates were to exercise all warrants and options held by them, members of management and their affiliates could
influence matters that require shareholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">The executive officers
and directors, together with institutions with which they are affiliated, own substantial amounts of our common stock, together
with outstanding options and warrants to purchase our common stock. Depending upon the warrants and options exercised by outside
investors, if directors, executive officers and affiliates were to exercise their options and warrants, members of management and
their affiliates could obtain effective control of us. As a result, these officers, directors and affiliates would be in a position
to significantly influence our strategic direction, the composition of our board of directors and the outcome of fundamental transactions
requiring shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our common stock does not have a vigorous
trading market and you may not be able to sell your securities when desired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">We have a limited active
public market for our common shares. We cannot assure you that a more active public market will develop thereby allowing you to
sell large quantities of our shares. Consequently, you may not be able to readily liquidate your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 1B. Unresolved Staff Comments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 2. Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Our headquarters are located
in Princeton, New Jersey. In addition to the lease relative to our headquarters, we have entered into leases for manufacturing,
warehousing and distribution facilities. Our facilities, locations, size, monthly rent and lease expirations are set forth in the
table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; border-bottom: black 1pt solid; padding: 0; text-align: left; text-indent: 0; vertical-align: bottom"> Location</TD>
    <TD STYLE="width: 1%; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 39%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0; vertical-align: bottom">&nbsp; Use</TD>
    <TD STYLE="width: 1%; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0; vertical-align: bottom">&nbsp;Square<BR> Footage</TD>
    <TD STYLE="width: 1%; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0; vertical-align: bottom">Base<BR> Monthly<BR> Rent</TD>
    <TD STYLE="width: 2%; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0; vertical-align: bottom">&nbsp; Lease Expiration</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Princeton, New Jersey</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">Headquarters</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">11,990</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">$20,060</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">November 2018</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Fenton, Missouri</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">Warehouse</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">42,400</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">$20,579</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">March 2015</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Houston, Texas</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">Warehouse</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">52,770</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">$16,735</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">March 2015</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Toronto, Canada</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">Manufacturing, Warehouse &amp; Offices</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">76,399</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">$35,263</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">August 2017</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Nantong, China</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">Manufacturing &amp; Offices</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">11,388</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">$1,934</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0">December 2013</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">We believe that our facilities
are adequate to meet our office, manufacturing and distribution requirements for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 3. Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">We are currently not a
party to any material pending legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 4. Mine Safety Disclosures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Part II</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 5. Market for Registrant&rsquo;s
Common Equity, Related Shareholder Matters and Issuer Purchases of </B> &nbsp;<B>Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Our common stock is traded
on the NASDAQ Capital Market under the symbol &ldquo;DSCI.&rdquo; Until February 10, 2010, our common stock traded on the OTC Bulletin
Board. The following table sets forth the high and low bid prices for our common stock during each of the indicated calendar quarters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify"><U>Quarter Ended</U></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify">March 31, 2011</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12.72</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4.50</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">June 30, 2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">11.65</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.19</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">September 30, 2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">11.34</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.48</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">December 31, 2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9.44</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">March 31, 2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">June 30, 2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.90</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.67</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">September 30, 2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.40</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">December 31, 2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.05</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The stock prices reflect
inter-dealer prices without retail mark-up, mark-down or commission and may not necessarily represent actual transactions. The
stock prices also reflect a 1-for-8 reverse split of our common stock effective February 1, 2010. There is no public market for
our preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Holders of common
stock</I>. As of the close of business on March 26, 2012, there were approximately 903 holders of record of our common stock.
We believe that the number of beneficial holders of our common stock is substantially greater. On March 26, 2012 the
closing sales price of our common stock as reported on the NASDAQ Capital Market was $9.35.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Dividends and dividend
policy. </I>We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable
future. The payment of dividends by us will depend on our future earnings, financial condition and such other business and economic
factors as our management may consider relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Securities authorized
for issuance under equity compensation plans. </I>The information called for by this item is incorporated by reference to our definitive
proxy statement relating to our 2012 annual meeting of shareholders, which we will file with the Securities and Exchange Commission
within 120&nbsp;days after December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Recent sales of unregistered
securities.</I>&nbsp;All prior sales of unregistered securities have been previously reported on a quarterly report on Form&nbsp;10-Q
or a current report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 6. Selected Financial Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 7. Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>This annual report on Form 10-K includes
certain &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, statements about the confidence, strategies, plans, expectations, intentions,
objectives, technologies, opportunities, market demand or acceptance of new or existing products of&nbsp;the Company, and other
statements contained in this annual report that are not historical facts. Forward-looking statements in this annual report or hereafter
included in other publicly available documents filed with the Securities and Exchange Commission reports to our shareholders and
other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors that
could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based
upon management's best estimates, current conditions and the most recent results of operations. When used in this annual report,
the words &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;seek,&rdquo;
&ldquo;estimate&rdquo; and similar expressions are generally intended to identify forward-looking statements, because these forward-looking
statements involve risks and uncertainties. There are important factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements, including our plans, objectives, expectations and intentions, changes
in political, economic, business, competitive, market and regulatory factors and other factors that are discussed under the section
in this annual report entitled &ldquo;Risk Factors.&rdquo; Neither we nor any other person assume responsibility for the accuracy
or completeness of these forward-looking statements. We are under no duty to update any of the forward-looking statements after
the date of this annual report to conform these statements to actual results.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Year Ended December 31, 2011 Compared
to Year Ended December 31, 2010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Overview</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
highlights the year ended December 31, 2011 versus 2010 operating results:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Variance</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">Gross sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">73,173,684</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">67,109,544</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,064,140</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">9.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Sales adjustments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,543,437</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,635,488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">92,051</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.9</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Net sales</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">62,630,247</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">56,474,056</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,156,191</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10.9</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cost of sales</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,218,300</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,946,724</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,271,576</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10.7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gross profit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">18,411,947</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">16,527,332</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">1,884,615</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11.4</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">%</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Selling, general and administrative expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,173,884</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,905,097</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,268,787</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(18.3</TD><TD STYLE="font-size: 10pt; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Research and development expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,057,094</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">292,660</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">764,434</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(261.2</TD><TD STYLE="font-size: 10pt; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">263,059</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">580,622</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(317,563</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">54.7</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Loss on debt extinguishment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">176,101</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">114,072</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">62,029</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(54.4</TD><TD STYLE="font-size: 10pt; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other expense (income), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,682</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(340,216</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">352,898</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(103.7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,682,820</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,552,235</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,130,585</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(22.3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Loss before income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,270,873</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,024,903</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,245,970</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(110.9</TD><TD STYLE="font-size: 10pt; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69,538</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">423,961</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">354,423</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83.6</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,340,411</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,448,864</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,891,547</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(77.2</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Gross to Net Sales Adjustments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gross to net sales
adjustments are comprised of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 85%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Gross sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">73,173,684</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">67,109,544</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Trade rebates</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,784,353</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,772,545</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Distributor fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,365,769</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,323,165</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Sales incentives</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(623,030</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(740,325</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Returns and allowances</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(257,381</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(341,722</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Cash discounts</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(512,904</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(457,731</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Total adjustments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,543,437</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,635,488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net sales</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">62,630,247</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">56,474,056</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trade rebates increased
slightly in 2011 versus 2010 due principally to higher U.S. and Canadian sales subject to rebate partially offset by the impact
of a reduction in the overall Canadian rebate percentage. This percentage reduction was attributable to an increase in Canadian
contract sale prices associated with higher cotton costs on our traditional wound care products without a commensurate increase
in the sale prices charged to our exclusive Canadian distributor. The slight increase in distribution fee expense is commensurate
with the increase in Canadian sales upon which the fee is based, partially offset by an increase in net sales (as a percentage
of overall Canadian sales) not subject to the fee by our exclusive Canadian distributor. The decrease in sales incentive expense
reflects the discontinuation of a sales incentive program with a major customer in the second quarter of 2011 partially offset
by higher sales subject to the incentives, coupled with an expansion of the underlying sales incentive programs. The sales returns
and allowances decrease principally reflects an improvement in order fulfillment processes. The increase in cash discounts reflects
higher U.S. sales subject to cash discount, coupled with a slight increase in sales to customers that normally take the cash discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Rebate Reserve Roll-Forward</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A roll-forward of the
trade rebate accruals for the years ended December 31, 2011 and 2010 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 85%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Beginning balance&nbsp;&ndash;&nbsp;January 1</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">3,033,091</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">2,493,232</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Rebates paid</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,622,438</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,232,686</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Rebates accrued</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,784,353</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,772,545</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Ending balance&nbsp;&ndash;&nbsp;December 31</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,195,006</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,033,091</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The $838,085 decrease
in the trade rebate reserve balance at December 31, 2011 from December 31, 2010 reflected a decrease in the Canadian reserve due
to the Canadian distributor taking its November 2010 monthly rebate payment in January 2011 (normally taken in December) and a
decrease in the Canadian average rebate reserve percentage due to an increase in overall Canadian contract sale prices associated
with higher cotton costs on our traditional wound care products without a commensurate increase in sale prices to our exclusive
Canadian distributor. There has been no other discernible change in the nature of our business in 2011 as it related to the accrual
and subsequent payment of rebates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 26.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Net Sales and Gross Margin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table highlights
the product line net sales and gross margin for the years ended December 31, 2011 versus 2010:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Variance</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: justify">Net Sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">62,630,247</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">56,474,056</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,156,191</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">10.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Cost of sales</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,218,300</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,946,724</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,271,576</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10.7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Gross Profit</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">18,411,947</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">16,527,332</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,884,615</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11.4</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Gross Profit %</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">29.4</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">29.3</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net sales increased
$6,156,191, or 10.9% (9.8% adjusted for exchange), in 2011 versus 2010. Advanced wound care sales increased $4,330,547, or 37.3%,
to $15,927,920 in 2011 from $11,597,373 in 2010. Traditional wound care sales increased $1,825,644, or 4.1%, to $46,702,327 in
2011 from $44,876,683 in 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales  from
the U.S. operating subsidiaries increased $4,482,826, or 10.9%, to $45,574,908 in 2011 from $41,092,083 in 2010. The increase
was driven by higher advanced wound care sales of $3,432,714, or 34.5%, coupled with a traditional wound care sales increase
of $1,050,112, or 3.4%, led by private label and first aid products. The advanced wound care sales increase was driven
by promoted products which increased 49.2%, led by, Medihoney, partially offset by a decrease in our older other advanced
wound care products. Sales from  the Canadian operating subsidiary increased $936,847, or 6.7%, to $15,016,487 in 2011 from
$14,079,639 in 2010. This increase was driven by favorable exchange of $569,972 associated with a 4.0% strengthening of the
Canadian dollar, coupled with sales growth of $366,876. Real growth as measured by sales of the Company&rsquo;s products
reported by our exclusive Canadian distributor, unadjusted for foreign exchange, was 5.7%. At the product line level, the
increase was driven by higher advanced wound care sales of $177,719, or 50.8%, coupled with a traditional wound care sales
increase of $759,129, or 5.5%. Sales from the international operating subsidiary increased $736,518, or 56.6% ($686,050 or
52.7% excluding exchange) to $2,038,852 in 2011 from $1,302,334 in 2010, due principally to the international growth
strategy implemented in Europe and the Middle East in February 2010. The increase was driven by higher advanced wound care
sales of $720,114 and traditional wound care sales of $16,404. The increase in advanced wound care product sales continues to
reflect our expanded sales and marketing efforts to grow these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gross profit increased
$1,884,615, or 11.4%, in 2011 versus 2010. Advanced wound care gross profit increased $2,623,543, or 55.9%, to $7,312,953 in 2011
from $4,689,410 in 2010. Traditional wound care gross profit decreased $738,928, or 6.2%, to $11,098,994 in 2011 from $11,837,922
in 2010. The overall gross profit margin percentage increased to 29.4% in 2011 from 29.3% in 2010. The increase in gross profit
dollars reflected higher sales, coupled with the higher gross profit margin percentage. The higher gross margin percentage principally
reflected favorable sales mix associated with an increase in higher margin advanced wound care sales, partially offset by higher
product costs and obsolescence reserves to cover slow moving inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table highlights
selling, general and administrative expenses by type for the years ended December 31, 2011 versus 2010:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Variance</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: justify">Distribution</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,909,734</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,786,617</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">123,117</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Marketing</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,143,733</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,654,405</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">489,328</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29.6</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Sales</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,336,888</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,859,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,476,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21.5</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,783,529</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,604,131</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,179,398</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15.5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">21,173,884</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,905,097</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,268,787</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18.3</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Selling, general and administrative
expenses increased $3,268,787, or 18.3% (17.4% adjusted for exchange), in 2011 versus 2010, including an increase of $114,661, or
4.1%, in Canada and $31,530, or 3.9%, attributable to exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Distribution expense
increased $123,117, or 6.9% (6.3% adjusted for exchange), in 2011 versus 2010, including an increase of $10,256 due to exchange.
The increase principally reflected the redeployment of one position into the Houston distribution center from a manufacturing support
position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marketing expense
increased $489,328, or 29.6% (29.2% adjusted for exchange), in 2011 versus 2010, including an increase of $5,891 due to
exchange. The increase was attributable to higher U.S. related compensation and benefit and travel expense associated with new
marketing and clinical personnel added in the second half of 2011 and advertising and promotion expense, coupled with higher
international expense in support of our advanced wound care growth initiatives, partially offset by lower U.S. traditional
wound care and Canada promotion spending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales
expense increased $1,476,944, or 21.5% (20.7% adjusted for exchange), in 2011 versus 2010. Expenses in the U.S. increased
$1,180,375. This increase was attributable to incremental costs of $1,341,227 consisting of compensation and benefits,
commission, travel, recruiting, sample, administrative, and advertising and promotional expenses associated with the ongoing
expansion of our advanced wound care sales force from 10 sales representatives in the first quarter of 2010 to 26 sales
representatives, three regional managers, two national sales vice presidents and one sales administrator positions by the end
of 2011. These increases were partially offset by lower traditional wound care expense of $248,850 related to severance and
operating expenses associated with an executive who was dismissed in the first quarter of 2010. Expenses in Canada increased
$182,980 (including a $32,847 increase related to exchange) resulting from higher compensation and benefit and travel
expenses related to annual cost increases and the addition of a sales representative, group purchasing organization expenses
due to higher fees and bid related expenses due to an increase in the volume of bid activity. International expenses
representing a full year of compensation and benefits, commission, travel and sample expenses in 2011 increased $113,589
(including a $23,139 increase related to exchange) versus the start-up of operations in late February 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses increased $1,179,398, or 15.5% (14.5% adjusted for exchange), in 2011 versus 2010. Expenses in the U.S. increased $813,565.
This increase reflected higher board and employee compensation and benefits due to annual increases, a performance bonus, and the
additions of a new finance and human resource position, equity based compensation, travel expenses and professional fees, partially
offset by lower amortization expenses. Expenses in Canada increased $463,903 (including a $67,332 increase related to exchange).
Net of exchange, expenses increased $396,571 due principally to higher compensation and benefit expenses associated with annual
cost increases, the addition of one new materials management position in the second quarter of 2010 and an increase in the number
of temporary personnel needed to support ongoing operations, coupled with higher information technology expense associated with
the installation of a new  manufacturing support module. International expenses decreased $98,070 (including a $6,726 increase
related to exchange). Net of exchange, expenses decreased $91,344 due principally to the non-recurrence of transition related expenses
associated with the start-up of our business in 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Research and Development Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expense increased $764,434 to $1,057,094 in 2011 from $292,660 in 2010. The increase reflected the ongoing build-up of DSC127 Phase
3 preparation related expenses of $819,834, partially offset by lower Phase 2 expenses of $55,400 associated with the completion
of this phase of development in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense decreased
$317,563 to $263,059 in 2011 from $580,622 in 2010. The decrease was attributable to lower line of credit interest associated with
the payoff of the line of credit balance in July 2011 and lower term and promissory note interest associated with the repayment
of these loans in February 2010. Interest rates were comparable period to period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Loss on Extinguishment of Debt</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with the
termination of our line of credit agreement in September 2011, we recorded a charge of $176,101 representing the remaining unamortized
deferred financing costs of $112,336 and payment of $63,765 in related fees. In 2010, a charge of $114,072 was recorded representing
the unamortized portion of the deferred financing costs related to the term loan which was paid off in February 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Other Expense/Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Other expense/income
decreased $352,898 to a $12,682 net expense in 2011 from $340,216 net income in 2010 principally related to  a reduction
in the exchange gain of $273,949, lower royalty income of $48,368 and higher loss on the disposition of equipment of
$26,079.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We recorded a $69,538
income tax provision for 2011 consisting of a $13,570 current foreign tax benefit and a $83,108 deferred tax provision consisting
of a $175,141 deferred tax provision related to the amortization of goodwill for tax and not financial reporting purposes, partially
offset by a $92,033 foreign tax benefit based on our Canadian subsidiary&rsquo;s operating results. No tax benefit was recorded
for our United States or United Kingdom operations in 2011 due to uncertainty surrounding our ability to use available net operating
loss carry forwards and net deferred tax assets. In 2010, we recorded a $423,961 income tax provision consisting of a $268,072
current foreign tax provision based on our Canadian subsidiary&rsquo;s operating results and a $155,889 deferred tax provision
consisting of a $175,141 deferred tax provision related to the amortization of goodwill for tax and not financial reporting purposes,
partially offset by a $19,252 deferred foreign tax benefit based on our Canadian subsidiary&rsquo;s operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Due to uncertainties surrounding
our ability to use our United States and United Kingdom net operating loss carry forwards and net deferred tax assets, a full valuation
allowance for the United States and United Kingdom net deferred tax assets has been provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Net Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We generated a net loss
of $4,340,411, or $0.49 per share (basic and diluted), in 2011 compared to a net loss of $2,448,864, or $0.39 per share (basic
and diluted), in 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Liquidity and Capital Resources</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Cash Flow and Working Capital</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">At December 31, 2011
and December 31, 2010, we had cash and cash equivalents of $17,110,350 and $404,216, respectively. The $16,706,134 increase
in cash and cash equivalents reflects net cash provided by financing activities of $23,893,788 and operating activities
of $249,542 partially offset by cash used in investing activities of $7,452,949 together with the exchange rate effect
of $15,754.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Net cash provided by financing
activities of $23,893,788 reflects $26,975,194 in net proceeds from the issuance of common stock, less $3,075,555 from the payoff
of our line of credit balance and $5,851 associated with scheduled capital lease payments. The net proceeds from issuance of common
stock consists of $26,357,075 from the private placement sale of common stock and warrants in June 2011 in connection with raising
funds principally for the further development of DSC127 and $618,119 from the exercise of warrants and stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Net cash provided by operating
activities of $249,542 stems from $1,277,718 cash provided from operations (net loss plus non-cash items), together with $1,028,176
cash used from the net change in operating assets and liabilities. Higher receivables, inventory, and prepaid expenses offset by
higher accounts payable and accrued liabilities were the main drivers behind the net cash used in connection with the net change
in operating assets and liabilities. The increase in receivables reflects a higher level of current sales and the final payoff
of rebates owed in connection with the discontinuation of a significant rebate program. The increase in inventory reflects a build-up
to support new products, growth of the international business and improved customer service levels in certain segments of our business.
The increase in prepaid expenses reflects initial advance fee payments on Phase 3 clinical trial preparations and timing of other
operating expenditure payments. The increase in accounts payable reflects the growth of the business resulting in higher overall
spending levels. The increase in accrued expenses and other current liabilities principally reflects higher accrued 2011 bonus,
accrued royalties payable due to higher sales of royalty bearing products partially offset by a decrease in the Canadian sales
rebate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Net cash used in investing
activities of $7,452,949 reflects $5,474,000 used for the purchase of investments, $1,000,000 for the milestone payment in August
2011 due in accordance with the terms of the Medihoney license agreement entered into in February 2010 and $978,949 for capital
expenditures. The majority of the capital expenditures are being made to upgrade and expand our manufacturing capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Working capital increased
$24,911,551 at December 31, 2011 to $34,855,480 from $9,943,929 at December 31, 2010. This increase principally reflects the proceeds
from our private placement sale of common stock and warrants in June 2011 together with funds received from warrant and stock exercises.
Management believes that this level of working capital is sufficient to support our existing operations for the next twelve months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional $1,000,000
Medihoney milestone payment is due when Medihoney sales exceed $10,000,000 on a trailing twelve month basis, which is anticipated
in the next twelve months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Financing Arrangements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2011, net cash
of $3,075,555 was used to pay off the line of credit. Effective September 30, 2011, we terminated
our existing credit agreement with our lender. In connection with the termination, we recorded a charge of $176,101,
representing the then unamortized remaining portion of the deferred financing costs of $112,356 together with a termination
fee of $60,000 and related expenses of $3,765, as a loss on debt extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 27, 2012, we entered into a definitive agreement to
acquire the stock of Medefficiency for $14,500,000 in cash. Medefficiency is a privately held company that sells a proprietary
line of total contact cast products for the treatment of diabetic foot ulcers. In 2011, Medefficiency had annual revenues of $5,300,000
and net income of $320,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since 2008, we have been a distributor of Medefficiency&rsquo;s
products. In 2011, we had $1,450,000 of revenue from the sale of Medefficiency products at a gross margin of 36%. The acquisition
of this business is consistent with our strategy to acquire higher margin proprietary advanced wound care products with growth
potential that can be leveraged by our global advanced wound care sales and marketing infrastructure. In making this acquisition,
we obtained a product line with an annual sales run rate of approximately $6,000,000, at a gross margin of 60% and significant
sales growth potential. Transaction and integration related expenses to be incurred in 2012 are expected to be approximately $1,500,000.
We anticipate this transaction will be accretive to our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will utilize existing cash on hand to fund the acquisition.
Going forward, we are confident that we can replenish these funds based on the strength of our growing advanced wound care business
and DSC127&rsquo;s continued development progress. Alternatives for funding consist of the sale of Company stock, licensing the
rights to DSC127, asset based lending, monetizing a non-strategic Company asset, or a combination of all of these. If market conditions
for raising capital are not acceptable to Company management, we believe we have sufficient liquidity to support our existing operations
for the next twelve months.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Prospective Assessment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategic objective
is to build the Company by both continuing to progress DSC127, with an initial indication of the treatment of diabetic foot ulcers,
as well as in-licensing, developing and launching novel higher margin advanced wound care products while utilizing our cash on-hand
and cash flow provided by our traditional wound care business (to the extent possible) to fund this objective. In addition, we
will continue to evaluate external opportunities to leverage our core capabilities for growth, and will consider initiating additional
development programs on new indications for DSC127. To the extent we determine that we cannot finance our growth initiatives internally,
additional sources of funding may be available to us through the sale of equity, the sale of licensing rights to DSC127 and/or
jointly developing products with third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The launch of a number
of new products in recent years bodes well for the future growth of our higher-margined advanced wound care products both domestically
and abroad. We continue to work on our pipeline and have identified several product line extensions and new products that are capable
of contributing to future sales growth. Traditional wound care sales are expected to remain relatively stable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy for growth
is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD>Assuming the existing resources in place are generating the expected return, we will continue to expand our worldwide
                                                                                 investment in sales and marketing resources in support of our higher margined advanced wound care products. In February 2010,
                                                                                 we in-licensed the worldwide rights to Medihoney. This has served as the catalyst for the expansion of our U.S., Canadian and
                                                                                 international businesses. We plan to add 12 additional sales representatives to the 26 already in place in the U.S. and one
                                                                                 additional sales representative in Canada and two in the UK during the first  half of 2012. Additional sales representatives
                                                                                 will continue to be added thereafter as needed to support the continued growth of the business. We have established a
                                                                                 presence in Europe and the Middle East through a direct presence in the U.K. and distribution representatives in a number of
                                                                                 the other countries. We plan to expand our presence in this and other areas of the world employing a direct presence or
                                                                                 distributor model as the basis for conducting business, as circumstances dictate.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD>While the commercial launch of DSC127 is estimated to
be four years away, we believe the market potential of this product for diabetic foot ulcers and other indications that we have
the rights to are significant. In February and May 2011, we reported positive top-line results for our DSC127 Phase 2 trial. We
met with the FDA to discuss the results of our Phase 2 study and the design of our Phase 3 study. The Company intends to meet
again with the FDA to discuss the Phase 3 protocols for the pivotal studies and to discuss the CMC portion of the program. With
the funds raised from our private placement sale of common stock and warrants in June 2011, we have started a number of initiatives
to prepare for initiation of the Phase 3 program. Should everything go according to plan, we will commence the Phase 3 study in
the second half of 2012. The cost of the Phase 3 trial and bringing the product to market are presently estimated to be approximately
$30 to $40 million. With available funds on-hand and those expected to be generated prospectively from ongoing operations, we
do not anticipate the need at this time for additional capital to complete the Phase 3 trial for diabetic foot ulcers and to bring
the product to market.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD>We will continue to nurture our traditional wound care
business in an effort to sustain it and grow it where possible, utilizing the appropriate amount of human and financial resources
to achieve our objectives. While this area of our business presently represents a significant (albeit diminishing) percentage
of our sales and realizes lower gross profit margins, it generates positive cash flow as it does not require extensive sales and
marketing resources to sustain it. Maintenance and growth of this business is important to us as we utilize this cash flow to
help support our advanced wound care and pharmaceutical wound care growth initiatives.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the planned improvement
in operations, expected working capital requirements and cash on-hand as of December 31, 2011, we anticipate having sufficient
liquidity in place to meet our existing operating and product development needs for at least the next twelve months. Further, if
needed, we believe the continued success of our advanced wound care business and the development of DSC127 will serve to improve
our ability to raise equity or generate capital from the sale of licensing rights going forward to fund prospective growth initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Additional Financial Information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Off-Balance Sheet Arrangements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2011, we had no off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Inflation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our management currently
believes that inflation has not had, and does not currently have, a material impact on continuing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Critical Accounting Policies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Estimates and assumptions
are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant
estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible
assets, the potential impairment of goodwill and the valuation of inventory. Some of these judgments can be subjective and complex
and, consequently, actual results may differ from these estimates. For any individual estimate or assumption made by us, there
may also be other reasonable estimates or assumptions. We believe, however, that given current facts and circumstances, it is unlikely
that applying any such other reasonable judgment would cause a material adverse effect on the consolidated results of operations,
financial position or cash flows for the periods presented. Our most critical accounting policies were discussed with the Audit
Committee of the Board of Directors and are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal"><I>Revenue
Recognition and Adjustments to Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We sell our products through
our own direct sales force and through independent distributors and manufacturers&rsquo; representatives. The primary end users
of our products are nursing homes, hospitals, clinics and home healthcare agencies. We recognize revenue from the sale of our products
when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed and determinable, and collectability
is reasonably assured, which is generally at the time of shipment or receipt by our customers, depending on the terms of the related
sales or distribution agreement. When we recognize revenue from the sale of our products, we simultaneously adjust revenue for
estimated trade rebates and distribution fees (in Canada), and estimates of returns and allowances, cash discounts and other sales
incentives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A trade rebate represents
the difference between the invoice price to the wholesaler/distributor and the end user&rsquo;s contract price. These rebates are
estimated monthly based on historical experience, distributor rebate submission trends, estimated distributor inventory levels,
and existing contract sales terms with our distributors and end users. We have a contract with our exclusive Canadian distributor
and we pay a fixed fee based on sales subject to the fee (as defined) for distribution services in Canada. Because the services
performed by the distributor cannot be separated from the purchase of our products by the distributor, we treat this distribution
fee as a reduction of revenue. The distribution fee is accrued monthly based on net sales to the distributor multiplied by the
ratio of recent historical distributor fee expense to net sales. The percentage of distributor fee expense to net sales is re-evaluated
quarterly for reasonableness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Sales incentives represent
credits granted to specific customers based on attainment of pre-determined sales objectives. Sales incentives are accrued monthly
in accordance with the terms of the underlying sales incentive agreement and actual customer sales. Sales incentive agreements
are generally for a period of one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We provide our customers
certain limited return rights and we have a formal returned goods policy that guides the disposition of returns with our customers.
We accrue for sales returns and allowances and cash discounts monthly based on current sales and historical activity. We do not
offer our customers price protection rights or concessions. Returns were less than 1% of gross sales in both 2011 and 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We continually monitor
the factors that influence rebates and fees, returns and allowances, and other discounts and sales incentives and make adjustments
as necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal"><I>Goodwill</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">At December 31, 2011,
we had $7,119,726 of goodwill consisting of $4,679,684 relating to the First Aid Products acquisition in November 2007 and $2,440,042
relating to the Western Medical acquisition in April 2006. We assess the impairment of goodwill annually in the fourth quarter
or whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. The assessment
is performed using the two-step process required by accounting guidance relating to goodwill. The first step is a review for potential
impairment, while the second step measures the amount of the impairment, if any. The first step of the goodwill impairment test
compares the fair value of a reporting unit with its carrying amount, including goodwill. For 2011 and 2010, the first step of
our goodwill impairment test reflected a fair value in excess of the carrying value of our reporting units. Accordingly, we did
not perform the second step of this test during these periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The cash generating unit
level or reporting unit at which we test goodwill for impairment is the operating segment level. Products are allocated to each
segment based on the nature and intended use of the product. All of our goodwill has been allocated to the traditional wound care
segment as the business acquisitions which gave rise to the goodwill were traditional wound care businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For 2011 and 2010 and
consistent with prior periods, we estimated the fair value of our segments using the &ldquo;income approach,&rdquo; where we use
a discounted cash flow model (&ldquo;DCF&rdquo;) in preparing our goodwill impairment assessment. This approach calculates fair
value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to
a present value using a risk-adjusted discount rate. We selected this method as being the most meaningful in preparing our goodwill
assessments because we believe the income approach most appropriately measures our income producing assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Significant estimates
used in the fair value calculation include: (i) estimates of future revenue and expense growth, (ii) future estimated effective
tax rates, (iii) future estimated capital expenditures, (iv) future required investments in working capital, (v) average cost of
capital, and (vi) the terminal value of the reporting unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The amount and timing
of future cash flows within our DCF analysis is based on our five year forecast. Beyond our five year forecast we assumed a terminal
value to calculate the value of cash flows beyond the last projected period in our DCF analysis. Annual revenue growth rates in
our DCF model reflect expected growth in our advanced and traditional wound care products. The weighted average cost of capital
used to discount cash flows for the annual 2011 goodwill impairment test was 17%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There have been no substantial
changes to the methodology employed, significant assumptions or calculations applied in the first step of the goodwill impairment
test over the past several years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal"><I>Inventory</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company writes down
the value of inventory by the estimate of the difference between the cost of the inventory and its net realizable value. The estimate
takes into account projected sales of the inventory on-hand and the age of the inventory in stock. If actual future demand or market
conditions are less favorable than those projected, additional inventory write-downs may be required. The provision for the write-down
of inventory is recorded in cost of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Stock-Based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We record compensation
expense associated with stock options and other equity-based compensation based on the fair value at the grant date and recognized
over the requisite service periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes
option pricing model for service and performance based awards. We use the quoted market price for restricted stock grants. Significant
judgment and the use of estimates to value the equity-based compensation, particularly surrounding Black-Scholes model assumptions
such as stock price volatility and expected option lives are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 7A.</B> <B>Quantitative and Qualitative
Disclosures About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 8. Financial Statements and Supplementary
Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Index</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding: 0; text-align: justify; text-decoration: underline; text-indent: 0">Description</TD>
    <TD STYLE="width: 2%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 8%; padding: 0; text-align: right; text-decoration: underline; text-indent: 0">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Report of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Consolidated Balance Sheets as of December 31, 2011 and 2010</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Consolidated Statements of Operations for the Years Ended December 31, 2011 and 2010</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Consolidated Statements of Shareholders' Equity for the Years Ended December 31, 2011 and 2010</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Consolidated Statements of Cash Flows for the Years Ended December 31, 2011 and 2010</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Notes to Consolidated Financial Statements &hellip;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">29</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors and Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Derma Sciences, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Derma Sciences, Inc. and subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2011 and 2010, and the related
consolidated statements of operations, shareholders' equity, and cash flows for the years then ended. These consolidated financial
statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of Derma Sciences, Inc. and subsidiaries
as of December 31, 2011 and 2010, and the results of their operations and their cash flows for the years then ended in conformity
with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ KPMG LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Philadelphia, Pennsylvania</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">March 28,
2012</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>DERMA SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidated Balance Sheets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<HR ALIGN="LEFT" NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; text-indent: 0; padding-left: 0"><B>December 31,</B></TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>Assets</B></TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>2011</B></TD><TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>2010</B></TD><TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Current Assets</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">17,110,350</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">404,216</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Short-term investments</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">5,225,000</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Accounts receivable, net</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">6,267,839</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">5,441,511</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Inventories</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">10,530,721</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">12,498,519</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; padding-left: 0.12in; text-indent: 0">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">2,099,197</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">609,164</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Total current assets</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">41,233,107</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">18,953,410</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Long-term investments</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">249,000</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&ndash;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Equipment and improvements, net</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">3,489,194</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">3,608,242</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Identifiable intangible assets, net</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">6,403,044</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">6,971,626</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Goodwill</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">7,119,726</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">7,119,726</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">Other assets</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">129,821</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">316,859</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; text-align: left; border-bottom: Black 2.5pt double; text-indent: 0; padding-left: 0">Total Assets</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">58,623,892</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">36,969,863</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: normal; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Current Liabilities</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.12in">Line of credit borrowings</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">3,075,555</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.12in">Current maturities of long-term debt</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">5,851</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Accounts payable</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">3,999,993</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">3,777,454</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; padding-left: 0.12in; text-indent: 0">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">2,377,634</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">2,150,621</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Total current liabilities</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">6,377,627</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">9,009,481</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Other long-term liabilities</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">252,684</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">211,581</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">Deferred tax liability</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">1,146,047</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">1,068,088</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">Total Liabilities</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">7,776,358</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">10,289,150</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Commitments (Note 15)</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Shareholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.12in; padding-left: 0.12in">Convertible preferred stock, $.01 par value; 1,468,750 shares&nbsp; authorized; issued and outstanding 73,332 at December 31, 2011 and &nbsp;&nbsp;284,844 at December 31, 2010 (liquidation preference of $3,222,368 at &nbsp;&nbsp;December 31, 2011)</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">733</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">2,848</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.12in; padding-left: 0.12in">Common stock, $.01 par value; 18,750,000 shares authorized; issued and outstanding 10,577,632 at December 31, 2011 and 6,563,076 at December 31, 2010</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">105,776</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">65,631</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Additional paid-in capital</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">77,374,821</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">48,803,210</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Accumulated other comprehensive income &ndash; cumulative translation adjustments</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">1,502,531</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">1,604,940</TD><TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">Accumulated deficit</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">(28,136,327</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">)</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">(23,795,916</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">Total Shareholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">50,847,534</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">26,680,713</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double; text-indent: 0; padding-left: 0">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">58,623,892</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double; text-indent: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0; padding-left: 0">36,969,863</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See accompanying consolidated notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DERMA SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidated Statements of Operations
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<HR ALIGN="LEFT" NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; font-weight: bold; text-align: left">Net Sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">62,630,247</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">56,474,056</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Cost of sales</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,218,300</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,946,724</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Gross Profit</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,411,947</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,527,332</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in">Selling, general and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,173,884</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,905,097</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; padding-left: 0.12in">Research and development</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,057,094</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">292,660</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; padding-left: 0.24in">Total operating expenses</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,230,978</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,197,757</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Operating loss</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,819,031</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,670,425</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Other expense, net:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">263,059</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">580,622</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in">Loss on debt extinguishment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">176,101</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">114,072</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; padding-left: 0.12in">Other expense (income), net</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,682</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(340,216</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; padding-left: 0.24in">Total other expense, net</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">451,842</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">354,478</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Loss before income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,270,873</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,024,903</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Income taxes</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69,538</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">423,961</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Net Loss</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,340,411</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,448,864</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(0.49</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(0.39</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">Shares used in computing loss per common share &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,780,981</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,335,798</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See accompanying consolidated notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DERMA SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidated Statements of Shareholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<HR ALIGN="LEFT" NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Preferred Shares Issued</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Convertible Preferred Stock</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Common Shares Issued</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Additional Paid-In Capital</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Accumulated Other Comprehensive Income</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Accumulated Deficit</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center; border-bottom: Black 1pt solid">Total Shareholders&rsquo; Equity</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 28%; font-size: 7pt; font-weight: bold; text-align: left">Balance, January 1, 2010</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">285,051</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">2,851</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">5,039,468</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">50,395</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">41,221,613</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">1,303,293</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">(21,347,052</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 7pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 7pt; text-align: right">21,231,100</TD><TD STYLE="width: 1%; font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left">Net loss</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(2,448,864</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(2,448,864</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">301,647</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right; border-bottom: Black 1pt solid">301,647</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; font-weight: normal; text-align: left">Comprehensive loss</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(2,147,217</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left; padding-left: 0.12in; text-indent: -0.12in">Issuance of common stock in private
    placement, net of issuance costs of &nbsp;&nbsp;$1,114,548</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">1,117,800</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">11,178</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">4,463,274</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">4,474,452</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left; padding-left: 0.12in; text-indent: -0.12in">Issuance of common stock and
    warrants for license rights</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">400,000</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">4,000</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">2,413,126</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">2,417,126</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left">Exercise of common stock options</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">5,601</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">55</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">16,223</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">16,278</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left">Preferred stock conversion</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(207</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(3</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">207</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">3</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left; border-bottom: Black 1pt solid">Stock-based compensation</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">688,974</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">688,974</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; font-weight: bold; text-align: left">Balance, December 31, 2010</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">284,844</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">2,848</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">6,563,076</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">65,631</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">48,803,210</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">1,604,940</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(23,795,916</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">26,680,713</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left">Net loss</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(4,340,411</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(4,340,411</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(102,409</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 7pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">(102,409</TD><TD STYLE="font-size: 7pt; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; font-weight: normal; text-align: left">Comprehensive loss</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(4,442,820</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left; padding-left: 0.12in; text-indent: -0.12in">Issuance of common stock in private &nbsp;&nbsp;placement, net of issuance costs of $2,717,872</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">3,524,239</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">35,242</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">26,321,833</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">26,357,075</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left">Exercise of warrants, net of costs of &nbsp;&nbsp;$68,204</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">179,304</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">1,793</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">364,672</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">366,465</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left">Exercise of common stock options</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">78,501</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">785</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">250,869</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">251,654</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left">Preferred stock conversion</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(211,512</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(2,115</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">211,512</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">2,115</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left">Vesting of restricted stock</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">21,000</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">210</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">(210</TD><TD STYLE="font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">-</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; text-align: left; border-bottom: Black 1pt solid">Stock-based compensation</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">1,634,447</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: right">1,634,447</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 7pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 7pt; font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">Balance, December 31, 2011</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">73,332</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">733</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">10,577,632</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">105,776</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">77,374,821</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">1,502,531</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">(28,136,327</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">)</TD><TD STYLE="font-size: 7pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: right">50,847,534</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 7pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See accompanying consolidated notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DERMA SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<HR ALIGN="LEFT" NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="margin: 0; text-align: left"></P>



<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Ended December 31,</B></FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>2011</B></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>2010</B></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(4,340,411</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(2,448,864</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.12in; text-indent: 0">Adjustments to reconcile net loss to net &nbsp;&nbsp;cash provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Depreciation of equipment and improvements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">991,045</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">895,264</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Amortization of identifiable intangible assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,568,582</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,689,750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Amortization of deferred financing costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">77,781</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">110,458</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Non-cash portion of loss on debt extinguishment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">112,336</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">114,072</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Provision for bad debts</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20,774</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,941</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Allowance for sales adjustments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(37,023</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">41,503</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Provision for inventory obsolescence</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,089,608</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">279,861</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Loss on disposal of equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,863</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,658</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Deferred rent expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">44,608</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">108,752</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Compensation charge for employee stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,299,675</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">617,737</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Compensation charge for restricted stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">334,772</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,267</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Interest charge for stock warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,970</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Deferred income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83,108</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">155,889</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.48in; text-indent: 0">Accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(813,622</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,112,243</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.48in; text-indent: 0">Inventories</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(292,004</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,122,105</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.48in; text-indent: 0">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(402,077</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(144,937</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.48in; text-indent: 0">Other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(641</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">310,945</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.48in; text-indent: 0">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">237,095</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">368,548</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.48in; text-indent: 0; padding-bottom: 1pt; border-bottom: Black 1pt solid">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">243,073</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">764,327</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Net cash provided by (used in) operating activities</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">249,542</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(291,207</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><B>Investing Activities</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Purchase of equipment and improvements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(978,949</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(634,939</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Purchase of license rights</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,250,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0; border-bottom: Black 1pt solid">Purchase of investments</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,474,000</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,452,949</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,884,939</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Change in restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,032,164</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Net change in borrowings under line of credit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,075,555</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">769,249</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Long-term debt repayments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,851</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,059,185</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0; border-bottom: Black 1pt solid">Proceeds from issuance of common stock, net of costs</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">26,975,194</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,490,730</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,893,788</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,232,958</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Effect of exchange rate changes on cash</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,754</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">103,880</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net increase in cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,706,134</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">160,692</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0; border-bottom: Black 1pt solid">Beginning of year</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">404,216</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">243,524</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0; border-bottom: Black 1pt solid">End of year</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,110,350</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">404,216</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Purchase of license rights</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4,667,126</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0; padding-bottom: 1pt">Issuance of common stock and warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">(2,417,126</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.36in; text-indent: 0; padding-bottom: 2.5pt">Cash paid</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">2,250,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 2.5pt">Issuance of warrants and stock options for payment of offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">490,980</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">121,634</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Cash paid during the year for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.24in; text-indent: 0">Interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">244,682</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">472,031</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; padding-left: 0.24in">Taxes</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">319,278</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">77,712</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">See accompanying consolidated notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA
                                                                                                                                                                                                                    SCIENCES,
                                                                                                                                                                                                                    INC.
                                                                                                                                                                                                                    AND
                                                                                                                                                                                                                    SUBSIDIARIES<BR><BR>Notes
                                                                                                                                                                                                                    to
                                                                                                                                                                                                                    Consolidated
                                                                                                                                                                                                                    Financial
                                                                                                                                                                                                                    Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><B>1.</B></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Description of Business</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Derma Sciences, Inc. and
its subsidiaries (the &ldquo;Company&rdquo;) is a medical technology company focused on three segments of the wound care marketplace:
pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that has
completed a Phase 2 study and is working towards initiating a Phase 3 study. The Company markets its products
principally through direct sales representatives in the United States (&ldquo;U.S.&rdquo;), Canada and the United Kingdom (&ldquo;U.K.&rdquo;),
and through independent distributors within other select international markets. The Company&rsquo;s U.S. distribution facilities
are located in St. Louis, Missouri and Houston, Texas. The Company utilizes third party distributors for distribution in Canada,
Europe and the Far East. The Company also has manufacturing facilities in Toronto, Canada and Nantong, China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><B>2.</B></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Summary of Significant Accounting Policies</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Principles of Consolidation</B>
&ndash; The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All
significant intercompany accounts and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Use of Estimates</B>
&ndash; The preparation of consolidated financial statements requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current
events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates
and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances.
Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable
intangible assets, the potential impairment of goodwill and the valuation of inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Foreign Currency Translation</B>
&ndash; Assets and liabilities are translated using the exchange rates in effect at the balance sheet date, while income and expenses
are translated using average rates during the period. Translation adjustments are reported as a component of shareholders&rsquo;
equity in accumulated other comprehensive income. For the Company&rsquo;s foreign subsidiaries, exchange rate fluctuations on foreign
currency denominated assets and liabilities other than the functional currency resulted in income of $133,681 and $159,949 for
the years ended December 31, 2011 and 2010, respectively, which is included in the consolidated statement of operations as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Cost of sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">(66,379</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">181,302</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Other expense (income), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(67,302</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(341,251</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(133,681</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(159,949</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Exchange rate fluctuations
of foreign currency denominated assets and liabilities associated with inventory are included in cost of sales, while all other
such fluctuations are included in other expense (income), net.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Concentration of Credit
Risk</B> &ndash; Financial instruments that subject the Company to a concentration of credit risk consist principally of cash and
cash equivalents and accounts receivable. The Company maintains cash and cash equivalents with various financial institutions in
amounts which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation
up to $250,000. The Company has not experienced any losses in such accounts. The Company does not require collateral or other security
to support credit sales, but provides an allowance for doubtful accounts based on historical experience and specifically identified
risks. Accounts receivable are charged off against the allowance for doubtful accounts when management determines that recovery
is unlikely and the Company ceases collection efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Inventories</B> &ndash;
Inventories consist of raw materials, packaging materials, work in process and finished goods valued at the lower of cost or market.
Cost is determined on the basis of the first-in, first-out method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Equipment and improvements</B>
&ndash; Equipment and improvements are stated at cost and are depreciated on a straight-line basis over the estimated useful lives
of the assets ranging from three to 10 years. Leasehold improvements are amortized over the lesser of the useful lives or the remaining
lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Fair Value of Financial
Instruments</B> &ndash; The carrying value of cash equivalents, accounts receivable, prepaid expenses and other current assets
and accounts payable reported in the consolidated balance sheets equal or approximate fair value due to their short term nature.
Based on the terms of the Company&rsquo;s credit facility with its lender, the carrying value of the borrowings that were outstanding
at December 31, 2010 are considered to approximate the respective fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Identifiable Intangible
Assets</B> &ndash; Identifiable intangible assets, which consist of customer lists, trademark and trade names, non-compete and
other agreements and certifications and product designs, are amortized over four to 13 years on a straight-line basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Long Lived Assets</B>
&ndash;The Company reviews its long-lived assets with definitive lives whenever events or changes in circumstances indicate that
the carrying amount of such assets may not be recoverable. If the carrying amount of the asset or group of assets exceeds its net
realizable value, the asset will be written down to its fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Goodwill</B> &ndash;
The Company tests goodwill for impairment using a two-step process. The first step tests for potential impairment, while the second
step measures the amount of impairment, if any. The Company uses a discounted cash flow analysis to complete the first step in
this process. If the first step indicates an impairment, i.e. when the carrying value exceeds the fair value, then the second step
is required to determine the implied fair value of goodwill. The implied fair value of goodwill is calculated in the same manner
that goodwill is calculated in a business combination. The allocation is to be performed as if the reporting unit had just been
acquired and the fair value of the unit was the purchase price. The goodwill impairment equals the carrying value of goodwill less
the implied fair value of goodwill. The Company performs its goodwill impairment test as of December 31 of each year, or more frequently
if impairment indicators are present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Stock-Based Compensation</B>
&ndash; Stock-based compensation for new, modified and unvested share-based awards with employees and non-employee directors, such
as grants of stock options and restricted stock, is recognized in the consolidated financial statements based on the fair value
of the award at the grant date and is recognized on a straight-line basis over the requisite service periods. The Company estimates
the fair value of stock options as of the date of grant using the Black-Scholes option-pricing model for service and performance
based awards. The fair value of restricted stock is based on the quoted market price. The Company issues new shares upon exercise
of share-based awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Income Taxes</B> &ndash;
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between
the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets,
including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income
tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of
the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics.
Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some
portion or all of the deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company measures and
recognizes the tax implications of positions taken or expected to be taken in its tax returns on an ongoing basis. In 2011 and
2010, the Company had no unrecognized tax benefits or liabilities, and no adjustment to its financial position, results of operations
or cash flows were required. The Company records interest and penalties related to tax matters within other expense on the accompanying
Consolidated Statements of Operations. These amounts are not material to the consolidated financial statements for the periods
presented. The Company&rsquo;s United States tax returns are subject to examination by federal and state taxing authorities. Tax
years prior to 2008 are no longer subject to federal or state examination. Tax years prior to 2003 are no longer subject to examination
in Canada. The United Kingdom tax returns since the inception in 2010 of the subsidiary in this country are subject to examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Revenue Recognition</B>
&ndash; Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross
sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions
in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component
of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Advertising and Promotion
Costs</B> &ndash; Advertising and promotion costs are expensed as incurred and were $1,560,903 and $1,197,309 in 2011 and 2010,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Royalties &ndash; </B>The
Company recognizes<B> </B>royalty expenses associated with the products sold at the time the related sale occurs and records them
as a component of cost of sales. Royalty expense for the years ended December 31, 2011 and 2010 was $1,159,908 and $911,893, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Net Loss per Share
</B>&ndash; Net loss per common share &ndash; basic is computed by dividing net loss by the weighted average number of common shares
outstanding for the period. Net loss per common share &ndash; diluted reflects the potential dilution of earnings by including
the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock (&ldquo;potentially
dilutive securities&rdquo;), including those attributable to stock options, warrants, convertible preferred stock and restricted
common stock in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed
exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not
been included in the computation of diluted loss per share for the years ended December 31, 2011 and 2010 as the effect would be
anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Potentially dilutive shares
excluded as a result of the effects being anti-dilutive are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Excluded dilutive shares:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify; padding-left: 0.12in">Preferred stock</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">73,332</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">284,844</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Restricted common stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,582,683</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,203,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,065,702</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,734,531</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.24in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.36in">Total dilutive shares</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,773,217</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,242,975</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><B>&nbsp;&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.</B></TD><TD><B>Cash and Cash Equivalents and Investments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers
cash and cash equivalents as amounts on hand, on deposit in financial institutions and highly liquid investments purchased with
an original maturity of three months or less. The Company considers highly liquid investments purchased with an original maturity
greater than three months as investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents
and investments at December 31, 2011 and 2010 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Cash</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">4,986,234</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">404,216</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Money market accounts</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,706,863</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Money market mutual funds</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,417,253</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.24in">Cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,110,350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">404,216</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Investments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,474,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total cash and cash equivalents and investments</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">22,584,350</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">404,216</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company maintains
cash with various domestic and foreign financial institutions within the ordinary course of business, which at times may exceed
jurisdictional insurance limits. The money market accounts are deposited in various U.S. financial institutions and are fully insured
by the Federal Deposit Insurance Corporation. Cash equivalents consist of funds deposited into mutual funds investing in U.S. government
obligations that are fully secured by the U.S. government. Investments consist of certificates of deposits in various U.S. financial
institutions and are fully insured by the Federal Deposit Insurance Corporation. The Company intends to hold its investments to
maturity and accordingly these investments are carried at amortized costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
provides fair value information as of December 31, 2011:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements, Using</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total carrying value as of December 31, 2011</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Quoted
    prices in active markets (Level 1)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Significant other observable inputs (Level 2)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Significant unobservable inputs (Level 3)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 34%; font-size: 10pt; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">17,110,350</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">17,110,350</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Investments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,474,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,453,429</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">&nbsp;Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">22,584,350</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">22,563,779</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets. Level 2 inputs are quoted prices for similar assets in active
markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially
the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&rsquo;s own assumptions used
to measure assets at fair value. A financial asset&rsquo;s classification is determined based on the lowest level input that is
significant to the fair value measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.</B></TD><TD><B>Accounts Receivable, net</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Accounts receivable, net include
the following:&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Accounts receivable</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">6,606,896</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">5,809,056</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Less: &nbsp;Allowance for doubtful accounts</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(79,216</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(89,736</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.36in">Allowance for trade rebates</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(128,875</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(163,789</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.36in">Allowance for cash discounts and returns</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(130,966</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(114,020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.36in">Accounts receivable, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,267,839</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,441,511</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><B>5.</B></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Inventories</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Inventories include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Finished goods</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">7,625,009</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">8,727,822</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Work in process</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">664,272</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">598,486</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Packaging materials</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">985,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">778,900</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Raw materials</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,255,840</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,393,311</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total inventory</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,530,721</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,498,519</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD><B>Equipment and Improvements, net</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Equipment and improvements, net
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Machinery and equipment</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">6,522,941</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">5,981,946</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Furniture and fixtures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">682,545</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">648,460</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,174,121</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,086,956</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,379,607</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,717,362</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Less:&nbsp;&nbsp; accumulated depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,890,413</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,109,120</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total equipment and improvements, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,489,194</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,608,242</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><B>7.</B></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Identifiable Intangible Assets, net</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Identifiable intangible assets,
net include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: justify">Medihoney license rights</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">5,667,126</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">4,667,126</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Other identifiable intangible assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,300,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,500,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,967,126</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,167,126</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Less accumulated amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,564,082</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,195,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total identifiable intangible assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,403,044</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,971,626</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with the
acquisition of the Medihoney worldwide license rights (note 15) the Company capitalized the consideration paid as an identifiable
intangible asset. The cost will be amortized over 10 years, and the expense is included as a component of cost of sales in the
Consolidated Statement of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Other identifiable intangible
assets result from acquisitions completed in 2006 and 2007 and consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Amortization Period</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: justify">Customer list</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">1,500,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Trademarks and trade names</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,600,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">10-13 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Certification and product designs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;5 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,300,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In 2011, $4,200,000 of
fully amortized identifiable intangible assets were written-off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Amortization expense of
the other identifiable intangible assets is included in selling, general and administrative expenses in the Consolidated Statement
of Operations. The weighted average useful life of identifiable intangible assets as of December 31, 2011 and 2010 is 7.0 and 3.9
years, respectively. Amortization expense for 2011 and 2010 and estimated amounts thereafter by year is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Medihoney License Rights</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Other Identifiable <U STYLE="text-decoration: none"><BR>
Intangible Assets</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: justify">Amortization expense for&nbsp; year ended December 31, 2011</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">519,200</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,049,382</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,568,582</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Amortization expense for&nbsp; year ended December 31, 2010</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">375,750</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,314,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,689,750</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Estimated amortization expense for&nbsp; years ending December 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 1.32in">2012</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">584,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">323,993</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">908,293</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 1.32in">2013</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">584,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">285,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">869,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 1.32in">2014</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">584,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">285,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">869,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 1.32in">2015</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">584,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">285,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">869,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 1.32in">2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">584,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">136,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">720,550</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 1.32in">Thereafter</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,850,676</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">315,625</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,166,301</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,772,176</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,630,868</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,403,044</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD><B>Line of Credit Borrowings</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30, 2011,
the Company terminated its five-year revolving credit agreement with its lender. In connection with the termination the Company
recorded a loss on debt extinguishment of $176,101, representing the then unamortized portion of deferred financing costs of $112,336
and related fees of $63,765.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><B>9.</B></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Accrued Expenses and Other Current Liabilities</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Accrued expenses and other current
liabilities include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Accrued Canadian sales rebate, net (see note 15)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">316,280</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">409,842</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Accrued compensation and related taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">575,710</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">265,334</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Accrued sales incentives and other fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">416,215</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">461,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Accrued royalties</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">425,796</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">220,232</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">643,633</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">793,269</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,377,634</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,150,621</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">At December 31, 2011 and
2010, the amount of the Canadian accrued sales rebate and other reserves exceeded the amount of the underlying trade receivables
outstanding. The net credit balance in trade receivables was reclassified for financial reporting purposes to accrued expense to
recognize it as a net liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.</B></TD><TD><B>Long-term Debt</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All borrowings under the
term debt agreements were fully repaid in 2011. During 2011 payments of $5,851 were made under capital lease obligations. In 2010
payments of $3,500,000 were made under a term note (fully repaid in February 2010 resulting in a $114, 072 loss on debt extinguishment),
$500,000 were made on a promissory note and $59,185 were made on capital lease obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.</B></TD><TD><B>Shareholders&rsquo; Equity</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There are 18,598 shares
of series A convertible preferred stock outstanding at December 31, 2011. The series A preferred stock is convertible into common
stock on a one-for-one basis, bears no dividend, has a liquidation preference of $32.00 per share, votes as a class on matters
affecting the series A preferred stock and has voting rights identical to the common stock on all other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There are 54,734 shares
of series B convertible preferred stock outstanding at December 31, 2011. The series B preferred stock is convertible into common
stock on a one-for-one basis, bears no dividend, has a liquidation preference of $48.00 per share, votes as a class on matters
affecting the series B preferred stock and has voting rights identical to the common stock on all other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In June 2011, the Company
received net cash proceeds of $26,357,075 (after $2,717,872 in commission and other cash basis offering expenses) from the sale
of 3,524,239 shares of common stock at $8.25 per share, together with 1,762,118 five-year series R warrants to purchase common
stock at $9.90 per share. Additionally, the placement agents received 70,484 five-year Series R warrants to purchase common stock
at $9.90 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During 2011, the Company
received $618,119 (net of $68,204 in expenses) and issued 257,805 shares of common stock upon the exercise of stock purchase warrants
and options. In addition, during 2011 the Company issued 211,512 shares of common stock upon the conversion of series B, C and
D preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2010, the
Company received net proceeds of $4,474,452 (after $1,114,548 in commission and other cash basis offering expenses) from the sale
of 1,117,800 shares of common stock at $5.00 per share, together with 372,600 five-year Series D warrants to purchase common stock
at $5.50 per share. In addition, the placement agent received 29,160 five-year Series P warrants to purchase common stock at $6.25
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In February 2010, the
Company issued 400,000 shares of its common stock together with 133,333 Series Q warrants to purchase its common stock at an exercise
price of $5.50 per share and 100,000 Series N warrants to purchase its common stock at an exercise price of $6.25 per share in
connection with the purchase of the world-wide Medihoney license rights. See Note 15 for further discussion of license rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During 2010, the Company
received $16,278 and issued 5,601 common stock shares upon the exercise of stock options. In addition, during 2010 the Company
issued 207 shares of common stock upon the conversion of series A and B preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Stock Purchase Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">At December 31, 2011,
the Company had warrants outstanding to purchase 3,065,702 shares of the Company&rsquo;s common stock consisting of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 70%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Series</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number of Warrants</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; border-bottom: Black 1pt solid">Expiration Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 20%; font-size: 10pt; text-align: center">J</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">267,858</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: center">6.16</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt; text-align: justify">May 31, 2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center">K</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">389,064</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">9.60</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">April 1, 2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: center">L</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">3.12</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">March 31, 2014</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center">N</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">6.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">February 22, 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: center">O</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">331,900</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">5.50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">February 22, 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center">P</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,695</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">6.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">February 16, 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: center">Q</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">133,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">5.50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">February 22, 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">R</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,832,602</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: center">9.90</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">June 22, 2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,065,702</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2011, 224,063 series
H, 94,351 series I, 10,000 series K, 40,700 series O and 24,465 series P warrants were exercised either on a for cash or cashless
basis. A total of 179,304 shares of common stock were issued upon exercise of those warrants. Also in 2011, 107,852 series H warrants
expired and 1,832,602 series R warrants were issued in connection with the June 2011 stock sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Stock Options</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has a stock
option plan under which options to purchase a maximum of 2,500,000 shares of common stock may be issued. The plan permits the granting
of both incentive stock options and nonqualified stock options to employees and directors of the Company and certain outside consultants
and advisors to the Company. The option exercise price may not be less than the fair market value of the stock on the date of the
grant of the option. The duration of each option may not exceed 10 years from the date of grant. As of December 31, 2011, options
to purchase 1,477,308 shares of the Company&rsquo;s common stock were issued and outstanding under the plan and 991,691 shares
were available for grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has previously
granted nonqualified stock options to officers, directors, agents and employees outside of the stock option plan (&ldquo;non-plan
options&rdquo;). All non-plan options were granted at the fair market value at the date of grant. As of December 31, 2011, non-plan
options to purchase 105,375 shares of the Company&rsquo;s common stock were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For the years ended December
31, 2011 and 2010, the fair value of each option award was estimated at the date of grant using the Black-Scholes option-pricing
model. The weighted-average assumptions for the years ended December 31, 2011 and 2010 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 70%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify">Risk-free interest rate</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.72</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2.53</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Volatility factor</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">76</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Dividend yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Expected option life (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The risk-free rate utilized
represents the U.S. treasury yield curve rate for the expected option life at the time of grant. The volatility factor was calculated
based on the Company&rsquo;s historical stock price volatility equal to the expected life of the option at the grant date. The
dividend yield is 0% since the Company does not anticipate paying dividends in the near future. Based on the Company&rsquo;s historical
experience of options that were forfeited before becoming fully vested, the Company has assumed an annualized forfeiture rate of
1.0% for all options. The Company will record additional expense if the actual forfeiture rate is lower than estimated, and will
record a recovery of prior expense if the actual forfeiture rate is higher than estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A summary of the Company&rsquo;s
stock option activity and related information for the years ended December 31, 2011 and 2010 follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average <U STYLE="text-decoration: none">Exercise Price</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average <U STYLE="text-decoration: none">Exercise Price</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: justify">Outstanding &ndash; beginning of year</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,203,600</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.07</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,066,328</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5.08</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">463,085</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">246,625</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.09</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Forfeited</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,501</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.41</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(79,999</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.99</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Expired</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(23,753</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Exercised</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(78,501</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.21</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,601</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.91</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Outstanding &ndash; end of year</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,582,683</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.82</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,203,600</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.07</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Expected to vest &ndash; end of year</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,566,856</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.82</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,191,564</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.07</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,118,152</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.43</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">990,374</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.17</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2011, service
based options of 320,585 and performance based options of 142,500 were granted to Company officers, directors, employees, and consultants.
The weighted average fair value per share of options granted during the year ended December 31, 2011 was $5.31. The intrinsic value
of options exercised in 2011 was $408,195.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table summarizes
information related to stock options outstanding and exercisable at December 31, 2011:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Range of <U STYLE="text-decoration: none">Exercise Prices </U></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number <BR>
<U STYLE="text-decoration: none">Outstanding</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Remaining <U STYLE="text-decoration: none"><BR>
Contractual Life</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted-Average <U STYLE="text-decoration: none">Exercise Price</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number <U STYLE="text-decoration: none">Exercisable</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted-Average <U STYLE="text-decoration: none">Exercise Price</U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 15%; font-size: 10pt; text-align: justify">$2.88 - $4.00</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">363,842</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">4.90</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">3.41</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">332,534</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">3.45</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">$4.01 - $6.00</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">630,438</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.08</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">460,284</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.04</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">$6.01 - $10.00</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">498,210</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.36</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.53</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">277,641</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.18</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">$10.01 - $13.60</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">90,193</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.80</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">11.59</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">47,693</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12.78</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,582,683</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.20</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.82</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,118,152</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.43</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During the year ended
December 31, 2011 and 2010, stock option compensation expense was recorded as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Cost of sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">81,725</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">40,985</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Selling, general and administrative expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,217,950</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">576,752</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total stock option compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,299,675</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">617,737</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of December 31, 2011,
there was $968,699 of unrecognized compensation cost related to non-vested service based awards and $154,955 nonvested performance
based awards granted under the plan. These costs are expected to be recognized over the options&rsquo; remaining weighted average
vesting period of 1.68 years for service based awards and 0.67 years for the performance based awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Restricted Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has a restricted
common stock plan under which 312,500 shares of common stock are reserved for issuance. There are 218,125 shares available for
issuance under the plan at December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2011,
1,000 shares of restricted common stock were granted under the plan to a Company employee which vest one year from date of grant.
The fair market value at the date of grant determined by the quoted market price was $7,810, or $7.81 per share. For the year ended
December 31, 2011, $2,604 of compensation expense was recorded for these grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2011, 21,000
shares of restricted common stock were granted under the plan to non-employee members of the Company&rsquo;s board of directors;
20,000 shares will vest one year from date of grant, and 1,000 shares vested immediately. The fair market value at the date of
grant determined by the quoted market price was $215,460, or $10.26 per share. For the year ended December 31, 2011, $147,060 of
compensation expense was recorded for these grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2011, 30,500
shares of restricted common stock were granted under the plan to Company employees on a performance basis which vest one year from
date of grant if the performance conditions are met. The fair market value at the date of grant determined by the quoted market
price was $150,975, or $4.95 per share. For the year ended December 31, 2011, $150,975 was recorded for these grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In May 2010, 20,000 shares
of restricted common stock were granted under the plan to non-employee members of the Company&rsquo;s board of directors that will
vest one year from date of grant. The fair market value at the date of grant determined by the quoted market price was $102,400,
or $5.12 per share. For the year ended December 31, 2011 and 2010, $34,133 and $68,267, respectively, was recorded for these grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During the year ended
December 31, 2011 and 2010, restricted stock compensation expense was recorded as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Cost of sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">22,275</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Selling, general and administrative expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">312,497</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">68,267</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total restricted stock compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">334,772</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">68,267</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of December 31,
2011, the intrinsic value of the non-vested awards was $80,215 and there was $73,606 of unrecognized costs related to the
restricted common stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Shares Reserved for
Future Issuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">At December 31, 2011,
the Company had reserved the following shares of common stock for future issuance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 83%; font-size: 10pt; text-align: justify">Convertible preferred shares (series A &ndash; B)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">73,332</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Common stock options outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,582,683</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Common stock options available for grant</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">991,691</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Common stock warrants outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,065,702</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Restricted common stock grants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Restricted common stock available for grant</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">218,125</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.12in">Total common stock shares reserved</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,983,033</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Securities Registration
Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company consummated
private syndications of its securities on April 18, 2006, November 8, 2007 and April 2, 2008. In connection with each such syndication,
the Company agreed with purchasers both to register the securities for public sale and to use its best efforts to maintain the
effectiveness of such registration statements until the subject securities are sold or may be sold without registration. The Company
has satisfied its obligations to register the securities issued in each of the aforementioned syndications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The registration statements
relative to the April 2006 and November 2007 syndications have expired. Although the securities sold in these syndications are
eligible for sale under Rule 144(b)(1)(i), the Company has accorded &ldquo;piggyback&rdquo; registration rights to the subject
purchasers for an indefinite period. The registration statement relative to the April 2008 syndication is currently effective and
there has been no lapse in its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The securities registration
provisions applicable to the April 2008 syndication require that if the Securities and Exchange Commission suspends the effectiveness
of the subject registration statement prior to all registered securities either having been sold or becoming eligible for unrestricted
sale pursuant to Rule 144(b)(1)(i) under the Securities Act of 1933, an event not now anticipated, the Company must pay purchasers
one thirtieth of one percent of the purchase price of the securities for each day the subject registration statement is not effective
up to a maximum of ten percent of the purchase price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The securities purchased
in the April 2008 syndication are all eligible for unrestricted sale under Rule 144(b)(1)(i) with the exception of securities purchased
by a single institutional investor in the total amount of $2,000,000. The Company&rsquo;s maximum potential liability to the subject
investor under the foregoing registration provisions would be $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company consummated
a public offering of its securities on February 22, 2010. A portion of the underwriter&rsquo;s compensation in this offering consisted
of warrants to purchase the Company&rsquo;s common stock. The Company agreed to accord the underwriter a single demand registration
right and thereafter &ldquo;piggyback&rdquo; registration rights as to the common stock issuable upon exercise of the underwriter&rsquo;s
stock purchase warrants. However, the Company, in lieu of providing the foregoing registration rights, has the absolute right,
in its discretion and without penalty, to satisfy the exercise of the underwriter&rsquo;s warrants with unregistered shares of
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On June 23, 2011, the
Company completed a private placement of its common stock and warrants to purchase the Company&rsquo;s common stock. In connection
with such private placement, the Company agreed with the purchasers to register the common stock and the common stock underlying
the warrants for public sale and to use its best efforts to maintain the effectiveness of such registration statement until such
securities are sold or may be sold without registration. The Company has filed a registration statement with respect to the common
stock and the common stock underlying the warrants, which was declared effective on July 21, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-underline-style: none"><B>12.</B></FONT></TD><TD><FONT STYLE="text-underline-style: none"><B>Operating
                                                                                                                             Segments</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2011, the Company
changed its segment reporting to reflect the current and foreseeable nature of its business operations. The former wound care,
wound closure and specialty securement devices and skin care segments no longer reflect how the Company operates its business.
The previously reported wound care segment reflected the combined operating activities of the advanced and traditional wound care
products. Under the new reporting format they are separately identified and form the basis for two new reporting segments. The
previously reported wound closure and specialty securement devices and skin care operating segments are now combined into the traditional
wound care segment. A new segment was created to reflect the Company&rsquo;s significant investment in pharmaceutical products.
Operating results for 2010  have been restated to conform to the new segment reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company currently
operates in three segments: advanced wound care, traditional wound care and pharmaceutical wound care products. They are and will
be managed separately because each segment requires different technology, marketing and sales strategies. Advanced wound care products
principally consist of both novel and otherwise differentiated dressings, bandages and ointments designed to promote wound healing
and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze
bandages, adhesive bandages, wound closer strips, catheter fasteners and skin care products. Pharmaceutical wound care products
consist of DSC127, a novel product for the treatment of diabetic foot ulcers which is presently under development having recently
completed its Phase 2 trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced and traditional
wound care products are marketed globally to acute care, extended care, home health care, wound and burn care clinics and physician
offices. The Company utilizes a broad network of well-established distributors to deploy its products to end users. Only a small
portion of the Company&rsquo;s sales are sold directly to end users. The advanced and traditional wound care products are both
manufactured internally and sourced from third party suppliers. The majority of marketing expenses are deployed in support of advanced
wound care products with traditional wound care products requiring limited support. The Company utilizes direct sales representatives,
distributor relationships and contractual relationships with buying groups and wound care service providers to sell its products.
Direct sales representatives are used solely in support of advanced wound care sales in the U.S. and U.K. for both advanced and
traditional wound care products in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical
wound care segment is presently limited to the development of DSC127. All expenses associated with this activity are being recorded
as research and development expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each operating segment
is managed at the segment contribution level consisting of gross profit minus direct expense consisting of distribution, marketing,
sales and research and development expenses. Expenses are allocated directly by segment to the extent possible. Expenses common
to all three operating segments are allocated consistently using activity based assumptions. The aggregation or allocation of indirect
expenses by segment is not practical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating segment sales,
gross profit, segment contribution and other related information for 2011 and 2010 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><U>Year ended December 31, 2011</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: italic; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">Advanced
    Wound Care</FONT><I> </I></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-style: italic; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: italic; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-weight: normal; font-style: normal">Traditional
    Wound Care</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-style: italic; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: normal; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-style: normal; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-style: normal">Pharmaceutical
Wound Care</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-style: normal; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: normal; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-style: normal; border-bottom: Black 1pt solid; text-align: center">Other</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-style: normal; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Total
    </FONT><U STYLE="text-decoration: none">Company<I> </I></U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: justify">Net sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">15,927,920</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">46,702,327</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">62,630,247</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Gross profit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,312,953</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,098,994</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,411,947</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Direct expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,778,797</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,611,558</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,057,094</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(13,447,449</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Segment contribution</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,465,844</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,487,436</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,057,094</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,964,498</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Indirect expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(9,304,909</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,304,909</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,340,411</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><U>Year ended December 31, 2010</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: justify">Net sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11,597,373</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">44,876,683</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">56,474,056</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Gross profit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,689,410</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,837,922</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,527,332</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Direct expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,649,457</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,651,508</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(292,660</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,593,625</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Segment contribution</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,960,047</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,186,414</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">($</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(292,660</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,933,707</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Indirect expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,382,571</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">(8,382,571</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,448,864</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A geographical breakdown
of the Company&rsquo;s sales, gross profit and equipment and improvements, net is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">United States</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Canada</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Other</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify"><U>2011</U></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">Net sales</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">41,502,059</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">15,387,066</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,741,122</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">62,630,247</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Gross profit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">13,216,794</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,772,647</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,422,506</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">18,411,947</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Equipment and improvements, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">292,914</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,745,779</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">450,501</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,489,194</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: left">2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Net sales</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">38,338,581</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">14,443,742</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,691,733</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">56,474,056</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Gross profit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">11,765,478</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,393,376</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,368,478</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">16,527,332</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Equipment and improvements, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">415,116</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,642,165</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">550,961</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,608,242</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For the years ended December 31,
2011 and 2010, the Company had a major Canadian customer comprising  24% and 25% of consolidated net sales, respectively. Due
to outstanding rebate obligations, the Company was in a net liability position to this customer at December 31, 2011 (see
Note 9 and 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><B>13.</B></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Income Taxes</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Loss before income taxes
for the year ended December 31 consists of the following components:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify">Domestic</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">(3,483,103</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">(2,329,148</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Foreign</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(787,770</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">304,245</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Loss before income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,270,873</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,024,903</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">The components of income taxes (benefit)
for the year ended December 31 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Current:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Federal</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">State</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">_</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Foreign</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(13,570</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">268,072</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">Total current</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(13,570</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">268,072</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Deferred:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Federal</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">144,399</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">144,399</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">State</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,742</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,742</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Foreign</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(92,033</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(19,252</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">Total deferred</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">83,108</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">155,889</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">Total income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">69,538</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">423,961</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The reconciliation of
income tax computed at the United States federal statutory tax rates to income tax expense along with percentage of loss before
income taxes for the year ended December 31, 2011 and 2010 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; text-align: center"></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: justify">Tax benefit at federal statutory rate</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">(1,452,097</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">34.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">(688,467</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">34.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">State tax, net of federal benefit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(113,482</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84,530</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Nondeductible expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">370,516</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8.7</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">168,389</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8.3</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,865</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1.6</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,383</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,195,736</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(28.0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,029,952</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(50.8</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">69,538</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.6</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">423,961</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(20.9</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Significant components
of the Company&rsquo;s deferred tax assets and liabilities are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Deferred tax assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%; font-size: 10pt; text-align: justify; padding-left: 0.12in">Net operating loss carryforwards</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">4,812,975</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">4,207,947</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Equity based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">312,675</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">236,232</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Allowance for sales deductions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">134,826</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">144,931</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Amortization of identified intangibles</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,753,702</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,519,140</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Inventory adjustments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">992,113</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">656,338</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">169,198</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">178,599</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">Deferred tax assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,175,489</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,943,187</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Deferred tax liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Prepaid expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(81,800</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(22,226</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(890,238</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(715,098</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">Depreciation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(123,625</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(244,856</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(576</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(626</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.24in">Deferred tax liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,096,239</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(982,806</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">Valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,220,710</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,024,974</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net deferred tax liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,141,460</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,064,593</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The net deferred tax liability
of $1,141,460 consists of a deferred tax asset of $4,587 and a net deferred tax liability of $1,146,047 as of December 31, 2011.
The net deferred tax liability consists of a deferred tax liability of $890,238 related to the differences in the basis of goodwill
for financial reporting and tax purposes coupled with a $251,222 net deferred tax liability ($255,809 deferred tax liability and
a deferred tax asset of $4,587) related to the Company&rsquo;s Canadian operations. The deferred tax asset is included in prepaid
expenses and other current assets in the Consolidated Balance Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The amount by which the
Company can utilize its United States federal net operating loss carryforwards in any year or in total may be limited under the
Internal Revenue Code Section 382 regarding changes in ownership of corporations. Due to uncertainties surrounding the Company&rsquo;s
ability to use its net operating loss carryforwards and to realize the other net deferred tax assets, a full valuation allowance
has been provided as of December 31, 2011 and 2010 for the deferred tax assets for the United States and United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">At December 31, 2011,
the Company has net operating loss carryforwards of approximately $12,603,000 for United States federal income tax purposes that
begin to expire in 2012. For state income tax purposes, the Company has net operating loss carryforwards in a number of jurisdictions
in varying amounts and with varying expiration dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>14.</B></TD><TD><B>Retirement Benefits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company maintains
a profit sharing/401(k) plan for eligible full-time United States employees. Participants may contribute a fixed percentage of
their salary to the plan, subject to IRS limitations. The Company makes a matching contribution of 50% on the first 6% of each
participant&rsquo;s annual earnings contributed to the plan. Company contributions to the plan for the years ended December 31,
2011 and 2010 were $75,324 and $66,442, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company&rsquo;s Canadian
subsidiary maintains a group retirement savings plan (Registered Retirement Savings Plan) for eligible full time Canadian employees.
The Canadian subsidiary makes a matching contribution of 50% of an employee&rsquo;s contribution to a maximum of 3% of annual gross
earnings. Employee contribution limits to the group retirement savings plan are set by the Canada Customs and Revenue Agency. The
Company&rsquo;s Canadian subsidiary&rsquo;s contributions to the plan for the year ended December 31, 2011 and 2010 were $75,186
and $64,855, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.</B></TD><TD><B>Commitments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Operating Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has non-cancelable
operating lease agreements for its facilities and equipment expiring in various years through 2018. Total lease expense under these
lease agreements was $1,561,174 and $1,541,356 in 2011 and 2010, respectively. Total minimum lease payments under each lease are
recorded on a straight-line basis to lease expense over the lease term. Differences between the recognition of lease expense on
a straight-line basis and payments owed and/or free rent are recorded as deferred rent. Tenant improvement allowances are recorded
as deferred lease expense as received, and amortized to lease expense over the lesser of the corresponding asset life or the lease
term. At December 31, 2011, the Company had deferred rent of $252,684 recorded on the Consolidated Balance Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The leases generally provide
for scheduled increases in future minimum annual lease payments over the life of the lease. The leases provide for renewal options
consistent with the terms of the existing lease. It is expected that these leases will be renewed or replaced by leases on other
property and equipment, as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Minimum future lease
payments under existing operating leases as of December 31, 2011 are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 60%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="font-size: 10pt; text-decoration: none; text-align: center; border-bottom: Black 1pt solid">Minimum Future Rental Payments</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-decoration: underline; text-align: justify; padding-bottom: 1pt">Year Ending December 31,</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><U STYLE="text-decoration: none">Amount </U></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-decoration: none; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: justify; padding-left: 0.12in">2012</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">1,510,131</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">2013</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,585,962</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">2014</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,577,188</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">2015</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,240,428</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,135,797</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">Thereafter</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,247,218</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.12in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net minimum future rental payments</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,296,725</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During 2011, the Company
extended its lease on the distribution center in Houston for three years through 2015, and also extended the lease on its Princeton
headquarters six years through 2018. During 2010, the Company extended the lease on the distribution center in St. Louis for four
years through 2015, and also extended the lease on the Toronto facility for five years through 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Comvita Licensing,
Manufacturing and Sales Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In February 2006, the
Company entered into an exclusive five year licensing, manufacturing and sales agreement (the &ldquo;2006 Agreement&rdquo;) with
Comvita New Zealand Limited (&ldquo;Comvita&rdquo;) whereby the Company manufactured and sold a line of Manuka Honey based wound
care products developed by Comvita. Under the 2006 Agreement, the Company received exclusive rights to manufacture and sell Manuka
Honey based products throughout North and South America within the professional medical-surgical marketplace (i.e. extended care,
acute care, home care, etc.) and non-exclusive rights within the consumer marketplace. Comvita retained the right to these products
in the consumer marketplace and maintained the option to purchase its Manuka Honey consumer product requirements from the Company.
In accordance with the 2006 Agreement, the Company purchases its requirements for medical grade honey exclusively from Comvita.
As consideration for the license, the Company paid Comvita a royalty based on sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On February 23, 2010,
the Company replaced the 2006 Agreement with a new agreement with Comvita (the &ldquo;2010 Agreement&rdquo;) under which the Company
received perpetual and exclusive worldwide licensing rights for Manuka Honey based (Medihoney&reg;) wound and skin care products
for all markets outside of the consumer market. The 2010 Agreement also provides that Comvita will serve as the Company&rsquo;s
exclusive supplier for Manuka Honey and will not provide Manuka Honey to any other entities for use in the professional medical-surgical
marketplace. The 2010 Agreement calls for graduated royalty payments based on sales and milestone payments of up to $20,000,000
based on achievement of specified net sales objectives. The license rights may be terminated or rendered non-exclusive by Comvita
if the Company fails to meet certain minimum royalty requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In consideration for the
2010 Agreement, the Company paid Comvita $2,250,000 and issued Comvita 400,000 shares of its common stock and warrants to purchase
133,333 shares of its common stock at $5.50 per share, the stock and warrants together valued at $2,000,000, and warrants to purchase
100,000 shares of common stock at $6.25 per share, which was valued at $417,126 using the Black&ndash;Scholes option pricing model.
Total consideration paid to Comvita was $4,667,126. During 2011, the Company made a milestone payment of $1,000,000 in accordance
with the agreement. The cost of the foregoing licensing rights and milestone payment has been recorded as an intangible asset and
is being amortized to cost of sales over an estimated useful life of 10 years (See Note 7).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Comvita is a major shareholder
of the Company and its Chief Executive Officer serves on the Company&rsquo;s Board of Directors. In 2011 and 2010, the Company
purchased $1,018,410 and $694,877 of medical grade honey from Comvita, respectively. In addition, in 2011 and 2010 the Company
paid Comvita royalties of $612,804 and $410,961, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Quick-Med Technologies,
Inc. &ndash; License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In March 2007, the Company
entered into a patent and technology license agreement (the &ldquo;Agreement&rdquo;) with Quick-Med Technologies, Inc. (&ldquo;QMT&rdquo;)
relating to QMT&rsquo;s proprietary anti-microbial technology (the &ldquo;Technology&rdquo;). The initial term of the Agreement
extended from March 2007 for the lesser of seven or five years from the date of first product regulatory approval employing the
Technology. Under the Agreement, QMT granted to the Company an exclusive, royalty-bearing right and license to make, use and sell
products incorporating the Technology in the United States and Canada (with the exception of sales to the United States government
and agencies thereof in which case the license will be non-exclusive). Royalties are based on net sales of products utilizing the
Technology at specified rates. In the event for a given contract year the Company fails to make the required minimum royalty payment,
QMT&rsquo;s exclusive remedies (depending on the magnitude of the failure) are either termination of the Company&rsquo;s exclusive
rights to the Technology or termination of the Agreement. QMT received clearance from the United States Food and Drug Administration
(&ldquo;FDA&rdquo;) for use of its Technology in February 2009. The Company launched its first products utilizing the Technology
in June 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In February 2010, the
parties amended the Agreement to clarify the term, the field of products included and the annual minimum royalty payment amounts.
The effective date of the amended Agreement was June 22, 2009, and the term of the Agreement is for a period of five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Due to delays on the part
of the Company in implementing plans for sale of these products, it has not met its minimum royalty commitment. Management continues
to work closely with QMT on this issue. The Company has been advised by QMT that it is not their intention to invoke either of
their exclusive remedies for failure to meet its minimum royalty commitments. Sales of products utilizing the technology were $1,842,540
and $1,315,867, for 2011 and 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>USC License Agreement
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On November 2, 2007, the
Company entered into a license agreement (the &ldquo;License Agreement&rdquo;) with the University of Southern California (&ldquo;USC&rdquo;)
pursuant to which the Company acquired exclusive rights to a number of United States and foreign patents and non-exclusive rights
to one patent, together with trade secrets and know-how, related to an angiotensin analog (the patents, trade secrets and know-how,
collectively, the &ldquo;Angiotensin Analog Technology&rdquo; or &ldquo;Technology&rdquo;). The Angiotensin Analog Technology relates
to a topical application for the treatment of chronic wounds such as diabetic ulcers, leg ulcers associated with venous insufficiency,
pressure ulcers (bed sores), burns and surgical scars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company paid to or
on behalf of USC an initial license fee of $839,348 which was charged to expense when incurred. Additionally, the Company will
pay USC royalties relative to sales of products employing the Technology (the &ldquo;Angiotensin Products&rdquo;) at specified
rates in respect of revenues less than $100 million and revenues equal to or greater than $100 million, respectively. In addition,
the Company is required to make milestone payments to USC of up to $9,625,000 predicated upon obtaining approval of the FDA of
various indications for the Angiotensin Products, as well as the attainment of various sales objectives. Further, the Company is
obligated to spend at least $1,250,000 on direct marketing of the initial Angiotensin Product within twelve months of the FDA&rsquo;s
approval thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The compound employing
the Technology is classified as a &ldquo;drug,&rdquo; the sale of which is conditioned upon FDA approval. The process of obtaining
FDA approval for the compound consists of subjecting the compound to a series of pre-clinical and clinical studies, these latter
known as Phase 1, Phase 2 and Phase 3 studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The compound has successfully
undergone pre-clinical, Phase 1 and Phase 2 clinical studies. The Company is working on a number of initiatives internally and
with the FDA to prepare for its Phase 3 clinical trial in the second half of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company is under no
obligation to undertake or complete further studies in respect of the Technology. Should it not do so, the Company may either sublicense
the Technology to one or more third parties or release the Technology to USC. In this latter event, USC would reimburse the Company
for certain of its costs incident to clinical studies that have heretofore been performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"><B>Canadian Distribution Agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In May 2005, the Company
entered into a distribution agreement with a Canadian company to serve as the exclusive distributor of its products in Canada.
The agreement also appoints the distributor as the Company&rsquo;s servicing agent to fulfill supply contracts held directly by
the Company. The agreement was most recently amended in January 2011, extending it through April 2016. The Company recognizes revenue
under the agreement when title and risk of loss pass to the distributor and collectability is reasonably assured, which is at the
time product is shipped to the distributor. Payment terms from the distributor are 30 days. Either party has the right to terminate
the agreement when an event of default (as defined) has occurred with respect to the other party. The distributor is entitled to
continue to sell or otherwise dispose of all inventory owned by it from and after the date of contract expiration or termination.
If termination of the agreement is not occasioned by breach by the distributor, the distributor will be entitled on notice to the
Company to return saleable inventory (as defined) to the Company. Estimated returns are reserved at the time of sale. Since the
inception of the agreement, sales returns have been minimal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The distributor assumes
responsibility for customer service, product delivery and maintenance and warehousing of sufficient inventory to meet agreed upon
order fulfillment requirements. On an ongoing basis, the distributor places inventory replenishment orders with the Company at
agreed upon prices, 120 days in advance of scheduled delivery. Unless amended, each order becomes non-cancelable 90 days in advance
of scheduled delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 100%">DERMA SCIENCES, INC. AND SUBSIDIARIES<BR><BR>Notes to Consolidated Financial Statements</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">With respect to sales
made by the distributor, the Company pays the distributor an agreed upon distribution fee. The Company reimburses the distributor
for the difference between the price paid by the distributor and the Company&rsquo;s contract price with the end customer, upon
submission by the distributor of an agreed upon rebate report. The distribution fee is recorded as a reduction of revenue under
this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Executive Employment
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The five executive officers
of the Company are appointed by and serve at the discretion of the Board of Directors pursuant to one year employment agreements
that are renewed annually as of April 1<SUP>st</SUP>. The agreements were renewed in March 2012. The agreements provide for annual
salary and provision for bonus and equity based compensation assuming financial and personal objectives are met. The agreements
also outline certain obligations that may be triggered by a change in control and severance for failure to renew an agreement
other than for cause.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>16.</B></TD><TD><B>Subsequent Event</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 27, 2012, the Company
entered into a definitive agreement to acquire the stock of Medefficiency, Inc. (&ldquo;Medefficiency&rdquo;) for $14,500,000 in
cash. Medefficiency is a privately held company that sells a proprietary line of total contact cast products for the treatment
of diabetic foot ulcers. Since 2008, the Company has been a distributor of Medefficiency&rsquo;s products. In 2011, the Company
represented approximately 25% of Medefficiency&rsquo;s annual revenues of $5,300,000. The acquisition is subject to customary closing
conditions and is anticipated to be completed by April 30, 2012.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 9. Changes in and Disagreements with
Accountants on Accounting and Financial Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-underline-style: none">Item
9A. Controls and Procedures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Evaluation of Disclosure Controls and Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of the end of the year
covered by this annual report, our president and chief executive officer (our principal executive officer) and our vice president
and chief financial officer (our principal financial officer) performed an evaluation of the effectiveness of our disclosure controls
and procedures as defined in Rules&nbsp;13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are
designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and forms and that such information
is accumulated and communicated to our management to allow timely decisions regarding required disclosures. Based on this evaluation,
our president and chief executive officer and our vice president and chief financial officer have concluded that our disclosure
controls and procedures were effective as of December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Management&rsquo;s Report on Internal Control
Over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)
and 15d-15(f)) for our Company. Internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with accounting principles generally accepted in the United States. Our management conducted an assessment of the effectiveness
of our internal control over financial reporting as of December 31, 2011 based on criteria established in <I>Internal Control&nbsp;&mdash;
Integrated Framework </I>issued by the Committee of Sponsoring Organizations of the Treadway Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based on this assessment,
management believes that, as of December 31, 2011, our internal control over financial reporting was effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This annual
report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting pursuant to the rules of the Securities and Exchange Commission based on the market capitalization of the Company as measured as of June 30,
2011 (end of the second quarter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 9B. Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Part III</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 10. Directors, Executive Officers
and Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Information in response
to this Item is incorporated herein by reference to our definitive proxy statement for our 2012 annual meeting of shareholders
to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Item 11. Executive Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Information in response
to this Item is incorporated herein by reference to our definitive proxy statement for our 2012 annual meeting of shareholders
to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 12. Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Information in response
to this Item is incorporated herein by reference to our definitive proxy statement for our 2012 annual meeting of shareholders
to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 13. Certain Relationships and Related
Transactions, and Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Information in response
to this Item is incorporated herein by reference to our definitive proxy statement for our 2012 annual meeting of shareholders
to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Item 14. Principal Accounting Fees and
Services</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Information in response
to this Item is incorporated herein by reference to our definitive proxy statement for our 2012 annual meeting of shareholders
to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Part IV</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Item 15. Exhibits, Financial Statement
Schedules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD><U>Financial Statements</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD>Financial statements and related documents are listed
in the Index under Item 8 of this report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD>All financial statement schedules are omitted because
they are not applicable, not material or the required information is shown in the financial statements or notes thereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(b) <U>Exhibits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Exhibit&nbsp;</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><U>Number</U></TD><TD STYLE="text-align: center"><U>Description</U></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.01</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Articles of Incorporation
effective June 3, 1996 (previously filed as Exhibit B to the Company&rsquo;s Proxy Statement filed on April 23, 1996 and incorporated
herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.02</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Amendment to the Articles
of Incorporation effective February 10, 1998 (previously filed as Exhibit A to the Company&rsquo;s Proxy Statement filed on December
22, 1997 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.03</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Amendment to the Articles
of Incorporation effective October 20, 1998 (previously filed as Exhibit A to the Company&rsquo;s Proxy Statement filed on August
14, 1998 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.04</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Amendment to the Articles
of Incorporation effective May 26, 1999 (previously filed as Exhibit A to the Company&rsquo;s Proxy Statement filed on April 13,
1999 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.05</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Amendment to the Articles
of Incorporation effective August 2, 1999 (previously filed as Exhibit 3 to the Company&rsquo;s Form 8-K filed on August 6, 1999
and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.06</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Amendment to the Articles
of Incorporation effective December 28, 2007 (previously filed as Appendix A to the Company&rsquo;s Proxy Statement filed November
21, 2007 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.07</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Amendment to the Articles
of Incorporation effective February 1, 2010 (previously filed as Exhibit 3.07 to the Company&rsquo;s Form 10-K filed on
March 31, 2010 and incorporated  herein by reference).</FONT> </TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.08</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Certificate of Designations,
Voting Powers, Preferences and Rights of the Series of Preferred Stock of Derma Sciences, Inc. Designated Series A Convertible
Preferred Stock (previously filed as Exhibit 10.03 to the Company&rsquo;s Form 8-K filed on November 24, 1997 and incorporated
herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.09</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Certificate of Designations,
Voting Powers, Preferences and Rights of the Series of Preferred Stock of Derma Sciences, Inc. Designated Series B Convertible
Preferred Stock (previously filed as Exhibit 10.05 to the Company&rsquo;s Form 8-K filed on July 9, 1998 and incorporated herein
by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.10</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Certificate of Designations,
Voting Powers, Preferences and Rights of the Series of Preferred Stock of Derma Sciences, Inc. Designated Series C Convertible
Preferred Stock (previously filed as Exhibit 10.05 to the Company&rsquo;s Form 8-K filed on August 20, 1999 and incorporated herein
by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.11</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Certificate of Designations,
Voting Powers, Preferences and Rights of the Series of Preferred Stock of Derma Sciences, Inc. Designated Series D Convertible
Preferred Stock (previously filed as Exhibit 10.05 to the Company&rsquo;s Form 8-K filed on January 10, 2000 and incorporated
herein by reference).</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">3.12</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Bylaws effective May 14,
1997 (previously filed as Exhibit 3.1 to the Company&rsquo;s Form 10-QSB filed on August 15, 1997 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">4.01</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Form of Warrant to Purchase Common Stock relative to
the private placement of common stock and series R warrants effected on June 23, 2011 (previously filed as Exhibit 4.01 to the
Company&rsquo;s Form 8-K filed on June 21, 2011 and incorporated herein by reference).</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.01*</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Employment Agreement, dated
March 7, 2012, between the Company and Edward J. Quilty (previously filed as Exhibit 10.01 to the Company&rsquo;s Form 8-K filed
on March 13, 2012 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.02*</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Employment Agreement, dated
March 7, 2012, between the Company and John E. Yetter, CPA (previously filed as Exhibit 10.02 to the Company&rsquo;s Form 8-K
filed on March 13, 2012 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.03*</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Employment Agreement, dated March 7, 2012, between the Company and Robert C. Cole
                                                                                                                        (previously filed as Exhibit 10.03 to the Company&rsquo;s Form</FONT> &nbsp;<FONT STYLE="font-size: 10pt">8-K
filed on March 13, 2012 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.04*</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Employment Agreement, dated
March 12, 2012, between the Company and Frederic Eigner (previously filed as Exhibit 10.05 to the Company&rsquo;s Form 8-K filed
on March 13, 2012 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.05*</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Employment Agreement, dated
March 8, 2012, between the Company and Barry J. Wolfenson (previously filed as Exhibit 10.04 to the Company&rsquo;s Form 8-K filed
on March 13, 2012 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.06*</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">The Derma Sciences, Inc. Amended and
                                                                                                                        Restated Stock
                                                                                                                        Option Plan,dated   February 9, 2011 (previously filed as Exhibit 10.06 to the Company&rsquo;s Form 10-K filed on
                                                                                                                        March 29, 2011 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: left">10.07*</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">The Derma Sciences, Inc. Restricted Stock Plan, dated March 31, 2006
                                                       (previously filed as Appendix  D to the Company&rsquo;s Proxy Statement filed on April 5, 2006 and incorporated herein by
                                                       reference).</TD>
</TR>     <TR STYLE="vertical-align: top">
<TD STYLE="text-align: left">10.08&nbsp;</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Form of Purchase Agreement relative to the private placement of securities effected on April 18, 2006
(previously filed as Exhibit 10.02 to the Company&rsquo;s Form 8-K filed on April 24, 2006 and incorporated herein by reference).</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="margin: 0"> </P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.09</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Form of Registration Rights
Agreement relative to the private placement of securities effected on April 18, 2006 (previously filed as Exhibit 10.03 to the
Company&rsquo;s Form 8-K filed on April 24, 2006 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.10</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Warrant Agreement between
the Company and StockTrans, Inc. relative to the private placement of securities effected on April 18, 2006 (previously filed
as Exhibit 10.04 to the Company&rsquo;s Form 8-K filed on April 24, 2006 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.11</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Placement Agreement between
the Company and Taglich Brothers, Inc. relative to the private placement of securities effected on April 18, 2006 (previously
filed as Exhibit 10.05 to the Company&rsquo;s Form 8-K filed on April 24, 2006 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.12</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement,
dated January 26, 2006, relative to the Company&rsquo;s purchase on April 18, 2006 of the assets of Western Medical, Inc. (previously
filed as Exhibit 10.01 to the Company&rsquo;s Form 8-K filed on April 24, 2006 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.13</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Purchase Agreement, dated
August 3, 2006, between the Company and Comvita New Zealand Limited relative to the private sale of securities (previously filed
as Exhibit 2.01 to the Company&rsquo;s Form 8-K filed on August 7, 2006 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.14</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Registration Rights Agreement,
dated August 3, 2006, between the Company and Comvita New Zealand Limited relative to the private sale of securities (previously
filed as Exhibit 10.03 to the Company&rsquo;s Form 8-K filed on August 7, 2006 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.15</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Patent and Technology License
Agreement, dated March 23, 2007, between the Company and Quick-Med Technologies, Inc. (previously filed as Exhibit 10.01 to the
Company&rsquo;s Form 8-K filed on March 29, 2007 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.16</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement,
dated November 8, 2007, between the Company and NutraMax Products, Inc. relative to the purchase by the Company&rsquo;s subsidiary,
Derma First Aid Products, Inc, of substantially all of the assets of the First Aid division of NutraMax (previously filed as Exhibit
2.01 to the Company&rsquo;s Form 8-K filed on November 15, 2007 and amended on January 15, 2008 and January 24, 2008 and incorporated
herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.17</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Form of Purchase Agreement
relative to the private placement of common stock and series H and I warrants effected on November 8, 2007 (previously filed as
Exhibit 10.01 and 10.02 to the Company&rsquo;s Form 8-K filed on November 15, 2007 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.18</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">License Agreement, dated
November 2, 2007, between the Company and the University of Southern California (previously filed as Exhibit 10.01 to the Company&rsquo;s
Form 8-K filed on November 8, 2007 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.19</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Patent and Technology License
Agreement, dated March 23, 2007, between the Company and Quick-Med Technologies, Inc. (previously filed as Exhibit 10.01 to the
Company&rsquo;s Form 8-K filed on March 29, 2007 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.20</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Credit and Security Agreement,
dated November 8, 2007, between the Company and Merrill Lynch Capital (previously filed as Exhibit 10.01 to the Company&rsquo;s
Form 8-K filed on November 15, 2007 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">10.21</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">First Amendment to Credit and Security Agreement, dated
March 28, 2008, between the Company and GE Business Financial Services, Inc. (previously filed as Exhibit 10.01 to the Company&rsquo;s
Form 8-K filed on April 2, 2008 and incorporated herein by reference).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.22</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Second Amendment to Credit
and Security Agreement, dated August 13, 2008, between the Company and GE Business Financial Services, Inc. (previously filed
as Exhibit 10.01 to the Company&rsquo;s Form 8-K filed on August 19, 2008 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.23</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Third Amendment to Credit
and Security Agreement, dated March 31, 2009, between the Company and GE Business Financial Services, Inc. (previously filed as
Exhibit 10.02 to the Company&rsquo;s Form 8-K filed on April 6, 2009 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.24</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Fourth Amendment to Credit
and Security Agreement, dated February 26, 2010, between the Company and GE Business Financial Services, Inc. (previously filed
as Exhibit 10.01 to the Company&rsquo;s Form 8-K filed on March 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.25</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Fifth Amendment to Credit
and Security Agreement, dated March 26, 2010, between the Company and GE Business Financial Services, Inc. (previously filed as
Exhibit 10.01 to the Company&rsquo;s Form 8-K filed on April 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.26</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Clinical Services Agreement,
dated January 22, 2008, between the Company and U.S. Biotest, Inc. (previously filed as Exhibit 10.01 to the Company&rsquo;s Form
8-K filed on January 28, 2008 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.27</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Form of Purchase Agreement
relative to the private placement of common stock and series K warrants effected on April 2, 2008 (previously filed as Exhibit
10.01 to the Company&rsquo;s Form 8-K filed on April 7, 2008 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.28</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">License Agreement, dated
February 23, 2010, between the Company and Comvita New Zealand Ltd. (previously filed as Exhibit 10.01 to the Company&rsquo;s
Form 8-K filed on March 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.29</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Restraint Agreement, dated
February 23, 2010, between the Company and Comvita New Zealand Ltd. (previously filed as Exhibit 10.02 to the Company&rsquo;s
Form 8-K filed on March 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.30</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Collaborative Research
and Development Agreement, dated February 23, 2010, between the Company and Comvita New Zealand Ltd. (previously filed as Exhibit
10.03 to the Company&rsquo;s Form 8-K filed on March 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.31</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Medical Honey Supply Agreement,
dated February 23, 2010, between the Company and Comvita New Zealand Ltd. (previously filed as Exhibit 10.04 to the Company&rsquo;s
Form 8-K filed on March 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.32</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Manufacturing Agreement,
dated February 23, 2010, between the Company and Comvita New Zealand Ltd. (previously filed as Exhibit 10.05 to the Company&rsquo;s
Form 8-K filed on March 1, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.33</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Nominating Agreement, dated
February 18, 2010, between the Company and Comvita New Zealand Ltd. (previously filed as Exhibit 10.01 to the Company&rsquo;s Form
8-K filed on February 24, 2010 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt">10.34</FONT></TD><TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Forbearance Agreement,
dated March 31, 2009, between the Company and Western Medical, Inc. (previously filed as Exhibit 10.01 to the Company&rsquo;s
Form 8-K filed on April 6, 2009 and incorporated herein by reference).</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">10.35</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Separation and Release Agreement by and between Derma
Sciences, Inc. and Derma First Aid Products, Inc., and Daniel Rivest, effective as of March 31, 2010 (previously filed as Exhibit
10.01 to the Company&rsquo;s Form 8-K filed on April 1, 2010 and incorporated herein by reference).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">10.36</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Form of Securities Purchase Agreement relative to the
private placement of common stock and series R warrants effected on June 23, 2011 (previously filed as Exhibit 10.01 to the Company&rsquo;s
Form 8-K filed on June 21, 2011 and incorporated herein by reference).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">10.37</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Form of Registration Rights Agreement relative to the
private placement of common stock and series R warrants effected on June 23, 2011 (previously filed as Exhibit 10.02 to the Company&rsquo;s
Form 8-K filed on June 21, 2011 and incorporated herein by reference).</TD>
</TR></TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">21.1&plusmn;</TD><TD>Information relative to subsidiaries.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">23.1&plusmn;</TD><TD>Consent of KPMG LLP.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">31.1&plusmn;</TD><TD>Certification of the Principal Executive Officer
pursuant to Section 302 of the Sarbanes-Oxley act of 2002.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">31.2&plusmn;</TD><TD>Certification of the Principal Financial Officer
pursuant to Section 302 of the Sarbanes-Oxley act of 2002.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">32.1&plusmn;</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Certification of the Principal Executive Officer
pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">32.2&plusmn;</TD><TD STYLE="padding-left: 10pt; text-indent: -10pt">Certification of the Principal Financial Officer
pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">101.INS#</TD><TD>XBRL Instance Document</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">101.SCH#</TD><TD>XBRL Taxonomy Extension Schema Document</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">101.CAL#</TD><TD>XBRL Taxonomy Extension Calculation Linkbase Document</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">101.LAB#</TD><TD>XBRL Taxonomy Extension Labels Linkbase Document</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">101.PRE#</TD><TD>XBRL Taxonomy Extension Presentation Linkbase Document</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="color: Black; width: 10%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">* Management contract or compensatory plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&plusmn; Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;# In accordance with Rule&nbsp;406T
of Regulation&nbsp;S-T, the XBRL related information in Exhibit&nbsp;101 to this annual report on Form 10-K shall not be deemed
to be &ldquo;filed&rdquo; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liability
of that section, and shall not be part of any registration statement or other document filed under the Securities Act of 1933 or
the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In accordance with Section
13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-align: left; text-indent: 0">DERMA SCIENCES, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-decoration: none; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-decoration: none; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding: 0; text-align: left; text-indent: 0">March 28, 2012</TD>
    <TD STYLE="width: 4%; padding: 0; text-align: left; text-indent: 0">By:<U> </U></TD>
    <TD STYLE="width: 38%; padding: 0; text-align: left; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Edward J. Quilty</TD>
    <TD STYLE="width: 10%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.36in; text-align: left; text-indent: 0">Edward J. Quilty</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0 0 0 0.36in; text-align: left; text-indent: 0">Chairman, President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant
and in the capacities indicated on March 28, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding: 0; text-align: center">Signatures:</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; padding: 0; text-align: center">Title:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Edward J. Quilty&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">President, Chief Executive Officer and&nbsp; Chairman of</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Edward J. Quilty</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.12in; text-align: justify; text-indent: 0">the Board of Directors&nbsp; (Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid"><U STYLE="text-decoration: none">/s/ John E. Yetter </U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Vice President and Chief Financial Officer &nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">John E. Yetter, CPA</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.12in; text-align: justify; text-indent: 0">(Principal Financial and Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid"><U STYLE="text-decoration: none">/s/ Srini Conjeevaram </U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Srini Conjeevaram</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid"><U STYLE="text-decoration: none">/s/ Stephen T. Wills </U> </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Stephen T. Wills, CPA, MST</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ James T. O&rsquo;Brien&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">James T. O&rsquo;Brien</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ C. Richard Stafford, Esq.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">C. Richard Stafford, Esq.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Richard J. Keim&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Richard J. Keim</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Robert G. Moussa&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Robert G. Moussa</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Bruce F. Wesson&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Bruce F. Wesson</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Brett Hewlett&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Brett Hewlett</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>v305353_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries of Derma Sciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding: 0; text-align: left; text-indent: 0">Legal&nbsp;Name</TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding: 0; text-align: left; text-indent: 0">Trade&nbsp;Name</TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; padding: 0; text-align: left; text-indent: 0">State/Province&nbsp;of&nbsp;Incorporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Derma First Aid Products, Inc.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Derma First Aid Products, Inc.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Pennsylvania, United States</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Derma Sciences Canada Inc.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Derma Sciences Canada Inc.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Ontario, Canada</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Sunshine Products, Inc.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Sunshine Products, Inc.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Missouri, United States</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Derma Sciences Europe, Ltd.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">Derma Sciences Europe, Ltd.</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0">England, United Kingdom</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v305353_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-underline-style: none">Consent
of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Derma Sciences, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
in the Registration Statement (No. 333-127527) on Form S-8, in the Registrations Statements (No. 333-163127 and No. 333-164942)
on Form S-1 and Form S-1/MEF, respectively, and in the Registration Statements (Nos. 333-138303, 333-148332, 333-151028, 333-135038,
333-173870 and 333-175421) on Form S-3 of Derma Sciences, Inc. and subsidiaries of our report dated March&nbsp;28, 2012, with respect
to the consolidated balance sheets of Derma Sciences, Inc. and subsidiaries as of December 31, 2011 and 2010, and the related consolidated
statements of operations, shareholders&rsquo; equity and cash flows for the years then ended, which report appears in the December
31, 2011 Annual Report on Form 10-K of Derma Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ KPMG LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Philadelphia, Pennsylvania</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">March 28, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>v305353_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Principal Executive
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Edward J. Quilty, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1.&#9;I have reviewed this annual report on
Form 10-K of Derma Sciences, Inc. (the &ldquo;Registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2.&#9;Based on my knowledge, this annual report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
annual report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3.&#9;Based on my knowledge, the financial
statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this annual report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">4.&#9;The Registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the Registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left"><BR>
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;<BR STYLE="mso-special-character: line-break">
<BR STYLE="mso-special-character: line-break">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left">(b) Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left"><BR>
(c) Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and<BR STYLE="mso-special-character: line-break">
<BR STYLE="mso-special-character: line-break">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left">(d) Disclosed in this report any
change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s most recent
fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 22.5pt"><BR>
5.&#9;The Registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left"><BR>
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial
information; and<BR>
<BR>
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Dated: March 28, 2012</TD>
    <TD STYLE="width: 40%; padding: 0; text-align: left; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Edward J. Quilty</TD>
    <TD STYLE="width: 10%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Edward J. Quilty</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Chairman, President and Chief Executive Officer</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">(Principal Executive Officer)</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>v305353_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Principal Executive
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, John E. Yetter, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1.&#9;I have reviewed this annual report on
Form 10-K of Derma Sciences, Inc. (the &ldquo;Registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2.&#9;Based on my knowledge, this annual report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
annual report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3.&#9;Based on my knowledge, the financial
statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this annual report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">4.&#9;The Registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the Registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left"><BR>
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;<BR STYLE="mso-special-character: line-break">
<BR STYLE="mso-special-character: line-break">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left">(b) Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left"><BR>
(c) Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and<BR>
<BR>
(d) Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during
the Registrant&rsquo;s most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial
reporting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 22.5pt"><BR>
5.&#9;The Registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left"><BR>
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial
information; and<BR>
<BR>
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Dated: March 28, 2012</TD>
    <TD STYLE="width: 40%; padding: 0; text-align: left; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ John E. Yetter</TD>
    <TD STYLE="width: 10%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">John E. Yetter, CPA</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Vice President and Chief Financial Officer</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">(Principal Financial Officer)</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>v305353_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Principal Executive
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">I, Edward J. Quilty, Chairman,
President and Chief Executive Officer of Derma Sciences, Inc., hereby certify that the Annual Report on Form 10-K for the period
ended December 31, 2011 of Derma Sciences, Inc. (the &ldquo;Form 10-K&rdquo;) upon my best knowledge and belief fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the
Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Derma Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Dated: March 28, 2012</TD>
    <TD STYLE="width: 40%; padding: 0; text-align: left; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ Edward J. Quilty</TD>
    <TD STYLE="width: 10%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Edward J. Quilty</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Chairman, President and Chief Executive Officer</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">(Principal Executive Officer)</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>v305353_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Principal Financial
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">I, John E. Yetter, Vice
President and Chief Financial Officer of Derma Sciences, Inc., hereby certify that the Annual Report on Form 10-K for the period
ended December 31, 2011 of Derma Sciences, Inc. (the &ldquo;Form 10-K&rdquo;) upon my best knowledge and belief fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the
Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Derma Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: left; text-indent: 0">Dated: March 28, 2012</TD>
    <TD STYLE="width: 40%; padding: 0; text-align: left; text-decoration: none; text-indent: 0; border-bottom: Black 1pt solid">/s/ John E. Yetter</TD>
    <TD STYLE="width: 10%; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">John E. Yetter, CPA</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Vice President and Chief Financial Officer</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0"></TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">(Principal Financial Officer)</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>dsci-20111231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.13.8 -->
<!-- Round: d4fdb515-66c0-4e66-810e-576ef111c697 -->
<!-- Creation date: 2012-03-27T22:03:44Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:dsci="http://www.dermasciences.com/20111231" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="dsci-20111231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20120326_0" unitRef="shares" decimals="INF">10630865</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat contextRef="eol_PE6794----1110-K0010_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">55127459</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">243524</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">21231100</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="0">-21347052</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x443982" unitRef="iso4217_USD" decimals="0">1303293</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x444581" unitRef="shares" decimals="INF">5039468</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="0">50395</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x444874" unitRef="shares" decimals="INF">285051</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x444874" unitRef="iso4217_USD" decimals="0">2851</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="0">41221613</us-gaap:StockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">316859</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">9009481</us-gaap:LiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">-23795916</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">609164</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">5441511</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">36969863</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">65631</us-gaap:CommonStockValue>
  <us-gaap:InventoryNet contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">12498519</us-gaap:InventoryNet>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="shares" decimals="INF">6563076</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="shares" decimals="INF">1468750</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">18953410</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">7119726</us-gaap:Goodwill>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">211581</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="shares" decimals="INF">284844</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">404216</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">48803210</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">1068088</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:LinesOfCreditCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3075555</us-gaap:LinesOfCreditCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">36969863</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="shares" decimals="INF">284844</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2848</us-gaap:PreferredStockValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">26680713</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="shares" decimals="INF">6563076</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3608242</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">5851</us-gaap:LongTermDebtCurrent>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="shares" decimals="INF">18750000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">10289150</us-gaap:Liabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3777454</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">1604940</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">6971626</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <dsci:AccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2150621</dsci:AccruedExpensesAndOtherCurrentLiabilities>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="0">-23795916</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x443982" unitRef="iso4217_USD" decimals="0">1604940</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="INF">6563076</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">65631</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x444874" unitRef="shares" decimals="INF">284844</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x444874" unitRef="iso4217_USD" decimals="0">2848</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">48803210</us-gaap:StockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">129821</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">6377627</us-gaap:LiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">-28136327</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">2099197</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">6267839</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">58623892</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">105776</us-gaap:CommonStockValue>
  <us-gaap:InventoryNet contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">10530721</us-gaap:InventoryNet>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="shares" decimals="INF">10577632</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="shares" decimals="INF">1468750</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">41233107</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">7119726</us-gaap:Goodwill>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">252684</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="shares" decimals="INF">73332</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">17110350</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">77374821</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">1146047</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:LongTermInvestments contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">249000</us-gaap:LongTermInvestments>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">58623892</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="shares" decimals="INF">73332</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">733</us-gaap:PreferredStockValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">50847534</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="shares" decimals="INF">10577632</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShortTermInvestments contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">5225000</us-gaap:ShortTermInvestments>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">3489194</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="shares" decimals="INF">18750000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">7776358</us-gaap:Liabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">3999993</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">1502531</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">6403044</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <dsci:PreferredStockLiquidationPreferenceValue contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">3222368</dsci:PreferredStockLiquidationPreferenceValue>
  <dsci:AccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0">2377634</dsci:AccruedExpensesAndOtherCurrentLiabilities>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="0">-28136327</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x443982" unitRef="iso4217_USD" decimals="0">1502531</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x444581" unitRef="shares" decimals="INF">10577632</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="0">105776</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x444874" unitRef="shares" decimals="INF">73332</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x444874" unitRef="iso4217_USD" decimals="0">733</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="0">77374821</us-gaap:StockholdersEquity>
  <us-gaap:GrossProfit contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">16527332</us-gaap:GrossProfit>
  <us-gaap:StockIssued1 contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2417126</us-gaap:StockIssued1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">688974</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="INF">764327</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="INF">108752</us-gaap:OtherOperatingActivitiesCashFlowStatement>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-2884939</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">340216</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2112243</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">39946724</us-gaap:CostOfGoodsSold>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">77712</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">301647</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1114548</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-291207</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-2147217</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-2024903</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:Depreciation contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">895264</us-gaap:Depreciation>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-6658</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:InterestExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">580622</us-gaap:InterestExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">155889</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">16278</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1941</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">4059185</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-2448864</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-354478</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">292660</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="INF">4667126</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
  <us-gaap:InventoryWriteDown contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">279861</us-gaap:InventoryWriteDown>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">617737</us-gaap:StockOptionPlanExpense>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">4474452</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">634939</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-114072</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1689750</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2250000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-1670425</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-41503</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2032164</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">368548</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">56474056</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">4490730</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">17905097</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">423961</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">160692</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">144937</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">103880</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:InterestPaid contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">472031</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1122105</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OperatingExpenses contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">18197757</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">769249</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">68267</us-gaap:RestrictedStockExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">3232958</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">110458</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:PaidInKindInterest contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2970</us-gaap:PaidInKindInterest>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-310945</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
  <dsci:SupplementalGrossCashPaidForAcquisition contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2250000</dsci:SupplementalGrossCashPaidForAcquisition>
  <dsci:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2417126</dsci:IssuanceOfCommonStockAndWarrantsValue>
  <dsci:LossOnEarlyDebtExtinguishment contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">114072</dsci:LossOnEarlyDebtExtinguishment>
  <dsci:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="shares" decimals="0">6335798</dsci:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <dsci:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">121634</dsci:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="0">-2448864</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x443982" unitRef="iso4217_USD" decimals="0">301647</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="INF">5601</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">55</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">3</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">11178</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="INF">1117800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="INF">207</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <dsci:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">4000</dsci:IssuanceOfCommonStockAndWarrantsValue>
  <dsci:IssuanceOfCommonStockAndWarrantsShares contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="INF">400000</dsci:IssuanceOfCommonStockAndWarrantsShares>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444874" unitRef="iso4217_USD" decimals="0">-3</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444874" unitRef="shares" decimals="INF">-207</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">688974</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">16223</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">4463274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <dsci:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">2413126</dsci:IssuanceOfCommonStockAndWarrantsValue>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">No</dei:EntityVoluntaryFilers>
  <dei:TradingSymbol contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">DSCI</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">DERMA SCIENCES, INC.</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">2011-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">0000892160</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GrossProfit contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">18411947</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">1634447</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Shareholders&amp;#x2019; Equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
There are 18,598 shares of series A convertible preferred stock
outstanding at December 31, 2011. The series A preferred stock is
convertible into common stock on a one-for-one basis, bears no
dividend, has a liquidation preference of $32.00 per share, votes
as a class on matters affecting the series A preferred stock and
has voting rights identical to the common stock on all other
matters.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
There are 54,734 shares of series B convertible preferred stock
outstanding at December 31, 2011. The series B preferred stock is
convertible into common stock on a one-for-one basis, bears no
dividend, has a liquidation preference of $48.00 per share, votes
as a class on matters affecting the series B preferred stock and
has voting rights identical to the common stock on all other
matters.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In June 2011, the Company received net cash proceeds of $26,357,075
(after $2,717,872 in commission and other cash basis offering
expenses) from the sale of 3,524,239 shares of common stock at
$8.25 per share, together with 1,762,118 five-year series R
warrants to purchase common stock at $9.90 per share. Additionally,
the placement agents received 70,484 five-year Series R warrants to
purchase common stock at $9.90 per share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
During 2011, the Company received $618,119 (net of $68,204 in
expenses) and issued 257,805 shares of common stock upon the
exercise of stock purchase warrants and options. In addition,
during 2011 the Company issued 211,512 shares of common stock upon
the conversion of series B, C and D preferred stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
In February 2010, the Company received net proceeds of $4,474,452
(after $1,114,548 in commission and other cash basis offering
expenses) from the sale of 1,117,800 shares of common stock at
$5.00 per share, together with 372,600 five-year Series D warrants
to purchase common stock at $5.50 per share. In addition, the
placement agent received 29,160 five-year Series P warrants to
purchase common stock at $6.25 per share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In February 2010, the Company issued 400,000 shares of its common
stock together with 133,333 Series Q warrants to purchase its
common stock at an exercise price of $5.50 per share and 100,000
Series N warrants to purchase its common stock at an exercise price
of $6.25 per share in connection with the purchase of the
world-wide Medihoney license rights. See Note 15 for further
discussion of license rights.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
During 2010, the Company received $16,278 and issued 5,601 common
stock shares upon the exercise of stock options. In addition,
during 2010 the Company issued 207 shares of common stock upon the
conversion of series A and B preferred stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Stock Purchase Warrants&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
At December 31, 2011, the Company had warrants outstanding to
purchase 3,065,702 shares of the Company&amp;#x2019;s common stock
consisting of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" align="center" style="width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Series&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Number of Warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify; border-bottom: Black 1pt solid"&gt;
Expiration Date&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 20%; font-size: 10pt; text-align: center"&gt;J&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 20%; font-size: 10pt; text-align: right"&gt;
267,858&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="width: 20%; font-size: 10pt; text-align: center"&gt;
6.16&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;May
31, 2013&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;K&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;389,064&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;9.60&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;April 1, 2013&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;L&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6,250&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;3.12&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;March 31,
2014&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;N&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;100,000&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;6.25&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;February 22,
2015&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;O&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;331,900&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;5.50&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;February 22,
2015&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;P&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;4,695&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;6.25&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;February 16,
2015&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;Q&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;133,333&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;5.50&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;February 22,
2015&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"&gt;R&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
1,832,602&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;9.90&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;June
22, 2016&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt"&gt;
Total&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
3,065,702&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
In 2011, 224,063 series H, 94,351 series I, 10,000 series K, 40,700
series O and 24,465 series P warrants were exercised either on a
for cash or cashless basis. A total of 179,304 shares of common
stock were issued upon exercise of those warrants. Also in 2011,
107,852 series H warrants expired and 1,832,602 series R warrants
were issued in connection with the June 2011 stock sale.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0; padding: 0; text-indent: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; padding: 0; text-indent: 0"&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding: 0; text-indent: 0"&gt;&lt;b&gt;Stock
Options&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company has a stock option plan under which options to purchase
a maximum of 2,500,000 shares of common stock may be issued. The
plan permits the granting of both incentive stock options and
nonqualified stock options to employees and directors of the
Company and certain outside consultants and advisors to the
Company. The option exercise price may not be less than the fair
market value of the stock on the date of the grant of the option.
The duration of each option may not exceed 10 years from the date
of grant. As of December 31, 2011, options to purchase 1,477,308
shares of the Company&amp;#x2019;s common stock were issued and
outstanding under the plan and 991,691 shares were available for
grant.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company has previously granted nonqualified stock options to
officers, directors, agents and employees outside of the stock
option plan (&amp;#x201C;non-plan options&amp;#x201D;). All non-plan options
were granted at the fair market value at the date of grant. As of
December 31, 2011, non-plan options to purchase 105,375 shares of
the Company&amp;#x2019;s common stock were issued and outstanding.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
For the years ended December 31, 2011 and 2010, the fair value of
each option award was estimated at the date of grant using the
Black-Scholes option-pricing model. The weighted-average
assumptions for the years ended December 31, 2011 and 2010 were as
follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" align="center" style="width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 72%; font-size: 10pt; text-align: justify"&gt;
Risk-free interest rate&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
1.72&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
2.53&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Volatility
factor&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;76&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;80&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Dividend
yield&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Expected option
life (years)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6.25&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6.25&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The risk-free rate utilized represents the U.S. treasury yield
curve rate for the expected option life at the time of grant. The
volatility factor was calculated based on the Company&amp;#x2019;s
historical stock price volatility equal to the expected life of the
option at the grant date. The dividend yield is 0% since the
Company does not anticipate paying dividends in the near future.
Based on the Company&amp;#x2019;s historical experience of options that
were forfeited before becoming fully vested, the Company has
assumed an annualized forfeiture rate of 1.0% for all options. The
Company will record additional expense if the actual forfeiture
rate is lower than estimated, and will record a recovery of prior
expense if the actual forfeiture rate is higher than estimated.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
A summary of the Company&amp;#x2019;s stock option activity and related
information for the years ended December 31, 2011 and 2010
follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Weighted Average &lt;u style="text-decoration: none"&gt;Exercise
Price&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Weighted Average &lt;u style="text-decoration: none"&gt;Exercise
Price&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 44%; font-size: 10pt; text-align: justify"&gt;
Outstanding &amp;#x2013; beginning of year&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
1,203,600&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
5.07&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
1,066,328&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
5.08&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Granted&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;463,085&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;7.30&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;246,625&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5.09&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Forfeited&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(5,501&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;4.41&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(79,999&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;4.99&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Expired&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(23,753&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6.00&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in"&gt;
Exercised&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(78,501&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;3.21&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(5,601&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2.91&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Outstanding &amp;#x2013; end of year&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,582,683&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5.82&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,203,600&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5.07&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Expected to vest &amp;#x2013; end of year&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,566,856&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5.82&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,191,564&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5.07&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Exercisable at end of year&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,118,152&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5.43&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
990,374&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5.17&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
During 2011, service based options of 320,585 and performance based
options of 142,500 were granted to Company officers, directors,
employees, and consultants. The weighted average fair value per
share of options granted during the year ended December 31, 2011
was $5.31. The intrinsic value of options exercised in 2011 was
$408,195.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The following table summarizes information related to stock options
outstanding and exercisable at December 31, 2011:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="10" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Options Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Options Exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Range of &lt;u style="text-decoration: none"&gt;Exercise Prices&lt;/u&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Number&lt;br /&gt;
&lt;u style="text-decoration: none"&gt;Outstanding&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Weighted-Average Remaining &lt;u style="text-decoration: none"&gt;&lt;br /&gt;
Contractual Life&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Weighted-Average &lt;u style="text-decoration: none"&gt;Exercise
Price&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Number &lt;u style="text-decoration: none"&gt;Exercisable&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Weighted-Average &lt;u style="text-decoration: none"&gt;Exercise
Price&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 15%; font-size: 10pt; text-align: justify"&gt;$2.88
- $4.00&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
363,842&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
4.90&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
3.41&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
332,534&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
3.45&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;$4.01 - $6.00&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;630,438&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6.08&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5.03&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;460,284&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5.04&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;$6.01 -
$10.00&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;498,210&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;7.36&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;7.53&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;277,641&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;7.18&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;$10.01
- $13.60&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
90,193&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5.80&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;11.59&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
47,693&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;12.78&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,582,683&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6.20&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5.82&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,118,152&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5.43&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
During the year ended December 31, 2011 and 2010, stock option
compensation expense was recorded as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 66%; font-size: 10pt; text-align: justify"&gt;Cost
of sales&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
81,725&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
40,985&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;
Selling, general and administrative expenses&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
1,217,950&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
576,752&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in"&gt;
Total stock option compensation expense&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
1,299,675&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
617,737&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
As of December 31, 2011, there was $968,699 of unrecognized
compensation cost related to non-vested service based awards and
$154,955 nonvested performance based awards granted under the plan.
These costs are expected to be recognized over the options&amp;#x2019;
remaining weighted average vesting period of 1.68 years for service
based awards and 0.67 years for the performance based awards.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Restricted Common Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company has a restricted common stock plan under which 312,500
shares of common stock are reserved for issuance. There are 218,125
shares available for issuance under the plan at December 31,
2011.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
In September 2011, 1,000 shares of restricted common stock were
granted under the plan to a Company employee which vest one year
from date of grant. The fair market value at the date of grant
determined by the quoted market price was $7,810, or $7.81 per
share. For the year ended December 31, 2011, $2,604 of compensation
expense was recorded for these grants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
In May 2011, 21,000 shares of restricted common stock were granted
under the plan to non-employee members of the Company&amp;#x2019;s board
of directors; 20,000 shares will vest one year from date of grant,
and 1,000 shares vested immediately. The fair market value at the
date of grant determined by the quoted market price was $215,460,
or $10.26 per share. For the year ended December 31, 2011, $147,060
of compensation expense was recorded for these grants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
In January 2011, 30,500 shares of restricted common stock were
granted under the plan to Company employees on a performance basis
which vest one year from date of grant if the performance
conditions are met. The fair market value at the date of grant
determined by the quoted market price was $150,975, or $4.95 per
share. For the year ended December 31, 2011, $150,975 was recorded
for these grants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In May 2010, 20,000 shares of restricted common stock were granted
under the plan to non-employee members of the Company&amp;#x2019;s board
of directors that will vest one year from date of grant. The fair
market value at the date of grant determined by the quoted market
price was $102,400, or $5.12 per share. For the year ended December
31, 2011 and 2010, $34,133 and $68,267, respectively, was recorded
for these grants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
During the year ended December 31, 2011 and 2010, restricted stock
compensation expense was recorded as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 66%; font-size: 10pt; text-align: justify"&gt;Cost
of sales&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
22,275&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;
Selling, general and administrative expenses&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
312,497&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
68,267&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in"&gt;
Total restricted stock compensation expense&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
334,772&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
68,267&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
As of December 31, 2011, the intrinsic value of the non-vested
awards was $80,215 and there was $73,606 of unrecognized costs
related to the restricted common stock awards.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Shares Reserved for Future Issuance&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
At December 31, 2011, the Company had reserved the following shares
of common stock for future issuance:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 83%; font-size: 10pt; text-align: justify"&gt;
Convertible preferred shares (series A &amp;#x2013; B)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
73,332&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Common stock
options outstanding&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,582,683&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Common stock
options available for grant&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;991,691&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Common stock
warrants outstanding&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;3,065,702&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Restricted common
stock grants&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;51,500&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;
Restricted common stock available for grant&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
218,125&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.12in"&gt;
Total common stock shares reserved&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
5,983,033&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Securities Registration Obligations&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company consummated private syndications of its securities on
April 18, 2006, November 8, 2007 and April 2, 2008. In connection
with each such syndication, the Company agreed with purchasers both
to register the securities for public sale and to use its best
efforts to maintain the effectiveness of such registration
statements until the subject securities are sold or may be sold
without registration. The Company has satisfied its obligations to
register the securities issued in each of the aforementioned
syndications.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The registration statements relative to the April 2006 and November
2007 syndications have expired. Although the securities sold in
these syndications are eligible for sale under Rule 144(b)(1)(i),
the Company has accorded &amp;#x201C;piggyback&amp;#x201D; registration
rights to the subject purchasers for an indefinite period. The
registration statement relative to the April 2008 syndication is
currently effective and there has been no lapse in its
effectiveness.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The securities registration provisions applicable to the April 2008
syndication require that if the Securities and Exchange Commission
suspends the effectiveness of the subject registration statement
prior to all registered securities either having been sold or
becoming eligible for unrestricted sale pursuant to Rule
144(b)(1)(i) under the Securities Act of 1933, an event not now
anticipated, the Company must pay purchasers one thirtieth of one
percent of the purchase price of the securities for each day the
subject registration statement is not effective up to a maximum of
ten percent of the purchase price.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The securities purchased in the April 2008 syndication are all
eligible for unrestricted sale under Rule 144(b)(1)(i) with the
exception of securities purchased by a single institutional
investor in the total amount of $2,000,000. The Company&amp;#x2019;s
maximum potential liability to the subject investor under the
foregoing registration provisions would be $200,000.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company consummated a public offering of its securities on
February 22, 2010. A portion of the underwriter&amp;#x2019;s
compensation in this offering consisted of warrants to purchase the
Company&amp;#x2019;s common stock. The Company agreed to accord the
underwriter a single demand registration right and thereafter
&amp;#x201C;piggyback&amp;#x201D; registration rights as to the common stock
issuable upon exercise of the underwriter&amp;#x2019;s stock purchase
warrants. However, the Company, in lieu of providing the foregoing
registration rights, has the absolute right, in its discretion and
without penalty, to satisfy the exercise of the underwriter&amp;#x2019;s
warrants with unregistered shares of common stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
On June 23, 2011, the Company completed a private placement of its
common stock and warrants to purchase the Company&amp;#x2019;s common
stock. In connection with such private placement, the Company
agreed with the purchasers to register the common stock and the
common stock underlying the warrants for public sale and to use its
best efforts to maintain the effectiveness of such registration
statement until such securities are sold or may be sold without
registration. The Company has filed a registration statement with
respect to the common stock and the common stock underlying the
warrants, which was declared effective on July 21, 2011.&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="INF">243073</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company has non-cancelable operating lease agreements for its
facilities and equipment expiring in various years through 2018.
Total lease expense under these lease agreements was $1,561,174 and
$1,541,356 in 2011 and 2010, respectively. Total minimum lease
payments under each lease are recorded on a straight-line basis to
lease expense over the lease term. Differences between the
recognition of lease expense on a straight-line basis and payments
owed and/or free rent are recorded as deferred rent. Tenant
improvement allowances are recorded as deferred lease expense as
received, and amortized to lease expense over the lesser of the
corresponding asset life or the lease term. At December 31, 2011,
the Company had deferred rent of $252,684 recorded on the
Consolidated Balance Sheet.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The leases generally provide for scheduled increases in future
minimum annual lease payments over the life of the lease. The
leases provide for renewal options consistent with the terms of the
existing lease. It is expected that these leases will be renewed or
replaced by leases on other property and equipment, as needed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
Minimum future lease payments under existing operating leases as of
December 31, 2011 are:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" align="center" style="width: 60%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="5" style="font-size: 10pt; text-decoration: none; text-align: center; border-bottom: Black 1pt solid"&gt;
Minimum Future Rental Payments&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-decoration: underline; text-align: justify; padding-bottom: 1pt"&gt;
Year Ending December 31,&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;
&lt;u style="text-decoration: none"&gt;Amount&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-decoration: none; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 76%; font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
2012&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 20%; font-size: 10pt; text-align: right"&gt;
1,510,131&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
2013&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,585,962&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
2014&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,577,188&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
2015&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,240,428&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
2016&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,135,797&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in"&gt;
Thereafter&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
1,247,218&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Net
minimum future rental payments&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
8,296,725&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
During 2011, the Company extended its lease on the distribution
center in Houston for three years through 2015, and also extended
the lease on its Princeton headquarters six years through 2018.
During 2010, the Company extended the lease on the distribution
center in St. Louis for four years through 2015, and also extended
the lease on the Toronto facility for five years through 2017.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Comvita Licensing, Manufacturing and Sales Agreement&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In February 2006, the Company entered into an exclusive five year
licensing, manufacturing and sales agreement (the &amp;#x201C;2006
Agreement&amp;#x201D;) with Comvita New Zealand Limited
(&amp;#x201C;Comvita&amp;#x201D;) whereby the Company manufactured and sold a
line of Manuka Honey based wound care products developed by
Comvita. Under the 2006 Agreement, the Company received exclusive
rights to manufacture and sell Manuka Honey based products
throughout North and South America within the professional
medical-surgical marketplace (i.e. extended care, acute care, home
care, etc.) and non-exclusive rights within the consumer
marketplace. Comvita retained the right to these products in the
consumer marketplace and maintained the option to purchase its
Manuka Honey consumer product requirements from the Company. In
accordance with the 2006 Agreement, the Company purchases its
requirements for medical grade honey exclusively from Comvita. As
consideration for the license, the Company paid Comvita a royalty
based on sales.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
On February 23, 2010, the Company replaced the 2006 Agreement with
a new agreement with Comvita (the &amp;#x201C;2010 Agreement&amp;#x201D;)
under which the Company received perpetual and exclusive worldwide
licensing rights for Manuka Honey based (Medihoney&amp;#xAE;) wound and
skin care products for all markets outside of the consumer market.
The 2010 Agreement also provides that Comvita will serve as the
Company&amp;#x2019;s exclusive supplier for Manuka Honey and will not
provide Manuka Honey to any other entities for use in the
professional medical-surgical marketplace. The 2010 Agreement calls
for graduated royalty payments based on sales and milestone
payments of up to $20,000,000 based on achievement of specified net
sales objectives. The license rights may be terminated or rendered
non-exclusive by Comvita if the Company fails to meet certain
minimum royalty requirements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In consideration for the 2010 Agreement, the Company paid Comvita
$2,250,000 and issued Comvita 400,000 shares of its common stock
and warrants to purchase 133,333 shares of its common stock at
$5.50 per share, the stock and warrants together valued at
$2,000,000, and warrants to purchase 100,000 shares of common stock
at $6.25 per share, which was valued at $417,126 using the
Black&amp;#x2013;Scholes option pricing model. Total consideration paid
to Comvita was $4,667,126. During 2011, the Company made a
milestone payment of $1,000,000 in accordance with the agreement.
The cost of the foregoing licensing rights and milestone payment
has been recorded as an intangible asset and is being amortized to
cost of sales over an estimated useful life of 10 years (See Note
7).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
Comvita is a major shareholder of the Company and its Chief
Executive Officer serves on the Company&amp;#x2019;s Board of Directors.
In 2011 and 2010, the Company purchased $1,018,410 and $694,877 of
medical grade honey from Comvita, respectively. In addition, in
2011 and 2010 the Company paid Comvita royalties of $612,804 and
$410,961, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Quick-Med Technologies, Inc. &amp;#x2013; License Agreement&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In March 2007, the Company entered into a patent and technology
license agreement (the &amp;#x201C;Agreement&amp;#x201D;) with Quick-Med
Technologies, Inc. (&amp;#x201C;QMT&amp;#x201D;) relating to QMT&amp;#x2019;s
proprietary anti-microbial technology (the
&amp;#x201C;Technology&amp;#x201D;). The initial term of the Agreement
extended from March 2007 for the lesser of seven or five years from
the date of first product regulatory approval employing the
Technology. Under the Agreement, QMT granted to the Company an
exclusive, royalty-bearing right and license to make, use and sell
products incorporating the Technology in the United States and
Canada (with the exception of sales to the United States government
and agencies thereof in which case the license will be
non-exclusive). Royalties are based on net sales of products
utilizing the Technology at specified rates. In the event for a
given contract year the Company fails to make the required minimum
royalty payment, QMT&amp;#x2019;s exclusive remedies (depending on the
magnitude of the failure) are either termination of the
Company&amp;#x2019;s exclusive rights to the Technology or termination
of the Agreement. QMT received clearance from the United States
Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;) for use of its
Technology in February 2009. The Company launched its first
products utilizing the Technology in June 2009.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In February 2010, the parties amended the Agreement to clarify the
term, the field of products included and the annual minimum royalty
payment amounts. The effective date of the amended Agreement was
June 22, 2009, and the term of the Agreement is for a period of
five years.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
Due to delays on the part of the Company in implementing plans for
sale of these products, it has not met its minimum royalty
commitment. Management continues to work closely with QMT on this
issue. The Company has been advised by QMT that it is not their
intention to invoke either of their exclusive remedies for failure
to meet its minimum royalty commitments. Sales of products
utilizing the technology were $1,842,540 and $1,315,867, for 2011
and 2010, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;USC License Agreement&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
On November 2, 2007, the Company entered into a license agreement
(the &amp;#x201C;License Agreement&amp;#x201D;) with the University of
Southern California (&amp;#x201C;USC&amp;#x201D;) pursuant to which the
Company acquired exclusive rights to a number of United States and
foreign patents and non-exclusive rights to one patent, together
with trade secrets and know-how, related to an angiotensin analog
(the patents, trade secrets and know-how, collectively, the
&amp;#x201C;Angiotensin Analog Technology&amp;#x201D; or
&amp;#x201C;Technology&amp;#x201D;). The Angiotensin Analog Technology
relates to a topical application for the treatment of chronic
wounds such as diabetic ulcers, leg ulcers associated with venous
insufficiency, pressure ulcers (bed sores), burns and surgical
scars.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company paid to or on behalf of USC an initial license fee of
$839,348 which was charged to expense when incurred. Additionally,
the Company will pay USC royalties relative to sales of products
employing the Technology (the &amp;#x201C;Angiotensin Products&amp;#x201D;)
at specified rates in respect of revenues less than $100 million
and revenues equal to or greater than $100 million, respectively.
In addition, the Company is required to make milestone payments to
USC of up to $9,625,000 predicated upon obtaining approval of the
FDA of various indications for the Angiotensin Products, as well as
the attainment of various sales objectives. Further, the Company is
obligated to spend at least $1,250,000 on direct marketing of the
initial Angiotensin Product within twelve months of the FDA&amp;#x2019;s
approval thereof.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The compound employing the Technology is classified as a
&amp;#x201C;drug,&amp;#x201D; the sale of which is conditioned upon FDA
approval. The process of obtaining FDA approval for the compound
consists of subjecting the compound to a series of pre-clinical and
clinical studies, these latter known as Phase 1, Phase 2 and Phase
3 studies.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The compound has successfully undergone pre-clinical, Phase 1 and
Phase 2 clinical studies. The Company is working on a number of
initiatives internally and with the FDA to prepare for its Phase 3
clinical trial in the second half of 2012.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company is under no obligation to undertake or complete further
studies in respect of the Technology. Should it not do so, the
Company may either sublicense the Technology to one or more third
parties or release the Technology to USC. In this latter event, USC
would reimburse the Company for certain of its costs incident to
clinical studies that have heretofore been performed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0; padding: 0; text-indent: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; padding: 0; text-indent: 0"&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding: 0; text-indent: 0"&gt;
&lt;b&gt;Canadian Distribution Agreement&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
In May 2005, the Company entered into a distribution agreement with
a Canadian company to serve as the exclusive distributor of its
products in Canada. The agreement also appoints the distributor as
the Company&amp;#x2019;s servicing agent to fulfill supply contracts
held directly by the Company. The agreement was most recently
amended in January 2011, extending it through April 2016. The
Company recognizes revenue under the agreement when title and risk
of loss pass to the distributor and collectability is reasonably
assured, which is at the time product is shipped to the
distributor. Payment terms from the distributor are 30 days. Either
party has the right to terminate the agreement when an event of
default (as defined) has occurred with respect to the other party.
The distributor is entitled to continue to sell or otherwise
dispose of all inventory owned by it from and after the date of
contract expiration or termination. If termination of the agreement
is not occasioned by breach by the distributor, the distributor
will be entitled on notice to the Company to return saleable
inventory (as defined) to the Company. Estimated returns are
reserved at the time of sale. Since the inception of the agreement,
sales returns have been minimal.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The distributor assumes responsibility for customer service,
product delivery and maintenance and warehousing of sufficient
inventory to meet agreed upon order fulfillment requirements. On an
ongoing basis, the distributor places inventory replenishment
orders with the Company at agreed upon prices, 120 days in advance
of scheduled delivery. Unless amended, each order becomes
non-cancelable 90 days in advance of scheduled delivery.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
With respect to sales made by the distributor, the Company pays the
distributor an agreed upon distribution fee. The Company reimburses
the distributor for the difference between the price paid by the
distributor and the Company&amp;#x2019;s contract price with the end
customer, upon submission by the distributor of an agreed upon
rebate report. The distribution fee is recorded as a reduction of
revenue under this agreement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;b&gt;Executive Employment Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The five executive officers of the Company are appointed by and
serve at the discretion of the Board of Directors pursuant to one
year employment agreements that are renewed annually as of April
1&lt;sup&gt;st&lt;/sup&gt;. The agreements were renewed in March 2012. The
agreements provide for annual salary and provision for bonus and
equity based compensation assuming financial and personal
objectives are met. The agreements also outline certain obligations
that may be triggered by a change in control and severance for
failure to renew an agreement other than for cause.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="INF">44608</us-gaap:OtherOperatingActivitiesCashFlowStatement>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-7452949</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">5474000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-12682</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">813622</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">44218300</us-gaap:CostOfGoodsSold>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">319278</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-102409</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="text-underline-style: none"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="text-underline-style: none"&gt;&lt;b&gt;Operating
Segments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
In 2011, the Company changed its segment reporting to reflect the
current and foreseeable nature of its business operations. The
former wound care, wound closure and specialty securement devices
and skin care segments no longer reflect how the Company operates
its business. The previously reported wound care segment reflected
the combined operating activities of the advanced and traditional
wound care products. Under the new reporting format they are
separately identified and form the basis for two new reporting
segments. The previously reported wound closure and specialty
securement devices and skin care operating segments are now
combined into the traditional wound care segment. A new segment was
created to reflect the Company&amp;#x2019;s significant investment in
pharmaceutical products. Operating results for 2010 have been
restated to conform to the new segment reporting.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
The Company currently operates in three segments: advanced wound
care, traditional wound care and pharmaceutical wound care
products. They are and will be managed separately because each
segment requires different technology, marketing and sales
strategies. Advanced wound care products principally consist of
both novel and otherwise differentiated dressings, bandages and
ointments designed to promote wound healing and/or prevent
infection. Traditional wound care products principally consist of
commodity related dressings, ointments, gauze bandages, adhesive
bandages, wound closer strips, catheter fasteners and skin care
products. Pharmaceutical wound care products consist of DSC127, a
novel product for the treatment of diabetic foot ulcers which is
presently under development having recently completed its Phase 2
trial.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
Advanced and traditional wound care products are marketed globally
to acute care, extended care, home health care, wound and burn care
clinics and physician offices. The Company utilizes a broad network
of well-established distributors to deploy its products to end
users. Only a small portion of the Company&amp;#x2019;s sales are sold
directly to end users. The advanced and traditional wound care
products are both manufactured internally and sourced from third
party suppliers. The majority of marketing expenses are deployed in
support of advanced wound care products with traditional wound care
products requiring limited support. The Company utilizes direct
sales representatives, distributor relationships and contractual
relationships with buying groups and wound care service providers
to sell its products. Direct sales representatives are used solely
in support of advanced wound care sales in the U.S. and U.K. for
both advanced and traditional wound care products in Canada.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
The pharmaceutical wound care segment is presently limited to the
development of DSC127. All expenses associated with this activity
are being recorded as research and development expense.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
Each operating segment is managed at the segment contribution level
consisting of gross profit minus direct expense consisting of
distribution, marketing, sales and research and development
expenses. Expenses are allocated directly by segment to the extent
possible. Expenses common to all three operating segments are
allocated consistently using activity based assumptions. The
aggregation or allocation of indirect expenses by segment is not
practical.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
Operating segment sales, gross profit, segment contribution and
other related information for 2011 and 2010 are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;u&gt;Year
ended December 31, 2011&lt;/u&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-style: italic; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;
&lt;font style="font-weight: normal; font-style: normal"&gt;Advanced
Wound Care&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-style: italic; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-style: italic; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;
&lt;font style="font-weight: normal; font-style: normal"&gt;Traditional
Wound Care&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-style: italic; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-style: normal; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; font-style: normal; border-bottom: Black 1pt solid; text-align: center"&gt;
&lt;font style="font-style: normal"&gt;Pharmaceutical &lt;u style="text-decoration: none"&gt;Wound Care&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-style: normal; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-style: normal; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; font-style: normal; border-bottom: Black 1pt solid; text-align: center"&gt;
Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-style: normal; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt; &lt;u style="text-decoration: none"&gt;Company&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;Net
sales&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
15,927,920&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
46,702,327&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
62,630,247&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Gross profit&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;7,312,953&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;11,098,994&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;18,411,947&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Direct
expense&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(8,778,797&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(3,611,558&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(1,057,094&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(13,447,449&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Segment contribution&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(1,465,844&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
7,487,436&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(1,057,094&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;4,964,498&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Indirect expenses&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(9,304,909&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(9,304,909&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Net
loss&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(4,340,411&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;u&gt;Year
ended December 31, 2010&lt;/u&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;Net
sales&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
11,597,373&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
44,876,683&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
56,474,056&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Gross profit&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;4,689,410&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;11,837,922&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;16,527,332&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Direct
expense&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(6,649,457&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(3,651,508&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(292,660&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(10,593,625&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Segment contribution&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(1,960,047&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
8,186,414&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
($&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(292,660&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;5,933,707&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Indirect expenses&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(8,382,571&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
(8,382,571&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Net
loss&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(2,448,864&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
A geographical breakdown of the Company&amp;#x2019;s sales, gross profit
and equipment and improvements, net is as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
United States&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Canada&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;u&gt;2011&lt;/u&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: justify"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 44%; font-size: 10pt; text-align: left"&gt;Net
sales&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
41,502,059&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
15,387,066&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
5,741,122&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
62,630,247&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Gross profit&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;13,216,794&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2,772,647&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2,422,506&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;18,411,947&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Equipment and
improvements, net&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;292,914&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2,745,779&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;450,501&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;3,489,194&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-decoration: underline; text-align: left"&gt;
2010&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-decoration: underline; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Net sales&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;38,338,581&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;14,443,742&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;3,691,733&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;56,474,056&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Gross profit&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;11,765,478&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;3,393,376&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,368,478&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;16,527,332&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Equipment and
improvements, net&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;415,116&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2,642,165&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;550,961&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;3,608,242&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
For the years ended December 31, 2011 and 2010, the Company had a
major Canadian customer comprising 24% and 25% of consolidated net
sales, respectively. Due to outstanding rebate obligations, the
Company was in a net liability position to this customer at
December 31, 2011 (see Note 9 and 15).&lt;/p&gt;
&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">2717872</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0px"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Long-term Debt&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
All borrowings under the term debt agreements were fully repaid in
2011. During 2011 payments of $5,851 were made under capital lease
obligations. In 2010 payments of $3,500,000 were made under a term
note (fully repaid in February 2010 resulting in a $114, 072 loss
on debt extinguishment), $500,000 were made on a promissory note
and $59,185 were made on capital lease obligations.&lt;/p&gt;
&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0px"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Line of Credit Borrowings&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
On September 30, 2011, the Company terminated its five-year
revolving credit agreement with its lender. In connection with the
termination the Company recorded a loss on debt extinguishment of
$176,101, representing the then unamortized portion of deferred
financing costs of $112,336 and related fees of $63,765.&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">249542</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-4442820</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-4270873</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:Depreciation contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">991045</us-gaap:Depreciation>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-32863</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:InterestExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">263059</us-gaap:InterestExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">83108</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0px"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Subsequent Event&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
On March 27, 2012, the Company entered into a definitive agreement
to acquire the stock of Medefficiency, Inc.
(&amp;#x201C;Medefficiency&amp;#x201D;) for $14,500,000 in cash.
Medefficiency is a privately held company that sells a proprietary
line of total contact cast products for the treatment of diabetic
foot ulcers. Since 2008, the Company has been a distributor of
Medefficiency&amp;#x2019;s products. In 2011, the Company represented
approximately 25% of Medefficiency&amp;#x2019;s annual revenues of
$5,300,000. The acquisition is subject to customary closing
conditions and is anticipated to be completed by April 30,
2012.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">251654</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">20774</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Retirement Benefits&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company maintains a profit sharing/401(k) plan for eligible
full-time United States employees. Participants may contribute a
fixed percentage of their salary to the plan, subject to IRS
limitations. The Company makes a matching contribution of 50% on
the first 6% of each participant&amp;#x2019;s annual earnings
contributed to the plan. Company contributions to the plan for the
years ended December 31, 2011 and 2010 were $75,324 and $66,442,
respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The Company&amp;#x2019;s Canadian subsidiary maintains a group
retirement savings plan (Registered Retirement Savings Plan) for
eligible full time Canadian employees. The Canadian subsidiary
makes a matching contribution of 50% of an employee&amp;#x2019;s
contribution to a maximum of 3% of annual gross earnings. Employee
contribution limits to the group retirement savings plan are set by
the Canada Customs and Revenue Agency. The Company&amp;#x2019;s Canadian
subsidiary&amp;#x2019;s contributions to the plan for the year ended
December 31, 2011 and 2010 were $75,186 and $64,855,
respectively.&lt;/p&gt;
&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">5851</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-4340411</us-gaap:NetIncomeLoss>
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0px"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Accounts Receivable, net&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Accounts receivable, net include the following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt"&gt;
Accounts receivable&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
6,606,896&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
5,809,056&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Less:
&amp;#xA0;Allowance for doubtful accounts&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;(79,216&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;(89,736&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt"&gt;
Allowance for trade rebates&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;(128,875&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;(163,789&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt"&gt;
Allowance for cash discounts and returns&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(130,966&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(114,020&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt"&gt;
Accounts receivable, net&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
6,267,839&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
5,441,511&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-451842</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">1057094</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Principles of Consolidation&lt;/b&gt; &amp;#x2013; The consolidated
financial statements include the accounts of Derma Sciences, Inc.
and its wholly owned subsidiaries. All significant intercompany
accounts and transactions have been eliminated in
consolidation.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Use of Estimates&lt;/b&gt; &amp;#x2013; The preparation of consolidated
financial statements requires management to make estimates and
assumptions that affect the amounts reported in the financial
statements and accompanying notes. Although these estimates are
based on knowledge of current events and actions which may be
undertaken in the future, actual results may ultimately differ from
these estimates. Estimates and assumptions are required in the
determination of sales deductions for trade rebates, sales
incentives, discounts and allowances. Significant estimates and
assumptions are also required in determining the appropriateness of
amortization periods for identifiable intangible assets, the
potential impairment of goodwill and the valuation of
inventory.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Foreign Currency Translation&lt;/b&gt; &amp;#x2013; Assets and liabilities
are translated using the exchange rates in effect at the balance
sheet date, while income and expenses are translated using average
rates during the period. Translation adjustments are reported as a
component of shareholders&amp;#x2019; equity in accumulated other
comprehensive income. For the Company&amp;#x2019;s foreign subsidiaries,
exchange rate fluctuations on foreign currency denominated assets
and liabilities other than the functional currency resulted in
income of $133,681 and $159,949 for the years ended December 31,
2011 and 2010, respectively, which is included in the consolidated
statement of operations as follows:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt"&gt;Cost
of sales&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
(66,379&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
181,302&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;Other
expense (income), net&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(67,302&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(341,251&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(133,681&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(159,949&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Exchange rate fluctuations of foreign currency denominated assets
and liabilities associated with inventory are included in cost of
sales, while all other such fluctuations are included in other
expense (income), net.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Concentration of Credit Risk&lt;/b&gt; &amp;#x2013; Financial instruments
that subject the Company to a concentration of credit risk consist
principally of cash and cash equivalents and accounts receivable.
The Company maintains cash and cash equivalents with various
financial institutions in amounts which at times may exceed
federally insured limits. Accounts are guaranteed by the Federal
Deposit Insurance Corporation up to $250,000. The Company has not
experienced any losses in such accounts. The Company does not
require collateral or other security to support credit sales, but
provides an allowance for doubtful accounts based on historical
experience and specifically identified risks. Accounts receivable
are charged off against the allowance for doubtful accounts when
management determines that recovery is unlikely and the Company
ceases collection efforts.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Inventories&lt;/b&gt; &amp;#x2013; Inventories consist of raw materials,
packaging materials, work in process and finished goods valued at
the lower of cost or market. Cost is determined on the basis of the
first-in, first-out method.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Equipment and improvements&lt;/b&gt; &amp;#x2013; Equipment and
improvements are stated at cost and are depreciated on a
straight-line basis over the estimated useful lives of the assets
ranging from three to 10 years. Leasehold improvements are
amortized over the lesser of the useful lives or the remaining
lease term.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt; &amp;#x2013; The carrying
value of cash equivalents, accounts receivable, prepaid expenses
and other current assets and accounts payable reported in the
consolidated balance sheets equal or approximate fair value due to
their short term nature. Based on the terms of the Company&amp;#x2019;s
credit facility with its lender, the carrying value of the
borrowings that were outstanding at December 31, 2010 are
considered to approximate the respective fair value.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Identifiable Intangible Assets&lt;/b&gt; &amp;#x2013; Identifiable
intangible assets, which consist of customer lists, trademark and
trade names, non-compete and other agreements and certifications
and product designs, are amortized over four to 13 years on a
straight-line basis.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Long Lived Assets&lt;/b&gt; &amp;#x2013;The Company reviews its long-lived
assets with definitive lives whenever events or changes in
circumstances indicate that the carrying amount of such assets may
not be recoverable. If the carrying amount of the asset or group of
assets exceeds its net realizable value, the asset will be written
down to its fair value.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Goodwill&lt;/b&gt; &amp;#x2013; The Company tests goodwill for impairment
using a two-step process. The first step tests for potential
impairment, while the second step measures the amount of
impairment, if any. The Company uses a discounted cash flow
analysis to complete the first step in this process. If the first
step indicates an impairment, i.e. when the carrying value exceeds
the fair value, then the second step is required to determine the
implied fair value of goodwill. The implied fair value of goodwill
is calculated in the same manner that goodwill is calculated in a
business combination. The allocation is to be performed as if the
reporting unit had just been acquired and the fair value of the
unit was the purchase price. The goodwill impairment equals the
carrying value of goodwill less the implied fair value of goodwill.
The Company performs its goodwill impairment test as of December 31
of each year, or more frequently if impairment indicators are
present.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Stock-Based Compensation&lt;/b&gt; &amp;#x2013; Stock-based compensation
for new, modified and unvested share-based awards with employees
and non-employee directors, such as grants of stock options and
restricted stock, is recognized in the consolidated financial
statements based on the fair value of the award at the grant date
and is recognized on a straight-line basis over the requisite
service periods. The Company estimates the fair value of stock
options as of the date of grant using the Black-Scholes
option-pricing model for service and performance based awards. The
fair value of restricted stock is based on the quoted market price.
The Company issues new shares upon exercise of share-based
awards.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Income Taxes&lt;/b&gt; &amp;#x2013; Deferred tax assets and liabilities are
recognized for the future tax consequences attributable to
temporary differences between the financial statement carrying
amounts of existing assets and liabilities and the respective tax
bases. Deferred tax assets, including tax loss and credit
carryforwards, and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The
effect on deferred tax assets and liabilities of a change in tax
rates is recognized in income in the period that includes the
enactment date. Deferred income tax expense represents the change
during the period in the deferred tax assets and deferred tax
liabilities. The components of the deferred tax assets and
liabilities are individually classified as current and non-current
based on their characteristics. Deferred tax assets are reduced by
a valuation allowance when, in the opinion of management, it is
more likely than not that some portion or all of the deferred tax
assets will not be realized.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company measures and recognizes the tax implications of
positions taken or expected to be taken in its tax returns on an
ongoing basis. In 2011 and 2010, the Company had no unrecognized
tax benefits or liabilities, and no adjustment to its financial
position, results of operations or cash flows were required. The
Company records interest and penalties related to tax matters
within other expense on the accompanying Consolidated Statements of
Operations. These amounts are not material to the consolidated
financial statements for the periods presented. The Company&amp;#x2019;s
United States tax returns are subject to examination by federal and
state taxing authorities. Tax years prior to 2008 are no longer
subject to federal or state examination. Tax years prior to 2003
are no longer subject to examination in Canada. The United Kingdom
tax returns since the inception in 2010 of the subsidiary in this
country are subject to examination.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Revenue Recognition&lt;/b&gt; &amp;#x2013; Sales are recorded when product
is shipped or title passes to customers and collectability is
reasonably assured. Gross sales are adjusted for cash discounts,
returns and allowances, trade rebates, distribution fees (in
Canada) and other sales deductions in the same period that the
related sales are recorded. Freight costs billed to and reimbursed
by customers are recorded as a component of revenue. Freight costs
to ship product to customers are recorded as a component of cost of
sales.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Advertising and Promotion Costs&lt;/b&gt; &amp;#x2013; Advertising and
promotion costs are expensed as incurred and were $1,560,903 and
$1,197,309 in 2011 and 2010, respectively.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Royalties &amp;#x2013;&lt;/b&gt; The Company recognizes royalty expenses
associated with the products sold at the time the related sale
occurs and records them as a component of cost of sales. Royalty
expense for the years ended December 31, 2011 and 2010 was
$1,159,908 and $911,893, respectively.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Net Loss per Share&lt;/b&gt; &amp;#x2013; Net loss per common share &amp;#x2013;
basic is computed by dividing net loss by the weighted average
number of common shares outstanding for the period. Net loss per
common share &amp;#x2013; diluted reflects the potential dilution of
earnings by including the effects of the assumed exercise,
conversion or issuance of potentially issuable shares of common
stock (&amp;#x201C;potentially dilutive securities&amp;#x201D;), including
those attributable to stock options, warrants, convertible
preferred stock and restricted common stock in the weighted average
number of common shares outstanding for a period, if dilutive. The
effects of the assumed exercise of warrants and stock options are
determined using the treasury stock method. Potentially dilutive
securities have not been included in the computation of diluted
loss per share for the years ended December 31, 2011 and 2010 as
the effect would be anti-dilutive.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Potentially dilutive shares excluded as a result of the effects
being anti-dilutive are as follows:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;Year Ended December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Excluded dilutive
shares:&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.12in; WIDTH: 66%; FONT-SIZE: 10pt"&gt;
Preferred stock&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
73,332&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
284,844&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.12in; FONT-SIZE: 10pt"&gt;
Restricted common stock&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;51,500&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;20,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.12in; FONT-SIZE: 10pt"&gt;Stock
options&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;1,582,683&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;1,203,600&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.12in; FONT-SIZE: 10pt"&gt;
Warrants&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
3,065,702&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
1,734,531&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt"&gt;
Total dilutive shares&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
4,773,217&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
3,242,975&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0px"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Cash and Cash Equivalents and Investments&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company considers cash and cash equivalents as amounts on hand,
on deposit in financial institutions and highly liquid investments
purchased with an original maturity of three months or less. The
Company considers highly liquid investments purchased with an
original maturity greater than three months as investments.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Cash and cash equivalents and investments at December 31, 2011 and
2010 consisted of the following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt"&gt;
Cash&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
4,986,234&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
404,216&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Money market
accounts&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;2,706,863&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;Money
market mutual funds&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
9,417,253&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;Cash
and cash equivalents&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;17,110,350&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;404,216&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
Investments&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
5,474,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
Total cash and cash equivalents and investments&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
22,584,350&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
404,216&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company maintains cash with various domestic and foreign
financial institutions within the ordinary course of business,
which at times may exceed jurisdictional insurance limits. The
money market accounts are deposited in various U.S. financial
institutions and are fully insured by the Federal Deposit Insurance
Corporation. Cash equivalents consist of funds deposited into
mutual funds investing in U.S. government obligations that are
fully secured by the U.S. government. Investments consist of
certificates of deposits in various U.S. financial institutions and
are fully insured by the Federal Deposit Insurance Corporation. The
Company intends to hold its investments to maturity and accordingly
these investments are carried at amortized costs.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The following table provides fair value information as of December
31, 2011:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 90%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="14"&gt;Fair Value Measurements, Using&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2"&gt;Total carrying value as of December 31, 2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 34%; FONT-SIZE: 10pt"&gt;Cash
and cash equivalents&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
17,110,350&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
17,110,350&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
Investments&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
5,474,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
5,453,429&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
&amp;#xA0;Total&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
22,584,350&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
22,563,779&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Level 1 inputs are quoted prices (unadjusted) in active markets for
identical assets. Level 2 inputs are quoted prices for similar
assets in active markets or inputs that are observable for the
asset, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument. Level
3 inputs are unobservable inputs based on management&amp;#x2019;s own
assumptions used to measure assets at fair value. A financial
asset&amp;#x2019;s classification is determined based on the lowest
level input that is significant to the fair value measurement.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
  <us-gaap:InventoryWriteDown contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">1089608</us-gaap:InventoryWriteDown>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">1299675</us-gaap:StockOptionPlanExpense>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">26357075</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">978949</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NatureOfOperations contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;Description of Business&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Derma Sciences, Inc. and its subsidiaries (the
&amp;#x201C;Company&amp;#x201D;) is a medical technology company focused on
three segments of the wound care marketplace: pharmaceutical wound
care, advanced wound care and traditional wound care products. The
Company has one drug candidate that has completed a Phase 2 study
and is working towards initiating a Phase 3 study. The Company
markets its products principally through direct sales
representatives in the United States (&amp;#x201C;U.S.&amp;#x201D;), Canada
and the United Kingdom (&amp;#x201C;U.K.&amp;#x201D;), and through
independent distributors within other select international markets.
The Company&amp;#x2019;s U.S. distribution facilities are located in St.
Louis, Missouri and Houston, Texas. The Company utilizes third
party distributors for distribution in Canada, Europe and the Far
East. The Company also has manufacturing facilities in Toronto,
Canada and Nantong, China.&lt;/p&gt;
&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-176101</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">1568582</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">1000000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-3819031</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">37023</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">237095</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">62630247</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;Inventories&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Inventories include the following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt"&gt;
Finished goods&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
7,625,009&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
8,727,822&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Work in
process&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;664,272&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;598,486&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Packaging
materials&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;985,600&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;778,900&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;Raw
materials&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
1,255,840&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
2,393,311&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
Total inventory&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
10,530,721&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
12,498,519&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">26975194</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0px"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Equipment and Improvements, net&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Equipment and improvements, net include the following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt"&gt;
Machinery and equipment&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
6,522,941&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
5,981,946&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Furniture and
fixtures&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;682,545&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;648,460&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
Leasehold improvements&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
2,174,121&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
2,086,956&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;9,379,607&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;8,717,362&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
Less:&amp;#xA0;&amp;#xA0; accumulated depreciation&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(5,890,413&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(5,109,120&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
Total equipment and improvements, net&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
3,489,194&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
3,608,242&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">21173884</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">69538</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">16706134</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">402077</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">15754</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0; padding: 0; text-indent: 0"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; padding: 0; text-indent: 0"&gt;
&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding: 0; text-indent: 0"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
Loss before income taxes for the year ended December 31 consists of
the following components:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 66%; font-size: 10pt; text-align: justify"&gt;
Domestic&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
(3,483,103&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
(2,329,148&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;
Foreign&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(787,770&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
304,245&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Loss
before income taxes&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(4,270,873&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(2,024,903&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"&gt;
The components of income taxes (benefit) for the year ended
December 31 are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Current:&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Federal&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
State&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;_&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 66%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in"&gt;
Foreign&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 13%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(13,570&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 13%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
268,072&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in"&gt;
Total current&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(13,570&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
268,072&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Deferred:&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Federal&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;144,399&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;144,399&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
State&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;30,742&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;30,742&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in"&gt;
Foreign&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(92,033&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(19,252&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in"&gt;
Total deferred&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
83,108&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
155,889&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in"&gt;
Total income taxes&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
69,538&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
423,961&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The reconciliation of income tax computed at the United States
federal statutory tax rates to income tax expense along with
percentage of loss before income taxes for the year ended December
31, 2011 and 2010 is as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="14" style="font-size: 10pt; text-align: center"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 40%; font-size: 10pt; text-align: justify"&gt;Tax
benefit at federal statutory rate&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;
(1,452,097&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;
34.0&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;
(688,467&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;
34.0&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;State tax, net of
federal benefit&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(113,482&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2.7&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(84,530&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;4.2&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Nondeductible
expenses&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;370,516&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(8.7&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;168,389&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(8.3&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Other&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;68,865&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(1.6&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(1,383&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Change
in valuation allowance&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
1,195,736&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(28.0&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
1,029,952&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(50.8&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;
Income taxes&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
69,538&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(1.6&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
423,961&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(20.9&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
Significant components of the Company&amp;#x2019;s deferred tax assets
and liabilities are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
2010&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="font-size: 10pt; text-align: center"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Deferred tax
assets:&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 66%; font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Net operating loss carryforwards&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
4,812,975&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;
4,207,947&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;Equity
based compensation&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;312,675&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;236,232&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Allowance for sales deductions&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;134,826&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;144,931&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Amortization of identified intangibles&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,753,702&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,519,140&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Inventory adjustments&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;992,113&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;656,338&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in"&gt;
Other&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
169,198&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
178,599&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in"&gt;
Deferred tax assets&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
8,175,489&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
6,943,187&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;Deferred tax
liabilities:&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Prepaid expenses&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(81,800&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(22,226&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Goodwill&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(890,238&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(715,098&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.12in"&gt;
Depreciation&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(123,625&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(244,856&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in"&gt;
Other&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(576&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(626&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.24in"&gt;
Deferred tax liabilities&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(1,096,239&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(982,806&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in"&gt;
Valuation allowance&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(8,220,710&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;
(7,024,974&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: justify"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;Net
deferred tax liabilities&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(1,141,460&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;
(1,064,593&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The net deferred tax liability of $1,141,460 consists of a deferred
tax asset of $4,587 and a net deferred tax liability of $1,146,047
as of December 31, 2011. The net deferred tax liability consists of
a deferred tax liability of $890,238 related to the differences in
the basis of goodwill for financial reporting and tax purposes
coupled with a $251,222 net deferred tax liability ($255,809
deferred tax liability and a deferred tax asset of $4,587) related
to the Company&amp;#x2019;s Canadian operations. The deferred tax asset
is included in prepaid expenses and other current assets in the
Consolidated Balance Sheet.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
The amount by which the Company can utilize its United States
federal net operating loss carryforwards in any year or in total
may be limited under the Internal Revenue Code Section 382
regarding changes in ownership of corporations. Due to
uncertainties surrounding the Company&amp;#x2019;s ability to use its
net operating loss carryforwards and to realize the other net
deferred tax assets, a full valuation allowance has been provided
as of December 31, 2011 and 2010 for the deferred tax assets for
the United States and United Kingdom.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;
At December 31, 2011, the Company has net operating loss
carryforwards of approximately $12,603,000 for United States
federal income tax purposes that begin to expire in 2012. For state
income tax purposes, the Company has net operating loss
carryforwards in a number of jurisdictions in varying amounts and
with varying expiration dates.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">244682</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">292004</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OperatingExpenses contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">22230978</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">-3075555</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;Identifiable Intangible Assets, net&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Identifiable intangible assets, net include the following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 62%; FONT-SIZE: 10pt"&gt;
Medihoney license rights&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%; FONT-SIZE: 10pt"&gt;
5,667,126&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%; FONT-SIZE: 10pt"&gt;
4,667,126&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;Other
identifiable intangible assets&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
3,300,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
7,500,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;8,967,126&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;12,167,126&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;Less
accumulated amortization&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(2,564,082&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
(5,195,500&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
Total identifiable intangible assets, net&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
6,403,044&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
6,971,626&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
In connection with the acquisition of the Medihoney worldwide
license rights (note 15) the Company capitalized the consideration
paid as an identifiable intangible asset. The cost will be
amortized over 10 years, and the expense is included as a component
of cost of sales in the Consolidated Statement of Operations.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Other identifiable intangible assets result from acquisitions
completed in 2006 and 2007 and consist of the following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt"&gt;
Amortization Period&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 62%; FONT-SIZE: 10pt"&gt;
Customer list&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%; FONT-SIZE: 10pt"&gt;
1,500,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 15%; FONT-SIZE: 10pt"&gt;10
years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Trademarks and
trade names&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;1,600,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-SIZE: 10pt"&gt;10-13 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
Certification and product designs&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
200,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;5
years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
3,300,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
In 2011, $4,200,000 of fully amortized identifiable intangible
assets were written-off.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Amortization expense of the other identifiable intangible assets is
included in selling, general and administrative expenses in the
Consolidated Statement of Operations. The weighted average useful
life of identifiable intangible assets as of December 31, 2011 and
2010 is 7.0 and 3.9 years, respectively. Amortization expense for
2011 and 2010 and estimated amounts thereafter by year is as
follows:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 90%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;Medihoney License Rights&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;Other Identifiable &lt;u style="TEXT-DECORATION: none"&gt;&lt;br /&gt;
Intangible Assets&lt;/u&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 58%; FONT-SIZE: 10pt"&gt;
Amortization expense for&amp;#xA0; year ended December 31, 2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 2%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"&gt;
519,200&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 2%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"&gt;
1,049,382&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 2%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"&gt;
1,568,582&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Amortization
expense for&amp;#xA0; year ended December 31, 2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
375,750&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
1,314,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
1,689,750&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Estimated
amortization expense for&amp;#xA0; years ending December 31,&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt"&gt;
2012&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;584,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;323,993&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;908,293&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt"&gt;
2013&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;584,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;285,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;869,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt"&gt;
2014&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;584,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;285,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;869,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt"&gt;
2015&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;584,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;285,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;869,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt"&gt;
2016&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;584,300&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;136,250&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;720,550&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt"&gt;
Thereafter&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
1,850,676&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
315,625&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
2,166,301&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
4,772,176&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
1,630,868&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
6,403,044&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">334772</us-gaap:RestrictedStockExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">23893788</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">77781</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">641</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
  <dsci:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">366465</dsci:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <dsci:LossOnEarlyDebtExtinguishment contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">112336</dsci:LossOnEarlyDebtExtinguishment>
  <dsci:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="shares" decimals="0">8780981</dsci:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <dsci:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0">&lt;div&gt;
&lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px"&gt;
&lt;b&gt;Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Accrued expenses and other current liabilities include the
following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt"&gt;
Accrued Canadian sales rebate, net (see note 15)&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
316,280&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt"&gt;
409,842&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Accrued
compensation and related taxes&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;575,710&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;265,334&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Accrued sales
incentives and other fees&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;416,215&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;461,944&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;Accrued
royalties&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;425,796&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;220,232&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
Other&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
643,633&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
793,269&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt"&gt;
Total accrued expenses and other current liabilities&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
2,377,634&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"&gt;
2,150,621&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
At December 31, 2011 and 2010, the amount of the Canadian accrued
sales rebate and other reserves exceeded the amount of the
underlying trade receivables outstanding. The net credit balance in
trade receivables was reclassified for financial reporting purposes
to accrued expense to recognize it as a net liability.&lt;/p&gt;
&lt;/div&gt;</dsci:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
  <dsci:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">490980</dsci:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings>
  <dsci:StockIssuedIssuanceCosts contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0" unitRef="iso4217_USD" decimals="0">68204</dsci:StockIssuedIssuanceCosts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="0">-4340411</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x443982" unitRef="iso4217_USD" decimals="0">-102409</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">78501</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="0">785</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="0">2115</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="0">35242</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">3524239</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">211512</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <dsci:VestingOfIssuedRestrictedStockValue contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="0">210</dsci:VestingOfIssuedRestrictedStockValue>
  <dsci:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="0">1793</dsci:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <dsci:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">179304</dsci:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <dsci:VestingOfIssuedRestrictedStock contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">21000</dsci:VestingOfIssuedRestrictedStock>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444874" unitRef="iso4217_USD" decimals="0">-2115</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444874" unitRef="shares" decimals="INF">-211512</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="0">1634447</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="0">250869</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="0">26321833</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <dsci:VestingOfIssuedRestrictedStockValue contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="0">-210</dsci:VestingOfIssuedRestrictedStockValue>
  <dsci:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="0">364672</dsci:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <context id="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x443982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20111231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x443982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_365_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x443982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20111231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x443982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x443982">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20091231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE6794----1110-K0010_STD_0_20120326_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000892160</identifier>
    </entity>
    <period>
      <instant>2012-03-26</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>dsci-20111231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: d4fdb515-66c0-4e66-810e-576ef111c697 -->
<!-- Creation date: 2012-03-27T22:03:44Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
  xmlns:us-types="http://fasb.org/us-types/2011-01-31"
  xmlns:dsci="http://www.dermasciences.com/20111231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
  targetNamespace="http://www.dermasciences.com/20111231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations" id="Role_NotesToFinancialStatementsNatureOfOperations">
        <link:definition>109 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock" id="Role_NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock">
        <link:definition>111 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Accounts Receivable, net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>113 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>114 - Disclosure - Equipment and Improvements, net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
        <link:definition>115 - Disclosure - Identifiable Intangible Assets, net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>116 - Disclosure - Line of Credit Borrowings</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
        <link:definition>117 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock" id="Role_NotesToFinancialStatementsLongTermDebtTextBlock">
        <link:definition>118 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>119 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" id="Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
        <link:definition>120 - Disclosure - Operating Segments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>121 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>122 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
        <link:definition>123 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>124 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="dsci-20111231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="dsci-20111231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="dsci-20111231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="dsci-20111231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <element name="AccruedExpensesAndOtherCurrentLiabilities" id="dsci_AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashPaidDuringPeriodForAbstract" id="dsci_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentDocumentandEntityInformationAbstract" id="dsci_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockAndWarrantsShares" id="dsci_IssuanceOfCommonStockAndWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockAndWarrantsValue" id="dsci_IssuanceOfCommonStockAndWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" id="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LossOnEarlyDebtExtinguishment" id="dsci_LossOnEarlyDebtExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesToFinancialStatementsAbstract" id="dsci_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockLiquidationPreferenceValue" id="dsci_PreferredStockLiquidationPreferenceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueStockWarrantsExercised" id="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedIssuanceCosts" id="dsci_StockIssuedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalGrossCashPaidForAcquisition" id="dsci_SupplementalGrossCashPaidForAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VestingOfIssuedRestrictedStock" id="dsci_VestingOfIssuedRestrictedStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VestingOfIssuedRestrictedStockValue" id="dsci_VestingOfIssuedRestrictedStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dsci-20111231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: d4fdb515-66c0-4e66-810e-576ef111c697 -->
<!-- Creation date: 2012-03-27T22:03:44Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfIncome" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsSold" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_LossOnEarlyDebtExtinguishment" xlink:label="dsci_LossOnEarlyDebtExtinguishment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_SupplementalGrossCashPaidForAcquisition" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1.2800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.2400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dsci_LossOnEarlyDebtExtinguishment" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RestrictedStockExpense" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dsci_SupplementalGrossCashPaidForAcquisition" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="1.3300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dsci_SupplementalGrossCashPaidForAcquisition" xlink:to="us-gaap_StockIssued1" order="1.3400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>dsci-20111231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: d4fdb515-66c0-4e66-810e-576ef111c697 -->
<!-- Creation date: 2012-03-27T22:03:44Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfIncome" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_PreferredStockLiquidationPreferenceValue" xlink:label="dsci_PreferredStockLiquidationPreferenceValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_PreferredStockLiquidationPreferenceValue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsSold" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfCommonStockAndWarrantsShares" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsShares"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfCommonStockAndWarrantsValue" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_VestingOfIssuedRestrictedStock" xlink:label="dsci_VestingOfIssuedRestrictedStock"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_VestingOfIssuedRestrictedStockValue" xlink:label="dsci_VestingOfIssuedRestrictedStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_IssuanceOfCommonStockAndWarrantsShares" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_IssuanceOfCommonStockAndWarrantsValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_VestingOfIssuedRestrictedStock" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_VestingOfIssuedRestrictedStockValue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedIssuanceCosts" xlink:label="dsci_StockIssuedIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_StockIssuedIssuanceCosts" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_CashPaidDuringPeriodForAbstract" xlink:label="dsci_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" xlink:label="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_LossOnEarlyDebtExtinguishment" xlink:label="dsci_LossOnEarlyDebtExtinguishment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_SupplementalGrossCashPaidForAcquisition" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dsci_LossOnEarlyDebtExtinguishment" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RestrictedStockExpense" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsci_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsci_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_CashPaidDuringPeriodForAbstract" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dsci_SupplementalGrossCashPaidForAcquisition" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>dsci-20111231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: d4fdb515-66c0-4e66-810e-576ef111c697 -->
<!-- Creation date: 2012-03-27T22:03:44Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedTotal" roleURI="http://xbrl.us/us-gaap/role/label/negatedTotal"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also included are current obligations not separately disclosed in the balance sheet due to materiality considerations. Accrued expenses and other current liabilities are expected to be paid within one year (or the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income - cumulative translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Stock issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization Of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization Of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of identifiable intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">End of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US">Cash Cash Equivalents And Short Term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents and Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_CashPaidDuringPeriodForAbstract" xlink:label="dsci_CashPaidDuringPeriodForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_CashPaidDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_CashPaidDuringPeriodForAbstract" xlink:to="dsci_CashPaidDuringPeriodForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments (Note 15)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.01 par value; 18,750,000 shares authorized; issued and outstanding 10,577,632 at December 31, 2011 and 6,563,076 at December 31, 2010</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost Of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Line of Credit Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US">Deferred Tax Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of equipment and improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_DocumentDocumentandEntityInformationAbstract" xlink:label="dsci_DocumentDocumentandEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document Documentand Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_DocumentDocumentandEntityInformationAbstract" xlink:to="dsci_DocumentDocumentandEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share - basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect Of Exchange Rate On Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain Loss On Sale Of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gains Losses On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase Decrease In Inventories</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Increase Decrease In Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Identifiable Intangible Assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets Net Excluding Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Identifiable intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write Down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Provision for inventory obsolescence</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfCommonStockAndWarrantsShares" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants for license rights (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_IssuanceOfCommonStockAndWarrantsShares" xlink:to="dsci_IssuanceOfCommonStockAndWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfCommonStockAndWarrantsValue" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsValue_lbl" xml:lang="en-US">Value of issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsValue_lbl" xml:lang="en-US">Issuance of common stock and warrants for license rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_IssuanceOfCommonStockAndWarrantsValue" xlink:to="dsci_IssuanceOfCommonStockAndWarrantsValue_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" xlink:label="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings_lbl" xml:lang="en-US">Issuance of warrants and stock options in connection with equity offerings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings_lbl" xml:lang="en-US">Issuance Of Equity Warrants In Connection With Equity Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings_lbl" xml:lang="en-US">Issuance of warrants and stock options for payment of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" xlink:to="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Lines Of Credit Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Line of credit borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans Notes Trade And Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Long Term Debt Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current maturities of long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_LossOnEarlyDebtExtinguishment" xlink:label="dsci_LossOnEarlyDebtExtinguishment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_LossOnEarlyDebtExtinguishment_lbl" xml:lang="en-US">Noncash unamortized portion of deferred financing costs related to the debt represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_LossOnEarlyDebtExtinguishment_lbl" xml:lang="en-US">Loss On Early Debt Extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_LossOnEarlyDebtExtinguishment_lbl" xml:lang="en-US">Non-cash portion of loss on debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_LossOnEarlyDebtExtinguishment" xlink:to="dsci_LossOnEarlyDebtExtinguishment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Noncash Or Part Noncash Acquisition Intangible Assets Acquired 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Purchase of license rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negatedTotal" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other expense, net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes To Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="dsci_NotesToFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl" xml:lang="en-US">Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other Noncash Income Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Allowance for sales adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US">Other Operating Activities Cash Flow Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US">Deferred rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Paid In Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Interest charge for stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments To Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of license rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Payments To Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment and improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_PreferredStockLiquidationPreferenceValue" xlink:label="dsci_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">The aggregate liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred Stock Liquidation Preference Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Convertible preferred stock, liquidation preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_PreferredStockLiquidationPreferenceValue" xlink:to="dsci_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Convertible preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $.01 par value; 1,468,750 shares authorized; issued and outstanding 73,332 at December 31, 2011 and 284,844 at December 31, 2010 (liquidation preference of $3,222,368 at December 31, 2011)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Proceeds From Repayments Of Lines Of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Net change in borrowings under line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities_lbl" xml:lang="en-US">Proceeds From Repayments Of Restricted Cash Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities_lbl" xml:lang="en-US">Change in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Equipment and Improvements, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment and improvements, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision For Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for bad debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Long-term debt repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted Stock Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Compensation charge for restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Sales Revenue Goods Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ending Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued 1</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Preferred stock conversion (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Number of shares issued during the period as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants, net of costs of $68,204 (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period Value Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Preferred stock conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Value stock issued during the period as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants, net of costs of $68,204</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedIssuanceCosts" xlink:label="dsci_StockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_StockIssuedIssuanceCosts_lbl" xml:lang="en-US">Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_StockIssuedIssuanceCosts_lbl" xml:lang="en-US">Stock Issued Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_StockIssuedIssuanceCosts_lbl" xml:lang="en-US">Exercise of warrants, costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_StockIssuedIssuanceCosts" xlink:to="dsci_StockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock Option Plan Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Compensation charge for employee stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_SupplementalGrossCashPaidForAcquisition" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition_lbl" xml:lang="en-US">Supplemental - Gross cash paid for acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition_lbl" xml:lang="en-US">Supplemental Gross Cash Paid For Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition_lbl" xml:lang="en-US">Cash paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_SupplementalGrossCashPaidForAcquisition" xlink:to="dsci_SupplementalGrossCashPaidForAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_VestingOfIssuedRestrictedStock" xlink:label="dsci_VestingOfIssuedRestrictedStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_VestingOfIssuedRestrictedStock_lbl" xml:lang="en-US">Number of shares issued during the period as a result of the vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_VestingOfIssuedRestrictedStock_lbl" xml:lang="en-US">Vesting Of Issued Restricted Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_VestingOfIssuedRestrictedStock_lbl" xml:lang="en-US">Vesting of restricted stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_VestingOfIssuedRestrictedStock" xlink:to="dsci_VestingOfIssuedRestrictedStock_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_VestingOfIssuedRestrictedStockValue" xlink:label="dsci_VestingOfIssuedRestrictedStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_VestingOfIssuedRestrictedStockValue_lbl" xml:lang="en-US">Vesting of Issued Restricted Stock, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_VestingOfIssuedRestrictedStockValue_lbl" xml:lang="en-US">Vesting Of Issued Restricted Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_VestingOfIssuedRestrictedStockValue_lbl" xml:lang="en-US">Vesting of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_VestingOfIssuedRestrictedStockValue" xlink:to="dsci_VestingOfIssuedRestrictedStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number Basic Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Shares used in computing loss per common share - basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>dsci-20111231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: d4fdb515-66c0-4e66-810e-576ef111c697 -->
<!-- Creation date: 2012-03-27T22:03:44Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfIncome" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="dsci-20111231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_DocumentDocumentandEntityInformationAbstract" xlink:label="dsci_DocumentDocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_DocumentDocumentandEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_PreferredStockLiquidationPreferenceValue" xlink:label="dsci_PreferredStockLiquidationPreferenceValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_PreferredStockLiquidationPreferenceValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1600" preferredLabel="http://xbrl.us/us-gaap/role/label/negatedTotal" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsSold" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfCommonStockAndWarrantsShares" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsShares"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfCommonStockAndWarrantsValue" xlink:label="dsci_IssuanceOfCommonStockAndWarrantsValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_VestingOfIssuedRestrictedStock" xlink:label="dsci_VestingOfIssuedRestrictedStock"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_VestingOfIssuedRestrictedStockValue" xlink:label="dsci_VestingOfIssuedRestrictedStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_IssuanceOfCommonStockAndWarrantsShares" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_IssuanceOfCommonStockAndWarrantsValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_VestingOfIssuedRestrictedStock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_VestingOfIssuedRestrictedStockValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_StockIssuedIssuanceCosts" xlink:label="dsci_StockIssuedIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_StockIssuedIssuanceCosts" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_CashPaidDuringPeriodForAbstract" xlink:label="dsci_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" xlink:label="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_LossOnEarlyDebtExtinguishment" xlink:label="dsci_LossOnEarlyDebtExtinguishment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_SupplementalGrossCashPaidForAcquisition" xlink:label="dsci_SupplementalGrossCashPaidForAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dsci_LossOnEarlyDebtExtinguishment" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.2800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.3000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RestrictedStockExpense" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1.1700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.0600" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.0700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_CashPaidDuringPeriodForAbstract" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" order="1.0300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dsci_SupplementalGrossCashPaidForAcquisition" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="dsci-20111231.xsd#dsci_NotesToFinancialStatementsAbstract" xlink:label="dsci_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsci_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001144204-12-017767-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-017767-xbrl.zip
M4$L#!!0````(`+.)?$!:8C<*8)```'TQ!@`1`!P`9'-C:2TR,#$Q,3(S,2YX
M;6Q55`D``P)_<T\"?W-/=7@+``$$)0X```0Y`0``[%WK<YM(MO_N*O\/7-_L
MU$R5)'<W;V<R6XX?<[U);*^=G<S>+RD,+8L=!+J`;&O^^GNZ05+S$`))8#N3
M5"6Q1=/].Z?/^S3HY[\_C3WI@8:1&_CO#O``'4C4MP/']>_?'4RCOA79KGL@
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M/.17YT/=*%`(UJO`)",6<T=NV<PP%!_^_NGCK3VB8ZN?I\"&#8K#V>).OD1$
M[<%]\'"87CQD[.PCW)?Q_#:'NN6WP(6RX2"N&7`.#<=,AD&H:<3EB=V$R?(6
MUW^@45R^2'*M9!T_\/WIN)QG3AP>QK,)/81!?1A%0]=>W+?^INP-H(+WEC59
MW#2THCM^0WJA!!M<83-%I??P*R4W,2!.CM7IKFJ'R<7,T+ATJ)H,C0]`T"6)
MB[IW%'&!N*%#B<O=$8/P[B!RQQ./20?_S`KM,/!H/0GG=XQ".GQWP/:[/]_1
MP5/D;*``]77K,"$+1._HS(_=>'82C,>!?QL']A^W(RNDT=4TYJ82S*=D!WY,
MG^(;AI,&WM?K,TTWE3[\`;BH_P'T!7V]_7SZ%7UEA@?)1/L*YG?JN\D]$9_Q
M0'*H[8XM#_;SXO+\X!>,-!D9FOKS83T<><S7TSO/M<^]P(H;0N0K9R"FEN'K
MOVY/19SHX!=5Q4175%-$*:R<@$IE^.C$BD;'OL/^._N_J?M@>>`HHN/XQ`K#
M&9#PF^5-:3.PR&0241,L4625*#\?-L*3)8'S?A1X8&\B=D\\:Q,O&XL16B(N
M+M\.O*^*2DRD/BD*,DD]L'V"945'*GE.M+)ID%IHL0QZ:,H-L&ZG]T6HBFK@
M]59`1;*I:(:`LUSOVV-I#F>%*0"HZG,RU-"5]0PEAHI4_)S\S,*LT'XC@[-K
M75)ES31J`54P(5C##93I*A[1\#B*:!Q=!KX]#4,PO`V]%&I@2&6L&<Q'5:Z?
MA?C1M>Y<SXU=&IVTCL\$]BN&L-O%U;/H;FAL01;BG%FA#S(;'=N0=4T]R&Z<
M4SIT;;=-M'TBZZ9J8FV)=SV>+/[KD$XLUSE[FE`_HN"#A1UIG]T:"+LFQ`$U
MT&3A`WDLDXENJ$TA;+CSZ"6-V\>M*@I6L2`F53ARB#DQ;:J89H*]T`0CD"R9
MBP"7`>P&P5ZS358U66!5?N4LK@M(`/TX"&?`OQ8Q8:*88-4%2R0N7&25&X]Y
M1`HQ*F`"Q8+T%DS";A%"GG_DNY`9Q>%TF?R4\&W;U*>(8X6/9EN'=*UT\];X
M:U#E(07Y=X3!Q]-X%(3NG]1I"S"&$$U74<:B5,`H4\WVK0<V3%56,,IK:*F]
M^#4(G$?7\UK$HV-LZD38Y?F:);&"X`\["1@(QJKHCU>#6"]^'2@,,11#4:K%
M;Z7*M)"5-^*U@N""ME56+MB':RN\"F]C%GGP@=<TY/3ODH"O$QI^+6X%.?@%
M#5"YSUD%*V<*',=E=6K+NX9XY,(_L29N;+6IA(IA0"*<,0KE&+)`3U/Y^FP]
M=:V:&&D&,H2,>!V6?%SO@RX,3^`&MX.0#?R8"G_$R+ZX_LK,`]1@V[QNRR!N
M'9CUYN\BBJ;M>=XZEB]!4(6T;1/'4*["V$*1L1DV#?1);Y*]%Z*Q=K=X?32X
M?H-?DE>HARQ/30"SQ[-KS_)C4$2V+1.6&[2;K\@:,HA"1.RK<>2L6.#??Z;A
M^)3>=9$99VIE)6NOD>`.4@26(""QEE\!8J5#:-6O$L/$8A(CK%M>_KBV9JSF
MT($7U75=495BX2.+H(!R7H/BX3OP>Q+2$?4C]X%>^'8PIA^#*#H/0NK>^\D4
M]NQS:/F1QT\+'#O_F49Q*MU70X@OVF2_AA1301D2=PT_7_.`=.#>!?:EE5`:
MGSW9WI1E"!VD?YJI8TU,_^K@29N<D>TR_H1@]=.B732OVJ6BT(W.$-`7C8#E
M:8:H'6^_4<^N4,EMN\]01%N_9Y=7D7HMIFVBDZ;MND*LLCI`V3TC:W?J<J71
M3ME8LTF7C>H[Y6+]_IP8U'>N-PWZ<X4<OXO^'&Y4%P<;D"^WM=R?:X)/@P!$
M(_HS]N>:H.T3`\N:+.)]_OY<$P((,DULZIF4Z=D:=(WDA&BZ(9O%.+6E!ET3
M;*JA$=DPA62NA09=(Z5'JKXBK=]MAZXA*'#@HBWJHD.W!F%G';HBCI6'$]G>
MR:0BF^VF15<?\7.UZ)I(GP)C98STO([NLD77!$_7+;I&3D(EFJ'D8H;.6W2U
MY4^799E42U^G';I&1A'D`,FB\KR('ETE"2^\1]=("W595S+Q\7/TZ!H)#%A;
MI`AFK&&/+JW?7O#',KB#;=.0*&:F+ENR>JL-NNV"N&=JT.W2[K73GVND8;*\
M"F(;[;E&.XX,15=EI7[ROIOVW"Y#P=+"#01:<7=*KA*B9K2\;/T..H@[\5G/
MW$%LPG=9,2"5SS3HZW80=]>DJR_+S]&D:Q8*@*JI1JGY;Z%'UVBG3?9'+M8^
M7G:/KE%8HR*BRMGSUZ^N1]>HGJ4@&8F%^(8]NJRA^NB"KCN<[N0">UBW;=<N
M$T)D]@!5(T`=]!D;A:BL_LQB@&?M,^(M^HR%BG3K_9("VOI]QKR:M]@@*Z"L
MUV<L!ETMMLC68:Q?XNV4D;4ZC;GTI%,NUFTT9K*3SO6F?I^Q6*=8!_;7$+PC
M1(3#)OTP65.;'ZY1B9[9:&'E$OXE`H!;Q404K&.25XYTY7S):1XE1)^#%;4?
M+KG\E2LL"`''P-W:#06N1VY,;VGXX-HL-W`#YX;:P;W/9VGH?C>@4S,,4Q>/
M;K5,3#Z`LD,*$YW2Y/\+/_6>V;H)=Z!7$_8N&XAD-G+J35F3F!]-R7C%;>&6
MU.47PX[MV'U(6M96-#KW@D>>-(X;I04;48D1Y%4D5ZJO@RM+#FN=P@C0V@?7
MH<[[V;]`0"[\)('/3-2J0$,P8RBFV.6M#ZQD?RX#/YBS(DD9TL"N52)D!64>
MNJF&4D.G<FWN=DTG^"BBR&O4)H<H7UR((-]B*4MT"_ZI75Z;IJ+IF1>/9%<O
ML!<X#ZD@C9A1;!6:KH,/RO!17+I$6DLRW++LUK)Y=NL[E;EN8L#SF]?N7B"L
MB8V)KHC:P*$OPP'V+WO'%A.;=FT;S*"HXK&V;9#6LMXE;J!EZVUB(G;8Z^,J
ME"?S0M.\!+41`5C1X5*F1KD*29EEX16I,!@G!U:F0&)*:^!'[^D0!%\P`Y]<
M/P@A;K\`@B`S8A7;["Q)6/^)QB,F]!N4\C=B`6)-.SEON#JA+-]D!=;;;O)V
MP39I-DR5B.^L$!?.)566ZS,:KOQ;RZ-7PTS%?5%N;W>#-$TL4M=#5*A\\FWI
M(AA2#:21C!O,K%W>5E^(4CKJ/?5IZWFLJD(V56RKK\"R,K,]G8:@'(FGXDD3
MOW8UX9IR]D1#VXV:5&`V2LF)GC\^W01<H;OUX+)WAH+?/@VF=_%PZLU#P';)
M,)5,8VXUC/P!X8DUX_;D:B@^KM8J6`6I)C:$AY%7H2AX[J5E;-FP*XIAB&8N
MLW8.UK,D3GU95111<FLF3>SUL%9HLU-3I_2!>@&W>5T@)B;1-"1N>@62`HMM
MB(VNPFLKC--?CNVD"@-2GN\&\4MAJX4S7D]0-"U;.ML4YXHCQE\@+J"GP6.[
M'IWHIJ&5'31>+%]BOQ,SR!QG%Z*C85;3S5GI`H3Z;N:2/O(K[5H1T$]%*;R'
M<AVDG$-)[2(D/8FPK#RWT.X&R-E*4WU8Q9@P8B:40A!V]L1L%2C'B`V\&K;N
M=V`*!>DD&Q!6PLFER^,@C-T_>:Q[-<QK<\MABF%FCHU78UDC1)U"3TX\H0KA
MJ49_E?5J[3M_K.E((4)X4H*@O(#*['V'(8""53'Y7(FB$*/:E#H\MQ0#+_#'
M<>C:,>7'J<]=W_+M[NHA['W4N9<A;@BS;I$X/0_4;IE/,S)EK+5H<CX,TM3H
M!H(C?TIYE;;1(;E-,E`-?!92Q6Y@"835\C2ONUT-A0-K+3M9$^DR*I>;4C@Y
M%E//8X>&(%,-+0\\U[$S=GT79`PT_J$3/<:ZB50D/F=8#]2*<GV'=0"%R&8V
M=*R1_Y<_L_$,-7BL(4T\PMX$V#HCDSXI.B^,E#XQVBYQH!AR94>W#L0LF6?#
M(;4A,CI[LD?@L.F-%=,KOYQM[1*'9,,0=+X)L/+R7NL=+D4'#X>+M;UB?ZNX
M4_.,K&T?S-J9&*E50B-`61&ES8\#MHO4P*:NJWI)C#9?OU[0DWD-7KLM3K`U
MBKD^OLD@*M1NTM"'.[).,F^#:)GG]\L0U&JP=1U0RD0FIEC]KX^K*NM;#.^B
M"8H4D8`J(/F$C[5%/[BLE928F98K>WHFO<LOOLZ^Y<[AM.\<^S)&IE)IZ,HP
MY;QA^@Z+^7,N[ZW(M5DQT_6F\:Z[%JL?R>FC@5B968-*.%!^.YU,/'Z\R?+X
M,42N';!YYT$H%"V[J0TT02304!K@`[5?K#"TP)RV?ZQP<7RR/AX!?]*-A#WS
M9JS<E"U!M6Q<DE+8>A@"W"^4?<<<=8X?0"_NZ>5T?$=#+F&I>&WQ&/M*&HI2
MSPN2LJJ;\\<IFN,JE:&DTS[?JPO_)/!]R@_;?''C47+U"D)-5KIMV?03O'S.
M8D.`+33/-GKDHD$K[:4?[=K@(8Z7<=!K1><A48N=-MT;?[&4AO(']1OA?*:S
M!9M\+U7^2ZDV/V90=3O8A/3[59D38C_'K+)^2VT8N4W4O0')^>=%-H7<86=O
MDZ>+,*Y[A&1%EZ]2[-LC:=5#78R>PK?]K877@*3N9735"QY1OJN\,>2NHM(-
M!%19AMA-`]1UXQ/F=+5=C)#:I"307I;AK/NH7;]3R]F=4M9Z%K*_<ZU\Z0^P
M;?"0X_,^SM9]G%6?,U@CI*;Z;!EJ[<XS-WB)KL*>7\^_AJ=>N-&A<ZI/$%&P
MO%D!A;I'IX$]93)_[D8V"#NG_!P^:[XC\]<@_'+^[^0[I%=.O5P]^9KIWP)O
MZL=6.#MW/;!%FZ]\&8C?7IV;=KDJ)(.L@G$[&]\%#5ZZD5_M]/;D(EDO,V&>
MNAMZS_O.D&]:X^9RL5SN[.;3L01KGEV>G-WVI(O+DX%(;G:=/(KTG1(W=,)*
MX(`UMN)M-OG?-,I\GWGI]$L0QR`(#A<&SVI>TEJL.@29I\FZF1GSU/(=/[%B
M>A^$#1Z;SR]W"SH&$TD+LB1F]BU_)I*>66N58OV;6N&6:L5^+E.LQ=3%M3_/
M)EL('+N879#-5UPET>PSWSD%)FQ'7Q^3OIRC,C-]0:QA0&AY%[Y#GS[0+;::
MA<6&23`[7[UR^OSJ7ZCG??"#1_^66E'@)T_-@;SLR("MF'Z)(M6ZI1QLO0E]
M<0=63;^[5S\T>F>3H6!LBI7`E:]^>'%1:B,Z-1GB?/U9`]/,FSXN@YB>@@QX
M030-Z6>@^[VWR:&TA9#]X,5O'??AA_OX[?X>^R5.CA&"N$\LAWE2Q@C^>S2Q
M[/GO43SSZ+N#1]>)1T<21NAO;Z4A8&`_3V+ILSN&.!("-NDF&%M^+_F@)P'M
M[O"M-+;">]?OQ\'D2(+ABP_N@C@.QORS`P%1.%^.9T0@_WW+<^_](PDF$,<Y
M.5B(7V27#F.G:MQ`=?VW$F/@?&:/#N/%W7?L!XP'?*:[%7-F!G,12#?N!VL\
M>?O?3\!T\ZV4[&+%1(=Q*/["-F/Y^V0.O"FK.4LEM()&F#S!>(P20),VETP_
M<<&.LQDY\X5=Y&Q9O%%,XBJ0X]>SP7L97/H\HB&5V%LRL=%334-**@]2,)0B
MRH]5'3-[,"\?2),%,R/&S/V]0.AH6K%T2FW*6HR2C'L2LPT#"998SI6[7W*C
M_3UQ?M>/`UB0)3CI"/C!@G]H?QB$??A?`FOH`NEWX+<BR0_V]\#DN$"9TY-&
M5@2#O>5+X]+UV%OC&$EO9#)`2)H`/DYG3WH`&P@0^'VV9T416V]LQ3'+5RQ^
M>(Y1%E?1`-3O[[&E83(V.&0MUTABF+B%`=/")RB0Y7E2P)I>^WOIBH/O(BF*
MI*KT=%DIBN3['8KD^^<62<786B2+-'P7R79\25)ZZ=Z1O"QV7/C2/Z8@]DR9
M>ER.TO19"OG+?$`,??8XAA6-0#*3PYQ<UHG6DU6]AW1U?^]':PCR!9_U=*SW
M#)V`HG%Y="-6M68BG(AB,@]7,9@D.<*QOT?3PZP_2<,P&"?:8'E<I>2>2I0>
MD4W!<F0$W8KW]]X8`Z**:A<']Y0O]^C&(PGW=(WT,#:D(=#3GX%FS[7M9G_O
M,:VY,36:3$-[E)R<R"PAO3$'IJ#8`VD9XGNSWOX>@SSQ+#MYOY=US\^&+QBH
MHYYB*,+JM^GJDK#X_E[MU;^K\?Y>4@6N$MLW&H1!D(U*/S(!9B*K&3V"%)!-
M4>28;+K).S`)R+.!U%6B-IW`C[`4NSNIHG,_QJ\M]FZQHUSFDZ+[0`(MLU*)
M`6EQEM@ST.<P@"05DRH8B<39B[Z0Z%![T@E?_#3O2?X:<L/R<'<XJS9YY_0N
MG%KAC.T!JC![&8NG]!0=_JID:?`P")C24Q5C9P:/S<BD$%4:/#479V0-GJR3
MG@8#"@;G="&>($!5YDX=J!ES)\IOH@(Y:[=D&S%[6"M9^[JNL=,RQKP#H7U9
MAJU:.E,3H2#40QD9<?EA<L;*_;V$ESDG*,L]69;GN_%/J=3ON3$/F+,[8OG2
MPN!-0C>-=;,BPB4>)ZCV]])%+E<N4MCUPAH0^@_SLI`HV?PP:$(7][SSF>$6
M+IR/0>@Y_4<(D:5/U'%'$-?/(&ZW^8,D2?P\`$Y0B97-)*Q*$/Q+PVF81,N.
M&]G3:&Y6<[?])6QH;=^[RG:^P5J/Z(;H7%4P23@GHJGXSAVK5/2K:STH*O6@
M2%_OQ$N]YS&'7$C"OF_[O/+X[2[^4JA,"L5<6*_GAFU^,."OFZ<>EQ1_LL9G
M9#E+?R/6C3+AAMQ#FMK3D1A>"[.(1?FLE^(&`\(X7H-);QH&GA<\P@='+]0^
MU&O:\%7>'8"?@Z`VW\/1T=]J]5R2'DUIVX7QH!^Y?]*$$5G:DE7?POVA0\-%
MJ^<]Q)=_2!AX$06>ZZ3S)H%%1>>FL%1*]V)>G+:0<CS+S68'C$$^>_1L]T0D
M#^XP&<JH=3E!)?B3CIJ`I09!KX@]\R-JTC6+`U\;:^JP8Y&BUN3'Q$U>JRJQ
MQGYU9W"=?L*:L,9]&$Q]IP_;&(1'4GA_]R-!2H^H*JN/_%35.B7SANZ:O>9S
M_&-]BY44IZO/Y'F7>1VDU=ZL&MM:6GE.D,Y,-$C;5>,9X7;!2F%WW^R"@\)\
M^WO:`&NOFW_R6H)3W><S?[)F^WMI,"/O7J^_C-R8;NJ0^7T?ZENX'9G&Y?F*
MK:=:*J=LF!#U*<^":4?$U-2[NG.8`PV]9G:(6G0\"5U/:DV+:GG'NGS_^&TH
ME`;<>-7RLV-UD@>8O&9V9)T29,HLQ8:0!N&BT7P!;NGRV]"BM%S^F@5GQWK$
MROVOF1VB'BV;."11I2)E+\LW77T;6B6#Z3*_:Y4P!^O4O69V=*U5VSNHZV]#
ME92>9KYJ>_S=/:U7)*R]#O?TSV]#I])S&*]9C+Z[I]?KGE:W-6Z:T+]5;Z2Z
MZ['CXNY6BXGU?=PS9':LKBK1K].1VHZ<#KM4.R\YFE5J_DVQ;M'@6[4$.W(/
M]H'PHF6QY_%B/&^1`C)0%P]A?@YBR]N&X\O)-M=E/H?D!-,[CS90Y\X77!P\
M::`$?*FNU:#AIM35_^XG^^:XN=*LB$I9L4R'SQ"+05$!T_.>_4].CA&B@$+*
M\W.?_].33*4GJWC^P44/P"1GK),//O0D!8'^HOV]]),K?E84YOG_]K[TN6TC
M>?0[J_@_H%S>*J<*4G#QRE6E2')6;QW+SU(V[[TO*0@8BO@%!+@X)&O_^M?=
M,X.#!TB*%TC!%<<2"<ST=/?T]/1I=3ORJ4*4^S.F/K*L-!3S*!@;DP/:+8PW
MILP`\:_/XIAG"9PK%TJ"<I62`7H#U=2LF5A6&3]+4XB85PIL+0;0)J.PD(\"
MX_IQB!'4M'[09S2,5S`R!.2`,PPX@1$II%MJ/5G&5"&%H#C]@M#L++=,$1&_
MME^+D/[5`N/(J__S.RQC\.ZU,.Z^FD$F#W[(4)&Q/I<\B^5-N=+!Z\>9C59<
M8:P'_.&.!U>*^F0TQ</<R78JO?C_Y]=[F(+_K(:AV?>E.%C,-BZ&SV-J8J"`
M>HC)("//&<FP^F):1KME`P#?O'$Z1NEAJ)V9')-2(/W8?E$>Y/:G-&Q*"@HP
M76.,*1ZX_1]14HB`66#[$8@)/,6])U8",.9)SD$8_">%!0^]+/FY`"@;3_SP
MA3&>6N>"B'*2,(JSI`^Y?OS6@2UD@TC",&#,`L'0W=1/LL0\VWWR8GR9YTYG
M+_-T<H&UJ:077'`0)KAH$M?)R.99"T/;HQSKZ&^6*$]4>T;$!V>YV/B+BT5_
MQ!>$%_D+G^Z<4]%-1:P??,GLC%39[.P;)J0!.RDOE*&>)9#A\)0T0V.#N"?,
MS(F9GD-[$/-6KP='31].EO7"HDMG$%&Q&'K->4YDQ_*TN,%`5[L#7;(5O6X_
MV9Y/$AD.QG:+K^"@&ZJF^WH2L2<O3&/_A9,9TQ2K-@TRQ!"8-P)@LAVCR@1E
M)$>^J^1>*?(NO%^0(!]R-KC\$>8]HT_%;/EW5S]^A]J&KTP_(C0&";F=9-M'
M*>T>\87<,$6&;K?F</3T/&76UCJJV2LD]?+<V;49NYA2T/`F3/@QY#N;RR$&
M3[BSXH:KR%FB&-%:BLAVJRC@;-`K,8$#A@(E?FP7.*3$"$H:BY(9[19=R,_N
MG%'H(VEIH#.4UOC$.'29SP7ZL^B<<6;SUAE8D2-.QX);AFLM1$BL&)5XS/Z(
M]Y#[L25UM@9Y'AO<A.=:"!?&$A\P@0'99:N6SC46=@K(VZZ9>-6%K65S79_]
MBP:1'3FKUJ7+VN;0;?G/CG`M>TVRZ<U)1:@RKWWUXK_/AA&C^E:\$5XT+U/H
MJ+)O]+6R;_3S7I5A?6U8__&6D&><=ZH"$K:`O$,YO8O[Y-\A]I;RO>0%5#<;
M;T)[$'5[B"CI5>5,;<[M1X2)_N9Q)#M@W<U]L44NOA+5"-NM%X_Y[FD0;A=T
M:Q!1(]F++92QG[*XH[=;OC=DR@>Z<7]W&J0[]N#0HT3*FZZ*C9:M*%/]4>-7
M4E1P_@O[+&(3N`>0E1=-6W^<WYTK";;,3*,7A4Z.=LM)HR?QGC2!L?(^56B;
M"BM<`F`7S+'D\'G*="J%JU1DP`.IXJ0^6?"HW+WT@,RSN;9;(R^&%ZF2K:BE
M2.Z6PM`,#=RRS&T&(L$FG3_2B)@4W"MH-N3V/UG"EZ]<\6)%^X<2HR^J[#IR
M0Q:3EP6]5HXW0=1,[!>T)LHA8O1TXQP!UK8;IDD:L?-VZ]=EZU0*R\0E1)ZL
M&IP9K4=8VH^LBT".(?,(?PQ^9O"/$XX1C&'J^R_*$USQF#M=_B869DVR5\-_
M`;H%D!G$<``IIS9&%IP#!I#J5"58%MFZ+R+CV8.O(I@X<K/26P)XK(?F<3<!
M4!V)DT_1;M$<@&,_?";G#]9VDR9=E>RHI:'I!SB-7A`NH#UZ@)9-HL@Y1B!J
M9B9IS/-2(I[NY'58Y84"NVUL<\Y=N/%+GGAL=OR$,@VW0<1(2+9;7@"L/>9^
MW_6\$4?HA9BV5+Q)OT.W\3O4#GDGZ7<X3`3NZTBU$:<UBUX)SKJSV]$X*HL!
MBZ<N<'>!OS]%3(9RP6,R%)PT+<63NGA#(*WH!XSQ8<*4Q*/RVJV\/F!*_-90
MHN'DAI,;/61CNI^*'M(LNEGTX1>]U]`9RUHO=.:V$*R>FVU,`(,]>D$@4A?0
M%E.!I),+"-$!SR:VD#D<P/M%Y@JU;-?#8.=<Z[T5Y.V6$[5N5S6-4Z^KO%-.
MW!_R#AQKD%\:$%PTUNM&9JW_C:>=K'[8U=FQ;G5-5>N?1L#!JZN+%&+@SLVC
MKB&T$QXQK*[:/9&@E"WP"`C"P2YQ49]`P4HQ^%'&%IP&DW_HJ!VMRNVU&D@'
M#$+;`FM;Y];F**C#-M\J9_0&ZF"P^98_=M;8`@J.5..[YH5,3H.=SYH-WF!D
MF<@S3+57F<OS%D1>]WRWY;_KJ.B5_$&5(E'4HUH'06^PVN>'7G^)7KE1P<HU
M-M@NZU1N<]>9Y\;.T+4U!_+)LRUU66ZX=G4;R?G@$%Q;AYRL4U-^#@Q6'6!H
M4-.@YMA04V=MNEA7=V&D`.:5+8\16'H^[KD6]E94E%>6PM;53M]0N_VJB^HQ
M%F_>(DVJ5)MMDJ)SWC^U@N3'O3.6!]Z\<9KL;V=41O#LC@K-W>!859D&-0UJ
M&M2\P;M!5MXF":DV0W-!V/B"T.VJ_4Y59;-&#6HN"`>GP@%VAC[`W3';E[VA
M27-!:"X(]=9G&M0TJ&E0\R8O"!1V0_61[*2Y$;Q&[]'[JMYI=-$:Z#U6X[BI
MS\X8##35[#7W@1KL"[T&]X&3*X*[O*?K51JA4Y[W`HM9](3E8T7A65%;%0Y;
MT]#43K]#E1,G+**"BX%\4!:0I2=UBYH?*J5F94F855J=UU*MW<H:J?$2IX6.
M@^4>5(KH057LA07PB,9[Q8*P<FJ7KT\6A5Q4$[+=PMJ[[SOGILYG](($7HP]
M)V]**(?.V]**AK!8MQ>VBJ7!(3OHU*%#Z]Y+*?-"FH1ITM-X;4_8F5CR-Z_/
M*8IV(D.4NNV5&Q]2:[VRTC=#L*V7[-Q^$].FHN>R\R\KP:)KNRO-I12"C]8X
M8HZW3-<N*GQ*7!;N8@?!Y5X*;:V(DZ]V\$@'`TZP1LDRA2J6\9)QRTJ6[8=C
M=E'8[7.*\AIG>HB4[_-Y5T#4](9M*A1N0@A98>],5MC[RL:V1]695J1'F8B7
M`%DDBLI_\H:'+KUWDB1:4Z+4HPCB*5""2ZTU\9^=A@WNFUW0E`+=#MLVBVX6
MW2SZK2]ZK_5/]<XZ]4_?&^?]?KMUIKRWJFLF'$-=27.=JHAFUU3[UE9;!J\'
M[NF@TCH?-'5B7\V'U96[3@IY.]W/IJ%VS"HOZ$FA<A=\6%4H\J2JQ'(,PHFG
M*W#RK5<MJ,XA5UU34RVSJMCOVPQ%ZU970#X>I&RG".KFY<'J@(MM,HC5U52C
M7W5X'`]>ML,C.\5%?8(V.<:Z=!*T6^]U[63.`FO05XW*CH;'P]+;Q$OOW*Q*
M*CL>I&RE:/H62D76`1?;9!"CUU.[)U)->2L\HN]4=ZI-^>#I,G5T&.AD&]/-
M\^Y:DO0-%AX<:*H^6"<LO.[U'_<O>3KG_>UV(#X&!&Y!1.GZ>:>JQ/FQ(>XX
M!8`%Q^8;%`#;X%_CO%=UQM:V!NEVKV%U4)B.+P&R04V#F@8U#6J.(MEZVW>U
M8H;UL6<I'B"C^C2+L!["OV2<6KW./?H:FO)2M1(*IUEF88_\?*#B"*>=!%Z<
M\G0F$I_,2T@^Z.17JR6<4Y(S_*"I2C$3NMURPO&$!3'/EV;?\&>&">9*A+D/
M.!;\S-.MXZTG0;^"5U^3Y=S')MQ\XJS/5IE\VT^<V-1<\EJ+V$Y39I"3-K1^
MG1Q"-O4#;/4F5TNSWMXC_]_48O::LM#MKI.R<!G&2;L5#I78]D4"^BG'Y?9U
MM5?9PKT):Z[T2FGJH/]F`IL7'V?MUAUH,_"-JCRR@$6V3\J;[8Z]P(L3S$=]
M8E)5J]I5C:N3FK3H/770.25O_7%2HM/KJKVUC!6-\[1Q:#2H.59?SVQK:\/*
M:[B%"1QK14N$,L\0<9R6X'T5L82S;3!0N[TJG>D8#<!'2(HN*!D]LRDING?S
MYP55`9TQ=ZIH$(VX(?/]H-M7NX,!/I@&:-9\#`#A[I3MTX'+:K%@9!`&9]@?
M"'XKURFUG^W(C5$GQS24C@7:90>?%@_/U"N5+\@2H2!X`5(TV$Y\.SBG@I8Q
MH_EAU(BK]K)#T0-3<HB5\$F\*>I8"B+`B@>`BR@KM#53OQ1APR\`."^D>N;Z
M>;=/%F.T[D9RB>W6]!H!V]U>X4&">\$2]U"*M,H,7P^.Q`D?\,>O@//((T)>
MAN,QL-@=GG<$'#U0`VOZW@NWRKJ\(]B8-K!VAB*'HXBK!+@QQ#YY'GG."/8U
ME?D5A7=ISY=>P&T#GP,3PU#(IEX<I\B?5%T7OL0'#'27&IUL$/O)]GQR)Q3?
MF-J?T]5@N1%\QYR^O([RODBZ')(;X&LV23B"N.S554W3E)Q4B\B,19O;K?ER
M$86?G;&++-@LV('ZMH4!=WFU6\,H'"LN"&Z<C(;C196I:C,L[F^6B++*0$R<
MH/1LN^6RA$5C+P`@'E[H@?^D(8(DWIU@G2]^EO34/OK0@%_>]\[[>J$:]+GR
M48C'*C^<JKPWU*YF"0[.CI]V:Z[O34C<6-2VWH>$K2.#_6Z_".P9Z_"6/'+;
MK5G>PN,]XZHQ$8G&2W(A53Q=8[@^P1%'UNRLDOB/`%01G&?/]\N\J<RR)D@0
M/%9+ZQ"J@S<>,]>#A_V7:@8&EBT.J:S!P(;>43&'&E8"/*S#K:R+3*RLQ\.Z
MU5.UKD;H6.Y!WC,7'YGT_%]VD-J19'!3HWKVFPO/:=$)@\%A-JV[>7&[-4>F
MSN%;Q1M.*W^H00>NQTLUXPD[9KN3O'I'4P>]#I>]UOF@\QK9*P8IL2><'R<O
M99=H9KF(U=0IF79@$0L/`^>L)%ASSFNWEK+>,I'9;A593S-42Q/'?N=<-U:4
MF.W6G/";]Z:EZJ9)G[R'FZG1[:F(8KSS>4\@^M7#<V<-1.?6PYX*7$SL6[O0
MIU<AO0F':L*A:H60)ASJZ"*(3FHQ33A47>)Y#$,U*GU333C48O2=[0UOM?,>
M-W%0.XB^00.Z-5C'0=E$0>V"#OS"=P`R-$%0)Q#ITZ#F>(ZQ58.@INT232#4
MVM$WIFFIO=ZIY<$>(2'6/MV.-@JJ_A;2JLBH>>V&\>,\YJG=$B%`9`#O:ZJA
M\W;,A;BJGJEVM>YT6!4/9,)HI"R4"H=>Y$1H(H?JD4=\\,DI).J..YV^%D-Y
M/J9)"BQW(^)S"-`W&3]U,:<OM5KTIBDCV\W#H))2GVSNSI,.^WS_(8:'',,R
M`NKMIGEO:@_L+[7P%.]`U-N4`,&U3B(V9%&$:B#?!!^`CA[\>Z'D7E+S1^77
M[^IF^EK/++>>$1'.&-/<7^NG.G0[N2QL3]BOHA-VN%)7\2.Z%JY2T^KPM\+M
M6CWFD[8<ATI._M,@\6"@J]W!3NNSUV_#@CY+81JGMV--5>MVU)Y6)8X/3]#M
M[MBOT]>6=HOK33P6YS0(V]$QYK#65-V=DVF&PO)BNHE4?I.^#9%?L8;YY_2<
M&RO;@75CR@Y<8CYQ!9!WN>.T.NZ](F)''?3AD#*;JGX'M.`P)XV\Q",KSJ/P
MTP-?WS[`.#;/6GRS%IQB!IP#F$C'8[*13B+O":.3XQ=0%QU;W/B&B@=J9)PC
M%+6/"WC65T#2*H:F=57E<_C$+4+\DQX9:?E#!GW2/U=N,+LU"##`&(=X]I*1
MPFQGI,0I_B^?M&Q-LA\C!L#1XY,T<D9VC!'<L'-&[582@G1"^HJ@[P*8>%Y.
M8.MZ#D4Z<;-QJ*0QHP4],`R#8D-X#'Z#+S!K-8&_-`Y\S@.A`Q83#@C&J,!*
MJ($!LL8,E>PT2&"E!$#Z\#_P9A$03$F`0\S%N.VQ_8+)M/@KQP"HYZ5A>?AX
M,3\177#QT,/$'%3G<P8&H-&^/7_U:$7#5P*.8F%9MV&U!#*\C];U(J7?7+K!
M/?D#"L*A0%!R&V!@C_`;"%8&7B<^DNR.L:;`[*4-,[)Y/)`7,?=<N?"1QH^C
M:?H00WC`13RFOC0"95_#$CRI]A'_\LR&KRG\J%O6AX?O/NC???"^4VF(<D:K
M(P+'<XO=Y8\3[_'Q!56._,.K'Z<XFDZQ6*Y9LG)ATR$P=J`@-H=>`+JP2.4F
MKI7,.(W-Q<CL%]>M8!(0X">"5_R7?`<6_#VXN`?&`B4(%=^>X$X.<%?0/L[W
M:^/&$=Q=X+<2:291^.3%G-<F$Y"0=,&8H4Y)/L`(_TF!IWDJC,C"*ARS2*7K
M;\`HP2-QXQ@D$!>3:3QA@1O/EZM%1IO//I0#@\DGH6+[?B;NJ2!"-COSD$-P
M[Z&7@7A$B-QVZX&!4HL?E_84.@OSD`?<8,#GZ'E(<";<9NU6<9\5<ML*J[X`
ML+&,P<`T5=P9[`D9/@CQ[S.F6(+F[TWP="T?:F/0TT%'?BEN+DPJ2D8>7!98
M0A(;/H#%LPBCE26NY/,B)TUBL'SLD<AW[1>>I%F-7MAV!&^^W]()SWH>V]^\
M<3J&.4#$`$(K(7F3IT<![1(;=.16"#F4[<#&(+&JF7&!M.=J$)&5?7,8KUF$
MZLD\2!Y`>5)BX'P?!25<#),4G[=A=H_JA&"]`0YM0I<_>PRW42+P>P.S[_!O
M22$I)<IA?AOGD$F8H$X!(_B>_>#Y7O(R?8AD$V;;B%+*V&.(.W.1='H.4]C$
MH#"]-P0TC6A?K+_;4M\-82]38MI\Y?TC>XAXKB_IYCK0^`)H&$EF0KH1F9[A
M)19-$;T4&$;LX\7YC`B/1VGD,%!FA`9FR,0%D7YNXF71]E#6@\4=`,42Z39\
MD`*,.:.[;(Q'48FC2*_)]0A[F*#JMIYVI`CER,[T(Z=D<">W->[G=$(!<R`L
MO9@M0Z<PM$CDY';[<^6?X3.<)E'IW%`1X;['4AR7]HDK\P^SS32EAG&P5=*=
MZ`KP``=C"IH;?:$*#4IQO=B)&!=10>%N`J2V_00FAD7SFPA/4UUU@05/!(DN
ME'3Y`3ZWC$JSQV'"VT#Y7RDH!(8Y+\("]Z#/Q)X7M_:);SO\1.>[GG9JP9`,
MW+]H/\[/@RYY&J:N[YR8="F>F;\$*NA`A?M[46^("(S2_74&8-KFI4^)S_P7
MR?79BJIO^Z@$QJ3C;'[;%Y=];K18>LM7Q$8J[\K96_[0\XF:"Y0T'`6'H/SL
M>0)(HDNIP%:^%U51P08#Z%SF^#;NQEP##)'YX`YFB/">F1WYO>L]X6\_?9_&
M9X^V/?F!BDJ-8,%`UVNX*"0OGT$IN`*IXH=Q&K%[8/1??7CFEW9+47Z2K]T$
M('6`&:X8__<FN'"<*&7N)Z%(`&HO`O<6Y?8M**`VU@\K?(<LB7OH*QO^_(Z%
M_E]?KKN]@74&?W1=U\[^I<'Q]M?=_=5?9K?S%ZY%-TS]+^T=H,;C;WEQ:!EZ
M[Z\_[J[>(3*\L>W'/[^[^?SQW2^&96H],U_EIN"6%T^WI(0,#G,0]>JE_8(4
M$@1Z?1B3KFDBF&4=47>6A!,2=]D'TL*M9:ZN:N\(#%`5VZ2]RRRVE9$X)$L7
M>0BEE5COG$]9@<MCEAXN4*OBI0.9WR604Z?7GLS;JUCDL^V@?,*=TYC?,]&/
MX<X.1CQR/V^8(<I'1''=EULEJ4`<GF9#V+5^;G=!R\R$S@FR.^*[<+(]V9$7
MIK&HFIB,(K)#@J#HGTMO'Y]!%IW(KF;P\\S<O`2)VNGJJMZS9-U)M6/IJMGI
MXGRSE2ZR8B)PWM%\F#.)%T8:O=V:V"_2?HXSD]E"3!RQO/X%50S"0Q$UUC/?
M"T3-(#*`EY>0E:;D'V-QE7/ERL/;"0,,H_DP>4;K4,+ME10N+N\]4T,MFA67
M*"%OMT!+=_&C[S&"%;"EH/VR##\=LB*J$K\%;(!6C98M;XQ*/#_B;8R1M0G(
MA6^7(;0IOMUA@&)7Y5FI8[S%_9=?E19B)@;E2^CMJ%U%2*F0(H1@R)@E<,,8
M,B6<1>3<T-]I^[-;7BRW)G0PQLXJD53<`P/R[]/]]5?;IX)0=R/&DC=I4")D
MQS+1&#0P?L<37@!GQ-S4)Q,35S]BW'8\;+K=DGO+#H(TV]K9#LO)3[0=YK05
MMGLQ=7%"(!][AJ%DA*"\VPM]E!N.@#'BC)G8-R_.11?<&<B\F%>2'?$B2'&V
M4BJI1-5E82K&[;41HZL$V:_$8[@_R<`+X(%X3%[*8D_%31+`+8.Y;XYM?A=D
M%]'S4V07@E629>IL(6L&FG?G5"R*CB@`GT;\^9VHZC&E"7:U?ZP1>U_6/;.Z
M(ITE=45<%&QT:?L!SW.V0?4:25"1</(5WH4]^$50=+.@HS4"BHHKXM=(;WI9
M*X2U_5^LBG7-SY8BDS4Q;#.3E6O2P+BI''8NA]&#%V2P)XC2)?>B6@2]O9+_
M9G=4.8'E-'+5"PQP),GJZR0E]58M4E09I`AGTPII.+6KN6-HZV0;P:T*+E"Z
M696R<%()1\M(OD9R3OVV=3G7J*,.NF\D<V$95:V3H6JOI^K]?JVINML-6A5M
M?U2D-"Q-M8QZDW)O&[1[*E35S8[:JRP[=GBJ[B"UJ#K=(XN$:.YB2[0QP^JI
MAEXE%&IQN3J<K#B-^U=3*RS+T?J,I>?'9<MBQ`U1DT6&J*-(!MM7":J^:@RZ
M2_IP'VD.&/__?/?ZE)WZ;*XGN'8^:E'%?S;,"E[@%?TQ0HY;UKGC"L/EDLA[
M2'EL$+?<H#/FGR%L+GB&=TM`=^",][4C7'5^'&83<!]:-@-.]P5@<AB.-6*V
M^Y_4CA(,F8J];_,=NODBM`6+*$U1M8B[Y%SY%*8>=S@/PS1ZU2KPE_LP`@*&
MBG!8O_`1,<9H9L3>'ETWM67%##*@WI.7V,HG#^@24_GAW^T@!3PFG-"(_3NL
MX*U<2"?]/M=0+R?83:#D0<V4D%C:`0$/-_60$S%)XYOCIS$R8<:)[9:?(WH\
M@V@JE9Y'0R@?</AB_#!.VF[EE"A$$8N8?4E07/W_8^CI=H&X8X^JW'THCB6>
MG!H#U771(B9+(LG@Y"$(/.#0QK4$Y.-%COG;!J$4L!?1(O,9%0C%P0B#212Z
MJ8.QO^R)^>&$/*X4FHW3GRM_9`DOE/>6+:Z,7!F`D&.UF$=6`)%#R'Q_'E@2
M%A0A)!$P]OAS&`'BB-'AUY%R,08^<6S"IXC<A/>&C!*-,*L!^Y:AYA2GP$@.
MQIM0%QUR)RL?O'-VGDM#1`'(,`=#H?G/HW",\1#T,TN<\^]H:FH?E#&,6%D!
M`AZ`S[)N/S39>4;NB&&4J9"^/`Z=1V_&!0)X@8S%X&.5X$8@9+2J&$?TJBY&
M\5)84`FQV6!B&IG`)4*)L'%1@8X8W]MN\>AZ"L+(//Q5Q)?3QWS^\@P8",L)
M@G4K7`8(1K@R9/HO'(J,X2YBC@+/92(`5K9ZY9N334UN>VZ&9\!T^(*1ZK)W
M+,;`XJYMHLFE'GBZD]=AE;?%(X@'[6O3DE+$M<SN*A'?;2L!`&:7/LTX?,Z9
MHVO*_"-']D'C4=YSQ?6$11.6I**=02[AGL/(=Y]A"Q:.1"GV<#O.$=X??H=M
M3IM;LOLUGEATTE"<8/PW2+CRF4.9Q+Z4T+Q,%<8=B<BD*4G(VU,KY15SY5,$
M+(D6;1)9%%=$54L4GO>R(.4H7W><8B8LBV8729D3.%X04C(J#Y`J/4)ZQ8N(
M4<)4N"P5,^5)R@1!\;!2JLXJGAXPM5IXQH]Y'S84IRF%S`FAEP?\E(4?/SP\
M'U/O@F+`)5;+I33/][S/'O7:R]ZUG9''GK)D$HSC]*@"08!V`3YR2'E]@+F8
M0RM$M&05D0+!N]L1J#R@S$5-K-TJGZJ@UTC">:7&?-A'S^>*!&.``A;A*9B;
M)N3RBP=/(_"Y0CS_)"TSU>(#M=UZ;ZA&AS,&<I$H*"'I9&G3_1GQTEI.B5N8
M<J2;6$_3K'A9L8'1WG?..UK>Y)`#.S>;Z9'1SJ,JTBY_-TM@51>G/NDSBYA:
M0**\[YX;G2(,>>),-IORWM)[JFYT8;=GJ39D/BJ63+US1B%MG(G(<O4P?DT9
MAR[S97QTF69(#RIQDDDUC,&VU&Z79CM7%AHNQJANV;A/Q-:7`H*B<?5LQWN!
M,D_ERTX@(7>QEK:4S'G2[LSQ4!(V<L9V*ZO:4`QIIBH2B1WP'&@>=LS9#)ZE
M:U<AE!G50@Z!D#T8S(H7N3CQ>.HKB-EAZF?!K<#CW+[PX8XQ!3.1VJW>=XUD
M^#&[WB&B,<7_?T+!V3QW:ZHQ*B<)D/82#H1ANW7]C<&%"47V[7`(Y(_X&1M+
M<\_<,_97[*=*5>!E.]5S$E!3^0+S[A4N,:O>5RU=$ZU*!Y;:[_4H:G7>[:)X
MHYC.08`YT>3*2PSA,5*"8/'=@I\R'I<0[[NZH?8UF0$!@*F#KCXU5<-H!5/6
M_TX]Y^\ST!&5>^:,@M`/'SV<X29PSLM%I3\)':*Q:/%>R+`)J)I6E3E+P>HB
M@<ANE_A]D<H[JS):59FK,J+!"3!+M9*]ZG__?E\>@-?[P8,P5$I?4CXXAO!'
M'DOPHH3U4<[&GA.%#U@](H>?@&V74O0S,%Y*LW'M$XL1\1&BL91AV?(P+T%8
M?4@\Y(C-#0Q94DR,)5R4LI4:W^+&;=F]>>A%6,`ELZP\IK#D$%<TP0L"0,);
M3F?J0`Y]T;!64,0`4;*+M<SOS84P5?O@RK(JE=ZS!X`M.WV)_I+F9'C[&Q[%
MVX<TNQ'FI;T)#N))*%(!R$Z?8U[8M?[`\DZN<H<IR#$7=I=V8+MP$<WTA'()
M$CJ:!>CEMQ_QP`XX*<AK\,@"QZ,[&W`RJG^!T*L<F9$NER(21*9N#$#UKYE0
MQGME=G6!&XI4$H8%JR(<6K[WWSFK!>TMO]Y$""V=$[0ZJN5#%]5VZQ&SPRDE
M-[*!XM3M>?Y%!1`O6HW0G<2526_MUM1E39W9'(7K*%YF7%S=!Y=A^23*WA#W
MR+&-26MI?EO&R=.(?<<KA_%22/+FE=?T6'H%+I?_*B`I+`U'W1M*W'M.W)N9
M%AP?L$,:969E+/%#N_4Q#+G%^BI*'Y6+0B]%@+8D7#Y>792%B[Q4RR('9<XM
M>@$&Y2Q[WTX#S*`B?8;V;V%'+.0/3]9AP/&:8WW:U2(5MXD=\;TXSGV-N>D"
M.`IK#'A#49$*F8F_!]O.=XM;%663G[K"H4&7$9[/-G7ESVP9HFB1L$+D-0RD
MI*8A!%0%>QOF3G+"\OJ4`S6;<.X9H@AOJ"TJWI$"FA\1#6N0'YV.'KC/VB_9
ME0`Y8_I6@35GL(`)5:*$/3?Q[8#0RXU+XO&"AP34]43D2B?*&$0\[N$9CG"R
M#/US-,_!*<,-9R'.DO+#Z3F,_E:PU`*Z'[BF`Z(KY&6,>!4?-EN=@ZZOMOOD
MB;):^`ZO@Y?53P.`O0@+:R6\O"9.Y@5/X=^91.:K\J)Y4I[<XER*TXV?S%US
M%JGD:P2.OUMVT!44JF<LH`BWJ;YEJ!U+W*9TU=0[:K\+&B9"@/<A?D+/2>%N
M./SD_2AUGIQN@7_<73:7Q)+/*2N\S(^QZJOBS)VPW9JY%,ZB=_9R*#0Z4.IC
MC.G!HY`\]*#D*Y<`.LB2P+/+BAR0KCQ2L=QFYJ?*=%3%=H3Z/$\_M94@I56#
M[)MS44$;)>!/7(WCQ7Y\&(J;*A-N#!>&9%&<.B&[4HRU?L0@?P?A\]DH?%:5
M0E]!&TNF/7I8`S%&@VI@@\`5F!40J)5C.:'O2S&K*C,7WXO"X!<TN#+_+DS9
M\RM?F2N'E8T3!;:3<$*6-E$MMN112")F)]*V[(RB,/`<0"!Z_V)>)0LK6'CV
M`TL\1TE]![A&!<Y^%#^C\3=T/,(FH1TN6F&*9W$0IVAE]."R"'B9P&F$!9+D
M:Q\>L((<4#K^3E4>TBC@:)7^-%`EG$8QRV+]RY9-Y/L(M9X'-K+](6TC$*UD
ME/=$(4\N!H:,T?Y^WS<'JFGU"_X/9P0`\2T@BXP\CQ@.056<L?BUL+9B*8NI
M.B%TK\<"N#AO;F`MEHJ><XTO&56*U[19VU:!N[^(]Z=<Y+-7?U1,98TUF#="
M"P#JC6@=0GTO`(U)T]#'X=,]F!>:%`_!=1\-4(391]P39..9>F=*IZ+K5&Z3
M+NG(<6Y!D&:%&><*+X&#*,P=N@.U:W3(NP,[ANK.HG\$BU*&#^@])>>*M%))
MRP!<L_%G63+(*U0CE_M\'D:I\,8SQG39,:>OG>`<4AS(\69=QA_3""7M])K;
M+5'@GJ^:*D>CC0:#2A/45Z5+$I;CDCM!^,U%M5-:C.3A.1!GD5L`-'#9&#;?
M**M#7;(UD*TRPY,P5#72Y$?I$1Q/*+YCX8X$_H4[?QSS[84>O_+9Y$;IHUHZ
MO<B[*ZY_7,IX5'.&[P[)Q$"DG"[\)(.?'5&X,6=QY.B,?)*')=@BSBQ.1+5'
MSIAB$=G:Z.@3[2])#+$SQX?1'1XT`X/(W^(D=<DZ+HK;P"Z`W8\G?(!+_\*]
MS:KXP:"#Z@LO^&K*EQO>FN8MZGZ1.DC;88K5D"BHZ9'D7X$6$JTZ)XK$\31Q
MRK=Z+R93@#"K%O1)*3Y(3J'B#$HME6+B84!"^T7NPDB"B$W0YBH*LPE`S`)G
M)!%*(F%3!_4OI'7Q(Q>+&314G])//%FT*`@+S4ZHEBM^G.`Y"-B6%7"5(3](
ML$`KD7GJ#"]+I7/E;D0EQ3U>I-^%(R94RQ</C%P2%IN8"LIRETI9NHF+`X:X
MAA$OV^^B29);02G4211.FWD/3FOA8H"E"DE!K@85OR+-V4>UPAN#4ENNSTM\
M)H*@\JB9F%M-/9>;6F?%$C=545\2/,:2$.]'W*8U81'\,MY!W:R]I`FM5AZ*
M:F7\_`XKFKY[[:IV7]@T2Y/[(=L]V5YYERU^E:*GKQ]GEE!+QBIFK*!WT`-]
M]ZJ05K302E/_=+5ZB$:*`R!W5J?2M%/,Y9J*(,:XXHPXCG@=E>M">&S!RI*-
M%$:9DZV8J<"]P/PTM<NQN*!OA1[=2D;E<>3M8*X#$N'@L7#H%R9[$!SW0XK@
MQ:#<E\SM"J.,T%_$-7_XHIP0,PT37E+'&#B&GDEL*@28$)X@=.O9@71B@6;&
M(P2H<FJ29:7)'AYZ5Q1)+$118^'0_]*-E>Y_A?8P!0#P.IQXB:A''GGQW^0\
M]4/05B=VG/E:2[@*7&D1DKTTZ"YHQW"1?J!%D!W$57,MF9=5A*G&F<\$/XY'
MWF22Q1.T6X5ISF5%.857<,P\M250X)@P->PD`]K3M<?/63SD7K)V`GE*BXST
MG8>#K#,.ZE<N&]JIGR@?>&53S&KYCL8+'6XXX&K65+%S4?\1)Q=1B45(L<ID
M0)BFU4J7#V=S8"3D91S@V8LY'B8A]R%C##KV)@DH>@/T=>[@`28@C%"TPE#6
MIQ<^1;H]\#@`JK<KG.PE)SD<\<,Y/OBBZ54XCF#5=LPO.##Q0T15<`5C%Y:H
M3G^`1DI>/#-;.<8_A`GV!9J*(*%"^TD:\;!P%+"\!0Q?=8D0Y3>![%F,)1^!
MXBVH%#WU!"VQGH@"`2T+<U?I<_QA,A<!JHPDE^.2@D):"3F]X';WUNSYTUR-
M&WU,&,("O;'WD.?0.IAG/!8!F$!Q-1/2Z']%T_Q+GCF&U89%)MDSA7KR.&6Z
M^@H+:U)D".F`%*T;N/$(D^.E8!9MW0I!]\IM0'%*8<"#@ZE4\@S/\B81<6''
M85(,"[QXQ/<$S1+G]ZS,&U`&AEI.P?"ZP:43!3*[3[A*$K!YJ5R)#(RZ(C.>
M.`%4T1>15D4=PC`N9:H4]V!F=&7^X`?WCC63OP7Y\.?4N<CE)P7[+SHP<K/_
M2SRC!)#KJK"M2DKDD$T%0F174J',%0>2!C8W*[5>K+0NFM61Z^'A91X8[N+P
M\>RLY8/DP8=D@1-B4.4+@`N[Z#LX!R%TW)<6C,?8`Y[I((7"*.'+G48"U[X*
MF0OP&\I9?J;A$&4%T"LDBC?6G>(-,<\>N":K,9TBV05QKQTAZH^U^Y$H3\`R
MK(4\YR+S5V2'(R;7\ZN7Z/I'29?\>I?(;2#;>XF79[,R2AYY2A>D*%>6TZK0
M#H),2KQ/`:_<SL/TT$Y*\-'5J=VB$J9PB\,UQ=P&('Z;NJS%/$!)CN;EX>^Z
M(2Y?A6>+5>I%?"#(0EOH/%D#0?K^(0Q2$1?`J#&1"!8N];$C30OU%M""X9SW
M1%KL!+#-2PODOBM:]9@E,PN@*W"8)E1](;/2Y?V:46K:2989"3>G1[K!4YM&
MT3C5$S'&H2_BMD&]X)&TJ/"+"#&NSE.J</&NSV](Y'(D#=%.X]FVG+.=FZJ[
M$)4[%I4;&UT@0BC5]=*.1Q_]\/DN:UBUV[Y,EM75^OD25@:KO)K/+,$GOG!F
M<G]]^0/XXB:XH5:5I8%VMQSMW2]G/:MC#*Q!OI[5`2LO2!:)OP\O>/0,?X.S
MYRZ7T+%ZEJ9I^0JJ()G#4I_#(&M-<!.@,GXM(@IVBGC=Z/:-*39:",H*C<LH
M$/DKA<%SP_0.@>_K9M<PEK0FFP)HNOU8G-P.?PM#-[[#PC&[A-:"S_MFD4.F
M9I_!+B#^WO[&XB^H-.X2-%,?&+U^"9'%N>=P*YZ[<(O&P((GQA__R"/.+JE]
MN?-R#T([MDE'O`A<^LVG0^#"Q>I[N`U@C]\.898O%$X^3;T=\[UF6-I@BO'W
ML*HR+N_8([[RE71OV&U-#[P]]\##A94\/UF?CS/ZM-!H(M/AI<<ZU]-QE`7P
M;#)1=IRW6X)1IB\("R<^4`^^/=T;LO*=53ZC.2UC2<%T13_H1V'!$UN/:Y1#
MG^P*5(F*MCS/*D1O<<S(:JP$-I7R$K[G![0C4N3-1-0LB(6N3D[EJ%!M3)4_
M\QW.M5N,OJ.L!NJCRA5'EZ$Y,^;!=7GA&`$RFLP5/X251!G`H_"YM%(.#`Y1
MA%&&"L'P81K[+V+QY9)H.6)H:%G2$&3A`Q7?ROLGV;EN*`W;W$(H$I<B6X8^
MBEC8<OV;8A(H*O(Y)1!S_-+VPBWM,8:8P'H`9'+QBX`J3ACNL^%]Z<@&\QR6
MQ\/W'X6)=@D"YE$&7Y\FC5*F3(Z3C$;X<1`^4T8.1QQY*7FT<(:8.8C'1N0(
MOJ0#I6DY%$SI3O'H`E\B;!%`D(.W6"]3.2G9?S*R`;,.2TG4%BB1=Z8$/D]]
M49R(2@)D+@ER>"02##B5..[#C(`S6VK'II_*!C@'E#U%@Z$0(GZ^)7D@%)9%
ME;SR0[YOGD5D'B_U,I]/Z%)>)F3^;>ZG)EX7AA%9O0GNW&-*"L-K=;:E'AC=
MD\D;D.T5Z=J(,WMF4DBE4@LAIUEQ2(P_PB$?*=+LHK2FJ=)7$ZSLZDW(6"+"
M$,F0"%K""+;-$^-W_\Q?F0/!@^1=#(2'R8%B#_`@K$B8-]``Q#>@RW`C<&:%
M><=AP@0H(P:DY(!CQ\H)62_)^3/DG;T!=?-1OQ1^JIWC>E2.R9^&-(--51[M
M]+\L`UT%!A@Q7C<R_RP72>CB2B)O`A\Z-J`$?;%#&[L04NY`4105Z?]E$9/D
MZ\AA5Z[N+G6CIV*,*B>`]*7-37+(DAF&89C(=`3IBT<@X+@DMN<F85%>D]X&
M@<(%#0](*#1RS\,'#3AT,&KPC4J0BP7GZ%P:DBV.=B.\\.B'#\B5E$%9K.PY
M5?03"WW21DA&)=T$)\1$$L%,/(Q.]'L=O<2>@P$TW`@[%4W*LRYQ'RH/46A3
MH30,+R5G),;'G^'I\>![,2:@%WP2,4^810LK<4"V,$RJP#T-LBDB[RI:5I5X
MC/$*=,+DEMSY!R$O_R::TJ.[183,\($5,>Y]A>(R5[+R:@LHJ4K59Z?B9.,P
MC1Q9;J,0'/F2E=D3<U,!(IY#5I"J(IV$3\:Q0W.`D(770YY0;%?)V"Q_JW(M
M7,SS6E94B5<1XR^@+D=B'K<@=CJ/%59+OB:>R`(29@2B2\3T<#]6BBIA^6N"
M]B&E,'HL\2_>*.E'Y.67AN\H)AZGT)8BVYP+:[XR%T)"9QI3VI3/<)]X@;($
MHWP@61/D_.Z<(/OC_%_GW"1-K+`"!RES0LC>IGPC+7SAZ20U$"]6\G-$<F<6
MQU4X4;+3"[0.X(9\ZTQEU7'')+^U8`P910"+LRCS;>*,Y'9!0A9G$<.^49)=
M4ZC(]#T':20U2N%FD]_07I<^9!_QF&6<B,`;V.8Q[=NAEV"\4RJE2Y9+5WJ^
MX"^G3+%,5JJ%0I^+J(?5@SA7G"O71=&*+<=Y?E@QHE(N0MQNZ/#$6BD`,!;K
M*XPAJB7B:>O[0K&??QT$ALOFRMM(HXH4%V[3TC5'WKA)T9Y@/SY&[#$+M!.#
MB4,0L]6*J(N+J^!1=BCT<1)G7VI5#1S,*T#R%N:OR5IO9\0';5RU)`G4^1*$
MW^[(O2NO5E[`#472RUTN94B;&^T8L$^>XQTW\MZ$XU]KE5_)C%[9T=O0%[?T
MI@^>&88VXRB^6UYPL5$OC$J=E_\O-9'@MXR9;NJTZOD-FC=HG[SEI<R0:1]=
MGK?5^IA_P'T)7@*C.@LZXKUF\25<+T'U%`RSTZW8!7[:;5*B8X!;WR_/R#^C
MM^4-NMWZDQ3+2Q`'RUPUZW6R6VVI&W2':RA:HNA]T9UP(D252SXD424,RYI%
M+@9G'E%GZ3=EC:13H^00G>YV3V]-$3H_0'9"<HF+AN35)*=@B6/`_+ZQO%W)
M.-4IE.KCEYA_U5TDS:.+=;!-^KCN1(%Z=2=7H2&;,FQE60]0&N1SUM1C>4B)
M,3OPZEJ;U-^7`9<%551UZ\PN`\M&*_7R[:@#HP=_M6V"N>(&/0T46EVUIQFJ
M:52UTVY0N!B%9PW>&KSM=<MV#;5K:MC&?&\H/'!O:WKQMX)A;76]:0,CQ/Q`
MRRWV)>^IIFZH@XYY$*CJC!E=5[5!7QT,K`8U:\C-!B,-1FC[8(<E71U4GA`;
M@[6?.]`JY\/<RS&-=B5"/(0K<</[]NJ$6F:.V*I:L]%D1<WB0U_M]>#OH(IO
MUK]4%];S74.!:@J8:A=V;J?3;RAP(`J`ZM'I@?I1I7H<"07J=19OA+2MV4Q/
MGW]-U;)Z\'>P/P8^\/UPEM#&>2=+SKN;$X.Q"1/E8[^>LC2&XH;I@\]61WR5
M*6'3::9DH-7MJ'UK'1E(<ZVZEHUDX.D3`+9O'_Z:W5WA?UL"]?1)\2I]H+9[
MH=X:P3&P\/XQ:*F#KJ5:@W6N!-O#9)UO^<53_F8Z:OBD>6*EL9KMU:"R0>5;
MU5L&J@E2=Z"M<PVLK=YRI'?Q`]"@#J[:4_.G'!BL.L#0H*9!38.:DT'-<=SJ
M*)05NVLT6O,Q:LT-*AM4-J@\850>X[784DU+P_"H`UW)=EO`<M62&V\B49MG
MA;R=1.TFSVA'$?<8D37HJ6:O*E*[25JH0J%EJ?U>5^WV&Q2^#H5-ODR#M_UN
MV4Y7M7J6JG6JHE":/*/ZFY0L$+L#4'FKLF3?IK$-#O:^B0G$1H.:)JNFP<BZ
MVZ>K=@S0B\V=;I\ZVZJ;/*-7^<7A(F#!B=1I\HP.F&?4@5NMUN09'8H"QL!0
MN]TJG>Q(\%^OD[C),MH+]^J:VAF`$#$Z^V/@)LMH3<K6W!6CJX.NIFJ56>K'
M':%8;P+T5;W?52U]9YDMQ^^6_+"WS;"^.E#;K5!OA>`8.'C_&.RH`]-4>]K.
M9'$-W)R;'_)-DE&SO1I4-JBLN]JR-ZVEKYI]0^WT]AA-=4!>7K4`\G:X?<79
M#D&#.OAI3\V9TN1$-*AI4-.@YG10<QRWNB;)Z*BUY@:5#2H;5)XP*H_Q6FRH
MEM57^]T]U@S;8Y(1OPK3)X=LB+H$C`OED86/D3T949.NAXC9?[OA\PI]ULM-
M/-LM[,.)K<5Y[V3\S1MCYVY&_7!5[`Z/?6GWUJ%S\8X\9(;7/N[OKXVUV&F_
MJS\"ZN9]E]A)I4-@E6B(T\(,;PS?H*2`DFVTFSLMC.2MX':'D1WWNRV)-5]D
MIB[I%'QP(E6F"I\P<S;K;M:]AW7O4^0TV&_6W:S[+:Y[K_4A+&OE+-\W5!S"
MPC0:0]4Z544^FTSS*A3J'=7L]U2MN[],\U-#84?M`2/JE8G,#0:K,/B&VJIF
MT-6CUD$5*5<DGVZJAMY5>R?2,'0+&#'47@\X>K<M((\+(99AP%%==<:\*82\
MF2ZA&9C712=.NS7CQ3EJ<F("T:`RE^M-<3?(/PN4HEZ55OZF$&)U-)!^54'"
M;PH=IFKU!ZJ^6X7AX`I>'8AU?(&+#6H:U#2HJ9,<W$`)=)D31C:68_A!@1%9
MY'L!6WA;S\H&-Y1MF+Y!38.:HQ.5ZZJ,Z\G'AJ@-OS>H:5!S[%)RBU;%SRQ1
MEKFZC\`>TE=-^-OI-Q8B:1^W5,LRU9YU&L6AMV(SZPYTM6=6]7!X4PA9J43^
MX85=XR;.Z[WWNAV@6579VS?%P:9J#N!OK_&*2A91S6Z_X9`W6.3];;B)+;VC
MZGJSW3,W<=<R5+U;5<;X32&DT]'40;>Y!.0JK]97C=W>`?:<NSW?E'>H/.V/
M843YV"_,CF)E?B='G;*NT3>C%G.WE9'M*G:[-;;_!P:A;%//#A0GC>&0@+<=
M>"SR8B]X5`SK'WR,SC\P`=P)`\I!M#%S-\B"U54E8O&$.8GWQ/R7<^4J94H2
M*F&:Q`F\C0-%[`%>4L('6!Q936,"J=V2,#W;L>(%BDUIX;YG/WB^E[PHDS#V
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MW5__GWLY&M_J\MULD^,+#Z1+:IR''Q:,67H8R726`)T4)%3%>ZN)SUDX.4J%
MS)I\6YT:!8P]S!'M.93S9.HL'/3)S>>K:YR=L+8Y;!>^C^G74?@,S!!SQPZ)
M3D*H"PA5[,>(<:U6>6814X:I[[^`?)O`C@()1KYP'65@1`(4A=+$?N$O@`A]
MWU'['9V_.K9=)N9P^$Z$I=DQ2,6"G#Q7;@*2X>5A3+6C::JF:3-#V01LNQ6@
M%/PP!9[RD3U$J1V]\"%!;J<^2CPN>]_KNJ4J6L]0L+(7@!'P-<,&AV=2+QXA
M`-^IL(J9R4,<`%3^L1?'(8R/T_,B(.\[`U7O=\K/EA9</!=6$-=S)5%96.%7
M<Z1X(Z[V(*[ZZT@K+V#(SY<1@Z-)^37;>W447,LUO^*D61&]70BJVP!^G21"
M^]&X]E/6\E`*>`&I:AX(C2$H9V<OU/<[8D^A_X2[WN%HSV2:\NPE(WK<1Y4R
M(N$#>R9`Y0YV+7U->IL<G72SPJP1^L51&;5)ABCS10B0O-UZK_>ZJJ[IJ#Y.
M0!+!YP@3B=L1"T"<V6/4Q_X+HY%B%E(5(I<-601PMUM#`"!P:!VD6*%<A`VK
MFF:7E+^(^;3\(6/\RZZ)ALP5),P"\5&6,9]9<FG'HR]1^.3!BG]]^2,&!2JX
MG3`,#`@>+U`A!GV+[5CELP8=JZ#QK0Y6>3E(P8@!XF/@E)L`;@$,AKH=WMO?
M=@K_F6591M_0\A540%(&F7_W"?CL(QP\ER$R4`I+%&N%T^17-@PC,0:\SN+?
MO2",X&9Q@[566)Q<!&YY%#1C)2^_LV04PC=/3"C/.T:!T=/Z/3-'P1Y7-GUP
M`NH=CV_L7:YY,-`UJU/<<OG$99!^L[T`UW`;W,%M\W8(G`U82%Z^^':0Y%;'
MG1+(-/K=`GE6`VF:63E=KGD3C-W*A*ZI=09%=BK-/4UR+E`S7A)/_<H"-O1V
MB]B^J6O](A-4@E*&^RY]B-E_4D#T]1/=;QLM;Y^7TNX::EY.*H5H54?M;I%.
MMR^U<?L:XN]VY(P4HT?:H5'6#JG6&*J&01*"K@9*E0>[%<[;7!D$)0^^<D":
M1:21`;2XN4"1^IW!\T//\5C@O*B@(SKG[=8'L5"8Z_+'TA/Y%U<_?J?`L05J
MFI7=7SV\#,8C&*'T$M6&A`NE]P0Z'%QA1\QWR31)NNW(3I08MPR_=,)C+(%;
M;;OEBPM%@O712!#83H(3)/B<FSJH"@O;:1(Q.Q'JJ.)Z]@-+/`?4RC!,E-1W
M6`27[SLO<!C@3^M/VU!CY8$QO/2Z7LQ[%\*PJ-<N6#L6RI0@R$O]E,J>Z<&H
MW=H3>/H;B$I:OK#`5HQM!T$*2P;EG@4I*;R@8G=4DZ/Y7+F'B8B:PJ(*^(W3
MA__!ODQ`9VY71<,`*KT@==HM0!XW%\:\>B?^`PCR)J14PSL/C`CB,_S]X46Y
M`#+X>!LA(XBQBN%UD0B?DO2Y@9+;5;X`HX?NOVT_9?3=[83@O/[&(L<#=7>W
MAVM'[W:LPB+6A:Z\.%+48WC@8QA=A>E#,DS]"\<)TUUKG8;6ZQ66407'%,2H
MF8<!*)A4E_$+7+XBV#H120UQ5,?[L+ZL7Z>5%Z!8QSES!L>J..[%![+RD'2]
M+?.^+SJ7!5C:LE-9/L?/A?E>LNQ4MM8XE;]F1%,DU38^F$_4W79?D-)C4/X3
M^"O.'E21XY&-&_][2],__/V=,H%K`)TR#`;W`%%PJ*2^?Y8`-$JI\*W"0'Z&
M+XS!D?#%CKAXQ8T_ME_RIK@,W75#[QL:0D"&`'3V(Q,5F;T(PVA1<).+C-'D
M:E&TWWR]PW-Q["72HEQ>S=\,5P+GC#/BMI2\%2_.T='@Y`E`&8"7AEX$!VF7
MCB)F@W(QR6&>>QHQ.PK0G$>GB5B,6X3T/`.D.&]<?$2>U^W6:LY.;FA^WX.S
MS[#HT_?=KFI9AHJFKX*C\J`<51/&/O')Z[#*^T5ETS/7.VS6V(.?HK)PP5"M
M"?)L)J9C^XD<4[0M/GQECZ!ZDAI?$.5WXAFT19"VW6Y),43.*H6D4#9W00`1
MH+,P8:3`*C)BJ!2&*ZVTL/N%+Q_'`MTV'>-KIGB9)`8O(B_EQKER+0:<&H/D
M628F"%/*(D39(`YBEH"*RJ48+["M7)+*RY7;KUQK5BX>4;$N2<CY-&NW<@25
MGU@JQRAF@TNQ>2$,LV),[W>%&+/4?J>S3(S-JMFO5=C*:M]7)CV0M\.B"VZG
M2FJGW]'SA2P"8<8PGUL^=VRX-2W-TO62]3V?>SJ`P@YBC$V)[R/;99(:7X$#
MX)(+VW,O.G-CRYJU9:VC-&=7LYQN>7CK3DU:_%]^"]BMZW+;TV<XB\HX4[S`
M\5.76Y=X%Q#@D<5]0':*HG7"4DI;2?!5'S>.V`Z?KC]*2]Y6MD-%O>LB3F0'
M`5SZV=W-_[N6H97TP9_7-[_]\QX'\]?JN3IOAB\75U<WGW_+]KV>S9)/N\X<
MO]Y^O;K^F@WW4.YY('SHU:M\EU<?[M+4Q:/U(,M;$)W?$'<CXAH\`EWVB3C<
MLHX8=57%6O:^'WZ]N/S7;U]O__A\=79Y^^GVZVQ6RH_**_=,%H,C9'2W^X]%
M<,\YHRJ0),8S%@RW-O^4-!1]P:A5@?G%P40?;#F:N7#-7;6K==7^H"JO96TH
M5^3LT\!@1^UK@R69K-O%X,J;Z!G35S??.?,`_,3B^(<BE!>HNF'<.-UQ7>$]
M4&RQIRJ0LT7:;V4H0?EY8WWH#;!<\L8PS78A/$YT]`=JS]P%.@YX3LB#3BKP
M9E=>)>:<&"6F3_!.+_)<3H7A=:.O]GM527YOB^-U#"#M5]7&W3G+;TFJSU7H
M7L_\&,"!<1!"A>+!MTD:!54[866E<NN:\F+*[$`MKV"H=NN#;F+BZ'I2=`UM
MO&KG-?A'_.N6JAFKWH>V@/\#'F[;M1P<D>#>-UAU@*%6J#GT\2:ZA*]UP"VP
M6:\A4,6LVQ6IY>;JJTK5JHOOFM-4RM.N:G1[:M]<3T=:`W$K"J>&%*V.:F&3
MM3EFTDI_U+QTRU?X+:<\LF$0ROPC[A[=1Q;$F=71^Z74J$5@3#NZ8X:AT[#2
M*_;$_)"R.?8!L:YU>MK`*CJ\*T"9"I+U'@-OZ#EVD`C9A:&HH`\Y'CM`;L1.
M7<@*Q43^_`Z]U1OYDZ?E!$7:E\/Q\9.I@P,_RCW1^==?N295^DQ@Y%LQ$FDU
MF;4^+-SQN28TY.`TJCW@JXONU8%^#9AWZ9ABU,.A4F!W)>=W13)\Q7*.)']X
M=U4.,G1^B;S`\28^3X^]S*J[>&&0XT_)PYO,'RDPJE@&)LO"M7U8!'S"LR6+
MCGUI!<8YKE@TMI4[RE]`L'CJ"*478$&%48C5"L+G@+EY`)J'L6E8F2$ND-Q#
MQY1(!X$!G(+E(8G@O+(='G\ULI\83]1@&#(F\J$#BB;+5[LX%/0ML,$?,043
M7X/R/,ZLEPMH/\%2$CP%=;HBT`)6B!AE$&%(<V`_\O"\)*2X8X7)*7G-.#N.
MT_%$!,YABH\]'%(0,W+16*KCF`M.1.1A(W+.=JLP*?(!,@7Q!\H%+$=!;)2,
MPO21DMCCTOP1:[<>;,P=@97]'83//G-YD+631A$"S9X*0W,@X;KBC"A6^P%>
MI_H;":PKR(!+$U"*5'R>Y^9@N0T>W(UU-T1NC^O!,B-E&(5C"E`L`G:>DX7/
M7$`1QC4*[$ITM%LN*Z;F`_A4H@G4#$P\HM=FK-4J?Z;=PERG`*,*X:.R-<^6
MYCY*B<JW804!$3K0:\(2B!(ZF>A/24Z3R(,A`A;SI"61]<\7,*%<&@ZTA[&U
M,#/I'1@F&_"H5IB5);*@U`0(#4\!MCT@OA?)_*[','2?/9`B)")@ZB?;3R62
M<.E(W3"JB`I_"Z+@8Q@Q(*]R23SOO"CW*$S]RB/A@M!/>)6%NSSD)F2`1+P.
MU$]C273VS1D![8#_B'.`+1C?YS;?Z@^VCZP&&WK$&-Q\X"D5MQI1';5VFHMQ
M)9@SVLP\(/8CD#;M%I_#Y>5X*!27..J\N#+%SJMDB5TEA(P=8^H%RI$P$(R$
MN1X,#BK8ZW$Q\E=AE%]/E70<)QVG')P0[TI\B*RF@5C&N2*KN,T--1X*6A0/
M0K7=*F%/&?HIRA:^Y<(@>\F1!(0]$\ISCV\4?MX62,5A1(DKI5;@\#)A^3!<
M=(FS4U"!ZFV8IMKM\ZCE]WIGH`ZL02G0>5Z^!B^25*A.5XQG5H54]3(M(I/U
MY=,F$_<(2)@51D":\5C">(-(PBWNY07!@LLO.91>\/,['H2SS3C!2N?^J^PK
M^_,=;"E`;+L+.`IT5#DYMK&`&H=W83G#=DLJ0Q5X.(VHI`_=KFI6]G!=&\8J
M1^)I($WOZZJI556L/>Y`KI6W^"W76(1^I7S@I_UWZWH_WJ0[N=M;FX<:;_[V
MT&]:.IPJJP:&GY0WO_%.-X[[DW7<;S=RI7$.8]P9W=LWDI05>%OGI'J3Z.>6
MDOVAOQY.KX<Y1,V==(>S?UY7V-2&K[.IP><AEK.$1WA176E@)@-CT;*%Q6O)
M!BV:*7!+I^W[PBX7I\ZH#-/T"&&%QKZ./7NGIN4:DCV#[3(DST?NUQ+UJ+]Z
M\=^+S-X?,V>7%\1)E)+U&/TW6)I.5M\IUF/&JA?.]$2B`G,$$Y%YTT-#Q83[
M96URA@YY=#7R%_V`9N8GX)2BFVLJ4.U\4<&BQ2,1CS[9D1>F<=&1AVOS$E',
M`DW;P@W';;1HL"<\HT>+?7,8>0&9RR*"'5Y.T?'#BW6<*UE,'3+P8VI'=I`P
M7CL.,?61OXA%,:COAW*#[U.0^648342_926=("[?&YU"8;MB6;X@3/A>B,C+
M#!B"+[`8-?<UT':22"N_[89,O"Y\5FA%0S,^0*5@=3^^'QD(`K3T`Q1Q.D%/
M@22CV,$/*1&1"C`CD7+WV?S\*"5S/(Z`_F&$U<.*2R"2H86<W&Z$6>$*@[>0
M=8JXS=F`NV!`LD6/./IPJ-B/R`;"H;H$IN<1"[#T2^:TE;X[)IRS6.K[B454
MJ3$-?.]O]&5*[]JE=,T[6.`_)D2*(N)L"!,FLX7^#[#YF^D/-7WM/)\WXGSV
M%L<_%!Z1LAK%<V0_8V4D&-3VT4$W`<70?D1W8_ZI\AQ&?Z/T`:G@H*,;]PF6
M7(U'L#71-QV30QJE5<*K%,'N9!&/L<!Y(JQ`]3><YPH:LW'/9?N1)`=WG`),
MHBX<"O$HQHI4*B_;=A:FB3*FZM\;^+CW781DIS0OM2Q4BAT+%[%`19-#7F8J
MX4IAPJE&YS-\[,KBYIQ6-CHO(QMO"&=4L%80[DETFY%1%>C,9BB4?8S)$(3-
M-,X(XQ^`RS!N!+Z(&'7=TC7N=CU7/J'D14>U,@UF%F.!X,A)X>2*.</A;^6)
M^1,10TV":L/RMBW(?P<7X[7CJH^V%RE4_161F:N)-[F:N(B]*+K.CJ(70O*3
M'&-:6U/G*7TJC\WR\L@(?BGA2HL,8K+S8(ULC(G]0B[JJ="J8HP<*FD\*D.A
MH(P8P>%*4:%.L3+$I7.P76H"1Z(,2U2.4$NB+DIP;0*E\%SY5>H\LK]2QN#S
MHB$`&*YB#6V'MX:;:E7"*RE+Y"D9[F@AA9Y.I+I0:;5B?SKX;+H2F\9W"@EZ
MEXKLH09?6"S?$C)PH;#V9DO,'*[%R*V;/'*+APXM/&\+;V'0R4S`%[^$%([B
MK#N@#Q]@1!B&N>&YR<4UCWH+;`(T"(,SC,IA"=>O^3XIM/>B>Q+6\D6EFRY`
M?$.)(MX@U#$@%3=C1.&)18$Z#-.(I+$I@F`62OV#,\LQW,^QUI_R"7:96\TR
MQ<M<Q)X\]AQS$8%-\?`LXS&*3%YX"V7O^4F'EQZ&!!3!GIC;3):AF`<->Y&3
MCE%J./2)BYS!N$PIB1]^3:9P,;IN\CGAEDQ]V;!RNK@]T75=N1DN>CT[\!$4
M7N:28B3Y@/S*S=>(]=0B9OO>?VF7D212"^]3\"-,_`QWUP2O=F[X3+4XJ3M4
M?837,?#C;R*8M.H<S_MP86^J+/R4`EFSR-1V2X0K*LES>!8G;")O"-PRP0LN
MT^=\''P]"W$E!52,).V&U*B!8>U^_MH8-+4THCL[R_FJ_*:'U5?+54]1`8QY
M<P/2$IBP&0WA6H)BT/9?4&7%S@&B!8"2E.$E)<*+\_4()J='4!32,WP'D9&D
M!-$Y[`K<C/-.=<'UHB1UQKDJ;QLVC0`OSB.0`=SLUL0U`YC41RM*07,I!`MS
ME%0_`V.@8<UW1,"GB%6,X93!D/>`1U8F.0?,/`X'PP.R`:-JI>,'$;PM6C;X
M?LB/'X7C^X%"6($/QCP^U1,Z3B2[UU*B&37Y1;>:Z%+A"`Q(^TQY+30`O89]
M>"E*-HU`\,48\.\YC(.2KR"/K"8U,!;JXHSRE;V!EPL:=PF^RX9+L4XNW^;-
MCGL"<4"9)9GZ1I%>5)X<SUZ5[LXAMNJ,>*\)M)\-B\,(-@PC<3L273@.+@IK
MI\=1.XLSKKDCD>":41D:SI_GUDVG\#PV68G@Q'I6@3(NMV,B9Z;4E@R3?S#(
M6KQH/]N1*P[LK%HU5\50AY,?@:B",Q6)J,I#%PY,6R0>B=XU,C<!M4%LB`7,
M3=/AMRH7%4[X&)`B-R?H>$&VR4/Q*C.SL_@"9'`[@40Q[2+OJ30G=5&MM`V0
M+(L]?!VNZT^P.66.1%E^YYD9LT#1<F&73+*`:0&I2TVZAP+(/&+_5W1VGMTY
MHY#R1/B+9R@:R,P5NHP?;!(B4I/YYJ4[8Y&0!"8P0`FB:5H@6DI8_4\:XI?<
M!B:$4EE8>-B!!=6@9\X]L9).T-HLNJYDH?N<JP#Y')K7F\).8#_S)&B%^@<N
MVL.R)YN2V-^*YH.2LS.B`RAC8YD`P/.?Z$W<1B1^47.V$UXBG315LA+`+@XC
M3.WDR5#\L0>6/#,VE>>5YY853"72+86"_QO<_4BG6@"K.`$+5W>`CR=_`7/.
M6:XJG*VT&^!3:FQ*MT,R28B##]9,'*7.PXY4PV1Z"@ML8G8<CC)4N+O'23(S
M@\\;>MC?1+83$4J()'ZEA%_X!3@9A3%;A$.<O#AT?O7`S85;-DE\YHI=*1)Q
MJ&OK<K)CU7YQ/R+0$(TBIV=:DI87P"46UXN$(UOH$(08[FZ"@0KD$`,@--+/
MG;7+XC*.`P+WFNE<'SGKHB45/\=.*=D"ST6ZJ\C^R<7D_(%*[PHGO>L]>6Y*
M/CO'AT?%61?G!CEQC(G?"TF(W'*&[CODE0BYVIG/H")GR4T=<J;"=BADM^5^
M/M2G58F,<`(W7^Z#SGU\\"VZ%MHMTI>$2X_R@O#6REW;2(6L'6_$XQ1FT5*X
M9\,#V9T7KZ=L+?_#*3J_CF;ZDSGQ2N$0\D;,R]0)*<5E".XINJ(X6?@/II3&
MH@\>3^[%QDYEB9HE_5)/$I3IO/H=Z7.@[8;!8X@RB5O\9/._0@)<,5`$;VY!
M"+IP+D%!N,.@#Z)3!P)0D#2JD"&%+,;,K).KJW(1:I:%7,Z:DU7\\((?<P.Y
MO#:+LZ'<XCOF*?A,>+E`(ML^R3W9=9N?7N@#A<=`I*#^+F.5,A$NM+M2JO9E
M4>&^R[5L)$7>_YB`BO.\<!2!*&:DSU5V7EDA0UUJ*S+7.&O"N+@/3+M5;N-5
MI#GY`?/V6^R;G:5C/[PH(CJ&GQ<$!+Y,^DH*!WDD#QX8D!_SH.N&9$O&)I1B
MF630Q)"OPCQR8#S3:=C"Q(O&,WF(2#;@(KB!;KQI#L>(6/N_`&J7<M8+JX^I
M829=]>&'B7R='"KBG"BT.Q)&(G2S`!5%<-Q\(-ZVIBX;%'WE,J'RTDT)_UPE
MP)V*$8AH&!-^"[)7Q2-O,N$*8.*!_J=,;(J/RCJ!LDBHN#QNAPN;%](-X!2/
MPP#4TA>J1D`"XC?JVA1G,W-1)&X"Y>J@U+Y([)1290%UNBI!UE@5>6@(EWZ,
M;`0Y1)SX7<%I,U/BH&B#*^J:PE#&!50\@Z=SY2-&>HZX]Q[N'Z"["(6<C@IO
M_)!&='F$C5S`4Q'5F#&>JXS\;DNDFQJ<NNLB&3)_4AGWU6.68T;?]M:X<*GC
M)K>C`YV^1.$X))[!2)F%]]JIURA@3[S'J2]O3D$L#*T!Z>C<4L6;<^EJIZNI
M`\WD(\#O^@`SP`9"Y"W*<:^#`EQ[)\O7\$6H%$6Z%<A9]O9E>EQ$[[T4PR"F
M8K'IL)?=H&.,D!'&.6J-QXT#N8P`]<T!RN?Z(BH_\-!X\;[DLN5<X4MXR4.S
MEU5&F&X!9\><JS!=`$]_K+(PT'6U/S`;CEH;ML\L4:@G')P)RAT:`Q<)!WS2
MET\"A<<@%<AZ6'J,+NN>0QX=X()4],&F.S\5'9*CB`#G9Y+_*$%D=9(@)<H3
MY^23Q*78E+)Z>EZ"C0J+S`<.P/`)HH@-\0@7?IVL/`Y]+<O?R'Z+"&G!V(6Q
M:&01*@:?I>AXDF95E2)D8#FQL`>@&9:L#?!"-IG/S;.\$(98H5PR:L%H\2WU
MCR^^R0%]8C+P&B,TBQWE"^8Y=`F&>"DHVQ?+UG\5ME5$C@%5X;`GO$<OZ/W"
M@,&?Y_L],TQ+3'/[=+`A16U!3_*^RB66K'`+<8Z?RR7PT/"R<R,JE($J%=[!
MAO>@L+V(%T0PJ/)E#K+1NR"QS8NH<1L.77.GJ[(@ZV<9#8+MVJUL_W#>7%/T
MV<*_*RR2SV$*8OJ!40_ZLPQ?AY8L=5&&YI%0<A[[)NA%QQ6__4O6$IP&@HQQ
M/:B`7*[(OZJ8SGYQ?3P%=K:<N%JG,C.\Y][_Q=:VUS-[>\=KVFZCO:8Z4E,=
M:6\\>JA*$=?R4"@<^'1<_%"!AUW6-)@FR8HB\;"E'@ZZED/59I#=$W0#C_7E
MG16_E-7J"@0<I)#4BL1Y54VIGJF:YOY*2ITP)HV^I?8M:V_@UJ@''=]G\U?P
M=?[U=-=R;S\E;CJZVM'6:\WT%BK_&)3WODN0ZG&RS`/ZKA2Y>!KT!"[O&VJW
M;S:</H,90S/5;DV8?7>2OK(+8Y7X_U-8`6MY^:I/74!3U;H=M;>[PHPUOP;7
MAQ*ZVC,MM6/NK$1CC4\UPUJ\D4]-<C>%&X^E<./N3[57-%^\#Y/,0YDY,M80
MK34J*;B+^2I%K*7V>J9JZ+V-1.Q)MV#<.TV`'I:A#N:T4E^S%^-J3?[*C0$O
M[7B$?Z_S`B(7@7N'%3GN632^H9P[BH3=?Y=`::+1M'^L[A!\5<O`>=)PU2Z!
M>:\_SJZO,$*1$S1[FR).S.J>>Z5G+V7A/OKA>JH$8(&$%4.N7P(T$^E[]I-G
M\^XZ%4`6=ZFJC(A><YE=%B@C>$;%@'ZLZ41%"KU`65`N$8<;@5CP7Q3?@Q%=
M*@(J"-5NR11K$91F8_B,]^AAVYTQULC!>%MRTV-EIS%LR!&/_)?%`?*(_'P9
M"Z=39F:#1<Q,]Q@Q#)^7K8`*$U/\8S;::G$7.R5C`\&Z$)S2)KZL+(E:Y/LY
ME9UT'JU+84:B>!#5Q^1YIA3M`H?&:O$NNZ7ONB$OV<DHE6P\=+9Q,C:A$UF(
M2Q/74DOB-'$M;RZN97GH`1X3%>L_C<95ECKH=U7#W)]S_.0PB&RI=_>&OWU;
MHN<!^'L8L!=13R5OH'T:)E9#[6E=M=]M/*K38YV]$9OSPI.,V![+VE,=H7%*
M?;F':>`V/M1J$^9`M?0>4&R]/=7X4+=/B?7V\''Z3M^"+&Y\I(V/='EL`%YA
M>*7`:5/7:9`:#A5=UU2STP1Z3H_UFFM)S2,]WP+9&KG>R/45M*UIIVVC\"Z:
MK:-:/6OMF/?FZM%</9HCJCFB:HF:&AU1"\(SJZ*5>7AF=5M2[U7'6XV"!/?5
M"]HPU$[?6OL"]*8"-O=%B]?<N+9%B"8\C\N6Q8V+BSV*@;9C;''@\$Z:O$/W
MPL;%HO8LU;V.7'@FPJ`YK.6(83^R^8K:;BUL:PR+CKS8]:C`)!]>M":6S8TI
M(F]<\*KE#?9$"T@,%^1ED^0B_CB_.R\6Z9T)'Z3"26FQEW*Y5[(RTRH9HP*S
M7LGG/%ZT*)L+W=+([5$"#$OQ%WTB0HIC:2"`FJ!]Q-+Q`149#A]\[U&4#Z;R
MFE1YBH-+U:-R<*=>/2^&K!9`PG;!LN$:KQ$FH(L78VTFYI+7M%T/:TH)::7@
M2BQSC*A(0H4WTTQ*H9#X>18_*=LJ(H\]^B]4P2IFY7BTB/<S\GB;T+QO'!6=
MK$-@9<V$01:0I_"@MZRO=J&#B!=0JQ%>[[[4#JC=DD%_:\;S[3=V;]#$[NTV
M'DJW:.9";];?>1GX,6^H^@<6R=OQVHXFG._U;+Y=4JX$QW3,F[R<E'J1S?0(
MXS*A#L@Y32K\;]ZOB1HUT>%M\U8[7#6*E0^?V!/S%?V[.F#F-$E0R!43==+#
M!VS0)1H*3=*<#$9#AKV0(0T6DL`\(`GJ=C!MQ2ZW$(RCK#37K*993?ULR>+V
M8EH+HJ!?%;QR&C'EKXQKV6I8_J)1&A2>%@H7;;_24BM_6L^Q^_8PO)A)ZX?A
M0]4Y:F)>FIB7TZ1$QU0M8]!0X@U&'S44.#0%:E8XOXEW:D+!&M0TJ#F6`,(=
M*?FOB!K,5T,NNC6.VC<8B=9$!=:+%EU3[?4VNP(TM-@"+3;30!L2'"T)FO!8
MFE6$34CG,483_J<4:O$A#63S]>_FQ%T,PZC=\EQL%NG8/K8691B\*L(`%@^+
MW3MC;^SY=D3]E%DR+ZH#^[_R$60\:#'F0'0`%>^K"O,H*L'U(N8D_@M_._LM
M&45A^CB2P;1.&$7A@PC15-LM`BA]P)ZJHN\E5>]+?5_!SJ=9.;]2F&B4\NA3
M6FZ[91;7.\\W_T`%,\,`@`CL1XH5$\Q@:/K@1UCP<T#+2<>B^6H:\X;Q8QY=
M)A",D9YYN.*Y<E$,^J5'RL,Z/GS(PV`QI-'#*-VLGVL&%*[/#Y]9G+1;/A&0
MP.:XAW?B0N0!@$3HR&,FQWG\VTS4Z6SAX5<4$2Y7(<8G@B2,7OZ,0"&]`L2]
MNL@PD,KC;WEQ:!EZ[Z\_[J[>`8H<;VS[,<9%_J)K_4%7Z^<+F)V_#!]UEKDE
M*G[Q[>!:-.S>*8S&8-#M=0K5G>?",`?.&^`XYEZE$59_IC;"%-,(HH.^B7<*
MMM$U.SUM!NYE,)67\<5^X=P27CC`4A'[$H43%B4ON/`$6`L9;4)AYKM<RZ#7
M'UB#?"6K@U5>SF>,`&>WPUMX6$3$[ZN$]JH'R*NJ9BO/GIN,?GZ'!;I7"C9>
M5$)[6@V@LZ]\0.(G4_=)_"@OOIU__97WSRU])C#R[5U135A)AUL?%GZ6KPG-
M`_ZH5Q?]7EV/6AWHUX!YQ6(G\B:RI_>O(D.F`O;U];,YK:+/YFM)_%_^U6YU
MM]VUK[Z"4])6[AR/!0Y^=Q,XYSQ1$M0#5&0\U[,C[+;^@72D7"&X_%&DHN0?
M7?WX'1[P-ASB+NEQ"7-&0>B'CR_4CAWS5H:ADW)%`=-0L)1WS!YY#HK0C9[#
ME")S(JG`3>!:P'Y0)B,;8'58RG5$>JS=PN=4Q7:?,%_&+;Z,JT@BV_5$;E3A
MJTD4NJF33!<L'V$\=L`4-TH?X4%0^EP[85QQP>]P#3Y#]=-6OF#5<E!-XR1U
M7W@P$2S].8S^IIR0\-F.*%$)9K<I4TF^8O)7:&J94B8KO\6$=@D=*KF@C$V$
M&LGU3JZ(*C$H.W&[%;%)Q&+`GHT*+^F^E-<44.;474+Y2A^*1,,LI1+%5.42
MM$C7YFLHO/TO@-H-Q].O_VOZ=?X:08>I8BX#]0`U>0`5NT`^I*#>9+EN/.(W
M9CXN`G.8HL`6]!$H."\EVY454$JQRH9%*3"$,\(''#.N+8."9XMDMKL$1OH4
MIAYP]>]>'(>@`A"L_PSA&A+B=F#?[+A$!P4&];W_,KPH>!%PU\2&0[:\$-3P
M2R#`7!R#JG*=XKFL2$1^Q%O)M1TGY4G@E`^)GV!3IK"`A)23XE)@R/LP@I,Z
M5+%:+`Y.@WZ&TSX,'H%D@$M[!?UX5@$H*PB_81KCIQ!4_?@6%#MD5$#8"/?C
M[?"*/>Q6S3G3>UU=TW-PEX)3AOZ"9ZG1PFZ'-[`+@D</)/P%O]WL5$GN=/N=
MOI&#7@W+$BUSOZ!K]*="NZR&7O!2\`AG13AF2*[=<HG9UP>:66"3.1!,@8A2
MYG,88'@G?V8?%R>SIQEF`<I%0$S?0)T([KSLBO%_;P+10B<&NI"*O=-;$P`]
MZ!3OHTN@F;KVX3'T%2[Y0<I^"T,W_LQV*S*Z<,W3#*M7N.7-`6'!'?_*BQT_
M1//"_EL*-?>A8[H/=8[C/B0YVV-OY0ZTO>D+N`-]R_%3E[VFT\JVP5HO0;MI
MKK)15%G37.6HB=,T5YF/CC?=7.6C%\"5D;G*(RJ#%9@XC82NGMHU.JJFK1<$
MTK19R9?:5WM&3^T;Z[5A/Z94F'D`_AE&?X/>TVY-HM"1-O2CCW+L=D'8]-:C
MY%N(_NP,^JK5KT?-[OT$Q'^!H]1^!'47;>MP<'JV?R(\/NAWU.Z:&5AO@<=[
MO;XZV"U>#AW>O%!9^VH_K\;G3;I0NZ63Z.E;31+CH2EAJ.;`5,W*^UN3P'64
MTKA)Q6E2<5Y7P-N3[IHUA.<;C'?7-;5C:G!WW4QX-KD'VZ"%H5IPP^KHLU:8
M2N?+;,!&E:]R*H@`[^W,C3]&X1A#63'^Z79X&8['84"1KSN.MAWT8+E6(8I@
M&3PSX,^/8#VDDU8:=33M'SOVV,X3S:LZ:7-7*]]4KS!;<2^1?)O<AMUJEV?I
MV3P*&J.2;L98_%B6K`U84C'0:WV1>TZ6V;97KXPP;QIAC0.R\7$U#LCC(T[C
M@&P<D#/*X.^V,_("%O&^"TQ*_@J4G(8?K:MV#$,=6.O=1QI/9+[4CCKHZX#!
M]?PTQ^Z)_)A&<-](><8&]LKYAK^<B+.FVS?4CM5I;&#3>+'ZJM6MA[/FH/U6
M/V&4->_@4[@5U%(!J)/?0.]9JKZAZ:OQX&R#$EJ_JPXZFS6G:UJPUD4N-VZ;
M8W';;.W4>CL4'*AF;Z!VM5[#VU-C]=6>WE/-[DXCYP[MD:S4PN+XAP+HV4_8
M-S$=ISYE%;N8;>UXE./9Z`65>L&'CMH?:*JEF[M2#%[5F.AM44#7!J`D[RS,
M:98"34S-"6@@#6IJ>X*].J:&5?L?UQ"E;S"ZPU2M/@C2@;61(&T";;9"BJ[6
M5PUK5D]=,\YFG?"3J9('S/>]X/$W%F#/;GCUPAUCRED240V>?12:,'2]9_;[
MA>";U8":*3P1CMF]_4U\^RN\//1V7+YAT#%+U0_G@E"&$^L[PHJFRCSR6G[3
MY2IV6SBEV].ZNFF5RT^N"MJRJA]?(C:Q/?>*#5D4,5=@!$:G.B)[J`MC:8;6
MZU65`ED%Q/(RKX=#YB2WP^MOSL@.'ME7N$?=!O/1MN-Z/;U.@7#KP+5@U^PC
M3FVZS,=T4$VQ[(<4MT.`8;6PM;$=/7K!61).1/B;^(!K*3R.;9ZZ\P2"$TNP
MG=F^]Q@LCE,CZ&"8'Q6Q!OH9$73F484P^'U9!)L<@X<R+1F'OTR!9[JY6@4/
M&D6L@Q]P*\!*@W)&``7+_K:%ZAOK4DU$>@D0"PM8/=YM:U-.XRF++<3Z:W&L
M/+!A&&'Q8D28DB"^9-%EY879D8+UXMQB&W3<2#&<7E@3$,L$%H+BJ`A?&.#&
M7!P?MS]LKK9/R\Q,,7-BK^$D9915[[6*&P0N^BSV_LOXRLN+$5>*U97#F='$
M^C+IH*^D:A9B@U:"4P89/821RZ)LLE_+9A#I?*H.O)H#\8_*U.PGAY`J:\\V
M$++@"EP7/MT9!=:YJ&V+QXYQ,6OQ![`UL/%CA)59SV`I831K&JQ2+2@*;V5^
M:K>NX`""WYWE"H<Q._#J9!1CZ,N`RTZ8JNNS',Q<-AI=G*7Q%VT6IJIK5>;W
MM<&L,KF?"-X,U30&JF[U=XNWC7?)GVA@?+5X77QXM5L?05>#9W=_$HK1J@^V
M55&\HC#;:+(2H_3Z/;77V_2T7;B:JJW6X+_=,O&$J(RKW`C]NSS@-MNZNU0F
M5@$C0]+F0^7T/#!8=8#AL*C9C]:V%,Q9449^`AH,30GMUAQ;PB:2,A_^]>*K
M[,I85<)4J2Z;3E,ZJ+`@EJ;V>U6:X%RT;$,K;`B`*J5F6.J@4A7?,@%V:G,L
MYI;NW?JXPN38:B$W$F)7D9+E\<,#=S)]-\<&B?U0<B,D-1&)A>EQ^];&C?#8
MV!T;NV.M$')"=L?+-(K0DW%00UWQ"#EVH^.NUU(#[77&L"(%K&YD$O8C<S$Z
MXW#WDBJ59T4"5G79/9X+6MT141OSX!PNIJ9BIW&W/@UFKJFUX:\#B>EU74-S
M%:IJ.;[40K[8&5)E>5_71[)7RVW1G;(]*[INJIU*(WIAN3NSIS?46HU:1K>O
M:I7%U;=%K?H>C8W4;P[$&NI[.[C`5)Z&F'$BS6V48.+P._/N[1A'[;5<?MXU
M3N,=HG_Y`=:<6HUH;E!S=*<6O2C34K9KMSUQ&C:HJ:O,KK<I>9ODU"U+-0=5
M#>S>)IOO`2_U$>%OQ>:,+1OFI"^_=5[?/5IJ(\ZW9V9N[G1PI1X8JF:N$UO5
M7*FW:M$8@.S?V95Z!YD3V[UTG)H<;FX=S:WC-?9?5UR^&W%9*2XI)Z\JMVQ7
M!LB&#$4RZ-C_LU]ULZJM(;@YO@XOHQO4',_Q)3(IEAY@34;1JL*S.U`[YCIG
MV%K)+-LZQ4Z?#I9AJH/N.HD(VR/$Z288S4M*I$_FE3?"5*.(.6'@>#XO"UU.
M-Z(\I!1+1]L)I1K]$7CX&]DSXW9KR,WX`+*=I-CUDUZ*\$LE"8L#,5%6T/;#
MX%%Y]I)1NS5A$69IV(\,9_5?46JIW3)U5<%T%JH+BFD<BA?O,NFI277:1'G(
M$B]T:^UR+]L#I.8E@#;.D.HV*6-[0<@)I8SM>K^O18$-]*@WM9B]YB-8VCJE
MJN[M;UCK@!?D!=UA5E&(JCVBM2W'M'2TLG=!M3J&J@VJ.K8<?QFK%=G[52@T
MK?,5\RM6@_4?=4/>]IFNV\?>A`W+U9?EZA!.2W<XO&+Q#NY8J%9*:2&X3\-N
M^$'7L9C@YK$9:[C2ZXP/X[Q*,KQ-V_*'OJ5VS*I-_Z98Q#JO=R33=GU(GT.T
M*:5.XCWXK-T2EJHUC.AU)J79T]2.7M7=]*WN^"V(P1/9[GJWKYJ5WN0WRR-5
M<7FOY9$Z*'_4\.0TJ`3,V^]6%5)]H\RKGV\N]4]$P'W00;[M8BL?)3;J7?EG
MMYG@--HEM4QJM[Q`>;+]E/L];?07VH&S1IK&VPP]4_5!1^V95<*E"0+<!R4^
M&/U*.U63-[#3;:`9`W6PN\R!9ANLN@TZVOG.(I+KJ;V?FJ[:1+TVJ&E0<W2H
MJ;.NGX?/MELW36CTBF=I$QJ]!$%[GW")&6>SO@M5L1!UH\(;"U"O+R$.NQT,
M[7R=M+=-]\/I-S\NG+E'.=$JR18[7UM%BL4=/.0-01\*DJFN+IC3<`F?V,&+
M(+BAZ8,?XRP7F1(G;.I*WVYA?H/OV0^>[R4>@'J@YB[E?J1-TD,M8],+38#4
M#2TC6[T#'"%YFO8[^T%(DTNQ&PILH&F^J<7LD3^N"L<[G.MTOC<U/QN3W/&8
MY%[?HF1.F;C/&'P^89&=P`,\"]BQH^AE&$;/=N166>QJFZ^Q5L]V2^WKACKH
M5<4P[3@_XN@Q:&@]=6!M->6E$H.U*1,RLZ&N_Y-ZR4N[]6#'S*4;)PMB"G$Y
M#3EJPE[I5NZ5MWF^&&97-<PW$K=?>:!<R$@NJAP1VSY#DPH%^(?!B83UZR:<
M&D83UC^#%\M2!V;5[?KPNV"'9=4OQB%`\=^\D@O:([VA!R>!%R1V\(@I+J>R
M!=1>QU1[6E.+>A8S'7V@ZM;F^6S'?QC<!$^P!;#@@.WB\V.TOI\&F0<#0]7U
MS</:3XW]NYVN:E9&,1R>^?==BWW-?)\W&4BJ=T%H#IKBM@>G0Z^O=BK;AC3%
M;8]2,#?6X6.W#N^[-OO5;"1$(SPKA6=?U7L=U3I(;?"&$J586G5@F:K>KS)*
M-P=9(ZT;U!S=03;'C5\(S6M\^0V3UX+)]V-A^Q*QB>VYRFG53?K0U]6^UE0$
MD^@P#-78@K^I=OFTE:S]6QBZSYY_(FUJ/_0'FFILP3!Z*CS=TSNJ5FGP.QA3
M[T=T7[%)Q!SOA*)#/NB&J7:-S<-#3H7'#<M2^YV3%MR-#V2;Q31Z.ROLTY24
M68+[;J6"5;<Z)HV)Z/!7Q`8U=341K>[6*%B.3H.^'W30JC$8=?.*LJ>BA0WZ
MAMK7:JF%-6+\\+*J04W]Q?BJ+NM_-Q5%U]5[^ZIA:&IOXQS@YN;Q6@KT5,VP
MU$'/:NX?C71N#JZ3/+CR,E&?6=)NN1O?00Y>B>H`)<'@;J-;NFIUUSFKUBM"
MU1!@"0&TKJ5V!E5Y#ULFP)Z+@(E/YA63FJ+J(=N&8\^XN3+D!1//WF?[1''"
M(/9B7O+*SEYIM[*03GH>2-KO41-O>Y6ANZIF];!X!GY2+'=$S<#/E240%F""
M0:HF$SY3)6*^C9W/DY#J=KG>$%YAH-S'BA?`8N"S!QO&Q)<>A=N8\D^'7@!W
M`,_V88@)9N<%C[1,G&J21I,PQD;J3IA.?!@>&Z,#!MX;'1V48J-J#1_>H^;3
MUP8+9/F+P.9L-;$<X=_)=<$*PL4%R2[MP'8].Y!U&@![',6S8[=;'F+$\5.7
MD@Z5R51X"$$5HBM&<5)X-TA$8"\^#!^W6Y<P/"JPA.]?;9]2>>]&C"7G!^7Z
M&FT^>PR:0J(\O"C/(\\9%2FG.$"G-`$.^"]3/$#K'X&'B*1VCW'>XS%84G8#
MR8'#O3`[4H"/D3IA8OOMUMA^41X8\-F8!@:5!6B)$-Q@C9X`QO[*GEB0(D@N
M4(Y1XK5B]HUV*V*/,#C.Z%`3#IHF?`Y8%(^\"3*F$\*>R)CL"D9)PG8K!1Z(
M$ML+J/9=#(R#JA*.LY!IY2X`QDYC0D6[M731M#-#V!4VX0\'Y[P:S.A,G&M5
MV&'#%/;ZG$XBR@CDTP-CN`G")\_%;;9`8M'$6`:+9$8R=VMAL;^(BYH23>E=
M\<F_8%UN.&XV"DQXD<SB62UM%:3/+$N`-"[Q!)Y;$Z#@-V\,Z/9?X`0RU*YF
MJIK&R;5@AWE9V>E,T,/L-FQ;]DB["66B%S'<`@";<:Y\Q'H%.`KVIIEY^36P
MXR96@I1P`.OXGS3R8M?CE1`4ZG\3O=")1`*%6*G=HD-(?D,P<L9&B1S/L-;W
MKO>$O_WT?1J?/=KVY`=>;_O>_G;EQ0Y`E4;L'HCTJQ\Z?__2;BG*3_F3(#%8
MG'S!$P(.9:3E5S;\^1T+_;^^7'=[`^L,_NBZKIW]2X/M\=?=_=5?9K?S%Q)3
M-TS]+^T=2""/O^7%H67HO;_^N+MZ!QO(`8+Y,1::_,6PK&[?*(*83SP-D@.[
M/V;`.O3O32!3B%'R[!3&@:%I5@F-BR$I`WTKF>!:GK([!=0P3&W0Z^>@SLQ?
M!N]+%#J,N?''*!Q_!77@A;*P;X>?O(#!/Y<@YKQDIR"?F5JO`W]RD%>":89;
M10F%"Y+'<]C[U8OX!;>2V$GB.D,55(6\_/WBZV\WG\_N;[^0)/Q1^7C[^7XU
M`2I>_?7V_O[V=WI[M@[K=)U6*I;T\SM=T_Y1M$!D5HQ_7W^]O[F\^'1V\>GF
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M1=AE%=SIR8KEGW&.%0LV;V,A"^S2#7'F$,>@B9>4:][N`HX"'57&[QWRZ*\7
ME__Z[>OM'Y^OSBYO/]U^G?4!_JALRL="[G6Q(N8\J-NMWT$Q'(4!>U%\ST%E
ME]NGJQPG8M!%8ZY$RMDS08RJ+QBURB)?'(R@ST?K+%QX1^UV>ZI>&:2Z-I0K
MNKI/`X/6WC&X\DYZ1F_CYMMGY=U/P?CMEE>I/-523G*B;,#+ZTPF6&O^;*9J
M:AI:H3:Z4BS$W(K+:2C1;O74SL$HL>\M_FK2;E%P;V6H"HKN&ZPZP%`KU!Q0
M`WP+1.RK@U<H(F\!,[JAZKM'36W5LD\,?4BVXZ3CE`<\V(62PHT64*D%?##4
M3M=2M7Y52>*-U("JX+"&`IB^JNJ##BIC^Z-`HW\=JY+1H*:.^M?T9A3!FU,N
M+DJY6;1)[S%02:FV+>3>K-7$J0!CNP*U'`2[JDRMLDNM.4VE-.VJ%D:Y6%59
M(<N%:07B7FEA>).D&/1TM;I`P.Y(\5K/;ME1S=V5!_'V[@*0FP"#/0(1W4@Q
M4^C>M9W_I%[LR0X<^%'N,7@.(]]]!L&$!0.+S@/E0Q`F3-$[WTW%<DZ\A$(1
M7?J<XI9=$8/;;E%@K8U16]7"C@?K.F&<*!27_`#S"[T>!@Z?6`3+IDA/C&<,
M^%PB8%<IQO/B7'D7XW:+XC5C"BCF?79X#*]2"N&EN#B,KL'';O,(XI7HEQT+
M)\,W9/E><C@I$8M3/U&&43@N<A1%BH\G/DMX<+6A:5T1.JKQZ'D1V2Y9[U7!
M!OO=MDW8P<%<N3/AL7M;3?UPP\<M-5#Z`OP;NG72C9=[IR_AT7`,)/5!"E2@
M[#0<JOJK_"[U=$E+QERV:EUKM^BHKJ4EXCZR73:VH[]%+'F"ORN!/:[,+#VB
M^S=HX:]@N<-:)JIDGJZ=Z::R(4/MW@I089*[Q)3JH>>([!M0@B91B.T>%9?%
MWF-ER\?&:-IN&2<71#"/]U\Q0Z<N@K8QJ>S`I+*=Z)GZD6*G'-18@N9;@GAN
MX7ML1$X\A?=O3`M]47([RX(K/^:$TIW_F45,>8Z\)&'!63@<KF8@>0/X+5W*
MI%E*&#C"5:PI7DP)E5E.>LQ\WPL>5>61!92J29GR[M@+X-*$YJDGEN>KSTU+
M7V33(D/;,T.Y@^:R)_CBD6'^,3`#VOR&K-B6=P&X%3G">%KK&MKD>N<:@6V>
M#Z3E+F+Q!,V13\Q_.5?F8HTRB,L)Q_@#`S$QENY^2@1%M#)["$<G9IE3$KB'
MD+5;W*04U\B@M)9I:="8EO9A6LIMWI^$H?OKLBCY4[<P3:.(&X)+Z6,X:5IB
MF:OKR]NO%_<WMS!P`/CD(,-C#Y'RO3Q^IA+U:!VI?+#!-C=,H$]XQRNH6V[5
M3HT'TPA>4=UM%G,BBSF\&;S37VC!7:3\Y.OA.@T+4"7<Q`\B;E)+K,&;V'26
M7:.7FK.W?Z.64VJ+D\7T`=Z%MG&WWHZYOJ';2G335<T:J.:&(:P-Y0Y!N4ZW
MKW8.3[DZN*&:J,\:N)T:U+P)U-0L5ZNH^K5;:^M^Z]0V>(M>DUY'[75.S6=R
MA(3055.W3M!]=92DZ/8'!]L5C;IUK`=G@YH&-4>O;EU+UV&64K#,Z!:CYH6E
M95>L>M9P0(.:!C5'5W.@H5S#U`UJCF"_[RYXF\?7Z.>FL3A7&RO?'XZL:V:D
MS!NBT[<PDO0DN'P+Z#`-4QU4=F=Z4^@8:'W5V"TZ#A6-ON+NKEK[$0GM4]KF
MV\2+T>\<63;4GDJL=0>[YI?C.>&K*H@<$4T;&=#(@&.5`8<Y_#NG0<AFXS<;
M_U@W_L$/_ZJ:54=$TT8&S!]+-[O`6PU>IL?J&9K:V2U>ZGSXWV<)A!48:,HO
M8/1(OZ.IW=YFI?WJ58#A."EAZAVU:U2IK`T=]D$'+,'>A;.V*@UG5Y2H671%
M$X*W&LM8:J\';+.A$&VB(;<3#6EJ:K_;;TAQ:%(L+N!<6<=E7D?OI9V/RZV2
MO[(XB3PG8>Y=`E^*MM`[;?%LFA;(@!SF^2"4P?S,DDL['GV)PB?/9>ZO+W_$
MS+T)/GJ!'6`AB`NLIN$E.^_\;?8'9J]?:*B].F#E!163'VZ'V>.789SL=@F]
M7J^OY_!7P;&LWSK51<@ZBG.&VRGL74NOZKH^#Y[R&J[M*("OXB\LNAO9$?O5
MCCWG(G"O/#_%HBI;!?XO@.2O&*>)B^LPWOURIIU;@WPE2Z#B2W!CQ_N!-LA-
M'*?,O4HC>(=7/OVW[:>,OOO3CB([2.+K;RQRO'C;2YK>R=VNU>W\]/TK82LL
M[%,8Q[<!(,)_N6(/R?4WI&#JQ2,JW;/+->"S9E>LH1*,`KA_BL)!%[QNT.<4
MHV.);()F1,?X-DUBD,<40[OY&F99"<#O]_K:`#?T*^$J+.K"<2(@GI"_,3`@
M;:C+-(I@]9\\^\'S29+-.51>O;Q?\!P3QY@X88NU@$3]']$'79R?_.BL+CZ4
ME0[*&[(G2TL'*<^>FXQ^?J=KVC_>S;M=3-\<DG`R]]JP>0O[5W2&7U&]6A\6
M7@?J-7WJ![PT&OV\D9:Y.M"O`5-POB)9GTIM\:H_@ON5`OM7+.FU5?<.4@%N
M>ZWJ)?Y8$7^\X)LC\.?G^)-="GBUME<5OM\>Z(LQUY2[W[HQ:7D=G"Y-O&*^
MR2E6@JHS<;*V\F^Y_<`<=*R3B;Y%'MUG'X/NX@).0O9?VH'M>G8@^LM$[,%.
M&/7N4C[$C"F!:)M3@:MC:G5@+D2(J7=5HW\*C0X.@S]+&ZA]:[WB.,=>!4=L
M(MXT"%2HO$)^Q'AWU\3^=BJ-&3I8F:)2:+[-.`2CVU%-<[T>?L=SDE2P/3\R
MJ/(SEEA]*ET@ANQ4^-["@Z$RT/)M\KW5U=7!FKTK:QY_4RGCH_#%]C-#PO&3
MSP!Q/F@:U,^(<T-3#7,]/>9XQ/D:01QD2*OE':\^D31=RU2[YGK9ATU$T_;I
MT!N8JM$='(`.=3BB3DT$-Z4-FM(&&W>GM]=R;JPA7]]@G).AFKT>''1-H_H:
MD$+':'9CL]C=?;<GV]A1Z@N7[Q1LN3OW@-VSDOFMI*C8K<I[UE/3)]E2*S.Y
MV_)J6;2]%^14Q&(6H5F%?7,8<T6/^M)@[58:N"SR7S!6A?>"C0`8[PE)$RMA
M'C'"6V>A7=^)F.LERH/MVX&#_;%D%]GBF\\V`N3X=AQ[0P^F'H:1,N1Q9B!=
M(S;!`#28=))&DS!&.U`23@M=!3Z"0<+'P/LO3)3P_O8(@Q2]+S--V/+@R(VC
M6PI!,AC@A*N]'5[_)X5I95#337`9!@$V]0J#/[UDQ+^]'0X9AD+M-BS.&FB#
MOB;6^4H`YP>9R<%V'Y;8[<.Q/QM)5@)@)B3T)G#",<.@K=?"]I?5,09:YYME
M:0-C-4C/+-/2+%TOQ8#FD)2!Y#P6CB<1&P'?>4^,/_DQC)CW&'#N<U[N@42Q
M3;0!QJ3??/(!7+BHT&#T&4QR.[RWO_&HNNG@Q\W7;P[ZQFKKUS4#L)4O?U]K
M+&-V0;@A#W"C+V\GU.IOXU#('$=6IZ]7!N3=?/[X[I=>OZ,5N&-]0%=::!Y7
MN?-U5@03]SM+%[H8T-77":+KB44QQ2CSGQ.,<;]CH(%O%/7]BC4;NK[BHI="
MO3H"0'.@;_:Y4+-C6,9J*\W`6V./[FY)"_8EK<<<K+@S7[.D_;/I@J4BC^K+
M:;<BU`7=X-_8@#1XO!WRP:92-X@7]KH5I=:S`EP'":-_Q:+TWL#<1DC]\G-G
M]ZM<P)ZXQ'G:WJIPKLR0^]MOFK8:*];KS.OWK-5TOGT?>ON3IV44+*#OV2X$
M:I:"E>F_\7UXX<*5&MZT_2^V!RKPI3WQ$MNG@1]`"78O"Q%"7QE<XF(O@:&C
M)\]A'(BO_**,#VQ'('?,[J"_FNSJFH#27B&];,=K.[2JO#IJC([6[RY7/K:A
M+6]/LUIC>5W3T/NF^2I]<6^JQ>KK.3LBW6+U59E=JXNIMQMI%P)<Q7,W`9?&
M@M$PXBMY$;_![YYHL\TB)79&;,Q^?C=*DLD/WW___/Q\'C/G_#%\^O[RYE_O
M?H$S5^L/#+T+E,I?RX>*V2/E[?WT[2'R7>\']FWB>XZ7_,YMK*XW1G-%&/S\
M+N=9.V'X#K>.H3P*`Q1>%]^\^-TON52;*\CXN#]]/W>Z7W[Z7L(C5OY]:>D_
M30C[!>@3.TJN`)Y?$(=G&OX'8V2?9@^RP,T?TXTS4\>AW<)#/WU?&/RG[P4!
MMT--?H(>,S6_1&S(HDCLYS=*1%1SCYF(\/DX#-XP!<E^>\P4O'"<=)Q2M/LB
MB_+;I"QY)HZ9LE]98GL!<V6=@[=$QIT3[DC1HS5*X<;,KJU&36W_U&R4PI,@
M8J,4'CD%&Z7P5"G;*(5'3,9Z*84U0(_6V`E?S>I>@)&924EOEY_MFD2-GE=?
MRC3*6QW)TFAD1T6N1LVJ&VT.KCOM<\V-E6Q3MM3V3:)&):HO91J5J(YD:52B
MHR)7HQ+5C39U4HEVO69MT*A$F[&E-M@WB1J5J+Z4:52B.I*E48F.BER-2E0W
MVM1()=KYFN&3KJG5:LT8:-8],[7=K=G03*-;KS4;9YIY9G3763.F;-""1=Z9
M?&7,;"Q`\@O_^*?OY>]\"'QKZOUBRL?T(.*['^"[]48J-K"2@[H>]CG+UX_O
M?4['V',KS"75*K-SW,Q_GX:]8D$X]H)%`\_#33[F[,L_?5^`/5LZEW'PP_\'
M4$L#!!0````(`+.)?$!VN%H;)PT``(&P```5`!P`9'-C:2TR,#$Q,3(S,5]C
M86PN>&UL550)``,"?W-/`G]S3W5X"P`!!"4.```$.0$``.U=W7/;-A)_[TS_
M!Y[Z<IVI+,M.G,03M^.O=#3G6!K9Z67NI4.3H(PK!2@`*4OWU]^"I$12(DA0
M,@5!Z4/K2%H`^ULN@/T"^/&WV=BWIHAQ3,E%JWMTW+(0<:B+R>BB]>6A??EP
MW>NU?OOUQQ\^_J/=MFYO?K\<6GWB8X*L7OLS"AB>65\=Y"-F!\AZM&>4T/'<
MNK9])_3M`+JU[C#YZ\GFZ!=+_-^UX*NO5\,[Z^2H:UG/03`Y[W1>7EZ.D#NR
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M0=867[5!PJ?=HQEW6[^*`3\RZJ,A\JR(A_-@/D$7+8['$Q^UDN^>&?(N6BYW
M<"3N[DG<_J<;ZH1C1(+%7YNXMR3`P;Q'/,K&$?<M2_3_9=C+P7`1_`S]@8XC
M'NE8D&AL1Y!WE'KN;,O_$%K^^1"`YHDQ^MXG3."I8=L?4([%$->^S3GV,'(W
M@Z'8]RZ!#&R&-GPH-08(GE&`'=M_?6@PN>D8;0T@Z>9UV(,O,UT_/(,$GJD/
MW/#;;R$H[25Q^R`1=DW'$_@)$8ZGZ)6`U!M-.][74;_Z0S:GD-<V?_[DTQ?>
M(RYFR`FV1K?>X^LP?4\#Q!_I<NXNA^3W=A`RU/?Z$V$^P'3FFX&H-4+3H![P
MB,"*Y-@DN'0<L$X",*8&U,?`/W]$L^#*I\Y?KPU4<=2FP0L=$O^)V3&U??$5
M3)&'9\J"1\#6(U/$@XBR,4ELPD+38KFC-N'QS\QVT6+5&"('`8]//N(WF#L^
MY:"LC0EF,R::%HUX'B2@;+X#"92.U330`:.P"`7S@2_F*!B6H)^3R-AL'GBM
ML9M_XF!7CS`HW"7G*-B%ZJL,V33L&_2TBT<M&Z9I>+#KL!"YM[,)&$&(+PVC
MD`DSZ`[;3]@'DWTG*]U6O#2_%Y"1V(C$@VIPK2\:I''3)X!1<O:QH-W!`U<?
MN'$1H)'X.T03L#?`!-L%>(4AFU_3A<OS:,]VLIB7C-7X+BY</$H62\J`\H"!
MB\>B7Z\001[>R8ZV,1^->P!T/,:Q?;T#,52,UOAL#Y\X^A;"/V^GC3HU\H$2
MB$X:<!?Q]AQ4H$7$%<'$^%LQUNN'16,^.BN,[(`[Q6AGQ`GP`E++C>^+>#=E
M>4U(AH^"VI[-GZ+(=LC;(]N>=(2&=)`?\,4WD<ZTC[M)@/NGY.L_$T^<#^RY
M\*\2^V,QDF\_(?^B54'<T<AWZAK>HT"-^\(F]3"LST+QS9_*1MT*AS4;:Y)W
M.!;S`TFCB7>4\T^4(3PB,=/.'+QXPN-)=>G^-XR#&B#UO@=[H_PQO?I(6B3F
MNM'\AIEN8[='KNT)#FQ?AEI"K87SR`&5,1K_J(^OBDF>H]'!I0CLP>1=C>\%
MUS9C<[!]_[#]$$FX5VNK!158,91$3DPI@%4R';S>(`_!\W=AYF>6S7M*G%+5
MJ6RF`\OOE+HOV)<M&\N?=?"V&K*"Y?9VYOBA*,VHX%NIJ1Y,2?P5.)+RGB'1
MP:/<D"BBT,RA2&RLA3ZJV2YNIAE+^=930*B'7X)XW[N&E0Q76,2%I%IXSL0"
M*U@NH-3)<2975\%QEE('QY$QG:RV55MA,:TVKNOLXB4-=/`_8(E546DZ%5%J
MXG@"+DCBAR[<4!7;6Z6E'D22U*)\CR]MH@/#$`4VK-;NK<T(V$@\XR6#W8H=
M+$.BT%`'GJ)B!PF"0E(M/*O:,6662R;.>,GRK-O,670(_UP+,N;+5Q.*#@_'
M<72SC0,T7K3W&!VO^>R+P:C,7;8H`Y:C(NNSX^.6]8)$F7#T&3Y-&*8,L%RT
M3EI6R($Y.HE#%ON*KG"33C&^.P2,Y8M;"O;](8!5\SA3T!\.`70!L.[Q(0"3
M6*0IRJYI*%?LHRQ8Q;!@JKN'!+YXMT^QGAP0UO+,5(KY](`PYZ-F*<8W!X11
MR2]*H;\U!WI!/#%G114$P-(UVB!#L0)G6:@AQ6N0T5B!MSI-DJ(VR'I4C3U+
M5#R+VB#S<1/4151+\"=F+F`E"WAQ8#Q]V@89(8J`BZ+J*5Z##!`UO+):IA2R
M0?9(.>2ZY4:I"`R:UFJK6&&$/5W&#/*4U?"N5V*D8`WR&=7`2HNH4LP&+=N*
MF)LHM4OE9="RKR8OE=1("G^3+6!_2X;S)[CW@=GD.+V6$C4.XXMH*7\`G9%6
MJ.6IM!1U@;YR,8?!'B6W,W$B)L3\.1:@L-9DU5Z5[;2@8<#1@%%/FH/,4N@I
MZEHNFK"^7%-Q\CP$X:5'[J^0!\OI\M@.XI\QB=:$'@D00UQD5O*]Q.O19Q0\
M4[<ZA[E+#O1)&/A.C-'D>$^I--:I-14Q1N)-6)'7*^:H='`*FWFJ`!(^\S1:
MN(1M(59J,HI9*9>LG%Y+N=&"E853):LR6J/3RFVE7A11:BOGJJLB%8WTE.-P
M!):LR.C=H"GR:91R+X=1WD9+08OM(SX$7DB((HM(7A!52*J%9^3[(ML/6P:S
M?9#EI3O&!/-`J,:T0I,4&VMU>@K,J5S0MO"9&9DVKD"Z9L]+\L7M_4:IP?C,
M9;6*]@@C:Z`T"[)DUS*R8J70G,PG]7<H;R/3,(HB+'"+)%F8/5_**@VWE5J]
MO&,EJ44\),P*@1TCBQ-K":'*QC>RBE'J&.9L,T7;U,@"*24)5/A%1I9'E7C9
MN;F?M6:-+/-3!%J@"))S`ZI+N^:41;V+@O4<OE]EH^(2C;(6?\<N2Z-3!:(K
M2K7:3C0WB5N:>!T@T'UA`S-D<W2#XK]E<:Y=#*]UE5%0YIS;E=<<(VO&:T+>
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MC0[V"%^<G-P"7U$'>X0O798VQ%?4P=^1Q9*J2`>$V&<#FP7)ATL'#,RXH'_5
M_XQ^@J6T*R^:W*P[G35_@LDZY7[K]-JX+U#V1?AF&=$I0Z/47LO5:-&IJG]A
M4:<1I^LE,`H(]?`[C]^+1A.=5@SW5+?;$S15!PE*F^P%!NF%5*J(Y!UHNCS0
M0<B-JI=ZG(?BY<5]+W,(4P:KLIUN-$.PVF/1][V[[-EX!43RMON$:@@S@V$G
M0%&D2MUDW;P_3>BG6+QIYQ-E-S1\"KS07X1(Y`#E3?34TV?T*7-M@;247D*N
MZ2Q`HA71O*X\!%!$K.TZ2[$TR>W,'(DV'OM1VE%L!Q75_<7$K^+)/X23B1_9
M:;8?5?I$/A$813"#,I9WD4^OVE1OBGJ#Y--*FE[9S33ROH*&!%089S#R$IZ&
M!%2X:R\%=&I0">FV`JJ7S4M%9-`DJQ]L7+D*=U,S,)UQ!MUGUXRT5ER!5#(&
M'17:3C)R8S05AE%'&%Y-3R0.<"H6D\XTU`[\YZ12(^PAN:O(3*W95#[K@3K)
ME43?FUB*#L'E;RDR4R(E&2:E^E[SS19%">0KR8PL<-Y.`%4%G$8>IGE-D:S6
MY1IY?FPS@:B441AYJFP[_2B/^1KY&I?M!%*29)9<=G#0NVI1Y9.1[X+93@RJ
MQ<&20]D'K2(U"AN,/+&]G71DB0=3K_K80A2R_):I5W9LL^T6E,L8>:'ZMAY+
MQ2D>(V]<WW;'53GA(+F'_:`WFHJS`9)7R7QG(E$KR)>\AN8[DU7QH0S)RVJ^
M,]FL'1(S\FTV#4BEUL$LHUX?L4E]RLK%=AO6IJ<Y9@-,GVW%E"^72J%O%*K7
M<??`/0T0?Z3+MPDL'3Q^;P<A`_<XO=E/WPT)<BX?\(A@#SLBOQ:O<C!M!]3'
MT!E_A(&O?)&-W$/.A9*MOOB3N$4OQ=QK&'?4)CS^F=GNTCA)[5M^@[GC4P[*
MM-=`EM$Q0_B5YI8-X7]U"S&$;9%K,(15Y5>!&8(G6W:SUXRNOZ)(T!HBY0<T
M$G^':"*RC61D"-O+L),A_`[$1531)5W1I!Q0'C`4@`TM?DUB9J9,3%'WA6-;
MQ1".'\(GCKZ%XAK2J:*)];$CF'@"UQ$^_!]02P,$%`````@`LXE\0,!8I[Z\
M%P``?<4!`!4`'`!D<V-I+3(P,3$Q,C,Q7V1E9BYX;6Q55`D``P)_<T\"?W-/
M=7@+``$$)0X```0Y`0``[5U;<]NX%7[O3/^#ZKZT,Y6O27;C2=IQ?.EHUK$\
MMG>S[4N&)B$9+45H`<J7_OH>D)0H2@`)4B0!<M&9;1(1`,]W`.(<G!L^_>-U
MY@^>$668!)_WCO8/]P8H<(F'@^GGO9_OAV?WYZ/1WC_^_L<_?/K3<#BXO/CG
MV=U@'/@X0(/1\"L**7X=_.HB'U$G1(,'YY4$9/8VN$`3'.`01AU<X^"_CPY#
M?QOP__<&\-.O7^ZN!\?[1X/!4QC.3P\.7EY>]I$W=>B01&/ONV1V,!@.E^_]
M):;P=/!A_^AD_\>U)W=D$7BG`^_=Q'M\?_1^^.&#>SA\ASY\&/YX=(B&[W_X
M@"9'1T?NAX\_K/4ZI\B)B/.`ZM/!\>'1\?#P9'C\P\/Q\>GAR>F[=_]>;TWF
M;Q1/G\+!7]R_0N/#]T/H<93AQM\&H\#='YSY_N".-V6#.\00?4;>?C*2G_!A
M`"P/V.>]->BOC]3?)W1Z`&.?'"P;[OWQ#X.X\>DKPYD.+R?+YD<'OWZ]OG>?
MT,P9XH"%3N!F.O+!1%V//G[\>!`]76\-='CAJODZ6>\/XH=Q:X9/6?3.:^)&
MC%2`,Y"VX/\:+IL-^4]#F(^3H_U7YNW]G;_P$R4^ND.3043Q:?@V1Y_W&)[-
M?;27_/9$T>3SGL=<'$W.T7'<_\\7Q%W,4!`N_W0"[S((<?@V"B:$SB+J]P9\
M_)_O1AD8'H+',!Y\$(A%*S),EO<!;WZ@-/+!KO3?0<_O]R&L4_Z.\>0*!S#'
MV/%O"8L^L'/?80Q/,/*JP5`<NTT@MPY%%2>EQ`O")Q1BU_'KAP9;`9FAG0$D
MP]1#'ORX-O3]$W#@B?A`#;O\;0&+]BSPQL`1>DYF<WB$`H:?44U`RKU-.]YZ
MEE_Y5S:W(,\=]G3EDQ<V"CQ,D1ONC&Y[Q'J(OB$A8@]D]>VN7LENG'!!T7@R
MGG-=`SYG5@U$J3<T#>H>3P/8D5PG",]<%W29$#2O6^)CH)\]H-?PBT_<_]8-
M5/&M38/G:XC_Q[^.9\?G/\$G<O]$:/@`V$;!,V)AU+(Q3E0AH6FV7!,G8/%C
MZGAHN6O<(1<!C8\^8A>8N3YAL%@;8TPU(IIF#9^/("3TK04.Y+ZK::"WE,`F
M%+[=^OP;!<42UN<\4C:;!U[JW<W/..C54PP+[HPQ%+:Q]%5>V33L"_38QE3+
M7M,T/)`Z=(&\R]<Y*$&(K12C!>5JT#5V'K$/*GLK.]U.M#0O"X(I%T1\HAK<
MZT4O:5SU">$M&?V8MVUAPM5?W#@+T)3_>8?FH&^`"M8&>(57-K^G\R//@_/:
MRF:>\Z[&I3@_XI%@N:7<$A92..+1Z.D7%*`);D6B5::C\1,`F<UPK%^WP(:"
MMS7^M2\>&?IM`7^]?&[T4"-_40+1H:XJ2HG1=FD.YM;:]Q%XQ_?W!LG`ZU!6
MO7`0'GAX=I"T.>`=&J0'7A6O^J&')L["#\M1M]V]'5K)S,%!95+CWDU2&KUA
M.$.S1T1+DIGIVB"-3S`$=1>/:+CB3#E*10,D]'HKOQ9W:V5HAH\,!1ZWPL>_
M\J'J]R=$9``A\#EGWNYS1PRA0I9%0!ER]Z?D^<!#^(#O6OPOT?8U/#Q*?"U_
MAI^^G\&K/?[Z*]^9+H?SG4?DPY:W]?R@<7H2/?P*-FS'_Q=RZ&7@7<!.)R!-
MVK1Y*I=S%K_[%E%,O"OXC0G(E+=MFT[.(S4JTY;MT;BV[.%C0R.0;GF$"INW
M1VT\C_+%*6[7'GT/,&P.6='CYJF)-C1N9.8F1`$YV><MT?-V#@R@CC^"[?OU
M)_0FHVNK76OT@>)*@NC<&GF5V'@1<E<_#].0$YO7J37*XRUY==SD2JIPN\EM
MWA:U%XGV):'N8EV]:IZ:*^PC>@Z[Q)10^9K,MFJ+MMO%HX_=*Y\XH92R]39M
MT76'IA@.MTX0WC@SZ0:SV:PMZGXA_@+T.AI/FOPSV&S7%GW?D.__%)"7X!XY
MC`3(&S&V0%1*IZQ]\_1>HZGCQT2<O6(1)S=;-$\3=Y3Q/>MM]DA\`479YRMZ
MTB/%&<U2!N>1Y3#)T43M5)WTF5`R4U"1EJ\D(@D\(!2.+9_WC@X/]P_A?]`Z
M.FV=<NL)\C[OA72!TA])$,(QZ-*/[!!PC(N-C7N#.>@\%&;B\][QWF#!``>9
M<RJ<QOBP<5#=A2-9#6K)D/W#(\Z.3B/;..NET(X[#TVBEJ<03WH#<>LLEX)\
MUS.0F8-U"O-]YV%NR(X4VH?.0Q,K9BG"'WJ"<.L0F4+\L?,0Y5:X%.7'SJ,L
MT()74(\.>P)5=CQ/D79?R9$<O5*(W5=VA/:"%&#W51T5,UB*M_M:C\#(DL+3
MI.T(W6J;((7VW26JK4-[*CMT;:A;CM=-0!)#0W:BEG;#LG@^'63]B<W[&!63
M?2K;2B8.>XPXO6##J>/,8X,)\D.V_&73<I+\_#T)1&>WSAM?.XEDVC"C%#2N
M;N/9G>XT,OH&A6K4"[N4P[`=A,)_^:X<T[AIIBK761._%[.%#\M8FDQS31B[
M(A3A:1`3[;[!^2I@?K3IGGG_6<0Q_<#U\>3!>95/4^UOTL(QS\/QMG/K8&\4
MG#MS'#J;%LJBUEHHC^*O983&#_71=?;(#[2N]"O/-M)'9\%FE&FCG4HEIFZV
MU4$USQJ"K7$S>2@\=RA]`X7T%\=?;#J@RO75@BH-D>0$DB@S#+:U;5&ATD,7
M@N20D#L%F\UTT'J!)@A6L@>284VLWI#`S?UD"[OUQ5]>G;/_),1[P;Y,R*T>
MZZ!M,[\(E(/+5]=?\&-L`=U*7?5@2I+E@"(I[6M-^N4AKLXWN2HN:J&90IX9
MNY4[4TRVN)N)6`J4#^7NFK'E*WR"AF;0J\Y]$_0_;KMCX\DYR&%<<-X7-M5"
M\UJB7P')@I8Z*5Y+Q"^@>+VE#HHC4T$BG8L4.7%;;527T4%S.NB@_Y8F.G&A
MXB]JJ8GBN8.75K:ED4WEQ*[24P\B2=T`N4Z8VT4'ACL4PI$%>9<.#4"G9FLV
M0%[2SL4R)`H==>`153*1(!`VU4+STD>QY1[;I'B[H59Z14D-DD9ZZ%34W0W1
MUDOKYRH:>6LNWWQ;,?<?%M@_5\[$8_,"%-3!"16X%)IYH0GJT/+E78K1O'`$
M=8QJMJH4JWF1F.I817C,"[]4QR,YB:3@S(N\++MIKJ,Q+\A2R<&U#DK1IY1B
M-B_DLC1FL8:Z@GAB7JAE:8CY(2(I5/-B+4M#S?H!4FBFJS`*T)0.["EBTS4;
ME74KPZ9+H]$;K:=CKLIZ+#*J=XZ%W>14KSJPY]DS3<X!JP-[<52!R0EB-:]\
ML]/$Z@";&[)C<B)9'>#S6IN<8E;S*I=XYDW.0%/W`V<QB[RN)N>@5<0I\M2:
MG']6#:8LZ-_D_+-R2,N&XYN<EE;UD]T.3-&>F[95)J/8^905.UF73P^K9)1C
MR*;!SN1DO'+(U"6T^1EZ^1Y+@]/T5":SC.HD#!=)Y\]<7;G\T2`;"Y]B-%<G
M+H=1FMV40C57^2T)M8G4MY1-YNK.Y=BD$L.3NE#ZLJ7EGO^.U=1H4_.1L[>C
MZ4TJ`EK&-"+;B_;46T2C8@22F!25GIK3I.):"F>+\`E6Q__2R90CV>IA!(*H
M3(LR]4EK(RB7EW-5ZM*7=*\&J/E^W(-4(TF2?U:)O<:PZ7N1F(\?\"U7%`A=
MKJ_^8.Z2&ZYB9_VX%+?=@DZFX,C=?',ZF$)_\19<U,N&2C<<*MU8,,'R?IAU
M);R#T01U1D>`W-2/R!IIZS5EJLK5+@2'5$&\+7&[$`I2'>E2)G<AW*,Z2G$1
M0(.#/?*AEE3MNQ#@H3:W2C:6+L1TE(:;MR^9;+NN!'-[4S+9[EP)HJ0LJ28M
MRA2OH%;C<NP=T6,Z9O!^GEO$[HDO-T]F6^DXG"W])<O=]HO#L'L6>!?87X32
MLWU1+Z/,@7IJ4<&+&7?,P<X07+[R\,P%9D_QPN0!7A+.%O?3@H8"1;>43*2I
M\.LM]-2B6GE"87^+`V(7P+PQ[(.1$L6^H`FA:'4U-&)?<1!M7B,X],$&SK,Y
MLZ/$'K6O"$2T5YQ*WR8%^C@,="<1;<D5TKG<V&ZMJ?9:Q-Z$%"G%V5;==R'4
MP[T;%*:+4L*[;!LM5((*$']HP30F)7^VY>V-HKZ@^$%Q/RUUA98D+6-?)=1O
MMS."V@*>R]MKI;[P&Q6UU%9UJNSG6M!)3]4@AN"XQ7.W+]`S\DE4!B(?1GX?
M+<X9QT?L#F@)%B@ZB<CK-@F;:J$9^3XO10$J!75\X.69-X/S)/\*0_Q<L)(4
M.UO'G@DUD"1!$-\0GC[!.?/L&>9PBFX6W)H3G4&3`VCAA<D51^F"%\\`'YZ"
ME4U9X]DH3)-5Y+6GE#2%5,%\T(5LBTK8BQ0$[2D730%7PFRNQZ=0D<[XZ15E
M>!=R%TH!+U`;NY#`4`JOX#"H/?O`QIC4ZPP3'R+Z$U&RY<[I3PA)QK+?GYB1
MG"VJ^]$BN;:?_L2&*.A0_8D,:=5_U9]($ZE3JC^1)AO^%^VA);4!*PP]Z$)!
M$(6XOBK6*NT506P`$6A\T<1DDW$#:1:VIOMSBY+#OV86;_G;3I/^.NS+DBS_
M?$2Y??2@6.;?LP<B(2]::(\.G!;Y#`#[(Y%_AV#-,1RB>T2?L<LC8C'Q[I!+
MIO'BS[ORI/'7:DZBS5T%V^TT4;OY-17</IS7P\;4Q5LPYQ$)8%T+"<UOVTFJ
M2Z<S2[QF/`C;`:$WGJQ]'B#0OCF4.K!-Q&J(R%.FV+,5*J79S6H=;517EZ*Z
M9$J)J-J-XT:Z;^#EUKZ)A1F,0A'(O0L4_YD7==+&Z_4G1.>*4V%3$V[JRJ5:
MTEC/C5R%Z?+:$^154^(-2X+?$)E,L.>J];$1/R9$_/R.;SV+O_V+!85O*I83
M\:=V3H)G(`_D"5=M^-]#?C?3/7*A:<XETCL.:AP?;M!+]*@2WK2S<;BBA^/(
M[,4N7Q%U,9-+B?(#U:*5%[]WJ6;+$%0>QJ#YBHX0-7^.BF.:QH6*'^-&7]-0
MU?`IYHS3Y)>8OG:7#S%OE%JH_P4Q[LX=3^)WW\$_*7;#Y&0AHK2@1PM422T.
M*MWT>:9R[4[R^AK+(U47;B)5ABBP&W?A.E)E?`6>DBY<2ZJ.5=WGU84K2I5Q
MRVP?^N\M[5OV0GZ1N%(6B$R\@WBF3<(KF+]ZX=H2<WT,_\TKR66N]J`ZVWE7
M;)FK.^P67-;]`.#6/$?]B2?.C5?H3URQJI&Q/\'%BH:<[H<%EXISZ'Z(<'73
M;/>CB,L$B_0DD+B*Z4][('$[V[;$<-N%_/#=M_!"\%U7YG9UCW8A8WSW95"*
M$5U5XI2\"%U(&M\9YI9LZZK2UEZ@O/;$\YI-+EMEE75=;&=*MI")P!0-J`G4
MX_XE1FF_R$]I8TD%Z_)0P;/^9>$-.PW9ETR.?D7$VUC,\A$H>9]*?EOKB[2N
M*E-U3.GZ[KY7J^`#UN[8,D61U*I=G3OLZ<HG+VP4>)@B-]2N-/&C5.!B'V7\
MA0^$4WI+R3,&Y%_>?H8]9!2LJM*<N2%^C@P/!165&WF5EE3O&:$A_E]T)EW=
M;1U,<Q7)O"[Z,8R"T`FFW(QTQAA21+'524OR-:P7.)3P/_@)Y=GQH[-6>.Y0
M^@8<SLN=5^MK+*J"SZW<&.:@+)6Z66J(6M3B:(,"/6+=+GM%J&0RE+KHX/U%
M$@Q<[KJ/HEYZD,Q!>.)H4Y*2O=9$2W&`R03D^WAR^>H^P9Z)[D`)&`?BQ2O!
M4&J(OI@>=KN8B6L4XX!7K1Q/0*<`+2)\N_6=V#0WCP\Y0EXK=M9Z/0]B?$N1
M`-ALI8G2S/8["LY<ERSX]NR\Y=@RBON9A08T600?7A5`:UV-P43AN'B-G4?L
MQXIV8O!=Z>!KS\K@+3.L&;S@I10#>%L9H.M]S$"Q8G!B]2A0&DL,8`B^S"K*
M/;TH=C8#URU%<ZXR)@K7LB1J\MF4Q*DTF,XKVW)%V5H3/33&W_3;-XI#=$%>
M9%JFH&'-I9)B']PR_&L4G),@0%%4\S<</L5/QZ`G\F-&086G<D-UWWDDX6VL
MY5TZU'_CUVUDK^`0<3"_@Z823R*CV<K&E!K-).NVQ`!FXRNZ1:_\0`;AC2L[
M[S"?H@',QE=M/O,&,@BOP*A=#J=H`+/Q59M/TZS_W2BI=T,"%Y@YIK<.#9-_
MG+EQ_!P(^4W;??0(5,,C&:"JPVDK)Y@06>;6R>WVVJ@7+/JENW#E0<Q#H]1?
M2SG"R`7_$^:7&,2*O02&H*$>>M^6803QFE9TE17W,P1-T7WGN5V,P)"QSL*A
MMLBZ6V(`/04[B8N0%UWM(4Q\DL$J[*<;S1V:)ZP?3ZYQ@."/<Q`24F^36E^3
M4*6Q^]%NJWP$JSZ>)O3/F,?L7!%Z01:/X63A+TW:<H#R+GI*S*ZM)Q),'Q"=
MQ1=N"NF7-M=#>R9#I/`N:E%C&WIK0NAM[:7N9/I[IHDV&N/D12YF"R[O%C?6
M0O=B/H\C8QU_J4&/@@FAL[A^1/Z15K5W/0';:R^+[OM;QIWP6)/TK":,WU;L
MJB_>M<DXQ?7(X6PT21>JQ[7%F:*(P2Y4G]/#J\T(T2[4JVN:4RK>%_TE[_3S
M24WG3CEE;B9T6YS*L?ZE;#(WB;HM-HG<VBE_S$V<;HL_J@&$*YZ=F%MBI]5/
M3\UTG;+-W%H];;%-=C9*>61N'EI;/)+9/%(>60U=Y%M)^6.U\L*<AY19OU_%
M/-4/U$-)4[Z9JZA72JG*E,U4RS1;\>*=>;PHD\"470OK89HI0O.TZ.H(-](J
M4I#FJL+EH[WS/W!11D,7JF?6S8=,Y'\72FC6S0"UX/,NE-NLFS/B=(,N5-]L
M:K-8)7-UH0AG`TPHE2^EOU9GSPKG*,QY]?CQ#?MKU8B/+I0E;99)U]E@GRZ4
M)ZV'(?(HDR[4+JU_44CBV;I0W+0>9I1)UNE"&=/JR1Q9PY5Z2&<7[N%HB"LY
M/G>#;^MHC!EKD<M=N,.C'CZ4R0[KPD4?U;.'5.XWTE4HN37@S5B#4_Z9>[*O
M;>$H)^=IORK55@FM_5:TZI_&B;F29B?TN?(H16^N1-D)?:XZGZ(W5R%70U^N
M'EGJ"S%7G"I>?5>JXF"*VUPQN`MNJ?,S!6ZN/5M1YJF&[Z>0S;5>E[HIK62M
MF!2_N7$B"O@+7;\I3DWF`U-*7VN9P'+)-!EY7;F>02>JN5=G3#;Y2WME]V;`
MELMO*GN]<?M5X&](B.!@GFB;_"Z"Y%MG-TZXH+!])X<0$K#J5>'-JN5J2B6P
MFNJK;,]3EM"<AC;WMN'<6^LSMV:D%DT)@JU`N])ABIIIDFR]Q],`3[#+?8IQ
M]!(_(Q`?PV#L`5[\Q>?N:"MO#92WBG,GD1-JG:U<MG+9RN7>R&75+</*:@-E
M-3_;;YJK`^_^B="0!]&M17_4(+AWN\*H+)GB/;/*2'VYYJ5GJHH5Z5:D6Y'>
ME!^S]'9KY;N!\OV:.`&+'U/'6^66I:F'[`(SOJX7%-FCN='RKMI4BL5,M;&L
ME+=2WDKYWDCYBAN*E?,&ROE5F;$>B_,:[A93EY"Y7:Q*8H6S%<Y6.#<HG/.W
M+"N##93!TFS:'LOD?LFS4C,HEAZEAK`RV\IL*[-[([/+;1]6AALHPS<3''HL
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M&[E>?5NQ,M]`F7].9C,<5WPU)/NJ@"+QWEC0R89WFZBA6"EMI;25TLW4^2[8
M1*TL-E`6WR\>&?IM`7^]Y"7B[(U:5GP9([[:I%/Z&4A(EK:WPM<*7QU>:/D"
MMG)7+G<_'?!7/#H,P3_^#U!+`P04````"`"SB7Q`ZO4D(N$J```200(`%0`<
M`&1S8VDM,C`Q,3$R,S%?;&%B+GAM;%54"0`#`G]S3P)_<T]U>`L``00E#@``
M!#D!``#=?6MSXSB2[?>-V/^`K9V(K8JPJ^QZ]M1,SX;*=O4ZQEWVM=W=L]MQ
M8X(F(8D[%*$F*=N:7W^1`)\2\2`E(='W2[?+S@0R@7,2#P*)/__G\R(ACS3+
M8Y9^_^+T]<D+0M.017$Z^_[%3W?'D[NSR\L7__F7?_V7/__;\3&Y./]A<DNN
MTR1.*;D\_I$66?Q,_A;2A&9!0<E]\,Q2MEB3J^"!)CFYBM-_/`0Y/2+PWXBP
ME/SMR^T5>?OZE)!Y42P_OWGS]/3TFD:S(#MFHMS7(5N\(<?'59T_2^L^DX^O
M3]^]_J[UEUNV2J//)'H_C1X^G'XX_O@Q/#E^3S]^//[N](0>?_CTD4Y/3T_#
MCW_\U-(ZRVA0\`))Q"W^3-Z>G+X]/GEW_/;3_=NWGT_>?7[__G_:TFRYSN+9
MO"`OPU=<^.3#,=<X[;3$$;E,P]=DDB3D%D1S<DMSFCW2Z'594E*V`^'-G>;?
MOVBY_OR0):]9-GO#RW[WIA)\\:__0J3PY^<\[B@\O:O$3]_\[<>KNW!.%\%Q
MG.9%D(8=12BL3_7TCW_\XQOQ5RF=QY]S4<H5"T736!A(E!+PK^-*[!A^=<Q;
M^-WIZ^<\>O$7J/#/&4OH+9T28</G8KVDW[_(X\4RH2_*W\TS.NVW(LFR-Z#_
M)J4SWH$1U/`==*"LX=_+7[\@(/33[65=BBAAE;]9Y<>S(%C*0A+`:574BS?.
MS+MG19",L5$JEH:*OP#'.J;2YX*F$32!_"T4HNE160>`010*Q;*P4V`"L&!9
MK_.BK&F0/X@"*[N!(F]H4M2>"-(<GYQ6S5#^^N^3,.0D+O*;8!T\)/1LE64T
M+:J:A'_?OS`(OZGM!O&.Y1G-V2H+Z:"F@%(&6?#WY`$4%@D7A[A)T^.?[E[\
MI1(FI30IQ?\LJ]BOU06/DO1J[Z8OI72?R9.LBY(@"ZNJ^8\&FTN)-R'C,6M9
M''<:?9JQA;'7J[J9E8MO$+%]2T,:/X)%WVAAA_!>%02<]]EA@DRC0[B2'Z`?
MXT=6ZQR1E/8ZX)H".B3U$4'I]C`Z1'D8"Y"?OBTA#K^!6K(5C2Z>ES3-:3Y)
MH^MB3K.RGJLX>(B3N(AIOM$Y`Y7W#/N(A:L%KT),=':R3`&@LR#+UGS^3!Z#
M9$5)D!,V);P$/@5.8(9&\CGEO(#9)_R%/23Q3!B3DS@-H9:(!&E4A=XCLJ19
M$<0I%%DP$K*<@[.8!P4),EX8=V3%>VS-E4G*?\ZX!ORA+HO/=#G$BBP(BU60
MM.L[(BPC0<C;8Y4(:_A"@!3Q@HKZI_R/3_,XG/.B'ED<TIS,@T=*4E:0-7?@
M@=*T)`G4PH5C/@&&OSY0_GL^`\E@`CQ)<@;&)*L('..6A;(E.YZ#6DZ7`:PB
MDC6)XCQ,&*P8N%<];<?;E3?%@@MG<<![8PTNYG$$JQ`HCU<K>Y'0LAN%2PPZ
MLJX_:;I2V`6B(9]B0='<A6401]RG8LY-8'RYLZ9!1EYR/\&>E&4+:,REJ)'W
M3+@.H:_B*4E8.J/9J]<'B7A]07LOJ*W:JRJ`\!*(****X*15B-MHOE<'[0"!
M$>W'!56(^R,:R.T(<"[YS(/3/5^=?.%U_&.G/NXKS]MQHL=8`T9;RGH>DJ9L
M\BN43D3Q_]?3V#.\)>S"D=-FV%.8VJ$M@J&AV:_(I0D&PX.9JAF1%GSE5*JT
MEBV6&9US#_@4Z3(-V8)>L3S_RC(:SU+I2[B^SX(T3T28F43_N\H+B#I\OGX]
MO0^>U>N:O=?D=GFY;_/5W*EJJBC3KHO(R@C41LKJ2%4?:55(FAK%JO9Z"GO=
M:(M:A-8KITJ=UHMEZQV34@Q^5[0:+:@K0@E+#GBYL>H^2+]X&LI^I(L'FHW'
M:*GO5]B11NT63'Z5A3B>?;AUTG,Z=[$YD*2MYD&A7A3%$`V"Y":(H\OT+%C&
MXF-1?W<KI%W2JM\$%;YJ:0+B'$^D5$#BRUCK87_H.$Y)J+;>&2/TD.G@7^.N
M1VC7#RY:'7SDZ^.K$O_8`\?NSASKR8Q,!\V@8'0=AQKU[/F>*4R\FP<9%6=K
M8"#CHYB82-[2WU9Q'A?TCF:/<4AO:!:SZ):&;):*4GZ&3Q-*'!RX6J<$/:PO
M2EK4U9)[1C24;RHG[=I)73TIZR?2`-*R@`@3L((%2L/>%2S\Q[%LK[!5*&ZT
M<4/3;L!RT/S>QCP`P66>KV@$_X7O@F?P4707J*J*]"U6*>S</0Y!P4263*JB
MB2C;XP`SK#6DCW'E''Q(]SYN&*`^.";H6@R=[Q"%TC`6IU6:_;)[=A;D\YN,
M/<81C;ZL?^(1[3*]KKZ\3\(B?A2?`B8/N3CE8(.H?56%%1_V9+]=W*@K$UO?
M[2US_D>HD515DB]K`I5":*FK)4V]Y->J9K1%#DHC%@Q.RI2-F/)&3*#U^&_A
MYQ!:<%FUX,.:O%S)DR^O6N=+@KK:S]X$K3WS51G,]ME/XX-<3L/7,_;X)J*Q
MC&_\A\VPQG_U]PFW.@++OR;!;/,3\=;?'020K4I5@*UD"`@Y_G:^-QL/_JU;
MU<7BVW6O&R@#ZX)E1?Q/,>>_GGZ-4S[6<U9H)\HZ%9<#G<8.)2P:%?@V6RNA
M3F%W](--242G5!SBG-8.A2J'G`T!%LCJA')3,^#3XS(M>"_$#PF=Y#FU),B6
M$AI%-BVQ)$FC1J2>#S09XPLG"I\"I$4\C<6U@[AQ+%`ZAD,7%=+4A.EM$!3*
M:*GAG@):>!P0SW`!3XMGG6'B^IZ&;LY0J4:?#R@S+>6[0LY19UKY"2'\M:Z]
MK?A0U"X&MQW!@Z;A`E]'QCDP#5?;)"X/>B//+CKJ[91!LKJ5X<$0WM?QVP!%
MOV_:ML(J@F[*8N'5+IY6A]W]B*MVIE<V^Q)F%>A0@AD]Z,(>WR2-X'\7OZWB
MQR"!/<%)4=VRU)UDL--U"'HK@Y372O.YN`4C?FBIDTE!ZCNGASL2L!0?BB_2
M2$>-71R\@/MX4W'-\H`.W!5!5AS*A2]T%J?BHNXA'3$&J)UA!A>,Q%<)VJAC
MQJY!0:`=R^Q;PMO89AC(AY7A6ZPSC9[V,0]]5K`W?W^7Y---*(:WC#]DE,>C
M+M,PHT%.SZG\_R`(*(I`IV*_78.96)Y+K,HA54$XR\L]N`IG'.+*&W&^_W=#
M2CU:S9S4M!,6)3>C1AK=S5E6W--L<9D^TNJ,@"*KP"XE.2;H0/-T/-T>+3EZ
M16D$BB.M\A"ORQ_(^:`O2,$O6P5A,W<DJ#<)/*;5]I+W0QR\">+H?)7Q\5M&
MC:\L4TQ5K51<9^\PV*-#F#@[*_6JT8]K'GH"VA<_?I^>Z!-H[.".R-@427<@
M29/(V#1E&<J)N2%$J=->V#B/,A*SQ2*6X01F#2R%$W8T#;>3N]EHN!Q9U6:H
MD-1HR`EO6P=IA-S)B9??6$')Z8=7J*.>&4"=T<W@,3('S.FL+)5PF&"?>JB-
M(R]R+.W+&T^X8$B%-,!;+$:P5-PIT=[7WI9SC/M.Y1IPL+2\"(5[$WN,R=B`
M[L7!)H:WG4*&[4V076=W!60#$;N0?,8EKDV:.T:IB0-ME3DV8.>ZY#HC4KO<
M3>?Z\FXR.@/&>9:#ZA%?$60R#:\G]##A34$8;1L@4T@8DD]6Q9QE\3^;5P?4
M/;JE@4.933-LJ")U2*.$3H]A7I2TR*4;@=8-!'JHL*2@1:_O7M!!7K&U[;U2
M&I,&TH0!%)`*GL#?QOH2^K'2;C2\=\&BQ7K+42]P?KTJX-DA>"[*MJ_:*IB(
M;]DQ`/8M+4^P;^U'20"F]P"-!3U0TE)ATV]D/FC/(6Z*X>!>>^RKC77$O$+#
MS"TA_8?7)Z?-5/]/Y/2[HT\?3HY.3DZV9SI_*D<`F?Z_P1`Y/3GZ\.G3T<=W
M;TE0P"D&L4@E[TZ/B'CP#>0_'GWX^.[HY-/'/I$33^BD/@S7U[9(M-G,N6G(
M=ZW3<$LFE1EJH&XGB#UT`FGC(9D=W8#D%<A@-^%G`_=:=W$HD',+?F`LRN]8
MHEXI=*6<0KU3M1(7N8"RD",@B#5L6%O+IB0/$IQW$@R]WP7MMD>'SUU2WOKX
M&N=AD/PW#;*+-#H/BLV)C5;444835?V&BSA2GH`"@1L'H.(^U<F!C7>1`\4$
ME2H=BM95C-![3A\*^P^X*FF'H5AA@@(K(.W7M]IA]E_!T](\2)]E-(JYX2S+
MV!.?H*,&;`-FVH%;YRT.W&4*&3GQX7.>\DV=+S2ETUAUK<2DY13^6E.4-"@S
MYY1S;JY7/:!$2DTL-NSD3OGD2A$\XTYA+&'598;9<TR&<(M:#TM]8VFHO>IO
M5$/@B,H6$ZJ`'>WWU!I-7)*,]8?3HW[-<>T#34S8ZN.)UGD<HO!U=!CWG:GN
M%7%*@*9>)3@:$2Q4#S(29D%PW6@I\AW"_F.\@#2A%/T$6Q\0N@C><'0OMP[.
MRS/]U?]YBURD!2?X93J%YWC%$UJ:*PB#]%W?1QABG`H[I2HY)O6/@!I9#FD5
MA'9789]>MLI`<%%_B<&GWG1RT6$,-^M;#X-;Z_`;894I<MNBNH@1KK;>LM?*
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M<SCG?4%O^9AQG?:GCE)U]I`B7))J@%TJAHDBX/1;50B!4LAU2I39TI`8MS=G
MX8M$Y6P&SLJ?<\)DGC14XHU`:X>%0UOI\#,GL0L:T_P>GC7IF21T_^YH[M2I
M5)G+MRC?^Q-2".O4?5GI8@[5V\W5)&K;$4>X6Y]QI&=!<IE&]/FO=*UJY"TY
MESC<K%S7TVM2"A,A3;@X$BX/8+4SG*I@T<%KKX/.<&M_2]%2R2VBA]_PJX#B
MTX7%?3MT9.F10R)87F$<T!+.*")/$MW2)3PUELX@MT3O5R"MN%M:]-I@P$]Y
M;KY6(E(+C0D']L$A]K4`VD"]VFM7>#]GBR#>.G>S^6>G>)9UZOO^5RF$-7W>
MV49W>.QV<!=_+2]<X>UKG-#LC"\@9RQ33YR[4D[1UZE:W\%"E%2R6%#<J\'N
M<-D+A"X\MSUSA=*;U4,2AU\3%FR=E^R5<8K05L7Z[I:"1$ABH7-OQKI#9D_G
M=W&YZ9,K5-[260QG_=+B6[!0[GIMBCG%9K=N?8\WL@2$L1"Z9Y/=X;0?#EVH
M]CCG"JT_LV25%D$FP[AZ";4IYQ2O&Y7K>[\6E@,IVF)I[T:[PZP"%%W0]OGG
M"K6_T"3Y:\J>TCL:Y"RED4@LMIF_URSO%,4*(_3``"4BM$BE)G/7.7Z;;P]N
M'/_#U@UW2#<`J8MXG><HW[=_6\E-N24W!JX?]&P2Z&5=?K'N,T`%&B%+:F&D
MC82#F^[LT[(.*)UOR$I/,?#]`Z_\BN7Y=7H7)/1Z>I.Q)<WXS)ZW>'%1W2Q4
M=)JELD,&V%FDP!4H$]"&\QF@#P<WJA*(*(+49>Q&$^'6JNZ=EF-O4CH+U(?.
M=G)0^,92$L7YDN5!TKD]BDF>82ALLVE`>V#1*P?[*+?PXAFVME=Q/@>;KJ>0
M!D33S7H]QZ32&J/A4TZD(E"JJPKD`F5$(HUQJN80Y-"A'3UL!ED!;9,\YC9`
MX0UCT5.<*!%9_=DE"\HZ56`O_XPS?=K!.&<(W>C2#A#;YJ/@+>,LX&.'.MM1
M6\(EZIIJ57T+$D2*X.0*W=U&9QC<[N8.##<<P4"BS'P$0?DK-UT^:[;B@?F:
M3VO$E;+\"YVRC-89DFC^8YRR3%R%YW&"YL4DC;JER"7'C[28P\N]]:N?BNYT
M:8%#)CET2\&",LV8F$&`-FF,((T51)K12DK&9T^5):0R11P=WRJP7!E+@TRO
MV1X^,.`WN6B:!]F@OJ1%0V!X.\BY[A2\("I>0P)#%!E_3-+.@].6"?I`4HNC
M);)Q8KY;7BI!L\VA?G_Q\,ZY:I^T5JOB'/G]=NCQ`PD)O4IBNY,K/HQ)>@!M
M$T#C*BH+:`X/9)MZJ93"P+JLV@(3XOEU9#1KC?4'N=U.[P5KRQ-4?%JE5_8@
MK?*P_,.^95$>9;TGJP.K9,F^)4GF]F0TR.DYE?^_3"=AR%9\(7`3K'NNI]KK
MN<6\WA@U?H0\J13Y\IM4JJ3412/"*)=JZY=JZQW2P@Y;&P2Q<-POJMS2D,:/
MH]C24O6",(T]HSC3J"-](MS!L]J)3.L$/GNVX69'H(T6\(9#V8I&K8SHDS2Z
M+N8T*S>WTEGK;T-Z?4BQV-P;8.M`7D+)G3<`8!-:%$[JTMM_]VBXV[U1*O^I
MG&SE\G5(X7R9=+]^3D#A.BK;1Q##&`F&-JH?40(VJ%->VY`0T-9!Y7?+D"'D
M;:EY,YC:N**U&H]//1#2DV735S^84!/U+%C&19"8OY/8%H#*$9550PC3C&=E
M(3Y\8]G-S[,R#U><$E9[%^0Y+>18UAJ]/OM%-Q-.]=S3-I,G1.P,FQ/1)_8P
MZ%/&)6"/18/(MS&EE"5X,W`-<$]Z$BCM1^24!G(&/JG<]X-+-QE=!G%4O9!5
M[HU6<].!W+(J#)5K-A8.X5Y9'JG?2:OV\INUGF=TW*$%*F<U:SH?N3L$XGHN
M6[<=#K<+WEGQ0T*E(4,.-Y@UG;+6:(Z2HI5FR3K?3CR,=BSBY(JG,>P@DBTO
MCTA*40\*#X!>EV!V[>$#F[[1XN(Y3%:06,YPW<)*%9%/??98$PJRAM?:!/<:
MQRZ.M0D5-UX&?A)*ASX=HY0M@D0I<1ZV'#;5G=J1<DN4=M5J3L@SY:48&O:'
MV$K5MCK$=%_W;\!WRRE,I&K/Q;5$$#"J/1%7=CKF:3AK*WV`I/HHW(8;.&"4
MF^'K(1-ZC8I3L*KM,'S$6/LV=1_M"?KG&#-\NI@W>(K*`3ZA,?40B&!@G-=K
MQ/2W_FFE0_R:K?0%KZVN[L5GY0DJ'G_)XH*>LR=5DJ,>00QLUK4;$2HD"8@B
M`]5D\DW&'N,<'KZ<LHPOX2H'V$/.*\I#RI'F!8ZW(-*+YJZ[PS`-3WX+I)Z^
MK?+2P2/@D`LLX'9>3UM9\B=I]$N006+'7";,W^B'(9I[1G)4/58.URK'FZ6"
M>*D,B50ZSSK`3GU50O4DPD&PW\=41WX=TBUU@K[]^<:F]0MUPC?X\/!4^0;\
M3^)0?';)XMF<_^IE7+YEE[]"R>8WG'XBK]_`!G,2)7X.DM56SF![1=]BA+!*
M`3?Q-\!:;(.[UWX%"9UC=C%"E.!AB+#R;&"$\#8J=.AF'12:)MIS3)"I"JIJ
M+M,SEJ8T!/+]$A=S^=?KZ91F\-JFOG.'%847-P;9:0'+&H4`20E.MI2Y2_@H
M%=:EDR=>O$@P6/!9;%4!6I39:S/`DY[2L3K:7*:D*9)`F95(72IJ+'((`PA/
MRV`MDCMPR:KO.39R+R+5J"#0$[N&-^GALW=?T5F0R&3*D^>X+]O\IH2C#-T;
MU:HR]H`4J1X.`D&$IXWV:JJ+3-N*3J]R:_?Y@['+9+Y]A721RGS]Y^#7FDS)
MM,PFWD,1IOM7KG:+#/>)?+@:U+VZ)&:@<Y9$/##(R&WNB'XU'-SVVF(&LU@Q
MM17+20LZR(?XLX5\,2<1&PNE^G]HW$*@A!9O"IZH&\1'\ACN$EFK>T0FP_T:
M"U*A7R+:U<7+R9?+J\O[RXL[,OEV3N[^:W)[\5_75^<7MW><8?_GI\O[__:9
M8;J+0X.:!IEQY7.IYDZN!'%85-9NP9=2$GW0T5LLAQG/;GNK8:%`=]M'/W!L
M/U9L*J#B>L!X4+W0[%'\MW.B,MR_584".WK0>Q#$4YI?3\\R&L6%*8SWB#H%
M_';]2JBG\,3'E$CAPX9S,\8'V2T^M$BS'UB6L2?51JT[C*LATD6WPD\47+,@
MS;^Q@N;W61#5-\B:-$$#;F^-*\LE,\88J,Q0SLLBHC`B2FM=M&P5Z-?AT7TV
M0$^^+_3;*CNAN</1T0V%0^)T=D^S!3S]8QB;>B2=$G"K>B6]TAD!4?'6%/+`
M9&UU->M:!,4JDS-(/DHE7/^X`%\BQ;M9[OBA!$H7_?T.8V/;/`#UR2+AVSR`
M=!#NP^`PS'@):=53<!B0-H1TE7N8L#8_Z],GB0!IFS=;*D`?_`$;6RC;&2V!
M'.N-=HUGPVLP*@_W<NI*/LQY$63)&MC2?6&P[["*7L'U"2JM-0H<?.,]$^1S
MLDJ#!<N*^)\T(DOX@:4PA$=55I5IG`9I6)^)(1E-(.D)*1CA$T3YNF1&E]PO
MZ!+YNQA.DL`M`/)`BR=*4_'K:1!GY+$ZZ`F_*4_>Y'SZP)<3\"4,?AL&6;86
M*;\6,-^NA$5-02%^+N*%/"W*=;M/6SH^M#6FY:N'>X66'`LOC,]S'BZ$[(*@
M8P&A%FP2OQX=M2=W?6;*W!(8H^<WF%_3ZVGS]I5B(.@1=#AV;M>NPHX0A(VX
M1A1GY+0V^9SF818O*Z1_6>6PK84Z=*I1T1XY%1ZBP)@69SQBB`MD$8V^K'_*
M:729?JW&F$E8Q(^Z4U<#"G`)>VNK5'2@?,4/H;0J@GQ9$R@$SNK6Q9"F')SO
MCWOQ4PX9E9\/Z]8,(]#ZYXQ5@T':8=NP-O*;A8;OG2,*\I*5AD^+@]F)_O5T
M;Z[;QA[_N*G[W#JR>3SBJEP%[S!B]A6`S\T>J\9PLB[&UQ%SF)]RG0Z^Q6FY
M:^/]:*D!J`435>WC-P/'C9:Z@KQDY"ZC91\S?1TMA[MN&W?\X^:(T=+4/!YQ
MM<D!/G*T["L`GYL]5HWA9"M]O9^CY3`_M]:7+\NA\U7[-0F?^:F!JP4O5:WE
M-Q_'C9VZ@KSDYRYC9Q]/?1T[A[MN&X7\X^:(L=/4/$A<E>_TPA<0=6^W9-PR
MK*E80Y[R<6200N.#E:')P2RT&&2M+%2UH4,";N-Q@UL;CJ#01GY'O\YN@JPH
M_S$)?UO%>0S?6C;3@HL_930Z5?7.V.)<DG&DC8:3"-<9@0))]>]6D=L/+Y"J
M5'**1/3]-L(--W`.+]O`1W3T?$G[`G>'KKLT&!*SZP6###3Z]/EJ>;?<[#="
M3;YF552.GGO)KB_LUKZ;)"XI[LD->>%1/HA4)MQ'/YMOQ,\&.S0.>P5_TU+-
MJ.<#'4P+,34M\)=<(WVZWF('ZNN9UOBRHLD.RR?%F5!Y&8:5'P6#Y*[@04L<
M5U00P%;+]>E0LTE*$L!=KX*16I4TNH>F01^K]^'./8X[^N.7*%WDY/"E/8OJ
M$YB6C8$Q)M;[-F744>V3;,LY'/.V*C?NN%6".!L2MO:6<[S::JJQVM4@I@1$
M>]#J=]`+_!KF<FIY3#Q;[R17"NA3MO$N>`ERW0Q-[RHJZ(W;VWV2&$`W[L]>
M;ZY-#K?A;1V]!QBMVOQV#FC]!K/*-100-\\<P]Z9]LY[OZQ+(/<9H%V55D^<
MUM)(<7JPX?BO;FN1T8&STCDT0)^QQ3*C<SY.Q(]4LNPKRV@\2^4M_'!]GP5I
M'HA,U9,T$O]*Q$IW$OWO2MX#_4:+Z^E]\'Q#LYA%FT^'ZWK:1?6N:>?`)RTA
M.O57PU-I`:E,("T;1!J9EA6D,4,\>7P])=P2(DTAE2VD,@8Q4.`U==6>8=6>
M1:O]@KIL]+#DD-];D<Y5[Z`%SU;2.+LI0;^"ZP#5:X4VI+3S$WHQ0QCN0I,1
MQY-DG&8$;1%*[34:!<K/R#9?9]7RK@G09X06/-6!"+>?9_?DPB1)V)-XB07>
M6LD#2!'7C%#X'-!!:(L"2K\Q&3#HD()!"8$+@[[SUX3`.K2P?V?*'3YX.!%4
M7J&?6[##51\W/#O!(,SJ.6H+)W*_\JA4?UC2=:J5OFO:V!BE!5WO67)Q\AS*
M:+XA(DZR=O#QO$I>)'(34G5D<$JI(4C<8I=U:V`0[2:(^=KHKW'*_\L[E^8J
M1O4(.J3.=NVJPYA<$&Y<@"BI9'&H8&US]6<2SH-L5LZVQ%MWU?-WF`10(Z2-
M=(6S.)"6J<GN67D0=?-\JK*_3'I.`6\P1HG_,B_;/:O.66^?P$:::8WVR<L#
MUM8PZ]+$I@D\88TIVZ=6!9<KIE2:_3394R;0?1+$Z$B+&YYD!;5!DH$3N^0)
M/1`=;C)8(A7K&][\Q22-X,&FI68%,J``3*HHK1I`G*H,(@H1'X7J8GQATF`_
M6[RBE:S(<QHOX(8Z]8]F1H1J2:=O(!0*PO<?\7U'+*-N6%YDM."F@E5?:$JG
M<3'@Q8_1Q;FDYT@;52"6Q;5>^^B62*HB_7KY8\^M<+OM+RIO=X1UA\6[M-1>
MKEK<9.6&C7C,\"KF42,2'V+E'R"3],^0-WJCJX?INKYV86N8ZK3SG))@-LO$
M",57++4Z6=;ZY"5?Y,,R.8O%5^S\%8PT*4MYK90NX-F64AHVP^1N`*AL_JXE
MGG/?DG659YO5Z6[A7W&>KVCVBO_,_\S'-1*T;9&YR5BRXFV2K3L6<T#G<40S
M7L,:Y.AS2/.\R0*>$;%9(?**=Q*$Y_`P;OZ:0&,HFB#6YASOVM<NHLHVWE-[
MWJG><4;Q'6%3J\M774FK`-*40$01"!===O3NC/%9?5;$/<`^4@`$[>;+T*!6
MWW\9U$8H<ZJ.@3_2Q0/-5*-PGZC+N5!/_9;,^55*8TU?1AN..BW1(*,SY5!Y
MAP_GFR"[SL0GE4BP[(9FXGEVJWY2*J-!7F61)0FX.N3ED`7(40-.8LH7ZWU@
MQD#_M`,(3`4>50,C#H5,:%232MLP^#03MN2353%G&;P]8]796TIHM-JTQ)).
M4HTT>CY0R-(7+77D1)T$6L=P**1"FIHZO0WB"V4N81$VA"ZE`C)5I!7#:")U
M_*&(U@<M/6*E)YB<Z$+)Q(>6][YPX7I5\'5[&L7I;$`WMK606=$R91@U6HK^
M\,/LC98D3.\3)E-Z@&:BRV9CX'.F;PM5)XG&C2'[6P@;6<.-UL+^#Z]/3INE
MQY_(Z='[C]\=??IPLCVI^E,YD(C-RQ9=R*=W1^_>O85=VW,:BM4T>7=Z1``6
M0O;M=^^/OGO_OD_@A+Q4[*RR*?G#NZ.W;]\>O?OX76_9K_SAZ=96FJF7D/BX
M#.*H2EE5?G"19W;TSYC;:+KEJ\D<-7]!LTZFUGQ5+*^`HSY\OKM?5;X.25'A
M6'E3RH.KX@/PMT$AJU;!H10+*8WRK]Q1F*'"3:/KZ1E;+%@J&*_L:9.>4SH9
MC%&"3NH14"25)MR8EKKJ#6$75-K1)X"N&.^"<C`*I4_EL)G20OXRQ^:4)0"[
MC+)I'&P^W=+J@>;KZ14\=LI-Y`-IK!ZD;'21>*4TR(I;C3:P2^@+FHD2\`DV
MU#GQ3LJ<_T9\%G]@6<:>^#PR)ZLT@MO*O`A!+J5[&.PRPE'%,'WK^,2RV_(L
M!XW$Y1[K9W''E^<!&XU&CF!H4V9YJ\W9&[IC:3NV%<YJ&F>-SW!)V4?:6N/;
MALIV+89$[_YCL`,.F@XIPBV)K>U2\U9YTMNS,Z2[.WO1.?9]V3KVC7[/>PQ*
M-W@YK'6\HB*?`@WM=5#Q@6K<CC'4^M8/-T0:J1VY4-Z6\)<V+419T:3R'HD6
MCS&<^O[*LG.V>BBFJV02AFREN:BG4W%+"Z4=:EI(%4A$1RHE4FFAL6*\'W"[
M^R&(2$0?T+<_C$#:8(/>:PPV=!:(+)W=TVQQSEM6T7-*<8<L4-F@O+[2V;_@
M"@0T"*@@W:X;Z,%5G4$-,$^R6AL3_2;@M)&O]1<']3GEOL[YF'1.'VG"Q*BD
M3Q^EUW&*?XTA2A)('3$O:FGM)W?4V'%@)T]@=A0U6KA<L(!3EQ`FQY%84>XJ
MB(UX(QWZA-WRH,<"-6RJ'2)Y>@(;^/:F0S97_N?R/EF3XJ:UZ95CWW[00V<#
M^BK7<3!?!'%*HXL@2^$S`)^0K1:K!`;O<SJ-0^47'PM%IUPP6:.^W"L42:5)
M6JJDU,4BR4B?VAY$:@_<<<,68EV>6'GO`V>TU^`4PHC<T-XHV^8#[F6X0<9;
M4A<+^.I+<1HO,0!^!ZEZ;_G$+%W1'QB+<O6.::^H0W#WU:]`AQ`EI2P1PG@;
MHP/LAB_V0AP3RSI(M)&L]`L%QW0&ZPJ^_&89)-"T_P9GH^D2Y69S5*"7FJ16
M]>LSVWC'FC2V91FX]+!'6H<MEN[CD"?A9<Y^H"EOZ(2OU"?1(DYC>-&MB!\-
MN<8ME9U2R,8B)8N$,BFUQ2Y25Q]W/;T/YX[(K/0.=I:"3@&XU!J"PRZ[K%L%
MA6#F2YU8US@M+CT>_J+F4CR\<Y%&6N2;+;V0%V6^!(DX3OPR3LOK-:AW6$SW
M,+VX>6E[UQ+U=J7M#41']R<E;.^*("O,P#5;_87.XC3U%L"&ZY'^7(B\F_,I
M%GQX,^<E[A5U"NCM^I68YJ+R>^[>T@^/GH0,-%M^TO4DZ;`.'EU`*YQ$P70\
M2^-I',+I(GF0@C/LAB5Q&-/<N,2U4W:)>RN+5)!JE$FC32IU']:Z.[FW6BP@
MMR*;$H.GJ"P:!,@.K^P;!X5IU4,K<(2O6,,G298"]R?/L7(8T>JXY)7.$!7>
M*ATBE4BC17X%/2P2[>++T2!GG)'&!EL=KAC;`)4B5W%*+_F/1EXT@AADJ&LW
M,N!7$"5"%AOU^S/:.;JW8-$+Z:Z#J#B^GE;/;.63!]@T"I4?P70J&-CNL<,(
M&+C36KT"!V&QU,-&_!A7V`!7G/-``ZM>1J@:`)D;Y:6[(+EA>2Q>SK;FB%H5
MARM*>VPX4RN32MLG[HQWC8UP#8%+1A@J.*5O&&1NB9.!<Y9$O*?E',^>7!I=
M'':I#;*A5UN[FKU[Q*\=G&-=Y_[#SCL$BIG1J."8H7%0278/3UZ8^E<*8=!&
MU&R>XPLQ;!;L;*MS3'<ZOQ>\C4\X*-TDCK(/M@2=HG6S=B4*MH(XXA=C6ZN[
MWXU1OQ7:FKSUL?`PH8$50;(7>^^A))G8=F,8Q(T3*OIU8T6ODW[$"^-\T8])
MXN#)DX^3P:%.>(]V_?3.PSG=IDG?6$$'G/6UUD?EAL*H`52!$CP[_KNKE]YS
MR0!%/;5TC8'&-'DD[537HY6(:[Z4]>HH41Y8)*=(J0\L[+Q4)#X5YW*?@BP+
ML,_*],!@"\AM'Y&Q>K[*X#"!G&N+`VDR*SOD(H'4JW6&]CL:<E%-LL4="\7A
MPPA+;1@DBR6RW.IQBJ9DF8JX27[?%(XXU.R[09HG"21#P\9]7TYI[H4&"G:/
M;4COXL$W^B3^-(KWC;(O_*XM&LUC7H+\NX]L-;FG'$!_#YS<@J(U][K-XAW'
MQ!^OQ:O2^<4SS<(XMYDEV1;D"_=ZK1O-0RE1%D?J\CPDY1"_J[]O$925COX>
MB*K%LS5IU<TVC,#P?+2@Y>G;DI3B06ESW;^4"PH5)4<7LV="1BQ<P9<9D09H
M3S:J+MROQ%-'')SE,TSETTN19*AX.EZR-,A)`'F(5DE1/1Q/6]BN%FN.WY'?
M7TO8!JBJ/*P(M6>W+WKZL/OLB'@AZ^-W1V]/WF,'JUUY7C\^/[;]/)IIB#>^
M]KRXMRP3?_YA9^APILNGOW]W*_N=FD.]L/=P/C(,]193DP%-YQOY1Z[D-W0]
M(?,.ZWA)6D^7\5;.J5;QOA)PS,*]IR%\(]0>ENV:<CPAVIX6[9)TOX<U^V"O
M34MV7UFYZRK=T%"'7*0W5>^R1M>5XLD276.B`HV2:!*`_W\LSH>W@64<\GEI
M/MSI02MSWU;C%H0V+<9-+;;O>%1-PLZ@:0T]VY5%C"T=0RS8<]2\GWNF>E/6
M24`8:K@+NZV);6-\/WW1'O*U0GL?);=]19NVRVD)O#!ER,C8+^QZ`KYE@1;F
M4EH\:8:<8'&([:H'"^ABF;`UI9[-G)4(VIH>]S<`"O17#SG];04Y,!XA\X7Q
MC*]2WB4!5$8H<_Y4\D0J^'!B=T<?4-%N`DT'\%I'<3"_7";B=EJ05"D!+E,>
M6!:!S?U[2VVG?+`R28FL1KM)]T!:!>#?#=F?@U%]#%RL<."59S(%?^.FO,^X
MY!J$SB[5[)MI/PN<5H4_9"S/H=:;((Z^LFP2_K:*94J`W@FOI:KSY8^=7390
M.R:B`(FQ)2]"3%Z"IA#'ZZ/]>2;]$K$""A!/@DX.[)?RLN0>G#NK>@AO\32,
M2<U::H#?X\?:G(:O9^SQ341C.<SR'S9'5_ZKO]]G`5SUO5LO'MA6-VW]W<$(
MN56IZOZLE"%2R/'Z?V\V'ARIJBX6<.QU8R_#S,\TARR6UU.Y:;#Q\EM?.#!H
MN!Y4].8<XO3<HZP1_IEM/.]'5FGL?+=^5`N42G!.IMRG:_3DKCS"3MU.GO1U
MAP_'WNP85H\Z%FW@@/AB#W]X%TDUOT*`L,F,'04+CL@CZ/O$:!N'U+26']Z\
M([=E+VTRW%-6=^AC2>VF!?;"[U]H/)OSLB>/-`MF5(YX7X(\#L_C9`65&M[-
M&%N*:_8/-U$!LZH@4I9$FEG"]K,<Y&E.,TI$/>+2<UD9X8)BEI`'"RK^D(F'
MLV@YE<BY;D()]\)Q3#EX,\FFJ)K!T4,F^I"S-Y]+;U8Y]XQ/*4*V6*Y$2$I@
ML<ZGBO5Y(Q`DQ^2AQD4D:T(+5./C0!VW1C:C#`2EXU>\1/YO_B_^`V\=RO_Q
M_P!02P,$%`````@`LXE\0/"KDQ`3&0``?Q\"`!4`'`!D<V-I+3(P,3$Q,C,Q
M7W!R92YX;6Q55`D``P)_<T\"?W-/=7@+``$$)0X```0Y`0``[5U;;^,XLGY?
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MT;MA=/_^\'W_PX?P3?\=^O"A__/A&]1__],'-#P\/`P_?/QIJ=8)0YEPD9#[
M4^_HS>%1_\W;_M%/=T='G]Z\_?3NW?\NEZ:3%X9'#TGOO\._B\)OWO=%C<,"
M'O_H79!POW<<Q[T;693W;@0&[!%%^[.6XAD./0$ZX5_VEKK^?,_B?<I&!Z+M
MMP?S@GM__4LO*_SIF>-"A:>W\^*'!W]\N[P-']`XZ&/"DX"$A8JR,575PX\?
M/QZD3[/2''_B:2N7-$RAL1"PIRTA_]6?%^O+/_4%PF\/]Y]YM/=/^<+/C,;H
M!@U[J0R?DI<)^K+'\7@2H[W9WQX8&G[9BWB(4[@/C[+Z?SNEX70LAM?\9T"B
M,Y+@Y.6"#"D;I]+O]63[O]U<%+H1(?%8M"<&.>+I&$MF0_9`%C^P:OE@4_EO
M1,T?MV)V(/F.P?`<$_'5<!!?4X[E*T[B@',\Q"BJUPW+MMOLR'7`4,V/4N$%
MR0-*<!C$S7=-3&XZ1AMW8-9,,^*)/RXU??L@$'B@L9"&G_TY%8/VF$0#@0@[
MH>.)>(0(QX^HH8Y4>YOS_C8S_*J_<GL#\B3@#^<Q?>(7),(,A<G&O5MOL1FA
MKVB"^!U=S-W%*_E5D$P9&@P'$\D?Q'3F]3I1Z0W;[M0M'A&Q(H4!28[#4+"3
M1+"I:QIC(3^_0\_)UYB&_VZZHY9OW7;GY1B2_\G9\1C$\D]BBMP^4);<B;Y=
MD$?$D[3DUI"H(\*V8;FD`>'98Q9$:+YJW*`0"1GO8\1/,0]CRL5@W1HP]838
M-C3R>Y"$LI<6$#"^:]L=O694+$+)RW4LYZ@@EF)\3E*RN?V.5WKW]K^XX-4C
M+`;<,><H:6/HV[QRV]T^1?=M?&K=:[;=/;'KL"F*SIXG@@0AOB!&4R9IT"4.
M[G$L*'LK*]U&LFQ_+R`CN1')#[7%M5[UDJU3GT2\I<"/9=D6/KC]B[<.`1K)
MGS=H(OB&H&!M=-[BE=M?TZ7*<Q<\M[*8&]ZU]5U<JGB4S)>4:\H3)E0\EC[]
MB@@:XE9VM-IR;%T#H.,QSOAU"S"4O&WKLWUZS]&?4_'KV>-6E1K]BV9=G"Q9
MW*7!O=!741B12%H3L[_*ES5O%TT%$:((L0IOCZ5!F;(BU+.7IU9CCL+]$7T\
MB!`^D.C+7]+/T']S.+,9_TW\Z<>Q>'4D7W\>!Z-Y<W%PCV+QZ=:>'VQ=GAF?
M.!<#+XC_!P7LC$2GXHLI1-,6K2;E^@"5?_EA\WF.[\4*$4@S45&XRO6WC^M<
MC`RM:\0PC<[%W[@"6'W9MN647]5.RKQD>S(N?4FQ/*`+L:Z8!%46;T_:[#OJ
MIY.Z7'ORW8EF#6*EC[<O33I'I7E/&F\4XA2?MR3/RXD`@`7QA=APGG]%+SJY
MULJU)I^@#)2D&D-JS^>#:2*/3>6AMUY84Z76),\VD071E_1`N=P8B[<E[2D=
M!YAHI9L];DN:<QPC=B)6B1%E^C%9+-66;-?3^QB'YS$-UG9G99FVY+I!(RPW
M?9)<!6/M`K-:K"WI?J?Q5%`5EGTT_318+=>6?-]1'/]*Z!.Y10&G!$47G$\1
MT\JI*[]]>2_1*(@S(8Z?L0K)U1+;ETD>4<@UZV5\3V.%1,7G"WF6U:!C5I0M
M8.&\(?'KF@Y4=&"9E3B8I*>X_?`!QPOU:<CHN`YSGDM#5=MSCS*AA:5.6.)_
M>SW1DR$2"WATF75:*VDJ9B)&-DI+RIJ8,B'"E[VCO=Z4BU[2B90C<(23)0N=
MPU+D6#DJASN-RHKNF\-RM-.P:!2&')ZW`(]*0\T!>@<`J4T-.43O=QJBE9TX
MA^7#3L.BIL@Y.C\!.NNF@!R>GW<:'KWE.$?HXTXC5*)#+6`ZW&VR;#8,Y2CM
M-GG6&`QR>':;1"LM9#DXNTVA;8S&.5:[S:85YLP<&O]8M/+\98[%FE'-9_N.
M$0GS")K#\N:-C\!H3*O%"3,_*6EOA'P^6/47:<.+Q#(LK;9M>1CP^Q25*>^/
M@F"2&9A1G/#Y7U8MS;,__YB%3/#KX$6.X!F?6C$[EQ2N;Q/?7.[<A_\*)7;2
M*ZLTXHUB[7VK<D6QK^P([^EX&HMAK`W[NJ2<GU.&\(AD0H<O=RP@/,Z6G.C_
MIEGTB4!],+P+GO6?J?$W.4$LBG"V]%P'.+H@)\$$)\'JB4Y9:2>2IY$".D&S
MA^[DTKAS:0JYD[-D,2J4<2ZE%:BK95U(+>/;Q-*X&N:6G`2,O0B5Y/<@GJX>
MV%>KZZ17N3.O%)"F,8QB65O?*FQJN.K!3$TT?H+58BYD/9VQ2[$S+&VK5Y2$
MQBE;6LT7_Z+ZR/Y":?2$8]TFMWCL0K;52#A!#LZ>PW@J#1DE<EM5==.G65BG
MD$@K^U(1OSQJZN.FI^*J$HXEE#'<:U%>Y6*KJW6Q+R7DP[JZX[Z9"9^B8#?D
MM4>_"_Q/VL_X8'@B]F%<HN\KBSJ1>2DDM41D14F7$B^EC"B1>+FD"XE34\%L
M=RXC<NJRSJ2NPD$-%5S(?STWU)82?U5)1Q)/`CRWLLV-;#8:NTU--SW29+C0
M<T)C%1=]N$&)4%E0=!8P(C@U7[(!"JT+AUC7$XN*+OJCRKFCZ8&RJ!.9YV<4
M:X><JQ*O%W0JK^),I8336%5UVB=58)NFD!LY+?61CF@@E74.&RVCQ0-5LP5<
MGJF66'47!ZQ'?CG\V`.CI+0Y+'ZY^MC#8F8/.3Y^N??8XV-G-<QQ\LO7QQXG
M%19^N<G;8Z'117-@_/*0K[HY+2-1QQF>)D'\&I#0V->6`;$\S<SQ\LLUOC)>
M:KUJ`<];O]SH*L-C=HK*8?++)[XR3,53LQP6GZFQ!2Q6IK$<+9\9L\U<T^%2
MAREW=TOKL"NOFP%2]3"SH(,:#M]\C6MO`C?3,8FO`>]-X%;NZ.1K-'S#LW73
MF/CNKN]-`&7T7O0U:KX)X$RE?8VG;WAF:IRC-@NW?U73U8*K7BJ=9GP-N*^)
MD<I)Q]=@^WH0Z6+%?`VVKX92U0@P7V/PZRY1ZWZ4FP7B=W\1UWM<K!L:%,3`
MLY#[:JC8TP=?X_#K^,$4R6?1U\1WPXW:MV;GDA:4PV&:B/[F++!W%5JQF:\[
MP.8KCI\J;W7K0#$R,,?'3]6V&C[:./$<)K]2QM6$:1L)"'*(_52!JT%LXX6=
MNR+`\J_V@\T1JJ,-5]%:NIS+IG@'M-N`="'+@*5B1^D.=(U8FLI,X_MK4]-Q
MB'V6B>UXFCR($?*?_&/J>[)6HQ,]2)-:6DL_*]T)R?57IUA5\2550%?"PC4)
MF8KT_!*+)3I*E\7L@5SB5$%KU>JZ#[RKN,!95G;?+\MEKJ125_IA7.P,%;HB
M?_F25U8+PMH@K*UR6!LXNW7`2&BTQ=MN1KZ[N-5!:WV+\]VAK3Y*\PW4=Z>U
M^@BI<W-[=HV+'4P5^;_O;FIV8\K*:.*[9UIEJ$QKN*^F^UH0K2_@OIK=:\&C
MN5G!<VH);@O@MN"3VX+S4YGL,-3-F0L7[Y>I`/@MC?5V_6(I%Q:)^1'GG-5\
M#3@.CTETBN-IHC72E=7RQ:J_00)@\6(NS^'%;D;.GF4@R!3SAVQ@2M=J#;+E
M]9STA@F)KAD=:O./+9=PDP!XX?@@ELDL]&8JP!M,$$M7&OX5#2F;.4C<!<^(
M?\,D7<`NB%C6$)=)7XJM9`?9WY"@LU%Y_K(V)7"'\&)Y+3'!ZDJ[DUP@/O-&
M_XH(TH]D76E'J;K3@3$312MQL=3K/\5L!KTKE.3328-=L8P3*05YR98(,LI$
M,7]M??E.25^R/I37<Y*&=B[2/&Y%(_UZN4Y(6X*YOKQ3Z4OGJ*JDLR3%5:=K
M224W268Y$HJF3+ATBAY13-,\=^9NF.LX.4L-8L1OA"QDBE(=2I_F5UG4B<PH
MCF6^/$$I6!`++(^C,2;I]>$)?BP929:5P;>@"^EE-7Y8WQ$>/0@-^?A1?,,1
MNIJ.[Q%+M>>9ZESF85*W%9>FJA+-81>-FN!@L3)&K'GD2D[2HGKDZXW5&Z%D
M88JR"Z5-I9XN%M<,M71=.B!B+*?F0I^`*^-[=@&UNX::%6`FWX)RP.YH&A?6
M4=1*U;+"AF?)"'T/%:P$6HD"XWN\8"6L%":-S8+]?$DGH=8?P353>7X)OIAK
MQV";.5_Z,HL,:]%NNUT:S9R;.5GZ,G8LZ"6X6+9^N.U[QL`JD"O.C,%E4W&T
MNIF/IB]CIM27RO?\@!:!"'4,X+XG"`3/5O!LK>;9FDZ28G(6HLT&Y,(!UB))
MT3<DI[[F[,V^OHOC0TVF*G./C'7<]&*>!XK?48UXZ4"[#SB*Y!<0\*=C^P:)
M,<=Q@FX1>\2A#(G"-+I!(1V1M!73!<A;?ZWCM"C&4;!>SI&TJ[,I3P6FDUM;
M`YR]LR588D2)&-=*0<UE&W$ND%%E@=@\!L.E828VAN\!8X&8;AFU4CD46-9L
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M'12M,=-9W7*`_,H%"=%W.I<+D[&MX.JD'EH[@].:.:_@GF)*05MCBY]DNEL2
ML,0+>(S75-?8YCW#1^=;N=-)GML[*(2PA5(7$0A?J&)#A1B&"C:NW4X87<F-
M9[<C$>I;RW<FH73](;9V/^W.QBO4L0+O3+Q"_>U18__W/7_+YEME*7"[K"1L
M>KIOE]!E1U&T/9/U_]+WTDVC[/#-]V0N&T.TQC]V41EH+T['_]O?[<VV:U?S
MU+G?/;-(GI'("UQ4SGN;W>[^VO"Q\8;=Q3269@=;B&`NCV!6'[C-`#H"@"#$
MVR;$^SI%_`$E.!0]Z&HL<:Y7S.U/,L^8SK%QHR9]B4GU*R81HF%V(QJFW*/6
MM`"8RX*_4)?V[\T55^V8V.U,G"439F?R<8+F!9H7*!9-*A8G`7\XC^D3OR`1
M9DA,(]?Z@C1(DA#'J.#Y=D>EI->,/F+1\Z\OOW&Q"I)%.M7C,,&/Z9%#"1';
MRJN<Y&L:4Y;@_Z0C9'%7-!D9=2A3%?=]N!#CG8SD`=(QY\BR%VN5G&10$N-%
MZ./RA]R3'H,X-=XD)P%C+P)A4P(LN[I>]LI1U+>5;"7+2+4VNM/+2OEP*C71
MB$Z8+KQ"(5@^:3ZG3/,QK*JXP/YTQA>J735;5LM-3P03"7&ZV&K%7BKB)-_:
M<"AXRV!X]AP^B+T`W0AR,R#JP:OI0Z4F?+$F;G:=N61*`R*OS1@,!5<2["AY
MN8Z#[`PCO8%%@[5E9:=70R,NEQ1-!U9+.9*TL/Q>D.,PI%.Y/`<O!D->>;UN
M]48P="0F7IT.+57M3)_85"B1.+C'<:9`S,YP%KK%TK,J_:W2;#>PD'<,$/&V
M*AU=KM.-7BP`GIDO2TACA08ZTK_"*#)J99:5N]&O:X8FDC+."-?\GI'9M*G8
M3ZO&W/0[N^S#N)4M%7$C8S:G7[XSG*!3^J1CF8J"#>>?S:S)<P?^"W)""4%I
M[.!WG#QD3P>")THUHR1M;K6F7O]YL`;;C.6=!2Q^D1>+%B\;52%HKN`H;Z[*
M&+BPG>7&0,VXK=!`M_M7LK?5:*A#_<VN/-K@>ZH:Z';_ZGU/4T,=ZJ_"6%^M
MGZH&NMV_>M^S:Z<:KR-/^14EH0!SP*X#ELS^<1QFWO5BDU\]DT@?"6IXJ.M0
MW>:<Y6B?";ERH;.R<_KRSJ17#/KY,>CB9-34&ZOZ3G*\I[XTOV)YNU]&[#7=
M4!1T(^_+W!\H&].61X#E]3K2FZ6+%&T[DE?I1!\*UEFAU)99=RLTX.86!!HB
M%*5W7BK#WG7=*JWGNC<W:#*#?C"\Q`2)'R=BD]">-MG5[5*O\JC`=+6U5L'J
MM^>H]X]8AM2>4W9*I_?)<!K/3=KZ#NJKN+FW8VD\43*Z0VPL%7J-_-KB;F0O
MQ)Z:R8VF,'C35_*F7_B@V3O1KU?QTW>^*3D7GL,Z':10Q)F,62H+217,\TY3
MV(G<T\DD3K]O$,]'Y0494C;./%U+AK1E[68B+I9>]@L3RO/<=T;ZR^3ZIC(`
MP[*J2V_?;7J1+OL,%WUB?$])W1:J9;Z@OJ>T=H/SJM^P[TFPMXVRS;F7KWFT
MVQ[)9DTI1]G/K#IMH6RP]^80FQ+RI!V<+GA4!G#*+0X(&LG,_#N/L<H+(@?7
MSRP\;6%KZZNZP/NM*>8+!K/=@F%WQ))C[F=&T;8@U^G..;Y^!DVWA:_.)ICC
M"[K?1DQ.<6Z98POZWF;6BI)8I!QH4/DV(W'V[N$YYGZJ@+5"+`L73MC%GBYP
M?%<#QU=S44P[:!;2.+ZKH31W/(UCE0#3XKQ>=J//$?(K"6U]=%9"YG*`_-1;
MJT<!F3<)5:2;W5T>KU@7;1K$0CB9W8T>@%[%<"B[ZS\`UI+H.;OK0`!&?6"S
M[]>";`'`2G''OMX>`GD;5P9:_>"OE6.XNNZ:OM^PLEV`+XM>OK[?M-(,F'K7
M5+MK6%[QQMS\:-1XT/M^44LS0%8)+=[L2I;N7[%:/VRU>(Q@'[QB=Z^O?[-]
M4T@-CGG&ZW\!26-TF-VMP#L/8I7P_<WN#GZU:V;%4RO=]?)U[KEZO5MW51_:
MK1PI;G2'ULY@7R7C0XYH'?^7[B\!=A<OU,$]/Z#VTWMV(^2,FU:.G)_*ST;(
M&56D'#D_3P[MD*N6S38_;?5SO[;#K%JNZQRS.ONL+[M"1:>2'#0_74DM+S^U
M#?;,X?+SC,KBNJ+:F15S[/PZ?ZJ`7:DC3HZ1GR<G-MD!X*(G!!<]E<%AFG1M
M7O3D")=JR0D*#+YVCCOOK^JK#VHQ$8?=M7VOV.A;`ZEJB2IR!.M0A2I4WLU%
M;5<T0?R.SM1F>3_F;!7C5T$R98);S:PXE/#Z%[=UZUJ2KB2U;BA5Z/IW*@IJ
M*-A(TA?]$#+=JF11"Y)<;3E!%+C&.0J#L)\RH(*4&H(5ZY_W!!&4L]>EG'6-
MW-WB$<%#'$JOI<S[75J!:(Q%8_Q.O/AK+!WM@/`U2OAV@D#9C2P-4;&K#,00
MB*%WFQD0PZ:/TBQ7(B"+0!:!+!K(HK2-KI[BD^CV@;)$!K<LN1DWP!PWNX^\
MJICJ;;%.2[[<V0Q<&3@E<$I/]CS@E%OP::N\QP#!!(()!--`,"]I0'CVF`71
M(B],GK"(GV(>QI1/&0+C9*=/H^M]2C63J-<6T$R@F4`S@69V"Z)J-+/F*@I$
M$X@F$$T#T5Q<@^$QGZR_[QK14>_"QBJOGQ,#.P1V".P0V&&WV*%YG082""00
M2*"!!&ISMGE,"H%0M4=0*HTO-7VIU`201B"-WFUO0!H;)HW55B4@D4`B@40:
M+8G%[`0><\=-#(KE(.GLBN4U@0V_!C8,3!&8(C#%CFWS)>9%BU4;""(01""(
M!H(HKWQIE!36W])THJCW-EUI"'`!\@?D#\A?I_8G('\-DS_M7@&$#P@?$#X#
MX9M=@CJ[VWAQ`^K)E+$4I,7]IQNS0@USV$@`!:?8J#U@B\`6@2T"6^S4Y@9L
ML<DK!#;;;X!/`I\$/FD,BL[OCO;N3+DKM*JIH&?5IU+S`759((-`!H$,`AGL
M%D15@Y:5JR`0/2!Z0/1,N;CEE3T/-!8M\.RJ.EG68X?"KI`_H%&>T:A6Y;2=
MM+HNV-8'D@@DL<L052.)%>8-$$<@CD`<3<01C>3/&S2A3.:V!\H(E+$):F,Q
MK#2DQJ(FD&"P)7JWAP%-;)HFVJQ!0!"!(`)!-`8IB]+H+GCVF!EN$IUL0$>]
MYQJK`+M]%>P6N"!P0>""W=K1C5S0O$X#"002""30E.X0$2Z_S\P]]YJ*]0<E
MF*5/OR*"AMCK]#5`KEI,?5AWK*EI3>WF@%@"L?1N"P1BV71*Q-JK%9!.()U`
M.@VD\X2.QSB["+,C27!*)%)O?R65(,@9*#+01*")G=JT@"8V?>=SR<X!9!#(
M()!!DY_B])ZC/Z?BUS-Y<1$'$R/P)^!/70MHT4Y2C<C:\L#^@/UU&:**GHCZ
M>0'$#XA?]XG?YP,IYWW`D?C'_P-02P,$%`````@`LXE\0)A8XI,`"0``$DH`
M`!$`'`!D<V-I+3(P,3$Q,C,Q+GAS9%54"0`#`G]S3P)_<T]U>`L``00E#@``
M!#D!``#M7%MOV[@2?E]@_P./7\XN4%F6<VN,I(O<NC#@C0,GVQ;GI:`EVB8J
MDRY))?:_WQE*LF5;460YQ38X>F@KB_/-A=]P2%%BS_Z83T/RR)3F4IPWO&:K
M09CP9<#%^+SQ][US<7_5[3;^^/#K+V?_<1QR<_WGQ8#T1<@%(UWG+V84GY,O
M/@N9HH:1!SJ70DX7Y-Z?L"E]1X94LX!(0;Y<#GJDW?0(F1@SZ[CNT]-3DP5C
MJAQIU35].76)XZ2F/L5.=<AQTSMHOL^T#&0D@@X)#D?!\,@[<HZ/_99SR(Z/
MG?=>BSE')\=LY'F>?WQZDD%=*48-*"0!.-HA[9;7=EH'3OODH=WNM`XZAX?_
MRTK+V4+Q\<20W_S?0;AUY`#"6^N`=Z0K_":Y"$,R0%%-!DPS]<B"9J))VUX@
MT,="GS<R@3\=-*4:NZ#7<[_\U8M[J_'K+R26[<R'*N1K"+R38@Y<+K2APF<9
M"'CTK0"!S4A&UL@6)''+.ST]=6UK1CK2SIC2V5)^1/702B<-+O:/T_*<`V\=
M918SIG-AMB4?%VA_/?Z`J2F%FY"=3-M<09S77D,)*40TS>^%P"@7#;H@Y(`4
M4]S/0E_&;6%0)C!+6+;#C]RX,2/M0]H:M5@7U\QOCN6CFS0^TQF,YZ.@(1_!
MQ2/3)A\4MVWB#%5C9F[IE.D9]=DN?0^#?\J$^2C5])J-:!2"X>\1#?F(LZ!!
MJ($B,8P,6Q.(Q$KD`VHYHT)(8X>H_8UW9C,N1C+Y"3<P)3M*ANP!""%X\?>@
M^X*K)BE)+HJ[U]*/T-GT7RJ"&V&X673!$$#1?(/PX+Q12G+I6NI<P$9<<!N$
MU_*(0U)X]A)4D5@7R2@[<S<U;"J/H);VQ0=[[=/0CT(+[,'O!)Q(%`%G"HJ4
M,!60*\^>QR5W4XY>D[I[\-DF6G_TD0NH?IR&=U);AZY"JG62;TC>``!?2P**
M.3P`XI:*"$X,0LN0XR02D$L:8A4F]Q/&C*X)?`T"[Z@"D0DS''IH9S8M^@5*
M#\M32GY;<^?WFN+2%,/:2$Y9/H%)6S%-1T4T+1LTD2/2G^'R$V#U&"Q/T/T$
M4GLB0X#HF^\1S$87(NA#JJLK.84`)TQH_LBV>/2Y4UE+,>/'Y1G/FOTOB0W7
MW/\8[I^KR'LD0IDR?;)?-M2ENW)V7%$]^1C*)]T5`5?,-_E5?%NLF-#WY0E%
MU<3JKFDKINU6&J8?Y'))M.K'6VHBQ?JCU>28H7$G6#&MI_AHP[4?2@U`_,&T
MK_C,;K8`EY>1YH+IFLG*3-[SL8#5K4^%N?#M3@$7XSL8.J!,/["YN0RE_ZT4
MNR55%3+NM389OX^F4ZH6MA2O#)"5!9*:J).@:A)@2<0_.+L]TA!OP01[/Y'*
M/(#2KMW5L9*[9405O<7IX6VFAZWFN.EA+S*&[,V,A3H[JF9'3U*AXV9%`Y8N
MO0;,9]#9PY#I%2.[Y4<US<49TM[,D*12X`YZJO8=$<S4"5$U(7!4"2/5HBKO
MA0J*Z3W8I#?554\`>S!ZIR0LR<SB+L3)6P181V=VA[HBPSLI+&;\<)/QI:ZX
MQ,,#H'R,K=;C>L]Q;:@8<RB0%UHS4[FLE]%3S/G1UB@/0#&L_;!ZDY5^$ANH
M>=^+]VLVK#S0G\,6\WN\R6\/7_KCP[EB`3?D4BHEGV!Q7]?TRJS"ND=%++B9
MSYC03"]WS"*%6U<]&$H\!+^KK][V,E"<'R<YBSBT15)CMO1;<R2Q1S(&ZZ2I
MOM878WPTPV&]ZUH^#UE,\_NM,@!*'`-:"*JI::R\JV.@\]<VS%&VZD`OKZV8
M[JW=O/I-RZN2SL;X[X#-I,*-L<ITE]!32'1[:Q,OV?`58Y(HKTOT'JMT?,OU
M0.?5E^<%"HJ)W=I^BW7AMYGUK+O'XS>^OY0B74'=26T4,US9UDLFP._J3V.5
ME1>GPM8^VV"IE*1:ZXRHO",OIU,>;UQ7Y?T%%<7L;FVS9;35K%:>H:.A9M\C
MN+QYW/UMRO/H8BZW-M!6BHC5]']`*/Z%GZ@/V(C8K\\[^-WU>4/SZ2QDC>0>
M53[BB[];=V?QWB8\9[JIVE3!%GK]0WF;'AO]EWB5:I@H-CIOX"?J3OHA]%=`
M-.?3,!4QW*"5JY4>W#[YIM\1&H8-]^>-?)W&$H$#("?PZZ6:-Q)W2(<L+!DR
MR.:$W$,-;R3:S6%>(FB`Y`1]EU&4%_N9F_V('WZM?^1_!J'#`PP1N><.GCGS
M0N)C-3WI6T4%$/SEI#@';SE>VSGPFG,=)"[NXL&JIW?S(,7MZD'N@9*RME,`
M&CTJ9:[P:,YS9JW)W+-`+@N-7NIR5KIV[_VM,SBE.F$3A3UQBMWO'>_C0N;X
MT(YN2'%;S9.BLU9[$(-W=N7EI5-+A>[DX=(?>SFR<1"JE!,I!B_V,KY]H*J4
M_0PLN7[&B^1\E77CO%%Z1S]>KV(1_[H#)IZ2[/G#SE0*9JA:=&%QB^NU!J%#
M>#"EOCEOC&AHIQPK"%,1E\&#A<;EUJ1-P_@\Q7G#MV^-&D3P,,0WA.<-`SY!
M5\%"%R:3"#OJ3R6C66J=@]4]N^#9Q[+=>B573=Q1\8G#CDGO[]150:22`V>O
MT"GX;=4=Y<%UI/"3/FOFHU07B1N9N%^4S.8`W`.AO+!B3W]P5&5.X>6$N!OL
M)XJWJW6$XZ4_PH=Y*>RV/F3F9ZH4Q>=+W(W/#NVR@+48[;U_+U5?\OD3#2.V
M0XR)_-ZE:Q7DCZM=JUCB5REI#%UQ!:6$^:CJ,S>3N+4_&C',QWS&=]3PX_HG
M8,-7ZIZ>U+HO;J@*%_AV\6:.+R0BKB<HD^F$%^3>0J@%+^VW"UH9X9^HC,%C
M(:0=C!H[5'L<4C&PVN,&W)7;'.3E(6]AB6*#P)'*UJ;9N!K;QG38WLR9\KE.
M3R[;OJB$_IDJ_#,!6`*K1E\(?A.U/Q-86L2OI#8Z/_8-D;=0TNZCV2R^04.`
M:)TN-7%YZ<.(CH]K9^,MBW@+X7^"9SA(U_XH)G#`L`K[)BEIF:A?$OR9AG*Q
MKYM5O)3TFQBLGQG^GSXLN'ADBH[9;30=,G5)-?>O>1AA1):8?F1P,L'_,"G3
M#57`_R+I9VZ\80&7_P!02P$"'@,4````"`"SB7Q`6F(W"F"0``!],08`$0`8
M```````!````I($`````9'-C:2TR,#$Q,3(S,2YX;6Q55`4``P)_<T]U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`"SB7Q`=KA:&R<-``"!L```%0`8````
M```!````I(&KD```9'-C:2TR,#$Q,3(S,5]C86PN>&UL550%``,"?W-/=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`LXE\0,!8I[Z\%P``?<4!`!4`&```
M`````0```*2!(9X``&1S8VDM,C`Q,3$R,S%?9&5F+GAM;%54!0`#`G]S3W5X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`+.)?$#J]20BX2H``!)!`@`5`!@`
M``````$```"D@2RV``!D<V-I+3(P,3$Q,C,Q7VQA8BYX;6Q55`4``P)_<T]U
M>`L``00E#@``!#D!``!02P$"'@,4````"`"SB7Q`\*N3$!,9``!_'P(`%0`8
M```````!````I(%<X0``9'-C:2TR,#$Q,3(S,5]P<F4N>&UL550%``,"?W-/
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`LXE\0)A8XI,`"0``$DH``!$`
M&````````0```*2!OOH``&1S8VDM,C`Q,3$R,S$N>'-D550%``,"?W-/=7@+
B``$$)0X```0Y`0``4$L%!@`````&``8`&@(```D$`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
</td>
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>2.</b></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>Summary of Significant Accounting Policies</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Principles of Consolidation</b> &#x2013; The consolidated
financial statements include the accounts of Derma Sciences, Inc.
and its wholly owned subsidiaries. All significant intercompany
accounts and transactions have been eliminated in
consolidation.</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Use of Estimates</b> &#x2013; The preparation of consolidated
financial statements requires management to make estimates and
assumptions that affect the amounts reported in the financial
statements and accompanying notes. Although these estimates are
based on knowledge of current events and actions which may be
undertaken in the future, actual results may ultimately differ from
these estimates. Estimates and assumptions are required in the
determination of sales deductions for trade rebates, sales
incentives, discounts and allowances. Significant estimates and
assumptions are also required in determining the appropriateness of
amortization periods for identifiable intangible assets, the
potential impairment of goodwill and the valuation of
inventory.</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Foreign Currency Translation</b> &#x2013; Assets and liabilities
are translated using the exchange rates in effect at the balance
sheet date, while income and expenses are translated using average
rates during the period. Translation adjustments are reported as a
component of shareholders&#x2019; equity in accumulated other
comprehensive income. For the Company&#x2019;s foreign subsidiaries,
exchange rate fluctuations on foreign currency denominated assets
and liabilities other than the functional currency resulted in
income of $133,681 and $159,949 for the years ended December 31,
2011 and 2010, respectively, which is included in the consolidated
statement of operations as follows:</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt">Cost
of sales</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
(66,379</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">)</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
181,302</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">Other
expense (income), net</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(67,302</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(341,251</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(133,681</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">)</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(159,949</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">)</td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Exchange rate fluctuations of foreign currency denominated assets
and liabilities associated with inventory are included in cost of
sales, while all other such fluctuations are included in other
expense (income), net.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Concentration of Credit Risk</b> &#x2013; Financial instruments
that subject the Company to a concentration of credit risk consist
principally of cash and cash equivalents and accounts receivable.
The Company maintains cash and cash equivalents with various
financial institutions in amounts which at times may exceed
federally insured limits. Accounts are guaranteed by the Federal
Deposit Insurance Corporation up to $250,000. The Company has not
experienced any losses in such accounts. The Company does not
require collateral or other security to support credit sales, but
provides an allowance for doubtful accounts based on historical
experience and specifically identified risks. Accounts receivable
are charged off against the allowance for doubtful accounts when
management determines that recovery is unlikely and the Company
ceases collection efforts.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Inventories</b> &#x2013; Inventories consist of raw materials,
packaging materials, work in process and finished goods valued at
the lower of cost or market. Cost is determined on the basis of the
first-in, first-out method.</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Equipment and improvements</b> &#x2013; Equipment and
improvements are stated at cost and are depreciated on a
straight-line basis over the estimated useful lives of the assets
ranging from three to 10 years. Leasehold improvements are
amortized over the lesser of the useful lives or the remaining
lease term.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Fair Value of Financial Instruments</b> &#x2013; The carrying
value of cash equivalents, accounts receivable, prepaid expenses
and other current assets and accounts payable reported in the
consolidated balance sheets equal or approximate fair value due to
their short term nature. Based on the terms of the Company&#x2019;s
credit facility with its lender, the carrying value of the
borrowings that were outstanding at December 31, 2010 are
considered to approximate the respective fair value.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Identifiable Intangible Assets</b> &#x2013; Identifiable
intangible assets, which consist of customer lists, trademark and
trade names, non-compete and other agreements and certifications
and product designs, are amortized over four to 13 years on a
straight-line basis.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Long Lived Assets</b> &#x2013;The Company reviews its long-lived
assets with definitive lives whenever events or changes in
circumstances indicate that the carrying amount of such assets may
not be recoverable. If the carrying amount of the asset or group of
assets exceeds its net realizable value, the asset will be written
down to its fair value.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Goodwill</b> &#x2013; The Company tests goodwill for impairment
using a two-step process. The first step tests for potential
impairment, while the second step measures the amount of
impairment, if any. The Company uses a discounted cash flow
analysis to complete the first step in this process. If the first
step indicates an impairment, i.e. when the carrying value exceeds
the fair value, then the second step is required to determine the
implied fair value of goodwill. The implied fair value of goodwill
is calculated in the same manner that goodwill is calculated in a
business combination. The allocation is to be performed as if the
reporting unit had just been acquired and the fair value of the
unit was the purchase price. The goodwill impairment equals the
carrying value of goodwill less the implied fair value of goodwill.
The Company performs its goodwill impairment test as of December 31
of each year, or more frequently if impairment indicators are
present.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Stock-Based Compensation</b> &#x2013; Stock-based compensation
for new, modified and unvested share-based awards with employees
and non-employee directors, such as grants of stock options and
restricted stock, is recognized in the consolidated financial
statements based on the fair value of the award at the grant date
and is recognized on a straight-line basis over the requisite
service periods. The Company estimates the fair value of stock
options as of the date of grant using the Black-Scholes
option-pricing model for service and performance based awards. The
fair value of restricted stock is based on the quoted market price.
The Company issues new shares upon exercise of share-based
awards.</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Income Taxes</b> &#x2013; Deferred tax assets and liabilities are
recognized for the future tax consequences attributable to
temporary differences between the financial statement carrying
amounts of existing assets and liabilities and the respective tax
bases. Deferred tax assets, including tax loss and credit
carryforwards, and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The
effect on deferred tax assets and liabilities of a change in tax
rates is recognized in income in the period that includes the
enactment date. Deferred income tax expense represents the change
during the period in the deferred tax assets and deferred tax
liabilities. The components of the deferred tax assets and
liabilities are individually classified as current and non-current
based on their characteristics. Deferred tax assets are reduced by
a valuation allowance when, in the opinion of management, it is
more likely than not that some portion or all of the deferred tax
assets will not be realized.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
The Company measures and recognizes the tax implications of
positions taken or expected to be taken in its tax returns on an
ongoing basis. In 2011 and 2010, the Company had no unrecognized
tax benefits or liabilities, and no adjustment to its financial
position, results of operations or cash flows were required. The
Company records interest and penalties related to tax matters
within other expense on the accompanying Consolidated Statements of
Operations. These amounts are not material to the consolidated
financial statements for the periods presented. The Company&#x2019;s
United States tax returns are subject to examination by federal and
state taxing authorities. Tax years prior to 2008 are no longer
subject to federal or state examination. Tax years prior to 2003
are no longer subject to examination in Canada. The United Kingdom
tax returns since the inception in 2010 of the subsidiary in this
country are subject to examination.</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Revenue Recognition</b> &#x2013; Sales are recorded when product
is shipped or title passes to customers and collectability is
reasonably assured. Gross sales are adjusted for cash discounts,
returns and allowances, trade rebates, distribution fees (in
Canada) and other sales deductions in the same period that the
related sales are recorded. Freight costs billed to and reimbursed
by customers are recorded as a component of revenue. Freight costs
to ship product to customers are recorded as a component of cost of
sales.</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Advertising and Promotion Costs</b> &#x2013; Advertising and
promotion costs are expensed as incurred and were $1,560,903 and
$1,197,309 in 2011 and 2010, respectively.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Royalties &#x2013;</b> The Company recognizes royalty expenses
associated with the products sold at the time the related sale
occurs and records them as a component of cost of sales. Royalty
expense for the years ended December 31, 2011 and 2010 was
$1,159,908 and $911,893, respectively.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Net Loss per Share</b> &#x2013; Net loss per common share &#x2013;
basic is computed by dividing net loss by the weighted average
number of common shares outstanding for the period. Net loss per
common share &#x2013; diluted reflects the potential dilution of
earnings by including the effects of the assumed exercise,
conversion or issuance of potentially issuable shares of common
stock (&#x201C;potentially dilutive securities&#x201D;), including
those attributable to stock options, warrants, convertible
preferred stock and restricted common stock in the weighted average
number of common shares outstanding for a period, if dilutive. The
effects of the assumed exercise of warrants and stock options are
determined using the treasury stock method. Potentially dilutive
securities have not been included in the computation of diluted
loss per share for the years ended December 31, 2011 and 2010 as
the effect would be anti-dilutive.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Potentially dilutive shares excluded as a result of the effects
being anti-dilutive are as follows:</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">Year Ended December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Excluded dilutive
shares:</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.12in; WIDTH: 66%; FONT-SIZE: 10pt">
Preferred stock</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
73,332</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
284,844</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.12in; FONT-SIZE: 10pt">
Restricted common stock</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">51,500</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">20,000</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.12in; FONT-SIZE: 10pt">Stock
options</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">1,582,683</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">1,203,600</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.12in; FONT-SIZE: 10pt">
Warrants</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
3,065,702</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
1,734,531</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt">
Total dilutive shares</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
4,773,217</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
3,242,975</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q
M,&$T.3-C,#`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E
M83(Q,&$T.3-C,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,35C
M8C@W-&%?,3$T8U\T,C4W7SAE93%?96$R,3!A-#DS8S`P+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4VAA/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?4VAA,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V%S:%]A;F1?
M0V%S:%]%<75I=F%L96YT<U]A;F1?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^06-C;W5N='-?4F5C96EV86)L95]N970\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E;G1O<FEE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6EP;65N
M=%]A;F1?26UP<F]V96UE;G1S7VYE=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DED96YT:69I86)L95]);G1A;F=I8FQE7T%S<V5T
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQI;F5?
M;V9?0W)E9&ET7T)O<G)O=VEN9W,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y!8V-R=65D7T5X<&5N<V5S7V%N9%]/=&AE<E]#=7(\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,;VYG=&5R
M;5]$96)T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4VAA<F5H;VQD97)S7T5Q=6ET>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D]P97)A=&EN9U]396=M96YT<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E=&ER96UE;G1?0F5N
M969I=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M;VUM:71M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-U8G-E<75E;G1?179E;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S
M/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N
M8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@
M(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R
M93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O
M=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-
M"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E
M(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-6-B
M.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,35C8C@W-&%?,3$T8U\T,C4W7SAE93%?96$R
M,3!A-#DS8S`P+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1595
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET
M>2!);F9O<FUA=&EO;B`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,C8L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!);F9O<FUA=&EO;B!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,3`M2SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D)
M,C`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I
M;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D99/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M<F%D:6YG(%-Y;6)O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M1%-#23QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^1$5234$@4T-)14Y#15,L($E.0RX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#
M96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,#`P,#@Y,C$V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M(%=E;&PM:VYO=VX@4V5A<V]N960@27-S=65R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@4F5P;W)T:6YG(%-T
M871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^665S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PV,S`L.#8U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M4'5B;&EC($9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4U+#$R-RPT-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R
M-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%44M!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI
M9&%T960@0F%L86YC92!3:&5E=',@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R
M<F5N="!!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPQ,3`L,S4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,#0L,C$V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#(R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4L(&YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR-C<L.#,Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT-#$L
M-3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`L-3,P+#<R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$R+#0Y."PU,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD
M(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`Y.2PQ.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,#DL,38T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#(S,RPQ,#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M."PY-3,L-#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;VYG+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(T.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N="!A;F0@:6UP
M<F]V96UE;G1S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L-#@Y+#$Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-C`X+#(T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^261E;G1I9FEA8FQE(&EN=&%N9VEB;&4@
M87-S971S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-#`S+#`T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L.3<Q+#8R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L,3$Y+#<R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3$Y+#<R-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,CDL.#(Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$V+#@U
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3@L-C(S+#@Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,V+#DV.2PX-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!,:6%B
M:6QI=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:6YE(&]F(&-R961I="!B;W)R;W=I;F=S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#`W-2PU-34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@;6%T=7)I=&EE
M<R!O9B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PX-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L.3DY+#DY,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S<W+#0U-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E
M>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS-S<L-C,T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-3`L-C(Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPS-S<L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,#DL-#@Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!L;VYG+71E
M<FT@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U,BPV.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,3$L-3@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!T87@@;&EA8FEL:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$T-BPP-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`V."PP.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPW-S8L,S4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L,C@Y+#$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@*$YO=&4@
M,34I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F5H;VQD97)S)R!%<75I='D\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"`D+C`Q('!A<B!V86QU93L@,2PT
M-C@L-S4P('-H87)E<R!A=71H;W)I>F5D.R!I<W-U960@86YD(&]U='-T86YD
M:6YG(#<S+#,S,B!A="!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C@T+#@T-"!A
M="!$96-E;6)E<B`S,2P@,C`Q,"`H;&EQ=6ED871I;VX@<')E9F5R96YC92!O
M9B`D,RPR,C(L,S8X(&%T($1E8V5M8F5R(#,Q+"`R,#$Q*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M)"XP,2!P87(@=F%L=64[(#$X+#<U,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960[
M(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@,3`L-3<W+#8S,B!A="!$96-E;6)E
M<B`S,2P@,C`Q,2!A;F0@-BPU-C,L,#<V(&%T($1E8V5M8F5R(#,Q+"`R,#$P
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#4L-S<V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4L-C,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S<L,S<T+#@R,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X+#@P,RPR,3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA
M=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("T@8W5M=6QA=&EV92!T
M<F%N<VQA=&EO;B!A9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PU,#(L-3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PV,#0L.30P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I
M8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PQ,S8L,S(W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(S+#<Y-2PY,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@4VAA<F5H;VQD97)S)R!%<75I='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#@T-RPU,S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPV.#`L
M-S$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@3&EA8FEL:71I97,@86YD(%-H87)E:&]L9&5R<R<@17%U
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4X+#8R,RPX
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,V+#DV.2PX-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P
M,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C
M7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E=#`S+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%34]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0V."PW-3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0V."PW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@:7-S=65D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPS,S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#0L.#0T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL(&]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPS,S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#0L.#0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL(&QI<75I9&%T:6]N('!R969E
M<F5N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPR,C(L
M,S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ."PW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#4W-RPV,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4V
M,RPP-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#4W-RPV,S(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4V,RPP-S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q
M-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C
M,#`O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,E%!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O
M9B!/<&5R871I;VYS("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(%-A;&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8R+#8S,"PR-#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4V+#0W-"PP-38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@
M;V8@<V%L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#(Q
M."PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS.2PY-#8L-S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)O<W,@4')O9FET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ."PT,3$L.30W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-3(W+#,S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<&5R871I;F<@97AP96YS97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5L;&EN9RP@9V5N97)A;"!A;F0@861M:6YI
M<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#$W
M,RPX.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-RPY,#4L,#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4W+#`Y-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y,BPV-C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!O<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(R+#(S,"PY-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PQ.3<L-S4W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG
M(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#$Y+#`S
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#8W,"PT,C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&5X<&5N<V4L(&YE=#H\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E
M<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8S
M+#`U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4X,"PV,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@;VX@9&5B="!E>'1I;F=U:7-H;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<V+#$P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-"PP-S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R(&5X<&5N<V4@*&EN8V]M92DL(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L-C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S0P+#(Q-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!E>'!E
M;G-E+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U,2PX
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-30L-#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&]S<R!B969O<F4@:6YC;VUE('1A>&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#(W,"PX-S,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP,C0L.3`S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M.2PU,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,C,L.38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H-"PS-#`L-#$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPT-#@L.#8T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@
M<&5R(&-O;6UO;B!S:&%R92`M(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-#DI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C,Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M('5S960@:6X@8V]M<'5T:6YG(&QO<W,@<&5R(&-O;6UO;B!S:&%R92`M(&)A
M<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#<X,"PY.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#,S-2PW.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P
M830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T
M85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E
M=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%54-$23X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!3:&%R96AO;&1E<G,G($5Q
M=6ET>2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E1O=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E!R969E<G)E9"!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y#;VUM;VX@4W1O8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^061D:71I;VYA;"!086ED+4EN($-A<&ET86P\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^06-C=6UU;&%T960@3W1H97(@0V]M
M<')E:&5N<VEV92!);F-O;64\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^06-C=6UU;&%T960@1&5F:6-I=#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@870@1&5C+B`S
M,2P@,C`P.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,2PR
M,S$L,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+#@U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-3`L,SDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,2PR,C$L-C$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#,P,RPR.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(Q+#,T-RPP-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A
M="!$96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.#4L,#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PP,SDL-#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPT-#@L.#8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-#0X+#@V-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@
M8W5R<F5N8WD@=')A;G-L871I;VX@861J=7-T;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`Q+#8T-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,2PV-#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS
M:79E(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,30W
M+#(Q-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R`H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,3<L.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0L-#<T+#0U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q+#$W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#8S+#(W-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K(&%N9"!W87)R86YT<R!F;W(@;&EC96YS92!R:6=H=',@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@
M9F]R(&QI8V5N<V4@<FEG:'1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#0Q-RPQ,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-#$S+#$R-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@8V]M
M;6]N('-T;V-K(&]P=&EO;G,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L-C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!C;VUM;VX@<W1O
M8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L
M,C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-BPR,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:R!C;VYV97)S:6]N("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VL@8V]N=F5R<VEO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X."PY-S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.#@L.3<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;F1I;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$P/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-BPV.#`L-S$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PV,S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT."PX
M,#,L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PV,#0L.30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C,L-SDU+#DQ-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E("AI
M;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X-"PX-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#4V,RPP-S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#,T,"PT,3$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PS-#`L-#$Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F]R96EG;B!C=7)R96YC>2!T<F%N<VQA=&EO;B!A9&IU<W1M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#(L-#`Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P,BPT,#DI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@T+#0T,BPX,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-3(T+#(S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-BPS-3<L,#<U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L,C0R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L,S(Q+#@S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V4@;V8@=V%R<F%N=',L(&YE="!O9B!C;W-T<R!O9B`D-C@L
M,C`T("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-SDL,S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT<RP@;F5T(&]F(&-O<W1S
M(&]F("0V."PR,#0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V
M-BPT-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#<Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,V-"PV-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&-O;6UO;B!S=&]C:R!O
M<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW."PU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&-O;6UO;B!S=&]C:R!O<'1I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3$L-C4T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P
M+#@V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K(&-O;G9E<G-I;VX@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q,2PU,3(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$Q+#4Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E9F5R<F5D('-T;V-K(&-O;G9E<G-I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(L,3$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3$U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG(&]F(')E<W1R
M:6-T960@<W1O8VL@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5F5S=&EN9R!O9B!R97-T<FEC=&5D('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-C,T+#0T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C,T+#0T-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@
M1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U,"PX-#<L-3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`W,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P-2PW-S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<W+#,W-"PX,C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3`R
M+#4S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,C@L,3,V+#,R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E("AI;B!S:&%R97,I
M(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<S+#,S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#4W-RPV,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P
M830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T
M85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E
M=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@4VAA<F5H;VQD97)S)R!%<75I
M='D@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=6%N8V4@8V]S=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#<Q-RPX-S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M,3$T+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V4@;V8@=V%R<F%N=',L(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8X+#(P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,35C8C@W-&%?,3$T8U\T,C4W
M7SAE93%?96$R,3!A-#DS8S`P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,"]7;W)K
M<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S2T)'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A<V@@
M1FQO=W,@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!!8W1I=FET:65S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L,S0P+#0Q,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(L-#0X+#@V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE
M(&YE="!L;W-S('1O(&YE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!O
M<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&]F(&5Q=6EP;65N="!A
M;F0@:6UP<F]V96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY.3$L,#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#DU+#(V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&ED96YT:69I86)L
M92!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU-C@L-3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV.#DL-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F
M97)R960@9FEN86YC:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-RPW.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3`L-#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!P;W)T:6]N(&]F(&QO
M<W,@;VX@9&5B="!E>'1I;F=U:7-H;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$R+#,S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Q-"PP-S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F;W(@8F%D
M(&1E8G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PW-S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#DT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06QL;W=A;F-E(&9O<B!S86QE<R!A9&IU<W1M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S<L,#(S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#4P,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES
M:6]N(&9O<B!I;G9E;G1O<GD@;V)S;VQE<V-E;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`X.2PV,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-SDL.#8Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1I
M<W!O<V%L(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S(L.#8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPV-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-C`X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`X+#<U,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M<&5N<V%T:6]N(&-H87)G92!F;W(@96UP;&]Y964@<W1O8VL@;W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.3DL-C<U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$W+#<S
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M<&5N<V%T:6]N(&-H87)G92!F;W(@<F5S=')I8W1E9"!S=&]C:SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,T+#<W,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+#(V-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YT97)E<W0@8VAA<F=E(&9O<B!S=&]C:R!W87)R86YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&EN8V]M92!T
M87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L,3`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34U
M+#@X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X,3,L-C(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,3$R+#(T,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.3(L,#`T*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M,3(R+#$P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,#(L,#<W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$T-"PY,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8T,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,3`L.30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S<L,#DU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8X+#4T.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!L:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0S+#`W,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V-"PS,C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@;W!E<F%T:6YG(&%C
M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T.2PU
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R.3$L,C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1I;F<@06-T:79I=&EE<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S
M92!O9B!E<75I<&UE;G0@86YD(&EM<')O=F5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.3<X+#DT.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,S0L.3,Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@
M;V8@;&EC96YS92!R:6=H=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L,#`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R+#(U,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!I;G9E<W1M
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PT-S0L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L-#4R+#DT.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#@X-"PY
M,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D9I;F%N8VEN9R!!8W1I=FET:65S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!R97-T
M<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,#,R+#$V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&-H86YG92!I;B!B;W)R;W=I;F=S('5N9&5R(&QI;F4@
M;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`W
M-2PU-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S8Y+#(T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&1E8G0@<F5P87EM96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PX-3$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PP-3DL,3@U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O
M9B!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.3<U
M+#$Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L-#DP+#<S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN
M9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,RPX.3,L-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPR,S(L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W0@;V8@97AC:&%N9V4@<F%T92!C
M:&%N9V5S(&]N(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#<U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,RPX.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC<F5A<V4@:6X@8V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38L-S`V+#$S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V,"PV.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"96=I;FYI;F<@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#`T+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T,RPU,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9"!O9B!Y96%R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ,3`L,S4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`T+#(Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=7!P;&5M96YT86P@9&ES8VQO<W5R97,@;V8@8V%S:"!F;&]W(&EN
M9F]R;6%T:6]N.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0=7)C:&%S92!O9B!L:6-E;G-E(')I9VAT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV-C<L,3(V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#0Q-RPQ,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#(U,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('=A
M<G)A;G1S(&%N9"!S=&]C:R!O<'1I;VYS(&9O<B!P87EM96YT(&]F(&]F9F5R
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3`L
M.3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(Q+#8S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#87-H('!A:60@9'5R:6YG('1H92!Y96%R
M(&9O<CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T
M-"PV.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-S(L,#,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S,3DL,C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`W-RPW,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A
M,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B
M.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3
M:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,'!X.R!415A4+4E.1$5.5#H@,'!X.R!0
M041$24Y'+4Q%1E0Z(#!P>#L@5TE$5$@Z(#!P>#L@4$%$1$E.1RU224=(5#H@
M,'!X.R!0041$24Y'+51/4#H@,'!X)SX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!P>#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E.
M1RU,1494.B`P<'@[(%=)1%1(.B`P+C5I;CL@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X)SX-"CQB/C$N/"]B/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@
M5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M
M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>"<^#0H\8CY$97-C<FEP=&EO
M;B!O9B!"=7-I;F5S<SPO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3`N-6EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"D1E<FUA(%-C:65N8V5S+"!);F,N(&%N9"!I=',@
M<W5B<VED:6%R:65S("AT:&4-"B8C>#(P,4,[0V]M<&%N>28C>#(P,40[*2!I
M<R!A(&UE9&EC86P@=&5C:&YO;&]G>2!C;VUP86YY(&9O8W5S960@;VX-"G1H
M<F5E('-E9VUE;G1S(&]F('1H92!W;W5N9"!C87)E(&UA<FME='!L86-E.B!P
M:&%R;6%C975T:6-A;"!W;W5N9`T*8V%R92P@861V86YC960@=V]U;F0@8V%R
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M/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,35C8C@W-&%?,3$T8U\T
M,C4W7SAE93%?96$R,3!A-#DS8S`P+U=O<FMS:&5E=',O4VAE970P.2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,'!X.R!415A4+4E.1$5.5#H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@
M5TE$5$@Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@
M,'!X)SX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!P
M>#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(
M.B`P+C5I;CL@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M)SX-"CQB/C(N/"]B/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@5$585"U)3D1%3E0Z(#!P>#L@
M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.
M1RU43U`Z(#!P>"<^#0H\8CY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,\+V(^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB/E!R:6YC:7!L97,@
M;V8@0V]N<V]L:61A=&EO;CPO8CX@)B-X,C`Q,SL@5&AE(&-O;G-O;&ED871E
M9`T*9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@
M;V8@1&5R;6$@4V-I96YC97,L($EN8RX-"F%N9"!I=',@=VAO;&QY(&]W;F5D
M('-U8G-I9&EA<FEE<RX@06QL('-I9VYI9FEC86YT(&EN=&5R8V]M<&%N>0T*
M86-C;W5N=',@86YD('1R86YS86-T:6]N<R!H879E(&)E96X@96QI;6EN871E
M9"!I;@T*8V]N<V]L:61A=&EO;BX\+W`^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*/&(^57-E(&]F($5S=&EM871E<SPO8CX@)B-X,C`Q
M,SL@5&AE('!R97!A<F%T:6]N(&]F(&-O;G-O;&ED871E9`T*9FEN86YC:6%L
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M=&5S(&%N9`T*87-S=6UP=&EO;G,@87)E(&%L<V\@<F5Q=6ER960@:6X@9&5T
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H\8CY&;W)E:6=N($-U<G)E;F-Y(%1R86YS
M;&%T:6]N/"]B/B`F(W@R,#$S.R!!<W-E=',@86YD(&QI86)I;&ET:65S#0IA
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M>2!R97-U;'1E9"!I;@T*:6YC;VUE(&]F("0Q,S,L-C@Q(&%N9"`D,34Y+#DT
M.2!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+`T*,C`Q,2!A;F0@
M,C`Q,"P@<F5S<&5C=&EV96QY+"!W:&EC:"!I<R!I;F-L=61E9"!I;B!T:&4@
M8V]N<V]L:61A=&5D#0IS=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!A<R!F;VQL
M;W=S.CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z
M(#@P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS
M1&-E;G1E<CX-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R
M/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4TE:13H@,3!P="<@8V]L
M<W!A;CTS1#(^,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR
M,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!724142#H@-C8E.R!&3TY4+5-)6D4Z(#$P
M<'0G/D-O<W0-"F]F('-A;&5S/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@
M,B4[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P
M="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)
M1%1(.B`Q,R4[($9/3E0M4TE:13H@,3!P="<^#0HH-C8L,S<Y/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M
M4TE:13H@,3!P="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#(E.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!&3TY4+5-)6D4Z(#$P<'0G/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@
M,3,E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,3@Q+#,P,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^3W1H97(-"F5X<&5N<V4@
M*&EN8V]M92DL(&YE=#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"B@V-RPS,#(\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0HI/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T**#,T,2PR-3$\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@
M,3!P="<^#0HI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P
M="<^#0HH,3,S+#8X,3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/BD\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$
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M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*)B-X03`[/&(^)B-X03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M="X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\8CXF(WA!,#L\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^0V]N8V5N=')A=&EO;B!O9B!#
M<F5D:70@4FES:SPO8CX@)B-X,C`Q,SL@1FEN86YC:6%L(&EN<W1R=6UE;G1S
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M;R`D,C4P+#`P,"X@5&AE($-O;7!A;GD@:&%S(&YO=`T*97AP97)I96YC960@
M86YY(&QO<W-E<R!I;B!S=6-H(&%C8V]U;G1S+B!4:&4@0V]M<&%N>2!D;V5S
M(&YO=`T*<F5Q=6ER92!C;VQL871E<F%L(&]R(&]T:&5R('-E8W5R:71Y('1O
M('-U<'!O<G0@8W)E9&ET('-A;&5S+"!B=70-"G!R;W9I9&5S(&%N(&%L;&]W
M86YC92!F;W(@9&]U8G1F=6P@86-C;W5N=',@8F%S960@;VX@:&ES=&]R:6-A
M;`T*97AP97)I96YC92!A;F0@<W!E8VEF:6-A;&QY(&ED96YT:69I960@<FES
M:W,N($%C8V]U;G1S(')E8V5I=F%B;&4-"F%R92!C:&%R9V5D(&]F9B!A9V%I
M;G-T('1H92!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S('=H96X-
M"FUA;F%G96UE;G0@9&5T97)M:6YE<R!T:&%T(')E8V]V97)Y(&ES('5N;&EK
M96QY(&%N9"!T:&4@0V]M<&%N>0T*8V5A<V5S(&-O;&QE8W1I;VX@969F;W)T
M<RX\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\+W`^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\+W`^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H\8CY);G9E;G1O<FEE<SPO8CX@)B-X,C`Q,SL@26YV96YT;W)I
M97,@8V]N<VES="!O9B!R87<@;6%T97)I86QS+`T*<&%C:V%G:6YG(&UA=&5R
M:6%L<RP@=V]R:R!I;B!P<F]C97-S(&%N9"!F:6YI<VAE9"!G;V]D<R!V86QU
M960@870-"G1H92!L;W=E<B!O9B!C;W-T(&]R(&UA<FME="X@0V]S="!I<R!D
M971E<FUI;F5D(&]N('1H92!B87-I<R!O9B!T:&4-"F9I<G-T+6EN+"!F:7)S
M="UO=70@;65T:&]D+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/&(^17%U:7!M96YT(&%N9"!I;7!R;W9E;65N
M=',\+V(^("8C>#(P,3,[($5Q=6EP;65N="!A;F0-"FEM<')O=F5M96YT<R!A
M<F4@<W1A=&5D(&%T(&-O<W0@86YD(&%R92!D97!R96-I871E9"!O;B!A#0IS
M=')A:6=H="UL:6YE(&)A<VES(&]V97(@=&AE(&5S=&EM871E9"!U<V5F=6P@
M;&EV97,@;V8@=&AE(&%S<V5T<PT*<F%N9VEN9R!F<F]M('1H<F5E('1O(#$P
M('EE87)S+B!,96%S96AO;&0@:6UP<F]V96UE;G1S(&%R90T*86UO<G1I>F5D
M(&]V97(@=&AE(&QE<W-E<B!O9B!T:&4@=7-E9G5L(&QI=F5S(&]R('1H92!R
M96UA:6YI;F<-"FQE87-E('1E<FTN/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
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M,C`Q.3MS#0IC<F5D:70@9F%C:6QI='D@=VET:"!I=',@;&5N9&5R+"!T:&4@
M8V%R<GEI;F<@=F%L=64@;V8@=&AE#0IB;W)R;W=I;F=S('1H870@=V5R92!O
M=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,"!A<F4-"F-O;G-I9&5R
M960@=&\@87!P<F]X:6UA=&4@=&AE(')E<W!E8W1I=F4@9F%I<B!V86QU92X\
M+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
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M"G-T<F%I9VAT+6QI;F4@8F%S:7,N/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*/&(^)B-X03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB
M/DQO;F<@3&EV960@07-S971S/"]B/B`F(W@R,#$S.U1H92!#;VUP86YY(')E
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M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB/B8C>$$P.SPO8CX\+W`^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H\8CY';V]D=VEL;#PO8CX@)B-X,C`Q,SL@5&AE
M($-O;7!A;GD@=&5S=',@9V]O9'=I;&P@9F]R(&EM<&%I<FUE;G0-"G5S:6YG
M(&$@='=O+7-T97`@<')O8V5S<RX@5&AE(&9I<G-T('-T97`@=&5S=',@9F]R
M('!O=&5N=&EA;`T*:6UP86ER;65N="P@=VAI;&4@=&AE('-E8V]N9"!S=&5P
M(&UE87-U<F5S('1H92!A;6]U;G0@;V8-"FEM<&%I<FUE;G0L(&EF(&%N>2X@
M5&AE($-O;7!A;GD@=7-E<R!A(&1I<V-O=6YT960@8V%S:"!F;&]W#0IA;F%L
M>7-I<R!T;R!C;VUP;&5T92!T:&4@9FER<W0@<W1E<"!I;B!T:&ES('!R;V-E
M<W,N($EF('1H92!F:7)S=`T*<W1E<"!I;F1I8V%T97,@86X@:6UP86ER;65N
M="P@:2YE+B!W:&5N('1H92!C87)R>6EN9R!V86QU92!E>&-E961S#0IT:&4@
M9F%I<B!V86QU92P@=&AE;B!T:&4@<V5C;VYD('-T97`@:7,@<F5Q=6ER960@
M=&\@9&5T97)M:6YE('1H90T*:6UP;&EE9"!F86ER('9A;'5E(&]F(&=O;V1W
M:6QL+B!4:&4@:6UP;&EE9"!F86ER('9A;'5E(&]F(&=O;V1W:6QL#0II<R!C
M86QC=6QA=&5D(&EN('1H92!S86UE(&UA;FYE<B!T:&%T(&=O;V1W:6QL(&ES
M(&-A;&-U;&%T960@:6X@80T*8G5S:6YE<W,@8V]M8FEN871I;VXN(%1H92!A
M;&QO8V%T:6]N(&ES('1O(&)E('!E<F9O<FUE9"!A<R!I9B!T:&4-"G)E<&]R
M=&EN9R!U;FET(&AA9"!J=7-T(&)E96X@86-Q=6ER960@86YD('1H92!F86ER
M('9A;'5E(&]F('1H90T*=6YI="!W87,@=&AE('!U<F-H87-E('!R:6-E+B!4
M:&4@9V]O9'=I;&P@:6UP86ER;65N="!E<75A;',@=&AE#0IC87)R>6EN9R!V
M86QU92!O9B!G;V]D=VEL;"!L97-S('1H92!I;7!L:65D(&9A:7(@=F%L=64@
M;V8@9V]O9'=I;&PN#0I4:&4@0V]M<&%N>2!P97)F;W)M<R!I=',@9V]O9'=I
M;&P@:6UP86ER;65N="!T97-T(&%S(&]F($1E8V5M8F5R(#,Q#0IO9B!E86-H
M('EE87(L(&]R(&UO<F4@9G)E<75E;G1L>2!I9B!I;7!A:7)M96YT(&EN9&EC
M871O<G,@87)E#0IP<F5S96YT+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB/E-T;V-K+4)A
M<V5D($-O;7!E;G-A=&EO;CPO8CX@)B-X,C`Q,SL@4W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N#0IF;W(@;F5W+"!M;V1I9FEE9"!A;F0@=6YV97-T960@<VAA
M<F4M8F%S960@87=A<F1S('=I=&@@96UP;&]Y965S#0IA;F0@;F]N+65M<&QO
M>65E(&1I<F5C=&]R<RP@<W5C:"!A<R!G<F%N=',@;V8@<W1O8VL@;W!T:6]N
M<R!A;F0-"G)E<W1R:6-T960@<W1O8VLL(&ES(')E8V]G;FEZ960@:6X@=&AE
M(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"G-T871E;65N=',@8F%S960@;VX@
M=&AE(&9A:7(@=F%L=64@;V8@=&AE(&%W87)D(&%T('1H92!G<F%N="!D871E
M#0IA;F0@:7,@<F5C;V=N:7IE9"!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@
M;W9E<B!T:&4@<F5Q=6ES:71E#0IS97)V:6-E('!E<FEO9',N(%1H92!#;VUP
M86YY(&5S=&EM871E<R!T:&4@9F%I<B!V86QU92!O9B!S=&]C:PT*;W!T:6]N
M<R!A<R!O9B!T:&4@9&%T92!O9B!G<F%N="!U<VEN9R!T:&4@0FQA8VLM4V-H
M;VQE<PT*;W!T:6]N+7!R:6-I;F<@;6]D96P@9F]R('-E<G9I8V4@86YD('!E
M<F9O<FUA;F-E(&)A<V5D(&%W87)D<RX@5&AE#0IF86ER('9A;'5E(&]F(')E
M<W1R:6-T960@<W1O8VL@:7,@8F%S960@;VX@=&AE('%U;W1E9"!M87)K970@
M<')I8V4N#0I4:&4@0V]M<&%N>2!I<W-U97,@;F5W('-H87)E<R!U<&]N(&5X
M97)C:7-E(&]F('-H87)E+6)A<V5D#0IA=V%R9',N/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB/DEN8V]M92!487AE<SPO8CX@
M)B-X,C`Q,SL@1&5F97)R960@=&%X(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@
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M;F-L=61I;F<@=&%X(&QO<W,@86YD(&-R961I=`T*8V%R<GEF;W)W87)D<RP@
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M<F5D('1A>`T*87-S971S('=I;&P@;F]T(&)E(')E86QI>F5D+CPO<#X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^
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M<F5T=7)N<R!O;B!A;@T*;VYG;VEN9R!B87-I<RX@26X@,C`Q,2!A;F0@,C`Q
M,"P@=&AE($-O;7!A;GD@:&%D(&YO('5N<F5C;V=N:7IE9`T*=&%X(&)E;F5F
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M9`T*9FEN86YC:6%L('-T871E;65N=',@9F]R('1H92!P97)I;V1S('!R97-E
M;G1E9"X@5&AE($-O;7!A;GDF(W@R,#$Y.W,-"E5N:71E9"!3=&%T97,@=&%X
M(')E='5R;G,@87)E('-U8FIE8W0@=&\@97AA;6EN871I;VX@8GD@9F5D97)A
M;"!A;F0-"G-T871E('1A>&EN9R!A=71H;W)I=&EE<RX@5&%X('EE87)S('!R
M:6]R('1O(#(P,#@@87)E(&YO(&QO;F=E<@T*<W5B:F5C="!T;R!F961E<F%L
M(&]R('-T871E(&5X86UI;F%T:6]N+B!487@@>65A<G,@<')I;W(@=&\@,C`P
M,PT*87)E(&YO(&QO;F=E<B!S=6)J96-T('1O(&5X86UI;F%T:6]N(&EN($-A
M;F%D82X@5&AE(%5N:71E9"!+:6YG9&]M#0IT87@@<F5T=7)N<R!S:6YC92!T
M:&4@:6YC97!T:6]N(&EN(#(P,3`@;V8@=&AE('-U8G-I9&EA<GD@:6X@=&AI
M<PT*8V]U;G1R>2!A<F4@<W5B:F5C="!T;R!E>&%M:6YA=&EO;BX\+W`^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^4F5V96YU92!2
M96-O9VYI=&EO;CPO8CX@)B-X,C`Q,SL@4V%L97,@87)E(')E8V]R9&5D('=H
M96X@<')O9'5C=`T*:7,@<VAI<'!E9"!O<B!T:71L92!P87-S97,@=&\@8W5S
M=&]M97)S(&%N9"!C;VQL96-T86)I;&ET>2!I<PT*<F5A<V]N86)L>2!A<W-U
M<F5D+B!'<F]S<R!S86QE<R!A<F4@861J=7-T960@9F]R(&-A<V@@9&ES8V]U
M;G1S+`T*<F5T=7)N<R!A;F0@86QL;W=A;F-E<RP@=')A9&4@<F5B871E<RP@
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M('-H:7`@<')O9'5C="!T;R!C=7-T;VUE<G,@87)E(')E8V]R9&5D(&%S(&$@
M8V]M<&]N96YT(&]F(&-O<W0@;V8-"G-A;&5S+CPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@
M,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H\8CY!9'9E<G1I<VEN9R!A;F0@4')O
M;6]T:6]N($-O<W1S/"]B/B`F(W@R,#$S.R!!9'9E<G1I<VEN9R!A;F0-"G!R
M;VUO=&EO;B!C;W-T<R!A<F4@97AP96YS960@87,@:6YC=7)R960@86YD('=E
M<F4@)#$L-38P+#DP,R!A;F0-"B0Q+#$Y-RPS,#D@:6X@,C`Q,2!A;F0@,C`Q
M,"P@<F5S<&5C=&EV96QY+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB
M/B8C>$$P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\8CY2;WEA
M;'1I97,@)B-X,C`Q,SL\+V(^(%1H92!#;VUP86YY(')E8V]G;FEZ97,@<F]Y
M86QT>2!E>'!E;G-E<PT*87-S;V-I871E9"!W:71H('1H92!P<F]D=6-T<R!S
M;VQD(&%T('1H92!T:6UE('1H92!R96QA=&5D('-A;&4-"F]C8W5R<R!A;F0@
M<F5C;W)D<R!T:&5M(&%S(&$@8V]M<&]N96YT(&]F(&-O<W0@;V8@<V%L97,N
M(%)O>6%L='D-"F5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,2!A;F0@,C`Q,"!W87,-"B0Q+#$U.2PY,#@@86YD("0Y,3$L
M.#DS+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M/&(^)B-X03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB/DYE
M="!,;W-S('!E<B!3:&%R93PO8CX@)B-X,C`Q,SL@3F5T(&QO<W,@<&5R(&-O
M;6UO;B!S:&%R92`F(W@R,#$S.PT*8F%S:6,@:7,@8V]M<'5T960@8GD@9&EV
M:61I;F<@;F5T(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4-"FYU;6)E
M<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG(&9O<B!T:&4@<&5R:6]D
M+B!.970@;&]S<R!P97(-"F-O;6UO;B!S:&%R92`F(W@R,#$S.R!D:6QU=&5D
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M,3$@86YD(#(P,3`@87,-"G1H92!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU
M=&EV92X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0I0;W1E;G1I86QL>2!D:6QU=&EV92!S:&%R
M97,@97AC;'5D960@87,@82!R97-U;'0@;V8@=&AE(&5F9F5C=',-"F)E:6YG
M(&%N=&DM9&EL=71I=F4@87)E(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)U=)1%1(
M.B`X,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1C96YT97(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M25I%.B`Q,'!T)R!C;VQS<&%N/3-$-CY996%R($5N9&5D($1E8V5M8F5R(#,Q
M+#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4+5-)6D4Z(#$P<'0G/D5X8VQU9&5D(&1I;'5T:79E#0IS:&%R97,Z/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@
M,3!P="<@8V]L<W!A;CTS1#(^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^
M#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M3$5&5#H@,"XQ
M,FEN.R!724142#H@-C8E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*4')E9F5R<F5D
M('-T;V-K/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,B4[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@
M,3,E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*-S,L,S,R/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@
M,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`R)3L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`Q,R4[($9/3E0M4TE:13H@,3!P="<^#0HR.#0L.#0T/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/
M3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!0041$24Y'+4Q%1E0Z(#`N,3)I;CL@1D].5"U325I%.B`Q
M,'!T)SX-"E)E<W1R:6-T960@8V]M;6]N('-T;V-K/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)
M6D4Z(#$P<'0G/C4Q+#4P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4TE:13H@,3!P="<^,C`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!0041$24Y'+4Q%1E0Z(#`N,3)I;CL@1D].5"U325I%.B`Q
M,'!T)SY3=&]C:PT*;W!T:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXQ
M+#4X,BPV.#,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/C$L,C`S+#8P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!0041$24Y'+4)/5%1/33H@,7!T.R!0041$24Y'
M+4Q%1E0Z(#`N,3)I;CL@1D].5"U325I%.B`Q,'!T)SX-"E=A<G)A;G1S/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,RPP-C4L-S`R/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*,2PW,S0L-3,Q/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M3$5&5#H@,"XR
M-&EN.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M4$%$1$E.1RU,1494.B`P+C,V:6X[($9/3E0M4TE:13H@,3!P="<^#0I4;W1A
M;"!D:6QU=&EV92!S:&%R97,\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T
M)SX-"C0L-S<S+#(Q-SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,BXU<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^#0HS+#(T
M,BPY-S4\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?
M-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O
M5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A;F0@
M26YV97-T;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',@86YD($EN=F5S=&UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'1A
M8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S
M='EL93TS1"=724142#H@,'!X)SX\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`P+C5I;B<^/&(^,RX\+V(^/"]T9#X-"CQT
M9#X\8CY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(&%N9"!);G9E<W1M96YT
M<SPO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*5&AE($-O;7!A;GD@8V]N<VED97)S
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@87,@86UO=6YT<R!O;B!H86YD
M+`T*;VX@9&5P;W-I="!I;B!F:6YA;F-I86P@:6YS=&ET=71I;VYS(&%N9"!H
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M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!4
M15A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I#87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S(&%N9"!I;G9E<W1M96YT<R!A="!$96-E;6)E<B`S
M,2P@,C`Q,2!A;F0-"C(P,3`@8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<Z
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A
M8FQE('-T>6QE/3-$)U=)1%1(.B`X,"4[($U!4D=)3BU,1494.B`P+C5I;B<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0V/D1E8V5M8F5R(#,Q+#PO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P
M<'0G(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M
M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!724142#H@-C8E
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*0V%S:#PO=&0^#0H\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!&3TY4+5-)
M6D4Z(#$P<'0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3,E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*-"PY.#8L,C,T
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,24[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U=)1%1(.B`R)3L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].
M5"U325I%.B`Q,'!T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@5TE$5$@Z(#$S)3L@1D].5"U325I%.B`Q,'!T)SX-"C0P-"PR
M,38\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/DUO;F5Y(&UA<FME=`T*86-C;W5N
M=',\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^,BPW,#8L.#8S/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXM/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^36]N97D-"FUA<FME="!M
M=71U86P@9G5N9',\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^#0HY+#0Q-RPR-3,\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4TE:13H@,3!P="<^#0HM/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/C$W+#$Q,"PS-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)
M6D4Z(#$P<'0G/C0P-"PR,38\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L
M,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M4TE:13H@,3!P="<^#0I);G9E<W1M96YT<SPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%
M.B`Q,'!T)SX-"C4L-#<T+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"BT\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR
M-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!0041$24Y'+4Q%1E0Z(#`N,C1I;CL@1D].5"U325I%.B`Q,'!T)SX-"E1O
M=&%L(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@86YD(&EN=F5S=&UE;G1S
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,C(L-3@T+#,U,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*-#`T+#(Q-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M(%1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
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M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*5&AE(&9O;&QO=VEN9R!T86)L92!P<F]V:61E<R!F
M86ER('9A;'5E(&EN9F]R;6%T:6]N(&%S(&]F($1E8V5M8F5R#0HS,2P@,C`Q
M,3H\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)U=)1%1(
M.B`Y,"4[($U!4D=)3BU,1494.B`P+C5I;B<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P
M86X],T0Q-#Y&86ER(%9A;'5E($UE87-U<F5M96YT<RP@57-I;F<\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<@8V]L<W!A;CTS1#(^5&]T86P@8V%R<GEI;F<@=F%L=64@
M87,@;V8@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M33H@,7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C;VQS<&%N
M/3-$,CY3:6=N:69I8V%N="!O=&AE<B!O8G-E<G9A8FQE(&EN<'5T<R`H3&5V
M96P@,BD\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0R/E-I
M9VYI9FEC86YT('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L(#,I/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T)R!C;VQS<&%N/3-$,CX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)
M6D4Z(#$P<'0G(&-O;'-P86X],T0R/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<@8V]L<W!A
M;CTS1#(^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@1D].5"U325I%.B`Q,'!T)R!C;VQS<&%N/3-$,CX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H
M,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!724142#H@,S0E.R!&3TY4
M+5-)6D4Z(#$P<'0G/D-A<V@-"F%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-
M"CQT9"!S='EL93TS1"=724142#H@,B4[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414
M2#H@,24[($9/3E0M4TE:13H@,3!P="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,R4[($9/3E0M4TE:13H@,3!P
M="<^#0HQ-RPQ,3`L,S4P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$S)3L@1D].5"U325I%
M.B`Q,'!T)SX-"C$W+#$Q,"PS-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#$E.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,30E.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[)B-X03`[)B-X03`[)B-X03`[+3PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=7
M24142#H@,24[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:
M13H@,3!P="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`Q,R4[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#LF(WA!
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M5"U325I%.B`Q,'!T)SX-"DEN=F5S=&UE;G1S/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*-2PT-S0L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*-2PT-3,L-#(Y/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*+3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"BT\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@4$%$1$E.1RU,1494.B`P+C(T:6X[($9/3E0M4TE:13H@,3!P="<^#0HF
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M15A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"C(R+#4X-"PS
M-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
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M:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"C(R+#4V,RPW-SD\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y
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M25I%.B`Q,'!T)SX-"BT\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T
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M15A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"BT\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0I,979E;"`Q(&EN<'5T<R!A<F4@<75O=&5D('!R:6-E<R`H=6YA
M9&IU<W1E9"D@:6X@86-T:79E(&UA<FME=',@9F]R#0II9&5N=&EC86P@87-S
M971S+B!,979E;"`R(&EN<'5T<R!A<F4@<75O=&5D('!R:6-E<R!F;W(@<VEM
M:6QA<@T*87-S971S(&EN(&%C=&EV92!M87)K971S(&]R(&EN<'5T<R!T:&%T
M(&%R92!O8G-E<G9A8FQE(&9O<B!T:&4-"F%S<V5T+"!E:71H97(@9&ER96-T
M;'D@;W(@:6YD:7)E8W1L>2!T:')O=6=H(&UA<FME="!C;W)R;V)O<F%T:6]N
M+`T*9F]R('-U8G-T86YT:6%L;'D@=&AE(&9U;&P@=&5R;2!O9B!T:&4@9FEN
M86YC:6%L(&EN<W1R=6UE;G0N($QE=F5L#0HS(&EN<'5T<R!A<F4@=6YO8G-E
M<G9A8FQE(&EN<'5T<R!B87-E9"!O;B!M86YA9V5M96YT)B-X,C`Q.3MS(&]W
M;@T*87-S=6UP=&EO;G,@=7-E9"!T;R!M96%S=7)E(&%S<V5T<R!A="!F86ER
M('9A;'5E+B!!(&9I;F%N8VEA;`T*87-S970F(W@R,#$Y.W,@8VQA<W-I9FEC
M871I;VX@:7,@9&5T97)M:6YE9"!B87-E9"!O;B!T:&4@;&]W97-T#0IL979E
M;"!I;G!U="!T:&%T(&ES('-I9VYI9FEC86YT('1O('1H92!F86ER('9A;'5E
M(&UE87-U<F5M96YT+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,35C8C@W-&%?,3$T8U\T,C4W7SAE93%?
M96$R,3!A-#DS8S`P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$U
M8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,"]7;W)K<VAE971S
M+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY!8V-O=6YT<R!296-E:79A8FQE+"!N970\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(%)E8V5I=F%B;&4L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#!P>"<^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,"XU:6XG/CQB/C0N/"]B/CPO=&0^#0H\
M=&0^/&(^06-C;W5N=',@4F5C96EV86)L92P@;F5T/"]B/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0@,'!X(#!P="`P+C5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0I!8V-O=6YT<R!R96-E:79A8FQE+"!N970@:6YC;'5D92!T:&4@9F]L;&]W
M:6YG.CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^)B-X03`[/"]B/CPO<#X-"CQT86)L
M92!S='EL93TS1"=724142#H@.#`E.R!-05)'24XM3$5&5#H@,"XU:6XG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U325I%
M.B`Q,'!T)R!C;VQS<&%N/3-$-CY$96-E;6)E<B`S,2P\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/C(P,3`\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L
M,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%=)1%1(.B`V-B4[($9/3E0M4TE:
M13H@,3!P="<^#0I!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"CQT9"!S='EL
M93TS1"=724142#H@,B4[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/
M3E0M4TE:13H@,3!P="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,R4[($9/3E0M4TE:13H@,3!P="<^#0HV+#8P
M-BPX.38\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
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M3$E'3CH@:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T)SY,97-S.@T*)B-X03`[
M06QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<SPO=&0^#0H\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M25I%.B`Q,'!T)SXH-SDL,C$V/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+W1D/@T*/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:
M13H@,3!P="<^*#@Y+#<S-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXI/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU,1494.B`P+C,V:6X[($9/3E0M4TE:
M13H@,3!P="<^#0I!;&QO=V%N8V4@9F]R('1R861E(')E8F%T97,\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4TE:13H@,3!P="<^*#$R."PX-S4\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^*3PO=&0^#0H\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U325I%.B`Q,'!T)SXH,38S+#<X.3PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXI/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&
M5#H@,"XS-FEN.R!&3TY4+5-)6D4Z(#$P<'0G/@T*06QL;W=A;F-E(&9O<B!C
M87-H(&1I<V-O=6YT<R!A;F0@<F5T=7)N<SPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B@Q,S`L.38V/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M*3PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"B@Q,30L,#(P/"]T9#X-"CQT9"!S
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M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
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M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*-BPR-C<L.#,Y/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M
M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^
M#0HU+#0T,2PU,3$\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A
M7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T
M.3-C,#`O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^26YV96YT;W)I97,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'1A8FQE('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S
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M.B`P<'@[(%=)1%1(.B`P+C5I;CL@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X)SX-"CQB/C4N/"]B/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#!P>#L@5$585"U)
M3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>"<^#0H\8CY);G9E;G1O<FEE<SPO8CX\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*26YV96YT;W)I97,@
M:6YC;'5D92!T:&4@9F]L;&]W:6YG.CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`X,"4[($U!4D=)3BU,1494
M.B`P+C5I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0V/D1E8V5M8F5R(#,Q
M+#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!7
M24142#H@-C8E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*1FEN:7-H960@9V]O9',\
M+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`R)3L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$S)3L@1D].5"U325I%
M.B`Q,'!T)SX-"C<L-C(U+#`P.3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,B4[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,R4[($9/3E0M
M4TE:13H@,3!P="<^#0HX+#<R-RPX,C(\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G
M/E=O<FL@:6X-"G!R;V-E<W,\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^-C8T
M+#(W,CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^
M-3DX+#0X-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/E!A8VMA9VEN9PT*;6%T97)I
M86QS/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/CDX-2PV,#`\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C<W."PY,#`\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^4F%W#0IM871E<FEA;',\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4TE:13H@,3!P="<^#0HQ+#(U-2PX-#`\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^#0HR
M+#,Y,RPS,3$\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#`N,C1I;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"E1O=&%L(&EN=F5N=&]R>3PO=&0^#0H\=&0@<W1Y;&4]
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M.B`Q,'!T)SX-"C$P+#4S,"PW,C$\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"C$R
M+#0Y."PU,3D\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q
M-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C
M,#`O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^17%U:7!M96YT(&%N9"!);7!R;W9E;65N=',L
M(&YE=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17%U:7!M96YT(&%N9"!);7!R;W9E;65N=',L(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#!P
M>"<^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414
M2#H@,"XU:6XG/CQB/C8N/"]B/CPO=&0^#0H\=&0^/&(^17%U:7!M96YT(&%N
M9"!);7!R;W9E;65N=',L(&YE=#PO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I%<75I<&UE;G0@86YD(&EM<')O
M=F5M96YT<RP@;F5T(&EN8VQU9&4@=&AE(&9O;&QO=VEN9SH\+W`^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@.#`E
M.R!-05)'24XM3$5&5#H@,"XU:6XG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U325I%.B`Q,'!T)R!C;VQS<&%N/3-$
M-CY$96-E;6)E<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U325I%.B`Q,'!T)R!C;VQS<&%N/3-$,CXR,#$Q/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R
M/C(P,3`\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>3L@5TE$5$@Z(#8V)3L@1D].5"U325I%.B`Q,'!T)SX-"DUA
M8VAI;F5R>2!A;F0@97%U:7!M96YT/"]T9#X-"CQT9"!S='EL93TS1"=72414
M2#H@,B4[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@
M,3!P="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`Q,R4[($9/3E0M4TE:13H@,3!P="<^#0HV+#4R,BPY-#$\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
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M=&EF>3L@1D].5"U325I%.B`Q,'!T)SY&=7)N:71U<F4@86YD#0IF:7AT=7)E
M<SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXV.#(L-30U/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXV-#@L-#8P/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0I,96%S96AO;&0@
M:6UP<F]V96UE;G1S/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,BPQ-S0L,3(Q
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*,BPP.#8L.34V/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/CDL,S<Y+#8P-SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
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M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T**#4L.#DP+#0Q
M,SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SX-"BD\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"C,L
M-#@Y+#$Y-#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,RPV,#@L,C0R/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E
M83(Q,&$T.3-C,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,35C
M8C@W-&%?,3$T8U\T,C4W7SAE93%?96$R,3!A-#DS8S`P+U=O<FMS:&5E=',O
M4VAE970Q-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DED96YT:69I86)L92!);G1A;F=I8FQE($%S<V5T<RP@;F5T/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)9&5N=&EF:6%B
M;&4@26YT86YG:6)L92!!<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!P>#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%=)
M1%1(.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P
M>"<^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%1%6%0M24Y$14Y4.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@
M,"XU:6X[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>"<^
M#0H\8CXW+CPO8CX\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M
M5$]0.B`P<'@G/@T*/&(^261E;G1I9FEA8FQE($EN=&%N9VEB;&4@07-S971S
M+"!N970\+V(^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*261E;G1I9FEA8FQE(&EN=&%N9VEB;&4@87-S971S+"!N
M970@:6YC;'5D92!T:&4@9F]L;&]W:6YG.CPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X
M03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`X,"4[($U!4D=)3BU,
M1494.B`P+C5I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0V/D1E8V5M8F5R
M(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!724142#H@-C(E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*365D:6AO;F5Y(&QI
M8V5N<V4@<FEG:'1S/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,B4[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q
M-24[($9/3E0M4TE:13H@,3!P="<^#0HU+#8V-RPQ,C8\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#(E
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M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SY/=&AE<@T*:61E
M;G1I9FEA8FQE(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*,RPS,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*-RPU,#`L,#`P/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C@L.38W+#$R-CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^,3(L,38W+#$R
M-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SY,97-S#0IA8V-U;75L
M871E9"!A;6]R=&EZ871I;VX\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
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M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B@U+#$Y-2PU,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M4TE:13H@,3!P="<^#0HI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,1494
M.B`P+C(T:6X[($9/3E0M4TE:13H@,3!P="<^#0I4;W1A;"!I9&5N=&EF:6%B
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M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q
M,'!T)SX-"C8L-#`S+#`T-#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
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M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I);B!C;VYN96-T:6]N
M('=I=&@@=&AE(&%C<75I<VET:6]N(&]F('1H92!-961I:&]N97D@=V]R;&1W
M:61E#0IL:6-E;G-E(')I9VAT<R`H;F]T92`Q-2D@=&AE($-O;7!A;GD@8V%P
M:71A;&EZ960@=&AE(&-O;G-I9&5R871I;VX-"G!A:60@87,@86X@:61E;G1I
M9FEA8FQE(&EN=&%N9VEB;&4@87-S970N(%1H92!C;W-T('=I;&P@8F4-"F%M
M;W)T:7IE9"!O=F5R(#$P('EE87)S+"!A;F0@=&AE(&5X<&5N<V4@:7,@:6YC
M;'5D960@87,@82!C;VUP;VYE;G0-"F]F(&-O<W0@;V8@<V%L97,@:6X@=&AE
M($-O;G-O;&ED871E9"!3=&%T96UE;G0@;V8@3W!E<F%T:6]N<RX\+W`^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*3W1H97(@:61E
M;G1I9FEA8FQE(&EN=&%N9VEB;&4@87-S971S(')E<W5L="!F<F]M(&%C<75I
M<VET:6]N<PT*8V]M<&QE=&5D(&EN(#(P,#8@86YD(#(P,#<@86YD(&-O;G-I
M<W0@;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#@P)3L@34%2
M1TE.+4Q%1E0Z(#`N-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^1&5C
M96UB97(@,S$L(#(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4TE:13H@
M,3!P="<^#0I!;6]R=&EZ871I;VX@4&5R:6]D/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@5TE$5$@Z(#8R)3L@1D].5"U325I%.B`Q,'!T)SX-
M"D-U<W1O;65R(&QI<W0\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`R)3L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$U)3L@1D].5"U325I%.B`Q,'!T)SX-"C$L-3`P+#`P,#PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@
M,B4[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%=)1%1(.B`Q-24[($9/3E0M4TE:13H@
M,3!P="<^,3`-"GEE87)S/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:
M13H@,3!P="<^5')A9&5M87)K<R!A;F0-"G1R861E(&YA;65S/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$L-C`P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4TE:13H@
M,3!P="<^,3`M,3,@>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
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M<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*,C`P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#LU#0IY96%R<SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!0041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M4TE:13H@
M,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^#0HS+#,P
M,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*26X@,C`Q,2P@)#0L,C`P+#`P,"!O9B!F=6QL>2!A;6]R=&EZ
M960@:61E;G1I9FEA8FQE(&EN=&%N9VEB;&4-"F%S<V5T<R!W97)E('=R:71T
M96XM;V9F+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M8V5M8F5R(#,Q+"`R,#$Q(&%N9`T*,C`Q,"!I<R`W+C`@86YD(#,N.2!Y96%R
M<RP@<F5S<&5C=&EV96QY+B!!;6]R=&EZ871I;VX@97AP96YS92!F;W(-"C(P
M,3$@86YD(#(P,3`@86YD(&5S=&EM871E9"!A;6]U;G1S('1H97)E869T97(@
M8GD@>65A<B!I<R!A<PT*9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0HF(WA!,#LF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z
M(#DP)3L@34%21TE.+4Q%1E0Z(#`N-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/D]T:&5R($ED96YT
M:69I86)L92`\=2!S='EL93TS1"=415A4+41%0T]2051)3TXZ(&YO;F4G/CQB
M<B`O/@T*26YT86YG:6)L92!!<W-E=',\+W4^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/E1O=&%L/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P
M86X],T0R/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U325I%.B`Q,'!T)R!C;VQS<&%N/3-$,CX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4TE:13H@
M,3!P="<@8V]L<W!A;CTS1#(^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>3L@5TE$5$@Z(#4X)3L@1D].5"U325I%.B`Q,'!T)SX-"D%M
M;W)T:7IA=&EO;B!E>'!E;G-E(&9O<B8C>$$P.R!Y96%R(&5N9&5D($1E8V5M
M8F5R(#,Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0[(%=)1%1(.B`R)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M
M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3`E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*-3$Y+#(P,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$
M5$@Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-
M"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4[($9/
M3E0M4TE:13H@,3!P="<^#0HQ+#`T.2PS.#(\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$
M5$@Z(#$E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`R)3L@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*,2PU-C@L-3@R/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`Q)3L@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^06UO<G1I>F%T:6]N
M#0IE>'!E;G-E(&9O<B8C>$$P.R!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$P/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,S<U+#<U,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*,2PS,30L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M
M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^
M#0HQ+#8X.2PW-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
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M#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)
M3D<M3$5&5#H@,2XS,FEN.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,C`Q,CPO=&0^
M#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P
M="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4TE:13H@,3!P="<^-3@T+#,P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/C,R,RPY.3,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M25I%.B`Q,'!T)SXY,#@L,CDS/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!0041$24Y'+4Q%1E0Z(#$N,S)I;CL@1D].5"U325I%.B`Q
M,'!T)SX-"C(P,3,\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^-3@T+#,P,#PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^,C@U+#`P
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^.#8Y
M+#,P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!0041$24Y'+4Q%1E0Z(#$N,S)I;CL@1D].5"U325I%.B`Q,'!T
M)SX-"C(P,30\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^-3@T+#,P,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^,C@U+#`P,#PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^.#8Y+#,P
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.
M1RU,1494.B`Q+C,R:6X[($9/3E0M4TE:13H@,3!P="<^#0HR,#$U/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-)6D4Z(#$P<'0G/C4X-"PS,#`\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C(X-2PP,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C@V.2PS,#`\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.1RU,
M1494.B`Q+C,R:6X[($9/3E0M4TE:13H@,3!P="<^#0HR,#$V/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-)6D4Z(#$P<'0G/C4X-"PS,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$S-BPR-3`\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C<R,"PU-3`\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%!!1$1)3D<M3$5&5#H@,2XS,FEN.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*5&AE<F5A9G1E<CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q
M,'!T)SX-"C$L.#4P+#8W-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"C,Q-2PV,C4\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@
M,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4TE:13H@,3!P="<^#0HR+#$V-BPS,#$\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:
M13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
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M.B`Q,'!T)SX-"C0L-S<R+#$W-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,BXU<'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,2PV
M,S`L.#8X/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^#0HV+#0P,RPP-#0\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A
M,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B
M.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3
M:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^3&EN92!O9B!#<F5D:70@0F]R<F]W:6YG<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EN92!O9B!#<F5D:70@0F]R<F]W
M:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#!P>"<^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,"XU:6XG/CQB/C@N/"]B/CPO=&0^#0H\
M=&0^/&(^3&EN92!O9B!#<F5D:70@0F]R<F]W:6YG<SPO8CX\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*3VX@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!T97)M
M:6YA=&5D(&ET<R!F:79E+7EE87(-"G)E=F]L=FEN9R!C<F5D:70@86=R965M
M96YT('=I=&@@:71S(&QE;F1E<BX@26X@8V]N;F5C=&EO;B!W:71H('1H90T*
M=&5R;6EN871I;VX@=&AE($-O;7!A;GD@<F5C;W)D960@82!L;W-S(&]N(&1E
M8G0@97AT:6YG=6ES:&UE;G0@;V8-"B0Q-S8L,3`Q+"!R97!R97-E;G1I;F<@
M=&AE('1H96X@=6YA;6]R=&EZ960@<&]R=&EO;B!O9B!D969E<G)E9`T*9FEN
M86YC:6YG(&-O<W1S(&]F("0Q,3(L,S,V(&%N9"!R96QA=&5D(&9E97,@;V8@
M)#8S+#<V-2X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P
M830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T
M85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E
M=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M06-C<G5E9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!,:6%B:6QI=&EE
M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!,:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L92!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!P>#L@5$585"U)3D1%3E0Z(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%=)1%1(.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P
M>#L@4$%$1$E.1RU43U`Z(#!P>"<^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!724142#H@,"XU:6X[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@
M4$%$1$E.1RU43U`Z(#!P>"<^#0H\8CXY+CPO8CX\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`P<'@[(%1%
M6%0M24Y$14Y4.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))
M1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@G/@T*/&(^06-C<G5E9"!%>'!E
M;G-E<R!A;F0@3W1H97(@0W5R<F5N="!,:6%B:6QI=&EE<SPO8CX\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I!8V-R
M=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S(&EN
M8VQU9&4@=&AE#0IF;VQL;W=I;F<Z/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#@P)3L@34%21TE.+4Q%1E0Z
M(#`N-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&
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M04Q)1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M
M4TE:13H@,3!P="<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U325I%.B`Q,'!T)R!C;VQS<&%N/3-$,CXR,#$P/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%=)
M1%1(.B`V-B4[($9/3E0M4TE:13H@,3!P="<^#0I!8V-R=65D($-A;F%D:6%N
M('-A;&5S(')E8F%T92P@;F5T("AS964@;F]T92`Q-2D\+W1D/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`R)3L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@
M1D].5"U325I%.B`Q,'!T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@5TE$5$@Z(#$S)3L@1D].5"U325I%.B`Q,'!T)SX-"C,Q
M-BPR.#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@,3,E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M-#`Y+#@T,CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^06-C<G5E9`T*8V]M<&5N
M<V%T:6]N(&%N9"!R96QA=&5D('1A>&5S/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P
M<'0G/C4W-2PW,3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(V-2PS,S0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
M*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T)SY!8V-R=65D('-A
M;&5S#0II;F-E;G1I=F5S(&%N9"!O=&AE<B!F965S/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)
M6D4Z(#$P<'0G/C0Q-BPR,34\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-)6D4Z(#$P<'0G/C0V,2PY-#0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($9/3E0M4TE:13H@,3!P="<^06-C<G5E9`T*<F]Y86QT
M:65S/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C0R-2PW.38\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C(R,"PR,S(\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SX-"D]T:&5R/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*-C0S+#8S,SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-
M"C<Y,RPR-CD\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#`N,C1I;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"E1O=&%L(&%C8W)U960@97AP96YS97,@86YD(&]T:&5R
M(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4TE:13H@,3!P="<^
M#0HR+#,W-RPV,S0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U325I%.B`Q,'!T)SX-
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M+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX-"C(L,34P+#8R,3PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQB/B8C>$$P.SPO8CX\+W`^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0I!="!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"P@
M=&AE(&%M;W5N="!O9B!T:&4@0V%N861I86X@86-C<G5E9`T*<V%L97,@<F5B
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M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-6-B.#<T85\Q,31C7S0R-3=?
M.&5E,5]E83(Q,&$T.3-C,#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO,35C8C@W-&%?,3$T8U\T,C4W7SAE93%?96$R,3!A-#DS8S`P+U=O<FMS
M:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/DQO;F<M=&5R;2!$96)T/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@1&5B=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L92!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4]
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M+V(^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*06QL(&)O<G)O=VEN9W,@
M=6YD97(@=&AE('1E<FT@9&5B="!A9W)E96UE;G1S('=E<F4@9G5L;'D@<F5P
M86ED(&EN#0HR,#$Q+B!$=7)I;F<@,C`Q,2!P87EM96YT<R!O9B`D-2PX-3$@
M=V5R92!M861E('5N9&5R(&-A<&ET86P@;&5A<V4-"F]B;&EG871I;VYS+B!)
M;B`R,#$P('!A>6UE;G1S(&]F("0S+#4P,"PP,#`@=V5R92!M861E('5N9&5R
M(&$@=&5R;0T*;F]T92`H9G5L;'D@<F5P86ED(&EN($9E8G)U87)Y(#(P,3`@
M<F5S=6QT:6YG(&EN(&$@)#$Q-"P@,#<R(&QO<W,-"F]N(&1E8G0@97AT:6YG
M=6ES:&UE;G0I+"`D-3`P+#`P,"!W97)E(&UA9&4@;VX@82!P<F]M:7-S;W)Y
M(&YO=&4-"F%N9"`D-3DL,3@U('=E<F4@;6%D92!O;B!C87!I=&%L(&QE87-E
M(&]B;&EG871I;VYS+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,35C8C@W-&%?,3$T8U\T,C4W7SAE93%?
M96$R,3!A-#DS8S`P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$U
M8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,"]7;W)K<VAE971S
M+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3:&%R96AO;&1E<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5H;VQD97)S)R!%<75I='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@
M,3`P)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN+71O<#H@,'!T.R!M87)G:6XM8F]T=&]M.B`P<'0G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`P)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C5I;CL@
M=&5X="UA;&EG;CH@;&5F="<^/&(^,3$N/"]B/CPO=&0^#0H\=&0^/&(^4VAA
M<F5H;VQD97)S)B-X,C`Q.3L@17%U:71Y/"]B/CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CQB/E!R969E
M<G)E9"!3=&]C:SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H97)E(&%R92`Q."PU.3@@<VAA
M<F5S(&]F('-E<FEE<R!!(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:PT*
M;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$N(%1H92!S97)I97,@
M02!P<F5F97)R960@<W1O8VL@:7,-"F-O;G9E<G1I8FQE(&EN=&\@8V]M;6]N
M('-T;V-K(&]N(&$@;VYE+69O<BUO;F4@8F%S:7,L(&)E87)S(&YO#0ID:79I
M9&5N9"P@:&%S(&$@;&EQ=6ED871I;VX@<')E9F5R96YC92!O9B`D,S(N,#`@
M<&5R('-H87)E+"!V;W1E<PT*87,@82!C;&%S<R!O;B!M871T97)S(&%F9F5C
M=&EN9R!T:&4@<V5R:65S($$@<')E9F5R<F5D('-T;V-K(&%N9`T*:&%S('9O
M=&EN9R!R:6=H=',@:61E;G1I8V%L('1O('1H92!C;VUM;VX@<W1O8VL@;VX@
M86QL(&]T:&5R#0IM871T97)S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE<F4@87)E(#4T+#<S
M-"!S:&%R97,@;V8@<V5R:65S($(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K#0IO=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,2X@5&AE('-E
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M:R!O;B!A;&P@;W1H97(-"FUA='1E<G,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\8CY#;VUM;VX@
M4W1O8VL\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*
M26X@2G5N92`R,#$Q+"!T:&4@0V]M<&%N>2!R96-E:79E9"!N970@8V%S:"!P
M<F]C965D<R!O9B`D,C8L,S4W+#`W-0T**&%F=&5R("0R+#<Q-RPX-S(@:6X@
M8V]M;6ES<VEO;B!A;F0@;W1H97(@8V%S:"!B87-I<R!O9F9E<FEN9PT*97AP
M96YS97,I(&9R;VT@=&AE('-A;&4@;V8@,RPU,C0L,C,Y('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@870-"B0X+C(U('!E<B!S:&%R92P@=&]G971H97(@=VET
M:"`Q+#<V,BPQ,3@@9FEV92UY96%R('-E<FEE<R!2#0IW87)R86YT<R!T;R!P
M=7)C:&%S92!C;VUM;VX@<W1O8VL@870@)#DN.3`@<&5R('-H87)E+B!!9&1I
M=&EO;F%L;'DL#0IT:&4@<&QA8V5M96YT(&%G96YT<R!R96-E:79E9"`W,"PT
M.#0@9FEV92UY96%R(%-E<FEE<R!2('=A<G)A;G1S('1O#0IP=7)C:&%S92!C
M;VUM;VX@<W1O8VL@870@)#DN.3`@<&5R('-H87)E+CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
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M;VXL#0ID=7)I;F<@,C`Q,2!T:&4@0V]M<&%N>2!I<W-U960@,C$Q+#4Q,B!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K('5P;VX-"G1H92!C;VYV97)S:6]N(&]F
M('-E<FEE<R!"+"!#(&%N9"!$('!R969E<G)E9"!S=&]C:RX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX-"DEN($9E8G)U87)Y(#(P,3`L('1H92!#;VUP86YY(')E8V5I=F5D(&YE
M="!P<F]C965D<R!O9B`D-"PT-S0L-#4R#0HH869T97(@)#$L,3$T+#4T."!I
M;B!C;VUM:7-S:6]N(&%N9"!O=&AE<B!C87-H(&)A<VES(&]F9F5R:6YG#0IE
M>'!E;G-E<RD@9G)O;2!T:&4@<V%L92!O9B`Q+#$Q-RPX,#`@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!A=`T*)#4N,#`@<&5R('-H87)E+"!T;V=E=&AE<B!W
M:71H(#,W,BPV,#`@9FEV92UY96%R(%-E<FEE<R!$('=A<G)A;G1S#0IT;R!P
M=7)C:&%S92!C;VUM;VX@<W1O8VL@870@)#4N-3`@<&5R('-H87)E+B!);B!A
M9&1I=&EO;BP@=&AE#0IP;&%C96UE;G0@86=E;G0@<F5C96EV960@,CDL,38P
M(&9I=F4M>65A<B!397)I97,@4"!W87)R86YT<R!T;PT*<'5R8VAA<V4@8V]M
M;6]N('-T;V-K(&%T("0V+C(U('!E<B!S:&%R92X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P+C5I;B<^#0I);B!&96)R=6%R>2`R,#$P+"!T:&4@0V]M
M<&%N>2!I<W-U960@-#`P+#`P,"!S:&%R97,@;V8@:71S(&-O;6UO;@T*<W1O
M8VL@=&]G971H97(@=VET:"`Q,S,L,S,S(%-E<FEE<R!1('=A<G)A;G1S('1O
M('!U<F-H87-E(&ET<PT*8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R
M:6-E(&]F("0U+C4P('!E<B!S:&%R92!A;F0@,3`P+#`P,`T*4V5R:65S($X@
M=V%R<F%N=',@=&\@<'5R8VAA<V4@:71S(&-O;6UO;B!S=&]C:R!A="!A;B!E
M>&5R8VES92!P<FEC90T*;V8@)#8N,C4@<&5R('-H87)E(&EN(&-O;FYE8W1I
M;VX@=VET:"!T:&4@<'5R8VAA<V4@;V8@=&AE#0IW;W)L9"UW:61E($UE9&EH
M;VYE>2!L:6-E;G-E(')I9VAT<RX@4V5E($YO=&4@,34@9F]R(&9U<G1H97(-
M"F1I<V-U<W-I;VX@;V8@;&EC96YS92!R:6=H=',N/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I$=7)I
M;F<@,C`Q,"P@=&AE($-O;7!A;GD@<F5C96EV960@)#$V+#(W."!A;F0@:7-S
M=65D(#4L-C`Q(&-O;6UO;@T*<W1O8VL@<VAA<F5S('5P;VX@=&AE(&5X97)C
M:7-E(&]F('-T;V-K(&]P=&EO;G,N($EN(&%D9&ET:6]N+`T*9'5R:6YG(#(P
M,3`@=&AE($-O;7!A;GD@:7-S=65D(#(P-R!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K('5P;VX@=&AE#0IC;VYV97)S:6]N(&]F('-E<FEE<R!!(&%N9"!"('!R
M969E<G)E9"!S=&]C:RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I
M;B<^#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!L969T)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\8CY3=&]C:R!0
M=7)C:&%S92!787)R86YT<SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0I!="!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE($-O;7!A;GD@
M:&%D('=A<G)A;G1S(&]U='-T86YD:6YG('1O#0IP=7)C:&%S92`S+#`V-2PW
M,#(@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C
M:PT*8V]N<VES=&EN9R!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T
M:#H@-S`E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"E-E
M<FEE<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
M:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*3G5M8F5R(&]F
M(%=A<G)A;G1S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!
M,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60G/@T*17AE<F-I<V4@4')I8V4\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*17AP:7)A=&EO;B!$871E/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#(P)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!C96YT97(G/DH\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N
M="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(P)3L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HR-C<L.#4X/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C
M96YT97(G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R,"4[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"C8N,38\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#,P)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY-87D-"C,Q+"`R,#$S/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SY+/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,X
M.2PP-C0\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXY
M+C8P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^07!R:6P@,2P@,C`Q,SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY,/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C8L,C4P/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@8V5N=&5R)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^,RXQ,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/DUA<F-H(#,Q+`T*,C`Q-#PO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^3CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXQ,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^-BXR-3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9E8G)U87)Y(#(R
M+`T*,C`Q-3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P
M-"DG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SY//"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,S,2PY,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXU+C4P/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C0L-CDU/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^-BXR-3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D9E8G)U87)Y(#$V+`T*,C`Q-3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G
M8B@R,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY1/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$S,RPS,S,\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SXU+C4P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
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M;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/@T*,2PX,S(L-C`R/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SXY+CDP/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O
M='1O;3H@,7!T)SY*=6YE#0HR,BP@,C`Q-CPO=&0^#0H\+W1R/@T*/'1R('-T
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M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
M(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M#0HS+#`V-2PW,#(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0HF(WA!,#L\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^#0I);B`R,#$Q+"`R,C0L,#8S('-E<FEE<R!(+"`Y-"PS-3$@<V5R:65S
M($DL(#$P+#`P,"!S97)I97,@2RP@-#`L-S`P#0IS97)I97,@3R!A;F0@,C0L
M-#8U('-E<FEE<R!0('=A<G)A;G1S('=E<F4@97AE<F-I<V5D(&5I=&AE<B!O
M;B!A#0IF;W(@8V%S:"!O<B!C87-H;&5S<R!B87-I<RX@02!T;W1A;"!O9B`Q
M-SDL,S`T('-H87)E<R!O9B!C;VUM;VX-"G-T;V-K('=E<F4@:7-S=65D('5P
M;VX@97AE<F-I<V4@;V8@=&AO<V4@=V%R<F%N=',N($%L<V\@:6X@,C`Q,2P-
M"C$P-RPX-3(@<V5R:65S($@@=V%R<F%N=',@97AP:7)E9"!A;F0@,2PX,S(L
M-C`R('-E<FEE<R!2('=A<G)A;G1S#0IW97)E(&ES<W5E9"!I;B!C;VYN96-T
M:6]N('=I=&@@=&AE($IU;F4@,C`Q,2!S=&]C:R!S86QE+CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[
M/"]P/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M=VED=&@],T0Q,#`E('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUT;W`Z(#!P=#L@;6%R9VEN+6)O
M='1O;3H@,'!T)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,#L@<&%D9&EN9SH@,#L@=&5X="UI
M;F1E;G0Z(#`G/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R!P
M861D:6YG.B`P.R!T97AT+6EN9&5N=#H@,"<^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG.B`P.R!T97AT+6EN9&5N=#H@
M,"<^/&(^4W1O8VL-"D]P=&EO;G,\+V(^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XU:6XG/@T*)B-X03`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!#;VUP86YY(&AA<R!A('-T;V-K(&]P
M=&EO;B!P;&%N('5N9&5R('=H:6-H(&]P=&EO;G,@=&\@<'5R8VAA<V4-"F$@
M;6%X:6UU;2!O9B`R+#4P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!M
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M<'1I;VX@;6%Y(&YO="!E>&-E960@,3`@>65A<G,@9G)O;2!T:&4@9&%T90T*
M;V8@9W)A;G0N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!O<'1I;VYS('1O
M('!U<F-H87-E(#$L-#<W+#,P.`T*<VAA<F5S(&]F('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&-O;6UO;B!S=&]C:R!W97)E(&ES<W5E9"!A;F0-"F]U='-T86YD
M:6YG('5N9&5R('1H92!P;&%N(&%N9"`Y.3$L-CDQ('-H87)E<R!W97)E(&%V
M86EL86)L92!F;W(-"F=R86YT+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
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M(&YO;BUP;&%N(&]P=&EO;G,@=&\@<'5R8VAA<V4@,3`U+#,W-2!S:&%R97,@
M;V8-"G1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!W97)E(&ES
M<W5E9"!A;F0@;W5T<W1A;F1I;F<N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I&;W(@=&AE('EE87)S
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"`R,#$P+"!T:&4@9F%I<B!V
M86QU92!O9@T*96%C:"!O<'1I;VX@87=A<F0@=V%S(&5S=&EM871E9"!A="!T
M:&4@9&%T92!O9B!G<F%N="!U<VEN9R!T:&4-"D)L86-K+5-C:&]L97,@;W!T
M:6]N+7!R:6-I;F<@;6]D96PN(%1H92!W96EG:'1E9"UA=F5R86=E#0IA<W-U
M;7!T:6]N<R!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q
M(&%N9"`R,#$P('=E<F4@87,-"F9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=W:61T:#H@-S`E)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*
M,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D
M/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60G/@T*,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL
M93TS1"=W:61T:#H@-S(E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/@T*4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$P)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^#0HQ+C<R/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,3`E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SX-"C(N-3,\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXE/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5F]L871I;&ET>0T*9F%C=&]R
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C<V/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^.#`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
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M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C`\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)3PO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXP/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY%>'!E8W1E9"!O<'1I;VX-
M"FQI9F4@*'EE87)S*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV+C(U/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV+C(U/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!R:7-K+69R964@<F%T92!U=&EL
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M(&1I=FED96YD('EI96QD(&ES(#`E('-I;F-E('1H90T*0V]M<&%N>2!D;V5S
M(&YO="!A;G1I8VEP871E('!A>6EN9R!D:79I9&5N9',@:6X@=&AE(&YE87(@
M9G5T=7)E+@T*0F%S960@;VX@=&AE($-O;7!A;GDF(W@R,#$Y.W,@:&ES=&]R
M:6-A;"!E>'!E<FEE;F-E(&]F(&]P=&EO;G,@=&AA=`T*=V5R92!F;W)F96ET
M960@8F5F;W)E(&)E8V]M:6YG(&9U;&QY('9E<W1E9"P@=&AE($-O;7!A;GD@
M:&%S#0IA<W-U;65D(&%N(&%N;G5A;&EZ960@9F]R9F5I='5R92!R871E(&]F
M(#$N,"4@9F]R(&%L;"!O<'1I;VYS+B!4:&4-"D-O;7!A;GD@=VEL;"!R96-O
M<F0@861D:71I;VYA;"!E>'!E;G-E(&EF('1H92!A8W1U86P@9F]R9F5I='5R
M90T*<F%T92!I<R!L;W=E<B!T:&%N(&5S=&EM871E9"P@86YD('=I;&P@<F5C
M;W)D(&$@<F5C;W9E<GD@;V8@<')I;W(-"F5X<&5N<V4@:68@=&AE(&%C='5A
M;"!F;W)F96ET=7)E(')A=&4@:7,@:&EG:&5R('1H86X@97-T:6UA=&5D+CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SX-"D$@<W5M;6%R>2!O9B!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!S=&]C:R!O<'1I;VX@86-T:79I='D@86YD(')E;&%T960-"FEN
M9F]R;6%T:6]N(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P
M,3$@86YD(#(P,3`-"F9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T
M:#H@,3`P)2<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/@T*)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"C(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L
M:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"C(P,3`\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@
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M=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C
M>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"D]P=&EO;G,\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97([
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M8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^
M#0I796EG:'1E9"!!=F5R86=E(#QU('-T>6QE/3-$)W1E>'0M9&5C;W)A=&EO
M;CH@;F]N92<^17AE<F-I<V4-"E!R:6-E/"]U/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-
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M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#0T)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX-"D]U='-T86YD:6YG("8C>#(P,3,[(&)E9VEN
M;FEN9R!O9B!Y96%R/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,B4[(&9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,2PR,#,L-C`P/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C4N,#<\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C$L,#8V
M+#,R.#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$P)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HU
M+C`X/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#`N,3)I
M;B<^#0I'<F%N=&5D/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C0V,RPP.#4\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXW+C,P/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR-#8L-C(U/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-2XP.3PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR
M,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,"XQ,FEN)SX-"D9O<F9E:71E
M9#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-2PU,#$\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^*3PO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^-"XT,3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^*#<Y+#DY.3PO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD
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M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^*#(S+#<U,SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXI/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV+C`P/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`P+C$R:6XG
M/@T*17AE<F-I<V5D/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#<X+#4P,3PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"BD\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,N,C$\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^#0HH-2PV,#$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HI
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR+CDQ
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0I/=71S=&%N9&EN9R`F
M(W@R,#$S.R!E;F0@;V8@>65A<CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U
M8FQE.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
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M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B0\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HU+C@R/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C$L,C`S+#8P,#PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/@T*-2XP-SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R
M9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^#0I%>'!E8W1E9"!T;R!V97-T("8C>#(P,3,[(&5N9"!O9B!Y96%R/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HQ+#4V-BPX-38\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU
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M;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P
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M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B0\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HU+C`W/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX-"D5X97)C:7-A8FQE(&%T(&5N
M9"!O9B!Y96%R/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L
M93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HQ+#$Q
M."PQ-3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/@T*.3DP+#,W-#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B
M;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D
M;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*
M-2XQ-SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*1'5R:6YG(#(P,3$L('-E<G9I8V4@8F%S960@;W!T:6]N
M<R!O9B`S,C`L-3@U(&%N9"!P97)F;W)M86YC92!B87-E9`T*;W!T:6]N<R!O
M9B`Q-#(L-3`P('=E<F4@9W)A;G1E9"!T;R!#;VUP86YY(&]F9FEC97)S+"!D
M:7)E8W1O<G,L#0IE;7!L;WEE97,L(&%N9"!C;VYS=6QT86YT<RX@5&AE('=E
M:6=H=&5D(&%V97)A9V4@9F%I<B!V86QU92!P97(-"G-H87)E(&]F(&]P=&EO
M;G,@9W)A;G1E9"!D=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L
M(#(P,3$-"G=A<R`D-2XS,2X@5&AE(&EN=')I;G-I8R!V86QU92!O9B!O<'1I
M;VYS(&5X97)C:7-E9"!I;B`R,#$Q('=A<PT*)#0P."PQ.34N/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE(&9O;&QO=VEN9R!T86)L
M92!S=6UM87)I>F5S(&EN9F]R;6%T:6]N(')E;&%T960@=&\@<W1O8VL@;W!T
M:6]N<PT*;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE(&%T($1E8V5M8F5R
M(#,Q+"`R,#$Q.CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N
M-6EN.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3`N-6EN)SX-
M"B8C>$$P.SPO<#X-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D(&-O
M;'-P86X],T0Q,"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-
M"D]P=&EO;G,@3W5T<W1A;F1I;F<\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/@T*)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"D]P=&EO;G,@17AE<F-I<V%B;&4\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*4F%N
M9V4@;V8@/'4@<W1Y;&4],T0G=&5X="UD96-O<F%T:6]N.B!N;VYE)SY%>&5R
M8VES92!0<FEC97,\+W4^/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^#0HF(WA!,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*3G5M8F5R/&)R("\^#0H\=2!S='EL
M93TS1"=T97AT+61E8V]R871I;VXZ(&YO;F4G/D]U='-T86YD:6YG/"]U/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G
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M#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S
M;VQI9"<^#0I796EG:'1E9"U!=F5R86=E(#QU('-T>6QE/3-$)W1E>'0M9&5C
M;W)A=&EO;CH@;F]N92<^17AE<F-I<V4-"E!R:6-E/"]U/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*3G5M8F5R
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M=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9"<^#0I796EG:'1E9"U!=F5R86=E(#QU('-T>6QE/3-$)W1E>'0M
M9&5C;W)A=&EO;CH@;F]N92<^17AE<F-I<V4-"E!R:6-E/"]U/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X
M03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z
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M=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C
M>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=W
M:61T:#H@,34E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B0R+C@X#0HM("0T+C`P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,S8S+#@T,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*
M-"XY,#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$S)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HS
M+C0Q/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$S)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^#0HS,S(L-3,T/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,3,E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SX-"C,N-#4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B0T+C`Q("T@)#8N
M,#`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-C,P+#0S.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-BXP.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4N,#,\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C0V,"PR.#0\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXU+C`T/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)#8N,#$@+0T*)#$P+C`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C0Y
M."PR,3`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/C<N,S8\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXW+C4S
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR-S<L
M-C0Q/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-RXQ.#PO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T)SXD,3`N,#$-"BT@)#$S+C8P
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*.3`L,3DS/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4N.#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C$Q+C4Y/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*-#<L
M-CDS/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ,BXW.#PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C$L-3@R+#8X,SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-BXR,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4N.#(\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
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M;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^-2XT,SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!L969T)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P+C5I;B<^#0I$=7)I;F<@=&AE('EE87(@96YD960@1&5C
M96UB97(@,S$L(#(P,3$@86YD(#(P,3`L('-T;V-K(&]P=&EO;@T*8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@=V%S(')E8V]R9&5D(&%S(&9O;&QO=W,Z/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF
M(WA!,#L\+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!S='EL93TS1"=W:61T:#H@.#`E.R!M87)G:6XM;&5F=#H@,"XU:6XG
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^#0HR,#$Q
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60G/@T*,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#8V)3L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#;W-T#0IO9B!S86QE
M<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,R4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/@T*.#$L-S(U/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,3,E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SX-"C0P+#DX-3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^#0I396QL:6YG+"!G96YE<F%L(&%N9"!A9&UI
M;FES=')A=&EV92!E>'!E;G-E<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C$L
M,C$W+#DU,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG
M+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C4W-BPW-3(\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O
M='1O;3H@,BXU<'0[('!A9&1I;F<M;&5F=#H@,"XR-&EN)SX-"E1O=&%L('-T
M;V-K(&]P=&EO;B!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G
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M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B
M;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D
M;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*
M-C$W+#<S-SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*07,@;V8@1&5C96UB97(@,S$L(#(P,3$L('1H97)E('=A
M<R`D.38X+#8Y.2!O9B!U;G)E8V]G;FEZ960-"F-O;7!E;G-A=&EO;B!C;W-T
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M9"`P+C8W('EE87)S(&9O<B!T:&4@<&5R9F]R;6%N8V4@8F%S960@87=A<F1S
M+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*/&(^4F5S=')I8W1E9"!#;VUM;VX@4W1O8VL\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE($-O;7!A;GD@
M:&%S(&$@<F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@<&QA;B!U;F1E<B!W:&EC
M:"`S,3(L-3`P#0IS:&%R97,@;V8@8V]M;6]N('-T;V-K(&%R92!R97-E<G9E
M9"!F;W(@:7-S=6%N8V4N(%1H97)E(&%R92`R,3@L,3(U#0IS:&%R97,@879A
M:6QA8FQE(&9O<B!I<W-U86YC92!U;F1E<B!T:&4@<&QA;B!A="!$96-E;6)E
M<B`S,2P-"C(P,3$N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I);B!397!T96UB97(@,C`Q
M,2P@,2PP,#`@<VAA<F5S(&]F(')E<W1R:6-T960@8V]M;6]N('-T;V-K('=E
M<F4-"F=R86YT960@=6YD97(@=&AE('!L86X@=&\@82!#;VUP86YY(&5M<&QO
M>65E('=H:6-H('9E<W0@;VYE('EE87(-"F9R;VT@9&%T92!O9B!G<F%N="X@
M5&AE(&9A:7(@;6%R:V5T('9A;'5E(&%T('1H92!D871E(&]F(&=R86YT#0ID
M971E<FUI;F5D(&)Y('1H92!Q=6]T960@;6%R:V5T('!R:6-E('=A<R`D-RPX
M,3`L(&]R("0W+C@Q('!E<@T*<VAA<F4N($9O<B!T:&4@>65A<B!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,2P@)#(L-C`T(&]F(&-O;7!E;G-A=&EO;@T*97AP
M96YS92!W87,@<F5C;W)D960@9F]R('1H97-E(&=R86YT<RX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I);B!-87D@,C`Q,2P@,C$L
M,#`P('-H87)E<R!O9B!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!W97)E(&=R
M86YT960-"G5N9&5R('1H92!P;&%N('1O(&YO;BUE;7!L;WEE92!M96UB97)S
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&)O87)D#0IO9B!D:7)E8W1O<G,[
M(#(P+#`P,"!S:&%R97,@=VEL;"!V97-T(&]N92!Y96%R(&9R;VT@9&%T92!O
M9B!G<F%N="P-"F%N9"`Q+#`P,"!S:&%R97,@=F5S=&5D(&EM;65D:6%T96QY
M+B!4:&4@9F%I<B!M87)K970@=F%L=64@870@=&AE#0ID871E(&]F(&=R86YT
M(&1E=&5R;6EN960@8GD@=&AE('%U;W1E9"!M87)K970@<')I8V4@=V%S("0R
M,34L-#8P+`T*;W(@)#$P+C(V('!E<B!S:&%R92X@1F]R('1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+"`D,30W+#`V,`T*;V8@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4@=V%S(')E8V]R9&5D(&9O<B!T:&5S92!G<F%N=',N/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^#0I);B!*86YU87)Y(#(P,3$L(#,P+#4P,"!S:&%R97,@
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M971E<FUI;F5D(&)Y('1H92!Q=6]T960@;6%R:V5T('!R:6-E('=A<R`D,34P
M+#DW-2P@;W(@)#0N.34@<&5R#0IS:&%R92X@1F]R('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$Q+"`D,34P+#DW-2!W87,@<F5C;W)D960-"F9O
M<B!T:&5S92!G<F%N=',N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/@T*26X@36%Y(#(P,3`L(#(P+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E
M9"!C;VUM;VX@<W1O8VL@=V5R92!G<F%N=&5D#0IU;F1E<B!T:&4@<&QA;B!T
M;R!N;VXM96UP;&]Y964@;65M8F5R<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[
M<R!B;V%R9`T*;V8@9&ER96-T;W)S('1H870@=VEL;"!V97-T(&]N92!Y96%R
M(&9R;VT@9&%T92!O9B!G<F%N="X@5&AE(&9A:7(-"FUA<FME="!V86QU92!A
M="!T:&4@9&%T92!O9B!G<F%N="!D971E<FUI;F5D(&)Y('1H92!Q=6]T960@
M;6%R:V5T#0IP<FEC92!W87,@)#$P,BPT,#`L(&]R("0U+C$R('!E<B!S:&%R
M92X@1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R#0HS,2P@,C`Q,2!A;F0@
M,C`Q,"P@)#,T+#$S,R!A;F0@)#8X+#(V-RP@<F5S<&5C=&EV96QY+"!W87,@
M<F5C;W)D960-"F9O<B!T:&5S92!G<F%N=',N/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I$=7)I;F<@
M=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`L(')E
M<W1R:6-T960@<W1O8VL-"F-O;7!E;G-A=&EO;B!E>'!E;G-E('=A<R!R96-O
M<F1E9"!A<R!F;VQL;W=S.CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!
M,#L\+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!S='EL93TS1"=W:61T:#H@.#`E.R!M87)G:6XM;&5F=#H@,"XU:6XG/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^#0HR,#$Q/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G
M/@T*,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#8V)3L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#;W-T#0IO9B!S86QE<SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,R4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/@T*,C(L,C<U/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL
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M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,7!T)SX-"E-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M(&5X<&5N<V5S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,S$R+#0Y-SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SX-"C8X+#(V-SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M<&%D9&EN9RUL969T.B`P+C(T:6XG/@T*5&]T86P@<F5S=')I8W1E9"!S=&]C
M:R!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO
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M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P
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M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P+C5I;B<^#0I!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2P@
M=&AE(&EN=')I;G-I8R!V86QU92!O9B!T:&4@;F]N+79E<W1E9`T*87=A<F1S
M('=A<R`D.#`L,C$U(&%N9"!T:&5R92!W87,@)#<S+#8P-B!O9B!U;G)E8V]G
M;FEZ960@8V]S=',-"G)E;&%T960@=&\@=&AE(')E<W1R:6-T960@8V]M;6]N
M('-T;V-K(&%W87)D<RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I
M;B<^#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*/&(^4VAA<F5S(%)E<V5R
M=F5D(&9O<B!&=71U<F4@27-S=6%N8V4\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/@T*070@1&5C96UB97(@,S$L(#(P,3$L('1H92!#
M;VUP86YY(&AA9"!R97-E<G9E9"!T:&4@9F]L;&]W:6YG('-H87)E<PT*;V8@
M8V]M;6]N('-T;V-K(&9O<B!F=71U<F4@:7-S=6%N8V4Z/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\
M+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@.#`E.R!M87)G:6XM;&5F=#H@,"XU:6XG/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`X,R4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M#0I#;VYV97)T:6)L92!P<F5F97)R960@<VAA<F5S("AS97)I97,@02`F(W@R
M,#$S.R!"*3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3,E.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C<S+#,S,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^0V]M;6]N('-T;V-K#0IO<'1I;VYS(&]U='-T86YD:6YG/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-3@R+#8X,SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/D-O;6UO;B!S=&]C:PT*;W!T:6]N<R!A=F%I;&%B;&4@9F]R(&=R
M86YT/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/CDY,2PV.3$\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M0V]M;6]N('-T;V-K#0IW87)R86YT<R!O=71S=&%N9&EN9SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXS+#`V-2PW,#(\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY2
M97-T<FEC=&5D(&-O;6UO;@T*<W1O8VL@9W)A;G1S/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C4Q+#4P,#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T
M)SX-"E)E<W1R:6-T960@8V]M;6]N('-T;V-K(&%V86EL86)L92!F;W(@9W)A
M;G0\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HR,3@L,3(U/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[('!A9&1I;F<M;&5F=#H@,"XQ,FEN)SX-"E1O=&%L(&-O;6UO
M;B!S=&]C:R!S:&%R97,@<F5S97)V960\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
M(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SX-"C4L.3@S+#`S,SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*/&(^4V5C=7)I=&EE<R!296=I<W1R
M871I;VX@3V)L:6=A=&EO;G,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*5&AE($-O;7!A;GD@8V]N<W5M;6%T960@<')I=F%T92!S
M>6YD:6-A=&EO;G,@;V8@:71S('-E8W5R:71I97,@;VX-"D%P<FEL(#$X+"`R
M,#`V+"!.;W9E;6)E<B`X+"`R,#`W(&%N9"!!<')I;"`R+"`R,#`X+B!);B!C
M;VYN96-T:6]N#0IW:71H(&5A8V@@<W5C:"!S>6YD:6-A=&EO;BP@=&AE($-O
M;7!A;GD@86=R965D('=I=&@@<'5R8VAA<V5R<R!B;W1H#0IT;R!R96=I<W1E
M<B!T:&4@<V5C=7)I=&EE<R!F;W(@<'5B;&EC('-A;&4@86YD('1O('5S92!I
M=',@8F5S=`T*969F;W)T<R!T;R!M86EN=&%I;B!T:&4@969F96-T:79E;F5S
M<R!O9B!S=6-H(')E9VES=')A=&EO;@T*<W1A=&5M96YT<R!U;G1I;"!T:&4@
M<W5B:F5C="!S96-U<FET:65S(&%R92!S;VQD(&]R(&UA>2!B92!S;VQD#0IW
M:71H;W5T(')E9VES=')A=&EO;BX@5&AE($-O;7!A;GD@:&%S('-A=&ES9FEE
M9"!I=',@;V)L:6=A=&EO;G,@=&\-"G)E9VES=&5R('1H92!S96-U<FET:65S
M(&ES<W5E9"!I;B!E86-H(&]F('1H92!A9F]R96UE;G1I;VYE9`T*<WEN9&EC
M871I;VYS+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H
M92!R96=I<W1R871I;VX@<W1A=&5M96YT<R!R96QA=&EV92!T;R!T:&4@07!R
M:6P@,C`P-B!A;F0@3F]V96UB97(-"C(P,#<@<WEN9&EC871I;VYS(&AA=F4@
M97AP:7)E9"X@06QT:&]U9V@@=&AE('-E8W5R:71I97,@<V]L9"!I;@T*=&AE
M<V4@<WEN9&EC871I;VYS(&%R92!E;&EG:6)L92!F;W(@<V%L92!U;F1E<B!2
M=6QE(#$T-"AB*2@Q*2AI*2P-"G1H92!#;VUP86YY(&AA<R!A8V-O<F1E9"`F
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M969F96-T:79E;F5S<RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!S96-U<FET:65S(')E9VES
M=')A=&EO;B!P<F]V:7-I;VYS(&%P<&QI8V%B;&4@=&\@=&AE($%P<FEL(#(P
M,#@-"G-Y;F1I8V%T:6]N(')E<75I<F4@=&AA="!I9B!T:&4@4V5C=7)I=&EE
M<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;@T*<W5S<&5N9',@=&AE(&5F9F5C
M=&EV96YE<W,@;V8@=&AE('-U8FIE8W0@<F5G:7-T<F%T:6]N('-T871E;65N
M=`T*<')I;W(@=&\@86QL(')E9VES=&5R960@<V5C=7)I=&EE<R!E:71H97(@
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M(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SX-"E1H92!S96-U<FET:65S('!U<F-H87-E9"!I;B!T:&4@07!R
M:6P@,C`P."!S>6YD:6-A=&EO;B!A<F4@86QL#0IE;&EG:6)L92!F;W(@=6YR
M97-T<FEC=&5D('-A;&4@=6YD97(@4G5L92`Q-#0H8BDH,2DH:2D@=VET:"!T
M:&4-"F5X8V5P=&EO;B!O9B!S96-U<FET:65S('!U<F-H87-E9"!B>2!A('-I
M;F=L92!I;G-T:71U=&EO;F%L#0II;G9E<W1O<B!I;B!T:&4@=&]T86P@86UO
M=6YT(&]F("0R+#`P,"PP,#`N(%1H92!#;VUP86YY)B-X,C`Q.3MS#0IM87AI
M;75M('!O=&5N=&EA;"!L:6%B:6QI='D@=&\@=&AE('-U8FIE8W0@:6YV97-T
M;W(@=6YD97(@=&AE#0IF;W)E9V]I;F<@<F5G:7-T<F%T:6]N('!R;W9I<VEO
M;G,@=V]U;&0@8F4@)#(P,"PP,#`N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I4:&4@0V]M<&%N>2!C
M;VYS=6UM871E9"!A('!U8FQI8R!O9F9E<FEN9R!O9B!I=',@<V5C=7)I=&EE
M<R!O;@T*1F5B<G5A<GD@,C(L(#(P,3`N($$@<&]R=&EO;B!O9B!T:&4@=6YD
M97)W<FET97(F(W@R,#$Y.W,-"F-O;7!E;G-A=&EO;B!I;B!T:&ES(&]F9F5R
M:6YG(&-O;G-I<W1E9"!O9B!W87)R86YT<R!T;R!P=7)C:&%S92!T:&4-"D-O
M;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K+B!4:&4@0V]M<&%N>2!A9W)E
M960@=&\@86-C;W)D('1H90T*=6YD97)W<FET97(@82!S:6YG;&4@9&5M86YD
M(')E9VES=')A=&EO;B!R:6=H="!A;F0@=&AE<F5A9G1E<@T*)B-X,C`Q0SMP
M:6=G>6)A8VLF(W@R,#%$.R!R96=I<W1R871I;VX@<FEG:'1S(&%S('1O('1H
M92!C;VUM;VX@<W1O8VL-"FES<W5A8FQE('5P;VX@97AE<F-I<V4@;V8@=&AE
M('5N9&5R=W)I=&5R)B-X,C`Q.3MS('-T;V-K('!U<F-H87-E#0IW87)R86YT
M<RX@2&]W979E<BP@=&AE($-O;7!A;GDL(&EN(&QI974@;V8@<')O=FED:6YG
M('1H92!F;W)E9V]I;F<-"G)E9VES=')A=&EO;B!R:6=H=',L(&AA<R!T:&4@
M86)S;VQU=&4@<FEG:'0L(&EN(&ET<R!D:7-C<F5T:6]N(&%N9`T*=VET:&]U
M="!P96YA;'1Y+"!T;R!S871I<V9Y('1H92!E>&5R8VES92!O9B!T:&4@=6YD
M97)W<FET97(F(W@R,#$Y.W,-"G=A<G)A;G1S('=I=&@@=6YR96=I<W1E<F5D
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I/;B!*=6YE(#(S
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82!P<FEV871E('!L86-E
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M=')A=&EO;B!S=&%T96UE;G0@=VET:`T*<F5S<&5C="!T;R!T:&4@8V]M;6]N
M('-T;V-K(&%N9"!T:&4@8V]M;6]N('-T;V-K('5N9&5R;'EI;F<@=&AE#0IW
M87)R86YT<RP@=VAI8V@@=V%S(&1E8VQA<F5D(&5F9F5C=&EV92!O;B!*=6QY
M(#(Q+"`R,#$Q+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,35C8C@W-&%?,3$T8U\T,C4W7SAE93%?96$R
M,3!A-#DS8S`P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$U8V(X
M-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,"]7;W)K<VAE971S+U-H
M965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY/<&5R871I;F<@4V5G;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!396=M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XM=&]P.B`P<'0[(&UA<F=I;BUB;W1T;VTZ(#!P="<^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#`G/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R!T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=T97AT+75N9&5R;&EN92US='EL
M93H@;F]N92<^/&(^,3(N/"]B/CPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T
M>6QE/3-$)W1E>'0M=6YD97)L:6YE+7-T>6QE.B!N;VYE)SX\8CY/<&5R871I
M;F<-"E-E9VUE;G1S/"]B/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I);B`R,#$Q+"!T
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M=&AE(&%D=F%N8V5D(&%N9"!T<F%D:71I;VYA;`T*=V]U;F0@8V%R92!P<F]D
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M(')E<W5L=',@9F]R(#(P,3`@:&%V92!B965N#0IR97-T871E9"!T;R!C;VYF
M;W)M('1O('1H92!N97<@<V5G;65N="!R97!O<G1I;F<N/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE($-O;7!A;GD@8W5R
M<F5N=&QY(&]P97)A=&5S(&EN('1H<F5E('-E9VUE;G1S.B!A9'9A;F-E9"!W
M;W5N9`T*8V%R92P@=')A9&ET:6]N86P@=V]U;F0@8V%R92!A;F0@<&AA<FUA
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M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SX-"D%D=F%N8V5D(&%N9"!T<F%D:71I;VYA;"!W;W5N
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M9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!S86QE<R!A<F4@<V]L9`T*9&ER96-T
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M>F5S(&1I<F5C=`T*<V%L97,@<F5P<F5S96YT871I=F5S+"!D:7-T<FEB=71O
M<B!R96QA=&EO;G-H:7!S(&%N9"!C;VYT<F%C='5A;`T*<F5L871I;VYS:&EP
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M8V%R92!P<F]D=6-T<R!I;B!#86YA9&$N/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE('!H87)M86-E=71I8V%L('=O=6YD
M(&-A<F4@<V5G;65N="!I<R!P<F5S96YT;'D@;&EM:71E9"!T;R!T:&4-"F1E
M=F5L;W!M96YT(&]F($130S$R-RX@06QL(&5X<&5N<V5S(&%S<V]C:6%T960@
M=VET:"!T:&ES(&%C=&EV:71Y#0IA<F4@8F5I;F<@<F5C;W)D960@87,@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V4N/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*16%C:"!O<&5R871I;F<@<V5G
M;65N="!I<R!M86YA9V5D(&%T('1H92!S96=M96YT(&-O;G1R:6)U=&EO;B!L
M979E;`T*8V]N<VES=&EN9R!O9B!G<F]S<R!P<F]F:70@;6EN=7,@9&ER96-T
M(&5X<&5N<V4@8V]N<VES=&EN9R!O9@T*9&ES=')I8G5T:6]N+"!M87)K971I
M;F<L('-A;&5S(&%N9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0-"F5X<&5N
M<V5S+B!%>'!E;G-E<R!A<F4@86QL;V-A=&5D(&1I<F5C=&QY(&)Y('-E9VUE
M;G0@=&\@=&AE(&5X=&5N=`T*<&]S<VEB;&4N($5X<&5N<V5S(&-O;6UO;B!T
M;R!A;&P@=&AR964@;W!E<F%T:6YG('-E9VUE;G1S(&%R90T*86QL;V-A=&5D
M(&-O;G-I<W1E;G1L>2!U<VEN9R!A8W1I=FET>2!B87-E9"!A<W-U;7!T:6]N
M<RX@5&AE#0IA9V=R96=A=&EO;B!O<B!A;&QO8V%T:6]N(&]F(&EN9&ER96-T
M(&5X<&5N<V5S(&)Y('-E9VUE;G0@:7,@;F]T#0IP<F%C=&EC86PN/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*3W!E<F%T:6YG('-E9VUE
M;G0@<V%L97,L(&=R;W-S('!R;V9I="P@<V5G;65N="!C;VYT<FEB=71I;VX@
M86YD#0IO=&AE<B!R96QA=&5D(&EN9F]R;6%T:6]N(&9O<B`R,#$Q(&%N9"`R
M,#$P(&%R92!A<R!F;VQL;W=S.CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M#0HF(WA!,#L\+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)2<^#0H\='(@<W1Y;&4],T0G
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M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&ET86QI
M8SL@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!I=&%L:6,[('1E>'0M86QI9VXZ(&-E
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M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
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M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!I=&%L:6,[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97(G/@T*/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L)SY0:&%R;6%C975T:6-A;"`\=2!S='EL93TS1"=T97AT
M+61E8V]R871I;VXZ(&YO;F4G/E=O=6YD($-A<F4\+W4^/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97(G/@T*3W1H97(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SY4;W1A;#PO9F]N=#X@
M/'4@<W1Y;&4],T0G=&5X="UD96-O<F%T:6]N.B!N;VYE)SY#;VUP86YY/"]U
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#,P)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY.970-"G-A;&5S/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HQ-2PY,C<L.3(P
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C0V+#<P
M,BPS,C<\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,"4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*-C(L-C,P+#(T-SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^1W)O<W,@<')O9FET/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/C<L,S$R+#DU,SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^,3$L,#DX+#DY-#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^,3@L-#$Q+#DT-SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/D1I<F5C=`T*97AP96YS93PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O
M;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SX-"B@X+#<W."PW.3<\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^#0HI/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#,L
M-C$Q+#4U.#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"BD\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^#0HH,2PP-3<L,#DT/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/@T**3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXM/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#$S+#0T
M-RPT-#D\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
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M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
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M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L
M93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HW+#0X
M-RPT,S8\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B@Q+#`U-RPP.30\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-"PY-C0L-#DX/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P="<^#0I);F1I<F5C="!E>'!E;G-E<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^#0HH.2PS,#0L.3`Y/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^*3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P="<^3F5T#0IL;W-S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^#0HH-"PS-#`L-#$Q/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^*3PO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/@T*)B-X
M03`[/"]P/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4G/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*/'1D(&-O;'-P86X],T0R,2!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L
M:6=N.B!C96YT97(G/CQU/EEE87(-"F5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P
M/"]U/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*/'1D(&-O;'-P86X],T0R,2!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT
M97(G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,P)3L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY.970-"G-A;&5S/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$P)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^#0HQ,2PU.3<L,S<S/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,3`E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SX-"C0T+#@W-BPV.#,\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/BT\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,"4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/BT\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,"4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/@T*-38L-#<T+#`U-CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1W)O<W,@<')O
M9FET/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C0L-C@Y+#0Q,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3$L.#,W+#DR,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,38L-3(W+#,S,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/D1I<F5C
M=`T*97AP96YS93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B@V+#8T.2PT-3<\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HI/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/@T**#,L-C4Q+#4P.#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SX-"BD\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HH,CDR+#8V,#PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"BD\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-
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M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0I396=M96YT(&-O;G1R:6)U=&EO
M;CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
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M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B@D/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B
M;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#(Y
M,BPV-C`\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-2PY
M,S,L-S`W/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0I);F1I<F5C="!E>'!E
M;G-E<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^
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M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P="<^3F5T#0IL;W-S/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HH,BPT-#@L.#8T/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*02!G96]G<F%P:&EC86P@8G)E86MD;W=N(&]F('1H92!#
M;VUP86YY)B-X,C`Q.3MS('-A;&5S+"!G<F]S<R!P<F]F:70-"F%N9"!E<75I
M<&UE;G0@86YD(&EM<')O=F5M96YT<RP@;F5T(&ES(&%S(&9O;&QO=W,Z/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^
M#0HF(WA!,#L\+W`^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)2<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"E5N:71E9"!3=&%T97,\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^#0I#
M86YA9&$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9"<^#0I/=&AE<CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT
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M;&EG;CH@:G5S=&EF>2<^/'4^,C`Q,3PO=3X\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P
M861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D
M/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=W:61T
M:#H@-#0E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/DYE
M=`T*<V%L97,\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SX-"C0Q+#4P,BPP-3D\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,34L,S@W+#`V-CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HU+#<T,2PQ,C(\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*-C(L-C,P+#(T-SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^1W)O<W,@<')O9FET/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXQ,RPR,38L-SDT/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,BPW-S(L-C0W/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,BPT,C(L-3`V/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,3@L-#$Q+#DT-SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/D5Q=6EP;65N="!A
M;F0-"FEM<')O=F5M96YT<RP@;F5T/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR.3(L
M.3$T/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,BPW-#4L
M-S<Y/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-#4P+#4P
M,3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,L-#@Y+#$Y
M-#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET
M92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UD96-O<F%T:6]N.B!U;F1E<FQI;F4[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UD
M96-O<F%T:6]N.B!U;F1E<FQI;F4[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U
M-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/DYE="!S86QE<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,S@L
M,S,X+#4X,3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$T
M+#0T,RPW-#(\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXS
M+#8Y,2PW,S,\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S
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M,T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^,3$L-S8U+#0W.#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C,L,SDS+#,W-CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$L,S8X+#0W.#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$V+#4R-RPS,S(\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SY%<75I<&UE;G0@86YD
M#0II;7!R;W9E;65N=',L(&YE=#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-#$U+#$Q
M-CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(L-C0R+#$V
M-3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4U,"PY-C$\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXS+#8P."PR-#(\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*1F]R('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,"P@=&AE($-O;7!A;GD@:&%D(&$-
M"FUA:F]R($-A;F%D:6%N(&-U<W1O;65R(&-O;7!R:7-I;F<@,C0E(&%N9"`R
M-24@;V8@8V]N<V]L:61A=&5D(&YE=`T*<V%L97,L(')E<W!E8W1I=F5L>2X@
M1'5E('1O(&]U='-T86YD:6YG(')E8F%T92!O8FQI9V%T:6]N<RP@=&AE#0I#
M;VUP86YY('=A<R!I;B!A(&YE="!L:6%B:6QI='D@<&]S:71I;VX@=&\@=&AI
M<R!C=7-T;VUE<B!A=`T*1&5C96UB97(@,S$L(#(P,3$@*'-E92!.;W1E(#D@
M86YD(#$U*2X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P
M830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T
M85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E
M=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O<#H@,'!T.R!M
M87)G:6XM8F]T=&]M.B`P<'0G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P.R!P861D:6YG.B`P
M.R!T97AT+6EN9&5N=#H@,"<^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,"XU:6X[('!A9&1I;F<Z(#`[('1E>'0M:6YD96YT.B`P)SX-"CQB/C$S+CPO
M8CX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<Z(#`[('1E>'0M:6YD96YT.B`P)SX\8CY);F-O;64-"E1A>&5S/"]B/CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SX-"DQO<W,@8F5F;W)E(&EN8V]M92!T87AE<R!F;W(@=&AE('EE87(@
M96YD960@1&5C96UB97(@,S$@8V]N<VES=',@;V8-"G1H92!F;VQL;W=I;F<@
M8V]M<&]N96YT<SH\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO<#X-"CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`X,"4[(&UA
M<F=I;BUL969T.B`P+C5I;B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED)SX-"C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9"<^#0HR,#$P/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=W
M:61T:#H@-C8E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/@T*1&]M97-T:6,\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@
M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3,E.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B@S+#0X,RPQ,#,\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,B4[(&9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@9F]N="US:7IE.B`Q,'!T
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M9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/@T*1F]R96EG;CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SX-"B@W.#<L-S<P/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T**3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C,P-"PR-#4\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0G/DQO<W,-"F)E9F]R92!I;F-O;64@=&%X97,\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HH-"PR-S`L.#<S/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU
M<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SX-"B@R+#`R-"PY,#,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXI/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"`P<'0@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*5&AE(&-O;7!O;F5N=',@;V8@:6YC;VUE('1A>&5S
M("AB96YE9FET*2!F;W(@=&AE('EE87(@96YD960-"D1E8V5M8F5R(#,Q(&%R
M92!A<R!F;VQL;W=S.CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T
M(#`N-6EN.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO<#X-"CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I
M9'1H.B`X,"4[(&UA<F=I;BUL969T.B`P+C5I;B<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"C(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97([
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M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('!A9&1I;F<M;&5F=#H@,"XQ,FEN)SX-"D9E9&5R86P\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/BT\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT
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M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SY?/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#8V)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N
M,3)I;B<^#0I&;W)E:6=N/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,B4[
M(&9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,3,E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#$S+#4W,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T**3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SX-"C(V."PP-S(\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('!A9&1I;F<M;&5F=#H@,"XR-&EN)SX-"E1O=&%L(&-U<G)E;G0\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^#0HH,3,L-3<P/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/@T**3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C(V."PP
M-S(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY$969E<G)E9#H\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI
M=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`P+C$R:6XG/@T*1F5D97)A;#PO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ-#0L,SDY/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
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M:G5S=&EF>3L@<&%D9&EN9RUL969T.B`P+C$R:6XG/@T*4W1A=&4\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^,S`L-S0R/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXS,"PW-#(\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`P+C$R:6XG/@T*1F]R96EG;CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O
M='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SX-"B@Y,BPP,S,\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^#0HI/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#$Y
M+#(U,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"BD\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N,C1I;B<^
M#0I4;W1A;"!D969E<G)E9#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C@S+#$P
M.#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O
M;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SX-"C$U-2PX.#D\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R
M9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[('!A9&1I;F<M;&5F=#H@,"XR-&EN)SX-"E1O=&%L(&EN8V]M92!T
M87AE<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
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M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/@T*-#(S+#DV,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!R96-O
M;F-I;&EA=&EO;B!O9B!I;F-O;64@=&%X(&-O;7!U=&5D(&%T('1H92!5;FET
M960@4W1A=&5S#0IF961E<F%L('-T871U=&]R>2!T87@@<F%T97,@=&\@:6YC
M;VUE('1A>"!E>'!E;G-E(&%L;VYG('=I=&@-"G!E<F-E;G1A9V4@;V8@;&]S
M<R!B969O<F4@:6YC;VUE('1A>&5S(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E
M;6)E<@T*,S$L(#(P,3$@86YD(#(P,3`@:7,@87,@9F]L;&]W<SH\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T)SX-"B8C
M>$$P.SPO<#X-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)W=I9'1H.B`X,"4[(&UA<F=I;BUL969T.B`P+C5I;B<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^
M)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
M:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D(&-O;'-P86X],T0V
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*,C`Q,3PO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$-B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-
M"C(P,3`\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#8@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U
M+#(P-"DG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`T,"4[(&9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&%X#0IB96YE9FET(&%T(&9E
M9&5R86P@<W1A='5T;W)Y(')A=&4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B@Q+#0U,BPP.3<\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
M,B4[(&9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[(&9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,S0N,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R
M)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
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M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C,T+C`\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXE/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^4W1A=&4@=&%X+"!N970@;V8-"F9E9&5R86P@8F5N969I=#PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXH,3$S+#0X,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C(N-SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^*#@T+#4S,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C0N,CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DYO;F1E
M9'5C=&EB;&4-"F5X<&5N<V5S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,W
M,"PU,38\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B@X+C<\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ-C@L
M,S@Y/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH
M."XS/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY/=&AE<CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV."PX-C4\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@Q+C8\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH,2PS.#,\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,2PQ.34L
M-S,V/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/@T**#(X+C`\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HI/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,2PP,CDL
M.34R/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/@T**#4P+C@\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P="<^#0I);F-O;64@=&%X97,\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O
M=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B0\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
M(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M#0HV.2PU,S@\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI)3PO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G
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M;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\
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M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
M.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0H\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`P+C5I;CL@=&5X="UA;&EG;CH@
M;&5F="<^#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*4VEG;FEF:6-A;G0@
M8V]M<&]N96YT<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!D969E<G)E9"!T
M87@@87-S971S#0IA;F0@;&EA8FEL:71I97,@87)E(&%S(&9O;&QO=W,Z/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P<'0@,"XU:6X[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/@T*)B-X03`[/"]P/@T*/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#@P)3L@;6%R
M9VEN+6QE9G0Z(#`N-6EN)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\
M+W1D/@T*/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60G/@T*1&5C96UB97(@,S$L/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9"<^#0HR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!
M,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60G/@T*,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$969E<G)E
M9"!T87@-"F%S<V5T<SH\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#8V)3L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE
M9G0Z(#`N,3)I;B<^#0I.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D
M<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,R4[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/@T*-"PX,3(L.3<U/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,3,E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SX-"C0L,C`W+#DT-SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@<&%D9&EN9RUL969T.B`P+C$R:6XG/D5Q=6ET>0T*8F%S960@8V]M<&5N
M<V%T:6]N/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,Q,BPV-S4\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(S-BPR,S(\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#`N,3)I;B<^#0I!;&QO
M=V%N8V4@9F]R('-A;&5S(&1E9'5C=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,3,T+#@R-CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^,30T+#DS,3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#`N,3)I
M;B<^#0I!;6]R=&EZ871I;VX@;V8@:61E;G1I9FEE9"!I;G1A;F=I8FQE<SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#<U,RPW,#(\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-3$Y+#$T,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR
M,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,"XQ,FEN)SX-"DEN=F5N=&]R
M>2!A9&IU<W1M96YT<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXY.3(L,3$S
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
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M9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F
M=#H@,"XQ,FEN)SX-"D]T:&5R/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*,38Y
M+#$Y.#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O
M='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SX-"C$W."PU.3D\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N,C1I;B<^#0I$969E<G)E9"!T87@@
M87-S971S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T*."PQ-S4L-#@Y/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/@T*-BPY-#,L,3@W/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1&5F97)R960@=&%X#0IL:6%B:6QI
M=&EE<SH\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L
M,C`T*2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#`N,3)I;B<^#0I0<F5P86ED
M(&5X<&5N<V5S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@X,2PX,#`\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH,C(L,C(V/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P
M861D:6YG+6QE9G0Z(#`N,3)I;B<^#0I';V]D=VEL;#PO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXH.#DP+#(S.#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B@W,34L,#DX/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F
M=#H@,"XQ,FEN)SX-"D1E<')E8VEA=&EO;CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXH,3(S+#8R-3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B@R-#0L.#4V/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG
M+6QE9G0Z(#`N,3)I;B<^#0I/=&AE<CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-
M"B@U-S8\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HI/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/@T**#8R-CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SX-"BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U
M-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#`N,C1I;B<^#0I$
M969E<G)E9"!T87@@;&EA8FEL:71I97,\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^*#$L,#DV+#(S.3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B@Y.#(L.#`V/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N,C1I;B<^#0I686QU871I;VX@86QL
M;W=A;F-E/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/@T**#@L,C(P+#<Q,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-"BD\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
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M;CH@:G5S=&EF>2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^3F5T#0ID
M969E<G)E9"!T87@@;&EA8FEL:71I97,\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
M(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX-
M"B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N
M-7!T(&1O=6)L93L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^#0HH,2PQ-#$L-#8P/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"B@Q+#`V-"PU.3,\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"B8C>$$P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P+C5I;B<^#0I4:&4@;F5T(&1E9F5R<F5D('1A>"!L:6%B:6QI='D@
M;V8@)#$L,30Q+#0V,"!C;VYS:7-T<R!O9B!A(&1E9F5R<F5D#0IT87@@87-S
M970@;V8@)#0L-3@W(&%N9"!A(&YE="!D969E<G)E9"!T87@@;&EA8FEL:71Y
M(&]F("0Q+#$T-BPP-#<-"F%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+B!4:&4@
M;F5T(&1E9F5R<F5D('1A>"!L:6%B:6QI='D@8V]N<VES=',@;V8-"F$@9&5F
M97)R960@=&%X(&QI86)I;&ET>2!O9B`D.#DP+#(S."!R96QA=&5D('1O('1H
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M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE(&%M;W5N="!B>2!W:&EC:"!T
M:&4@0V]M<&%N>2!C86X@=71I;&EZ92!I=',@56YI=&5D(%-T871E<PT*9F5D
M97)A;"!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!I;B!A;GD@
M>65A<B!O<B!I;B!T;W1A;`T*;6%Y(&)E(&QI;6ET960@=6YD97(@=&AE($EN
M=&5R;F%L(%)E=F5N=64@0V]D92!396-T:6]N(#,X,@T*<F5G87)D:6YG(&-H
M86YG97,@:6X@;W=N97)S:&EP(&]F(&-O<G!O<F%T:6]N<RX@1'5E('1O#0IU
M;F-E<G1A:6YT:65S('-U<G)O=6YD:6YG('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&%B:6QI='D@=&\@=7-E(&ET<PT*;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y
M9F]R=V%R9',@86YD('1O(')E86QI>F4@=&AE(&]T:&5R(&YE=`T*9&5F97)R
M960@=&%X(&%S<V5T<RP@82!F=6QL('9A;'5A=&EO;B!A;&QO=V%N8V4@:&%S
M(&)E96X@<')O=FED960-"F%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"`R
M,#$P(&9O<B!T:&4@9&5F97)R960@=&%X(&%S<V5T<R!F;W(-"G1H92!5;FET
M960@4W1A=&5S(&%N9"!5;FET960@2VEN9V1O;2X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"D%T($1E
M8V5M8F5R(#,Q+"`R,#$Q+"!T:&4@0V]M<&%N>2!H87,@;F5T(&]P97)A=&EN
M9R!L;W-S#0IC87)R>69O<G=A<F1S(&]F(&%P<')O>&EM871E;'D@)#$R+#8P
M,RPP,#`@9F]R(%5N:71E9"!3=&%T97,-"F9E9&5R86P@:6YC;VUE('1A>"!P
M=7)P;W-E<R!T:&%T(&)E9VEN('1O(&5X<&ER92!I;B`R,#$R+B!&;W(@<W1A
M=&4-"FEN8V]M92!T87@@<'5R<&]S97,L('1H92!#;VUP86YY(&AA<R!N970@
M;W!E<F%T:6YG(&QO<W,-"F-A<G)Y9F]R=V%R9',@:6X@82!N=6UB97(@;V8@
M:G5R:7-D:6-T:6]N<R!I;B!V87)Y:6YG(&%M;W5N=',@86YD#0IW:71H('9A
M<GEI;F<@97AP:7)A=&EO;B!D871E<RX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?
M-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O
M5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4F5T:7)E;65N="!"96YE9FET<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5T:7)E;65N="!"96YE
M9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT
M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P<'0[(&UA<F=I;BUB;W1T;VTZ(#!P
M="<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#`G/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#`N-6EN.R!T97AT+6%L:6=N.B!L969T)SX\8CXQ-"X\+V(^/"]T9#X-"CQT
M9#X\8CY2971I<F5M96YT($)E;F5F:71S/"]B/CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!#;VUP
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M9R!C;VYT<FEB=71I;VX@;V8@-3`E(&]N#0IT:&4@9FER<W0@-B4@;V8@96%C
M:"!P87)T:6-I<&%N="8C>#(P,3D[<R!A;FYU86P@96%R;FEN9W,-"F-O;G1R
M:6)U=&5D('1O('1H92!P;&%N+B!#;VUP86YY(&-O;G1R:6)U=&EO;G,@=&\@
M=&AE('!L86X@9F]R('1H90T*>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P
M,3$@86YD(#(P,3`@=V5R92`D-S4L,S(T(&%N9"`D-C8L-#0R+`T*<F5S<&5C
M=&EV96QY+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!#;VUP86YY)B-X,C`Q
M.3MS($-A;F%D:6%N('-U8G-I9&EA<GD@;6%I;G1A:6YS(&$@9W)O=7`-"G)E
M=&ER96UE;G0@<V%V:6YG<R!P;&%N("A296=I<W1E<F5D(%)E=&ER96UE;G0@
M4V%V:6YG<R!0;&%N*2!F;W(-"F5L:6=I8FQE(&9U;&P@=&EM92!#86YA9&EA
M;B!E;7!L;WEE97,N(%1H92!#86YA9&EA;B!S=6)S:61I87)Y#0IM86ME<R!A
M(&UA=&-H:6YG(&-O;G1R:6)U=&EO;B!O9B`U,"4@;V8@86X@96UP;&]Y964F
M(W@R,#$Y.W,-"F-O;G1R:6)U=&EO;B!T;R!A(&UA>&EM=6T@;V8@,R4@;V8@
M86YN=6%L(&=R;W-S(&5A<FYI;F=S+B!%;7!L;WEE90T*8V]N=')I8G5T:6]N
M(&QI;6ET<R!T;R!T:&4@9W)O=7`@<F5T:7)E;65N="!S879I;F=S('!L86X@
M87)E('-E="!B>0T*=&AE($-A;F%D82!#=7-T;VUS(&%N9"!2979E;G5E($%G
M96YC>2X@5&AE($-O;7!A;GDF(W@R,#$Y.W,@0V%N861I86X-"G-U8G-I9&EA
M<GDF(W@R,#$Y.W,@8V]N=')I8G5T:6]N<R!T;R!T:&4@<&QA;B!F;W(@=&AE
M('EE87(@96YD960-"D1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"`R,#$P('=E<F4@
M)#<U+#$X-B!A;F0@)#8T+#@U-2P-"G)E<W!E8W1I=F5L>2X\+W`^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U
M8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E
M83(Q,&$T.3-C,#`O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;BUT;W`Z(#!P=#L@;6%R9VEN+6)O='1O;3H@,'!T)SX-
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M:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*/&(^)B-X
M03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\8CY/<&5R871I;F<@
M3&5A<V5S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-
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M(#(P,3`L(')E<W!E8W1I=F5L>2X@5&]T86P@;6EN:6UU;2!L96%S90T*<&%Y
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M#0IT:&4@0V]M<&%N>2!H860@9&5F97)R960@<F5N="!O9B`D,C4R+#8X-"!R
M96-O<F1E9"!O;B!T:&4-"D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T+CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!L96%S97,@
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M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"DUI;FEM=6T@
M9G5T=7)E(&QE87-E('!A>6UE;G1S('5N9&5R(&5X:7-T:6YG(&]P97)A=&EN
M9R!L96%S97,@87,@;V8-"D1E8V5M8F5R(#,Q+"`R,#$Q(&%R93H\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T)SX-"B8C
M>$$P.SPO<#X-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`V,"4G/@T*/'1R
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M(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
M:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^#0H\=2!S='EL93TS1"=T97AT
M+61E8V]R871I;VXZ(&YO;F4G/D%M;W5N=#PO=3X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=W:61T:#H@
M-S8E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A
M9&1I;F<M;&5F=#H@,"XQ,FEN)SX-"C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,C`E.R!F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C$L-3$P+#$S
M,3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`P+C$R:6XG
M/@T*,C`Q,SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#4X-2PY-C(\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#`N,3)I;B<^#0HR,#$T
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-3<W+#$X.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P
M861D:6YG+6QE9G0Z(#`N,3)I;B<^#0HR,#$U/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C$L,C0P+#0R.#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M
M;&5F=#H@,"XQ,FEN)SX-"C(P,38\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M,2PQ,S4L-SDW/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I
M;F<M;&5F=#H@,"XQ,FEN)SX-"E1H97)E869T97(\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^#0HQ+#(T-RPR,3@\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U
M-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,"XQ,FEN)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T)SY.970-"FUI;FEM=6T@9G5T=7)E(')E;G1A
M;"!P87EM96YT<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
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M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"`P
M<'0@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XU
M:6XG/@T*/&(^)B-X03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I$
M=7)I;F<@,C`Q,2P@=&AE($-O;7!A;GD@97AT96YD960@:71S(&QE87-E(&]N
M('1H92!D:7-T<FEB=71I;VX-"F-E;G1E<B!I;B!(;W5S=&]N(&9O<B!T:')E
M92!Y96%R<R!T:')O=6=H(#(P,34L(&%N9"!A;'-O(&5X=&5N9&5D#0IT:&4@
M;&5A<V4@;VX@:71S(%!R:6YC971O;B!H96%D<75A<G1E<G,@<VEX('EE87)S
M('1H<F]U9V@@,C`Q."X-"D1U<FEN9R`R,#$P+"!T:&4@0V]M<&%N>2!E>'1E
M;F1E9"!T:&4@;&5A<V4@;VX@=&AE(&1I<W1R:6)U=&EO;@T*8V5N=&5R(&EN
M(%-T+B!,;W5I<R!F;W(@9F]U<B!Y96%R<R!T:')O=6=H(#(P,34L(&%N9"!A
M;'-O(&5X=&5N9&5D#0IT:&4@;&5A<V4@;VX@=&AE(%1O<F]N=&\@9F%C:6QI
M='D@9F]R(&9I=F4@>65A<G,@=&AR;W5G:"`R,#$W+CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G/@T*/&(^)B-X03`[
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\8CY#;VUV:71A($QI8V5N
M<VEN9RP@36%N=69A8W1U<FEN9R!A;F0@4V%L97,@06=R965M96YT/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"DEN($9E8G)U87)Y
M(#(P,#8L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!E>&-L=7-I=F4@
M9FEV92!Y96%R#0IL:6-E;G-I;F<L(&UA;G5F86-T=7)I;F<@86YD('-A;&5S
M(&%G<F5E;65N="`H=&AE("8C>#(P,4,[,C`P-@T*06=R965M96YT)B-X,C`Q
M1#LI('=I=&@@0V]M=FET82!.97<@6F5A;&%N9"!,:6UI=&5D#0HH)B-X,C`Q
M0SM#;VUV:71A)B-X,C`Q1#LI('=H97)E8GD@=&AE($-O;7!A;GD@;6%N=69A
M8W1U<F5D(&%N9"!S;VQD(&$-"FQI;F4@;V8@36%N=6MA($AO;F5Y(&)A<V5D
M('=O=6YD(&-A<F4@<')O9'5C=',@9&5V96QO<&5D(&)Y#0I#;VUV:71A+B!5
M;F1E<B!T:&4@,C`P-B!!9W)E96UE;G0L('1H92!#;VUP86YY(')E8V5I=F5D
M(&5X8VQU<VEV90T*<FEG:'1S('1O(&UA;G5F86-T=7)E(&%N9"!S96QL($UA
M;G5K82!(;VYE>2!B87-E9"!P<F]D=6-T<PT*=&AR;W5G:&]U="!.;W)T:"!A
M;F0@4V]U=&@@06UE<FEC82!W:71H:6X@=&AE('!R;V9E<W-I;VYA;`T*;65D
M:6-A;"US=7)G:6-A;"!M87)K971P;&%C92`H:2YE+B!E>'1E;F1E9"!C87)E
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M;@T*86-C;W)D86YC92!W:71H('1H92`R,#`V($%G<F5E;65N="P@=&AE($-O
M;7!A;GD@<'5R8VAA<V5S(&ET<PT*<F5Q=6ER96UE;G1S(&9O<B!M961I8V%L
M(&=R861E(&AO;F5Y(&5X8VQU<VEV96QY(&9R;VT@0V]M=FET82X@07,-"F-O
M;G-I9&5R871I;VX@9F]R('1H92!L:6-E;G-E+"!T:&4@0V]M<&%N>2!P86ED
M($-O;79I=&$@82!R;WEA;'1Y#0IB87-E9"!O;B!S86QE<RX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-
M"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T)SX-"CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0I/;B!&96)R=6%R>2`R,RP@,C`Q,"P@=&AE($-O;7!A;GD@
M<F5P;&%C960@=&AE(#(P,#8@06=R965M96YT('=I=&@-"F$@;F5W(&%G<F5E
M;65N="!W:71H($-O;79I=&$@*'1H92`F(W@R,#%#.S(P,3`@06=R965M96YT
M)B-X,C`Q1#LI#0IU;F1E<B!W:&EC:"!T:&4@0V]M<&%N>2!R96-E:79E9"!P
M97)P971U86P@86YD(&5X8VQU<VEV92!W;W)L9'=I9&4-"FQI8V5N<VEN9R!R
M:6=H=',@9F]R($UA;G5K82!(;VYE>2!B87-E9"`H365D:6AO;F5Y)B-X044[
M*2!W;W5N9"!A;F0-"G-K:6X@8V%R92!P<F]D=6-T<R!F;W(@86QL(&UA<FME
M=',@;W5T<VED92!O9B!T:&4@8V]N<W5M97(@;6%R:V5T+@T*5&AE(#(P,3`@
M06=R965M96YT(&%L<V\@<')O=FED97,@=&AA="!#;VUV:71A('=I;&P@<V5R
M=F4@87,@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&5X8VQU<VEV92!S=7!P;&EE
M<B!F;W(@36%N=6MA($AO;F5Y(&%N9"!W:6QL(&YO=`T*<')O=FED92!-86YU
M:V$@2&]N97D@=&\@86YY(&]T:&5R(&5N=&ET:65S(&9O<B!U<V4@:6X@=&AE
M#0IP<F]F97-S:6]N86P@;65D:6-A;"US=7)G:6-A;"!M87)K971P;&%C92X@
M5&AE(#(P,3`@06=R965M96YT(&-A;&QS#0IF;W(@9W)A9'5A=&5D(')O>6%L
M='D@<&%Y;65N=',@8F%S960@;VX@<V%L97,@86YD(&UI;&5S=&]N90T*<&%Y
M;65N=',@;V8@=7`@=&\@)#(P+#`P,"PP,#`@8F%S960@;VX@86-H:65V96UE
M;G0@;V8@<W!E8VEF:65D(&YE=`T*<V%L97,@;V)J96-T:79E<RX@5&AE(&QI
M8V5N<V4@<FEG:'1S(&UA>2!B92!T97)M:6YA=&5D(&]R(')E;F1E<F5D#0IN
M;VXM97AC;'5S:79E(&)Y($-O;79I=&$@:68@=&AE($-O;7!A;GD@9F%I;',@
M=&\@;65E="!C97)T86EN#0IM:6YI;75M(')O>6%L='D@<F5Q=6ER96UE;G1S
M+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*26X@8V]N<VED97)A=&EO;B!F;W(@=&AE(#(P,3`@06=R
M965M96YT+"!T:&4@0V]M<&%N>2!P86ED($-O;79I=&$-"B0R+#(U,"PP,#`@
M86YD(&ES<W5E9"!#;VUV:71A(#0P,"PP,#`@<VAA<F5S(&]F(&ET<R!C;VUM
M;VX@<W1O8VL-"F%N9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q,S,L,S,S('-H
M87)E<R!O9B!I=',@8V]M;6]N('-T;V-K(&%T#0HD-2XU,"!P97(@<VAA<F4L
M('1H92!S=&]C:R!A;F0@=V%R<F%N=',@=&]G971H97(@=F%L=65D(&%T#0HD
M,BPP,#`L,#`P+"!A;F0@=V%R<F%N=',@=&\@<'5R8VAA<V4@,3`P+#`P,"!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K#0IA="`D-BXR-2!P97(@<VAA<F4L('=H
M:6-H('=A<R!V86QU960@870@)#0Q-RPQ,C8@=7-I;F<@=&AE#0I";&%C:R8C
M>#(P,3,[4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X@5&]T86P@8V]N
M<VED97)A=&EO;B!P86ED#0IT;R!#;VUV:71A('=A<R`D-"PV-C<L,3(V+B!$
M=7)I;F<@,C`Q,2P@=&AE($-O;7!A;GD@;6%D92!A#0IM:6QE<W1O;F4@<&%Y
M;65N="!O9B`D,2PP,#`L,#`P(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@86=R
M965M96YT+@T*5&AE(&-O<W0@;V8@=&AE(&9O<F5G;VEN9R!L:6-E;G-I;F<@
M<FEG:'1S(&%N9"!M:6QE<W1O;F4@<&%Y;65N=`T*:&%S(&)E96X@<F5C;W)D
M960@87,@86X@:6YT86YG:6)L92!A<W-E="!A;F0@:7,@8F5I;F<@86UO<G1I
M>F5D('1O#0IC;W-T(&]F('-A;&5S(&]V97(@86X@97-T:6UA=&5D('5S969U
M;"!L:69E(&]F(#$P('EE87)S("A3964@3F]T90T*-RDN/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I#
M;VUV:71A(&ES(&$@;6%J;W(@<VAA<F5H;VQD97(@;V8@=&AE($-O;7!A;GD@
M86YD(&ET<R!#:&EE9@T*17AE8W5T:79E($]F9FEC97(@<V5R=F5S(&]N('1H
M92!#;VUP86YY)B-X,C`Q.3MS($)O87)D(&]F($1I<F5C=&]R<RX-"DEN(#(P
M,3$@86YD(#(P,3`L('1H92!#;VUP86YY('!U<F-H87-E9"`D,2PP,3@L-#$P
M(&%N9"`D-CDT+#@W-R!O9@T*;65D:6-A;"!G<F%D92!H;VYE>2!F<F]M($-O
M;79I=&$L(')E<W!E8W1I=F5L>2X@26X@861D:71I;VXL(&EN#0HR,#$Q(&%N
M9"`R,#$P('1H92!#;VUP86YY('!A:60@0V]M=FET82!R;WEA;'1I97,@;V8@
M)#8Q,BPX,#0@86YD#0HD-#$P+#DV,2P@<F5S<&5C=&EV96QY+CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/@T*/&(^475I8VLM365D(%1E8VAN;VQO9VEE<RP@26YC+B`F(W@R,#$S.R!,
M:6-E;G-E($%G<F5E;65N=#PO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0I);B!-87)C:"`R,#`W+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!P871E;G0@86YD('1E8VAN;VQO9WD-"FQI8V5N<V4@86=R965M
M96YT("AT:&4@)B-X,C`Q0SM!9W)E96UE;G0F(W@R,#%$.RD@=VET:"!1=6EC
M:RU-960-"E1E8VAN;VQO9VEE<RP@26YC+B`H)B-X,C`Q0SM1350F(W@R,#%$
M.RD@<F5L871I;F<@=&\@44U4)B-X,C`Q.3MS#0IP<F]P<FEE=&%R>2!A;G1I
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M9VAT(&%N9"!L:6-E;G-E('1O(&UA:V4L('5S92!A;F0@<V5L;`T*<')O9'5C
M=',@:6YC;W)P;W)A=&EN9R!T:&4@5&5C:&YO;&]G>2!I;B!T:&4@56YI=&5D
M(%-T871E<R!A;F0-"D-A;F%D82`H=VET:"!T:&4@97AC97!T:6]N(&]F('-A
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M;V8@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&5X8VQU<VEV92!R:6=H=',@=&\@
M=&AE(%1E8VAN;VQO9WD@;W(@=&5R;6EN871I;VX-"F]F('1H92!!9W)E96UE
M;G0N(%%-5"!R96-E:79E9"!C;&5A<F%N8V4@9G)O;2!T:&4@56YI=&5D(%-T
M871E<PT*1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H)B-X,C`Q0SM&
M1$$F(W@R,#%$.RD@9F]R('5S92!O9B!I=',-"E1E8VAN;VQO9WD@:6X@1F5B
M<G5A<GD@,C`P.2X@5&AE($-O;7!A;GD@;&%U;F-H960@:71S(&9I<G-T#0IP
M<F]D=6-T<R!U=&EL:7II;F<@=&AE(%1E8VAN;VQO9WD@:6X@2G5N92`R,#`Y
M+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/@T*26X@1F5B<G5A<GD@,C`Q,"P@=&AE('!A<G1I97,@86UE
M;F1E9"!T:&4@06=R965M96YT('1O(&-L87)I9GD@=&AE#0IT97)M+"!T:&4@
M9FEE;&0@;V8@<')O9'5C=',@:6YC;'5D960@86YD('1H92!A;FYU86P@;6EN
M:6UU;2!R;WEA;'1Y#0IP87EM96YT(&%M;W5N=',N(%1H92!E9F9E8W1I=F4@
M9&%T92!O9B!T:&4@86UE;F1E9"!!9W)E96UE;G0@=V%S#0I*=6YE(#(R+"`R
M,#`Y+"!A;F0@=&AE('1E<FT@;V8@=&AE($%G<F5E;65N="!I<R!F;W(@82!P
M97)I;V0@;V8-"F9I=F4@>65A<G,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I$=64@=&\@9&5L87ES
M(&]N('1H92!P87)T(&]F('1H92!#;VUP86YY(&EN(&EM<&QE;65N=&EN9R!P
M;&%N<R!F;W(-"G-A;&4@;V8@=&AE<V4@<')O9'5C=',L(&ET(&AA<R!N;W0@
M;65T(&ET<R!M:6YI;75M(')O>6%L='D-"F-O;6UI=&UE;G0N($UA;F%G96UE
M;G0@8V]N=&EN=65S('1O('=O<FL@8VQO<V5L>2!W:71H(%%-5"!O;B!T:&ES
M#0II<W-U92X@5&AE($-O;7!A;GD@:&%S(&)E96X@861V:7-E9"!B>2!1350@
M=&AA="!I="!I<R!N;W0@=&AE:7(-"FEN=&5N=&EO;B!T;R!I;G9O:V4@96ET
M:&5R(&]F('1H96ER(&5X8VQU<VEV92!R96UE9&EE<R!F;W(@9F%I;'5R90T*
M=&\@;65E="!I=',@;6EN:6UU;2!R;WEA;'1Y(&-O;6UI=&UE;G1S+B!386QE
M<R!O9B!P<F]D=6-T<PT*=71I;&EZ:6YG('1H92!T96-H;F]L;V=Y('=E<F4@
M)#$L.#0R+#4T,"!A;F0@)#$L,S$U+#@V-RP@9F]R(#(P,3$-"F%N9"`R,#$P
M+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P+C5I;B<^#0H\8CY54T,@3&EC96YS92!!9W)E96UE;G0\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*3VX@3F]V96UB97(@,BP@
M,C`P-RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;&EC96YS92!A9W)E
M96UE;G0-"BAT:&4@)B-X,C`Q0SM,:6-E;G-E($%G<F5E;65N="8C>#(P,40[
M*2!W:71H('1H92!5;FEV97)S:71Y(&]F#0I3;W5T:&5R;B!#86QI9F]R;FEA
M("@F(W@R,#%#.U530R8C>#(P,40[*2!P=7)S=6%N="!T;R!W:&EC:"!T:&4-
M"D-O;7!A;GD@86-Q=6ER960@97AC;'5S:79E(')I9VAT<R!T;R!A(&YU;6)E
M<B!O9B!5;FET960@4W1A=&5S(&%N9`T*9F]R96EG;B!P871E;G1S(&%N9"!N
M;VXM97AC;'5S:79E(')I9VAT<R!T;R!O;F4@<&%T96YT+"!T;V=E=&AE<@T*
M=VET:"!T<F%D92!S96-R971S(&%N9"!K;F]W+6AO=RP@<F5L871E9"!T;R!A
M;B!A;F=I;W1E;G-I;B!A;F%L;V<-"BAT:&4@<&%T96YT<RP@=')A9&4@<V5C
M<F5T<R!A;F0@:VYO=RUH;W<L(&-O;&QE8W1I=F5L>2P@=&AE#0HF(W@R,#%#
M.T%N9VEO=&5N<VEN($%N86QO9R!496-H;F]L;V=Y)B-X,C`Q1#L@;W(-"B8C
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M4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/@T*5&AE($-O;7!A;GD@<&%I9"!T;R!O<B!O;B!B96AA;&8@;V8@55-#(&%N
M(&EN:71I86P@;&EC96YS92!F964@;V8-"B0X,SDL,S0X('=H:6-H('=A<R!C
M:&%R9V5D('1O(&5X<&5N<V4@=VAE;B!I;F-U<G)E9"X@061D:71I;VYA;&QY
M+`T*=&AE($-O;7!A;GD@=VEL;"!P87D@55-#(')O>6%L=&EE<R!R96QA=&EV
M92!T;R!S86QE<R!O9B!P<F]D=6-T<PT*96UP;&]Y:6YG('1H92!496-H;F]L
M;V=Y("AT:&4@)B-X,C`Q0SM!;F=I;W1E;G-I;B!0<F]D=6-T<R8C>#(P,40[
M*0T*870@<W!E8VEF:65D(')A=&5S(&EN(')E<W!E8W0@;V8@<F5V96YU97,@
M;&5S<R!T:&%N("0Q,#`@;6EL;&EO;@T*86YD(')E=F5N=65S(&5Q=6%L('1O
M(&]R(&=R96%T97(@=&AA;B`D,3`P(&UI;&QI;VXL(')E<W!E8W1I=F5L>2X-
M"DEN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!M86ME
M(&UI;&5S=&]N92!P87EM96YT<R!T;PT*55-#(&]F('5P('1O("0Y+#8R-2PP
M,#`@<')E9&EC871E9"!U<&]N(&]B=&%I;FEN9R!A<'!R;W9A;"!O9B!T:&4-
M"D9$02!O9B!V87)I;W5S(&EN9&EC871I;VYS(&9O<B!T:&4@06YG:6]T96YS
M:6X@4')O9'5C=',L(&%S('=E;&P@87,-"G1H92!A='1A:6YM96YT(&]F('9A
M<FEO=7,@<V%L97,@;V)J96-T:79E<RX@1G5R=&AE<BP@=&AE($-O;7!A;GD@
M:7,-"F]B;&EG871E9"!T;R!S<&5N9"!A="!L96%S="`D,2PR-3`L,#`P(&]N
M(&1I<F5C="!M87)K971I;F<@;V8@=&AE#0II;FET:6%L($%N9VEO=&5N<VEN
M(%!R;V1U8W0@=VET:&EN('1W96QV92!M;VYT:',@;V8@=&AE($9$028C>#(P
M,3D[<PT*87!P<F]V86P@=&AE<F5O9BX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!C;VUP;W5N
M9"!E;7!L;WEI;F<@=&AE(%1E8VAN;VQO9WD@:7,@8VQA<W-I9FEE9"!A<R!A
M#0HF(W@R,#%#.V1R=6<L)B-X,C`Q1#L@=&AE('-A;&4@;V8@=VAI8V@@:7,@
M8V]N9&ET:6]N960@=7!O;B!&1$$-"F%P<')O=F%L+B!4:&4@<')O8V5S<R!O
M9B!O8G1A:6YI;F<@1D1!(&%P<')O=F%L(&9O<B!T:&4@8V]M<&]U;F0-"F-O
M;G-I<W1S(&]F('-U8FIE8W1I;F<@=&AE(&-O;7!O=6YD('1O(&$@<V5R:65S
M(&]F('!R92UC;&EN:6-A;"!A;F0-"F-L:6YI8V%L('-T=61I97,L('1H97-E
M(&QA='1E<B!K;F]W;B!A<R!0:&%S92`Q+"!0:&%S92`R(&%N9"!0:&%S90T*
M,R!S='5D:65S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE(&-O;7!O=6YD(&AA<R!S=6-C97-S
M9G5L;'D@=6YD97)G;VYE('!R92UC;&EN:6-A;"P@4&AA<V4@,2!A;F0-"E!H
M87-E(#(@8VQI;FEC86P@<W1U9&EE<RX@5&AE($-O;7!A;GD@:7,@=V]R:VEN
M9R!O;B!A(&YU;6)E<B!O9@T*:6YI=&EA=&EV97,@:6YT97)N86QL>2!A;F0@
M=VET:"!T:&4@1D1!('1O('!R97!A<F4@9F]R(&ET<R!0:&%S92`S#0IC;&EN
M:6-A;"!T<FEA;"!I;B!T:&4@<V5C;VYD(&AA;&8@;V8@,C`Q,BX\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX-"E1H92!#;VUP86YY(&ES('5N9&5R(&YO(&]B;&EG871I;VX@=&\@=6YD
M97)T86ME(&]R(&-O;7!L971E(&9U<G1H97(-"G-T=61I97,@:6X@<F5S<&5C
M="!O9B!T:&4@5&5C:&YO;&]G>2X@4VAO=6QD(&ET(&YO="!D;R!S;RP@=&AE
M#0I#;VUP86YY(&UA>2!E:71H97(@<W5B;&EC96YS92!T:&4@5&5C:&YO;&]G
M>2!T;R!O;F4@;W(@;6]R92!T:&ER9`T*<&%R=&EE<R!O<B!R96QE87-E('1H
M92!496-H;F]L;V=Y('1O(%530RX@26X@=&AI<R!L871T97(@979E;G0L(%53
M0PT*=V]U;&0@<F5I;6)U<G-E('1H92!#;VUP86YY(&9O<B!C97)T86EN(&]F
M(&ET<R!C;W-T<R!I;F-I9&5N="!T;PT*8VQI;FEC86P@<W1U9&EE<R!T:&%T
M(&AA=F4@:&5R971O9F]R92!B965N('!E<F9O<FUE9"X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P(#!P="`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z("TP+C5I;B<^#0H\8CXF(WA!,#L\+V(^/"]P/@T*/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q
M,#`E('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;BUT;W`Z(#!P=#L@;6%R9VEN+6)O='1O;3H@,'!T
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"CQT9"!S
M='EL93TS1"=W:61T:#H@,#L@<&%D9&EN9SH@,#L@=&5X="UI;F1E;G0Z(#`G
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R!P861D:6YG.B`P
M.R!T97AT+6EN9&5N=#H@,"<^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG.B`P.R!T97AT+6EN9&5N=#H@,"<^#0H\8CY#
M86YA9&EA;B!$:7-T<FEB=71I;VX@06=R965M96YT/"]B/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`@,'!T(#`N-6EN
M.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3`N-6EN)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0I);B!-87D@,C`P-2P@=&AE
M($-O;7!A;GD@96YT97)E9"!I;G1O(&$@9&ES=')I8G5T:6]N(&%G<F5E;65N
M="!W:71H#0IA($-A;F%D:6%N(&-O;7!A;GD@=&\@<V5R=F4@87,@=&AE(&5X
M8VQU<VEV92!D:7-T<FEB=71O<B!O9B!I=',-"G!R;V1U8W1S(&EN($-A;F%D
M82X@5&AE(&%G<F5E;65N="!A;'-O(&%P<&]I;G1S('1H92!D:7-T<FEB=71O
M<B!A<PT*=&AE($-O;7!A;GDF(W@R,#$Y.W,@<V5R=FEC:6YG(&%G96YT('1O
M(&9U;&9I;&P@<W5P<&QY(&-O;G1R86-T<PT*:&5L9"!D:7)E8W1L>2!B>2!T
M:&4@0V]M<&%N>2X@5&AE(&%G<F5E;65N="!W87,@;6]S="!R96-E;G1L>0T*
M86UE;F1E9"!I;B!*86YU87)Y(#(P,3$L(&5X=&5N9&EN9R!I="!T:')O=6=H
M($%P<FEL(#(P,38N(%1H90T*0V]M<&%N>2!R96-O9VYI>F5S(')E=F5N=64@
M=6YD97(@=&AE(&%G<F5E;65N="!W:&5N('1I=&QE(&%N9"!R:7-K#0IO9B!L
M;W-S('!A<W,@=&\@=&AE(&1I<W1R:6)U=&]R(&%N9"!C;VQL96-T86)I;&ET
M>2!I<R!R96%S;VYA8FQY#0IA<W-U<F5D+"!W:&EC:"!I<R!A="!T:&4@=&EM
M92!P<F]D=6-T(&ES('-H:7!P960@=&\@=&AE#0ID:7-T<FEB=71O<BX@4&%Y
M;65N="!T97)M<R!F<F]M('1H92!D:7-T<FEB=71O<B!A<F4@,S`@9&%Y<RX@
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M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F="<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*5&AE(&1I<W1R:6)U
M=&]R(&%S<W5M97,@<F5S<&]N<VEB:6QI='D@9F]R(&-U<W1O;65R('-E<G9I
M8V4L#0IP<F]D=6-T(&1E;&EV97)Y(&%N9"!M86EN=&5N86YC92!A;F0@=V%R
M96AO=7-I;F<@;V8@<W5F9FEC:65N=`T*:6YV96YT;W)Y('1O(&UE970@86=R
M965D('5P;VX@;W)D97(@9G5L9FEL;&UE;G0@<F5Q=6ER96UE;G1S+B!/;B!A
M;@T*;VYG;VEN9R!B87-I<RP@=&AE(&1I<W1R:6)U=&]R('!L86-E<R!I;G9E
M;G1O<GD@<F5P;&5N:7-H;65N=`T*;W)D97)S('=I=&@@=&AE($-O;7!A;GD@
M870@86=R965D('5P;VX@<')I8V5S+"`Q,C`@9&%Y<R!I;B!A9'9A;F-E#0IO
M9B!S8VAE9'5L960@9&5L:79E<GDN(%5N;&5S<R!A;65N9&5D+"!E86-H(&]R
M9&5R(&)E8V]M97,-"FYO;BUC86YC96QA8FQE(#DP(&1A>7,@:6X@861V86YC
M92!O9B!S8VAE9'5L960@9&5L:79E<GDN/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;B<^#0H\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA
M;&EG;CH@;&5F="<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*
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M;VUP86YY)B-X,C`Q.3MS(&-O;G1R86-T('!R:6-E('=I=&@@=&AE(&5N9`T*
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M;CH@,'!T(#`[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I
M;B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6XG/@T*/&(^17AE8W5T
M:79E($5M<&QO>6UE;G0@06=R965M96YT<SPO8CX\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX-"E1H92!F
M:79E(&5X96-U=&EV92!O9F9I8V5R<R!O9B!T:&4@0V]M<&%N>2!A<F4@87!P
M;VEN=&5D(&)Y(&%N9`T*<V5R=F4@870@=&AE(&1I<V-R971I;VX@;V8@=&AE
M($)O87)D(&]F($1I<F5C=&]R<R!P=7)S=6%N="!T;R!O;F4-"GEE87(@96UP
M;&]Y;65N="!A9W)E96UE;G1S('1H870@87)E(')E;F5W960@86YN=6%L;'D@
M87,@;V8@07!R:6P-"C$\<W5P/G-T/"]S=7`^+B!4:&4@86=R965M96YT<R!W
M97)E(')E;F5W960@:6X@36%R8V@@,C`Q,BX@5&AE#0IA9W)E96UE;G1S('!R
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M;65N="!O=&AE<B!T:&%N(&9O<B!C875S92X\+W`^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q
M-&-?-#(U-U\X964Q7V5A,C$P830Y,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C
M,#`O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=#QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM
M0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#!P>"<^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,"XU:6XG/CQB/C$V+CPO8CX\+W1D/@T*/'1D
M/CQB/E-U8G-E<75E;G0@179E;G0\+V(^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0I/;B!-87)C:"`R-RP@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O(&$@9&5F:6YI=&EV92!A9W)E96UE;G0-"G1O(&%C<75I<F4@=&AE
M('-T;V-K(&]F($UE9&5F9FEC:65N8WDL($EN8RX-"B@F(W@R,#%#.TUE9&5F
M9FEC:65N8WDF(W@R,#%$.RD@9F]R("0Q-"PU,#`L,#`P(&EN(&-A<V@N#0I-
M961E9F9I8VEE;F-Y(&ES(&$@<')I=F%T96QY(&AE;&0@8V]M<&%N>2!T:&%T
M('-E;&QS(&$@<')O<')I971A<GD-"FQI;F4@;V8@=&]T86P@8V]N=&%C="!C
M87-T('!R;V1U8W1S(&9O<B!T:&4@=')E871M96YT(&]F(&1I86)E=&EC#0IF
M;V]T('5L8V5R<RX@4VEN8V4@,C`P."P@=&AE($-O;7!A;GD@:&%S(&)E96X@
M82!D:7-T<FEB=71O<B!O9@T*365D969F:6-I96YC>28C>#(P,3D[<R!P<F]D
M=6-T<RX@26X@,C`Q,2P@=&AE($-O;7!A;GD@<F5P<F5S96YT960-"F%P<')O
M>&EM871E;'D@,C4E(&]F($UE9&5F9FEC:65N8WDF(W@R,#$Y.W,@86YN=6%L
M(')E=F5N=65S(&]F#0HD-2PS,#`L,#`P+B!4:&4@86-Q=6ES:71I;VX@:7,@
M<W5B:F5C="!T;R!C=7-T;VUA<GD@8VQO<VEN9PT*8V]N9&ET:6]N<R!A;F0@
M:7,@86YT:6-I<&%T960@=&\@8F4@8V]M<&QE=&5D(&)Y($%P<FEL(#,P+`T*
M,C`Q,BX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S$U8V(X-S1A7S$Q-&-?-#(U-U\X964Q7V5A,C$P830Y
M,V,P,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-6-B.#<T85\Q
M,31C7S0R-3=?.&5E,5]E83(Q,&$T.3-C,#`O5V]R:W-H965T<R]F:6QE;&ES
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M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"CPO>&UL/@T*
M+2TM+2TM/5].97AT4&%R=%\Q-6-B.#<T85\Q,31C7S0R-3=?.&5E,5]E83(Q
,,&$T.3-C,#`M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
</td>
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>1.</b></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>Description of Business</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Derma Sciences, Inc. and its subsidiaries (the
&#x201C;Company&#x201D;) is a medical technology company focused on
three segments of the wound care marketplace: pharmaceutical wound
care, advanced wound care and traditional wound care products. The
Company has one drug candidate that has completed a Phase 2 study
and is working towards initiating a Phase 3 study. The Company
markets its products principally through direct sales
representatives in the United States (&#x201C;U.S.&#x201D;), Canada
and the United Kingdom (&#x201C;U.K.&#x201D;), and through
independent distributors within other select international markets.
The Company&#x2019;s U.S. distribution facilities are located in St.
Louis, Missouri and Houston, Texas. The Company utilizes third
party distributors for distribution in Canada, Europe and the Far
East. The Company also has manufacturing facilities in Toronto,
Canada and Nantong, China.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 17,110,350<span></span></td>
        <td class="nump">$ 404,216<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
        <td class="nump">5,225,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
        <td class="nump">6,267,839<span></span></td>
        <td class="nump">5,441,511<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">10,530,721<span></span></td>
        <td class="nump">12,498,519<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">2,099,197<span></span></td>
        <td class="nump">609,164<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">41,233,107<span></span></td>
        <td class="nump">18,953,410<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
        <td class="nump">249,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and improvements, net</a></td>
        <td class="nump">3,489,194<span></span></td>
        <td class="nump">3,608,242<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, net</a></td>
        <td class="nump">6,403,044<span></span></td>
        <td class="nump">6,971,626<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">7,119,726<span></span></td>
        <td class="nump">7,119,726<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">129,821<span></span></td>
        <td class="nump">316,859<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">58,623,892<span></span></td>
        <td class="nump">36,969,863<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit borrowings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,075,555<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,851<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">3,999,993<span></span></td>
        <td class="nump">3,777,454<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">2,377,634<span></span></td>
        <td class="nump">2,150,621<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">6,377,627<span></span></td>
        <td class="nump">9,009,481<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump">252,684<span></span></td>
        <td class="nump">211,581<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
        <td class="nump">1,146,047<span></span></td>
        <td class="nump">1,068,088<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">7,776,358<span></span></td>
        <td class="nump">10,289,150<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 15)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $.01 par value; 1,468,750 shares authorized; issued and outstanding 73,332 at December 31, 2011 and 284,844 at December 31, 2010 (liquidation preference of $3,222,368 at December 31, 2011)</a></td>
        <td class="nump">733<span></span></td>
        <td class="nump">2,848<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 18,750,000 shares authorized; issued and outstanding 10,577,632 at December 31, 2011 and 6,563,076 at December 31, 2010</a></td>
        <td class="nump">105,776<span></span></td>
        <td class="nump">65,631<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">77,374,821<span></span></td>
        <td class="nump">48,803,210<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive income - cumulative translation adjustments</a></td>
        <td class="nump">1,502,531<span></span></td>
        <td class="nump">1,604,940<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(28,136,327)<span></span></td>
        <td class="num">(23,795,916)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
        <td class="nump">50,847,534<span></span></td>
        <td class="nump">26,680,713<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
        <td class="nump">$ 58,623,892<span></span></td>
        <td class="nump">$ 36,969,863<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_AccruedExpensesAndOtherCurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also included are current obligations not separately disclosed in the balance sheet due to materiality considerations. Accrued expenses and other current liabilities are expected to be paid within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_AccruedExpensesAndOtherCurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 17, 18, 19, 22, 23, 24, 25, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 133<br><br><br><br> -Paragraph 45<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 52<br><br><br><br> -Paragraph 31<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 52<br><br><br><br> -Paragraph 12, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 109<br><br><br><br> -Paragraph 41, 42<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 42, 45<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Line-of-Credit Arrangement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6517033<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LinesOfCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
        <td class="nump">$ 2,717,872<span></span></td>
        <td class="nump">$ 1,114,548<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_StockIssuedIssuanceCosts', window );">Exercise of warrants, costs</a></td>
        <td class="nump">$ 68,204<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_StockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued, Issuance Costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_StockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
        <td class="text"><div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.5in; text-align: left"><b>15.</b></td>
<td><b>Commitments</b></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
<b>&#xA0;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Operating Leases</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company has non-cancelable operating lease agreements for its
facilities and equipment expiring in various years through 2018.
Total lease expense under these lease agreements was $1,561,174 and
$1,541,356 in 2011 and 2010, respectively. Total minimum lease
payments under each lease are recorded on a straight-line basis to
lease expense over the lease term. Differences between the
recognition of lease expense on a straight-line basis and payments
owed and/or free rent are recorded as deferred rent. Tenant
improvement allowances are recorded as deferred lease expense as
received, and amortized to lease expense over the lesser of the
corresponding asset life or the lease term. At December 31, 2011,
the Company had deferred rent of $252,684 recorded on the
Consolidated Balance Sheet.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The leases generally provide for scheduled increases in future
minimum annual lease payments over the life of the lease. The
leases provide for renewal options consistent with the terms of the
existing lease. It is expected that these leases will be renewed or
replaced by leases on other property and equipment, as needed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
Minimum future lease payments under existing operating leases as of
December 31, 2011 are:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" align="center" style="width: 60%">
<tr style="vertical-align: bottom">
<td colspan="5" style="font-size: 10pt; text-decoration: none; text-align: center; border-bottom: Black 1pt solid">
Minimum Future Rental Payments</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-decoration: underline; text-align: justify; padding-bottom: 1pt">
Year Ending December 31,</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">
<u style="text-decoration: none">Amount</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-decoration: none; text-align: justify">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 76%; font-size: 10pt; text-align: justify; padding-left: 0.12in">
2012</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 20%; font-size: 10pt; text-align: right">
1,510,131</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
2013</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,585,962</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
2014</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,577,188</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
2015</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,240,428</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
2016</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,135,797</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">
Thereafter</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
1,247,218</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net
minimum future rental payments</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
8,296,725</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">
<b>&#xA0;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
During 2011, the Company extended its lease on the distribution
center in Houston for three years through 2015, and also extended
the lease on its Princeton headquarters six years through 2018.
During 2010, the Company extended the lease on the distribution
center in St. Louis for four years through 2015, and also extended
the lease on the Toronto facility for five years through 2017.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
<b>&#xA0;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Comvita Licensing, Manufacturing and Sales Agreement</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In February 2006, the Company entered into an exclusive five year
licensing, manufacturing and sales agreement (the &#x201C;2006
Agreement&#x201D;) with Comvita New Zealand Limited
(&#x201C;Comvita&#x201D;) whereby the Company manufactured and sold a
line of Manuka Honey based wound care products developed by
Comvita. Under the 2006 Agreement, the Company received exclusive
rights to manufacture and sell Manuka Honey based products
throughout North and South America within the professional
medical-surgical marketplace (i.e. extended care, acute care, home
care, etc.) and non-exclusive rights within the consumer
marketplace. Comvita retained the right to these products in the
consumer marketplace and maintained the option to purchase its
Manuka Honey consumer product requirements from the Company. In
accordance with the 2006 Agreement, the Company purchases its
requirements for medical grade honey exclusively from Comvita. As
consideration for the license, the Company paid Comvita a royalty
based on sales.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
On February 23, 2010, the Company replaced the 2006 Agreement with
a new agreement with Comvita (the &#x201C;2010 Agreement&#x201D;)
under which the Company received perpetual and exclusive worldwide
licensing rights for Manuka Honey based (Medihoney&#xAE;) wound and
skin care products for all markets outside of the consumer market.
The 2010 Agreement also provides that Comvita will serve as the
Company&#x2019;s exclusive supplier for Manuka Honey and will not
provide Manuka Honey to any other entities for use in the
professional medical-surgical marketplace. The 2010 Agreement calls
for graduated royalty payments based on sales and milestone
payments of up to $20,000,000 based on achievement of specified net
sales objectives. The license rights may be terminated or rendered
non-exclusive by Comvita if the Company fails to meet certain
minimum royalty requirements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In consideration for the 2010 Agreement, the Company paid Comvita
$2,250,000 and issued Comvita 400,000 shares of its common stock
and warrants to purchase 133,333 shares of its common stock at
$5.50 per share, the stock and warrants together valued at
$2,000,000, and warrants to purchase 100,000 shares of common stock
at $6.25 per share, which was valued at $417,126 using the
Black&#x2013;Scholes option pricing model. Total consideration paid
to Comvita was $4,667,126. During 2011, the Company made a
milestone payment of $1,000,000 in accordance with the agreement.
The cost of the foregoing licensing rights and milestone payment
has been recorded as an intangible asset and is being amortized to
cost of sales over an estimated useful life of 10 years (See Note
7).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
Comvita is a major shareholder of the Company and its Chief
Executive Officer serves on the Company&#x2019;s Board of Directors.
In 2011 and 2010, the Company purchased $1,018,410 and $694,877 of
medical grade honey from Comvita, respectively. In addition, in
2011 and 2010 the Company paid Comvita royalties of $612,804 and
$410,961, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Quick-Med Technologies, Inc. &#x2013; License Agreement</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In March 2007, the Company entered into a patent and technology
license agreement (the &#x201C;Agreement&#x201D;) with Quick-Med
Technologies, Inc. (&#x201C;QMT&#x201D;) relating to QMT&#x2019;s
proprietary anti-microbial technology (the
&#x201C;Technology&#x201D;). The initial term of the Agreement
extended from March 2007 for the lesser of seven or five years from
the date of first product regulatory approval employing the
Technology. Under the Agreement, QMT granted to the Company an
exclusive, royalty-bearing right and license to make, use and sell
products incorporating the Technology in the United States and
Canada (with the exception of sales to the United States government
and agencies thereof in which case the license will be
non-exclusive). Royalties are based on net sales of products
utilizing the Technology at specified rates. In the event for a
given contract year the Company fails to make the required minimum
royalty payment, QMT&#x2019;s exclusive remedies (depending on the
magnitude of the failure) are either termination of the
Company&#x2019;s exclusive rights to the Technology or termination
of the Agreement. QMT received clearance from the United States
Food and Drug Administration (&#x201C;FDA&#x201D;) for use of its
Technology in February 2009. The Company launched its first
products utilizing the Technology in June 2009.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In February 2010, the parties amended the Agreement to clarify the
term, the field of products included and the annual minimum royalty
payment amounts. The effective date of the amended Agreement was
June 22, 2009, and the term of the Agreement is for a period of
five years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
Due to delays on the part of the Company in implementing plans for
sale of these products, it has not met its minimum royalty
commitment. Management continues to work closely with QMT on this
issue. The Company has been advised by QMT that it is not their
intention to invoke either of their exclusive remedies for failure
to meet its minimum royalty commitments. Sales of products
utilizing the technology were $1,842,540 and $1,315,867, for 2011
and 2010, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>USC License Agreement</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
On November 2, 2007, the Company entered into a license agreement
(the &#x201C;License Agreement&#x201D;) with the University of
Southern California (&#x201C;USC&#x201D;) pursuant to which the
Company acquired exclusive rights to a number of United States and
foreign patents and non-exclusive rights to one patent, together
with trade secrets and know-how, related to an angiotensin analog
(the patents, trade secrets and know-how, collectively, the
&#x201C;Angiotensin Analog Technology&#x201D; or
&#x201C;Technology&#x201D;). The Angiotensin Analog Technology
relates to a topical application for the treatment of chronic
wounds such as diabetic ulcers, leg ulcers associated with venous
insufficiency, pressure ulcers (bed sores), burns and surgical
scars.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company paid to or on behalf of USC an initial license fee of
$839,348 which was charged to expense when incurred. Additionally,
the Company will pay USC royalties relative to sales of products
employing the Technology (the &#x201C;Angiotensin Products&#x201D;)
at specified rates in respect of revenues less than $100 million
and revenues equal to or greater than $100 million, respectively.
In addition, the Company is required to make milestone payments to
USC of up to $9,625,000 predicated upon obtaining approval of the
FDA of various indications for the Angiotensin Products, as well as
the attainment of various sales objectives. Further, the Company is
obligated to spend at least $1,250,000 on direct marketing of the
initial Angiotensin Product within twelve months of the FDA&#x2019;s
approval thereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The compound employing the Technology is classified as a
&#x201C;drug,&#x201D; the sale of which is conditioned upon FDA
approval. The process of obtaining FDA approval for the compound
consists of subjecting the compound to a series of pre-clinical and
clinical studies, these latter known as Phase 1, Phase 2 and Phase
3 studies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The compound has successfully undergone pre-clinical, Phase 1 and
Phase 2 clinical studies. The Company is working on a number of
initiatives internally and with the FDA to prepare for its Phase 3
clinical trial in the second half of 2012.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company is under no obligation to undertake or complete further
studies in respect of the Technology. Should it not do so, the
Company may either sublicense the Technology to one or more third
parties or release the Technology to USC. In this latter event, USC
would reimburse the Company for certain of its costs incident to
clinical studies that have heretofore been performed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">
<b>&#xA0;</b></p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0; padding: 0; text-indent: 0"></td>
<td style="width: 0.5in; padding: 0; text-indent: 0"></td>
<td style="text-align: left; padding: 0; text-indent: 0">
<b>Canadian Distribution Agreement</b></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In May 2005, the Company entered into a distribution agreement with
a Canadian company to serve as the exclusive distributor of its
products in Canada. The agreement also appoints the distributor as
the Company&#x2019;s servicing agent to fulfill supply contracts
held directly by the Company. The agreement was most recently
amended in January 2011, extending it through April 2016. The
Company recognizes revenue under the agreement when title and risk
of loss pass to the distributor and collectability is reasonably
assured, which is at the time product is shipped to the
distributor. Payment terms from the distributor are 30 days. Either
party has the right to terminate the agreement when an event of
default (as defined) has occurred with respect to the other party.
The distributor is entitled to continue to sell or otherwise
dispose of all inventory owned by it from and after the date of
contract expiration or termination. If termination of the agreement
is not occasioned by breach by the distributor, the distributor
will be entitled on notice to the Company to return saleable
inventory (as defined) to the Company. Estimated returns are
reserved at the time of sale. Since the inception of the agreement,
sales returns have been minimal.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The distributor assumes responsibility for customer service,
product delivery and maintenance and warehousing of sufficient
inventory to meet agreed upon order fulfillment requirements. On an
ongoing basis, the distributor places inventory replenishment
orders with the Company at agreed upon prices, 120 days in advance
of scheduled delivery. Unless amended, each order becomes
non-cancelable 90 days in advance of scheduled delivery.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
With respect to sales made by the distributor, the Company pays the
distributor an agreed upon distribution fee. The Company reimburses
the distributor for the difference between the price paid by the
distributor and the Company&#x2019;s contract price with the end
customer, upon submission by the distributor of an agreed upon
rebate report. The distribution fee is recorded as a reduction of
revenue under this agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Executive Employment Agreements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The five executive officers of the Company are appointed by and
serve at the discretion of the Board of Directors pursuant to one
year employment agreements that are renewed annually as of April
1<sup>st</sup>. The agreements were renewed in March 2012. The
agreements provide for annual salary and provision for bonus and
equity based compensation assuming financial and personal
objectives are met. The agreements also outline certain obligations
that may be triggered by a change in control and severance for
failure to renew an agreement other than for cause.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E3KBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (4,340,411)<span></span></td>
        <td class="num">$ (2,448,864)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of equipment and improvements</a></td>
        <td class="nump">991,045<span></span></td>
        <td class="nump">895,264<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of identifiable intangible assets</a></td>
        <td class="nump">1,568,582<span></span></td>
        <td class="nump">1,689,750<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="nump">77,781<span></span></td>
        <td class="nump">110,458<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_LossOnEarlyDebtExtinguishment', window );">Non-cash portion of loss on debt extinguishment</a></td>
        <td class="nump">112,336<span></span></td>
        <td class="nump">114,072<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
        <td class="nump">20,774<span></span></td>
        <td class="nump">1,941<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Allowance for sales adjustments</a></td>
        <td class="num">(37,023)<span></span></td>
        <td class="nump">41,503<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory obsolescence</a></td>
        <td class="nump">1,089,608<span></span></td>
        <td class="nump">279,861<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
        <td class="nump">32,863<span></span></td>
        <td class="nump">6,658<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Deferred rent expense</a></td>
        <td class="nump">44,608<span></span></td>
        <td class="nump">108,752<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Compensation charge for employee stock options</a></td>
        <td class="nump">1,299,675<span></span></td>
        <td class="nump">617,737<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Compensation charge for restricted stock</a></td>
        <td class="nump">334,772<span></span></td>
        <td class="nump">68,267<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest charge for stock warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,970<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
        <td class="nump">83,108<span></span></td>
        <td class="nump">155,889<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(813,622)<span></span></td>
        <td class="num">(2,112,243)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
        <td class="num">(292,004)<span></span></td>
        <td class="num">(1,122,105)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(402,077)<span></span></td>
        <td class="num">(144,937)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(641)<span></span></td>
        <td class="nump">310,945<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">237,095<span></span></td>
        <td class="nump">368,548<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">243,073<span></span></td>
        <td class="nump">764,327<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
        <td class="nump">249,542<span></span></td>
        <td class="num">(291,207)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment and improvements</a></td>
        <td class="num">(978,949)<span></span></td>
        <td class="num">(634,939)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of license rights</a></td>
        <td class="num">(1,000,000)<span></span></td>
        <td class="num">(2,250,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
        <td class="num">(5,474,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(7,452,949)<span></span></td>
        <td class="num">(2,884,939)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities', window );">Change in restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,032,164<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Net change in borrowings under line of credit</a></td>
        <td class="num">(3,075,555)<span></span></td>
        <td class="nump">769,249<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Long-term debt repayments</a></td>
        <td class="num">(5,851)<span></span></td>
        <td class="num">(4,059,185)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of costs</a></td>
        <td class="nump">26,975,194<span></span></td>
        <td class="nump">4,490,730<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">23,893,788<span></span></td>
        <td class="nump">3,232,958<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
        <td class="nump">15,754<span></span></td>
        <td class="nump">103,880<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
        <td class="nump">16,706,134<span></span></td>
        <td class="nump">160,692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Beginning of year</a></td>
        <td class="nump">404,216<span></span></td>
        <td class="nump">243,524<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">End of year</a></td>
        <td class="nump">17,110,350<span></span></td>
        <td class="nump">404,216<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Purchase of license rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,667,126<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock and warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,417,126)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_SupplementalGrossCashPaidForAcquisition', window );">Cash paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,250,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings', window );">Issuance of warrants and stock options for payment of offering costs</a></td>
        <td class="nump">490,980<span></span></td>
        <td class="nump">121,634<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump">244,682<span></span></td>
        <td class="nump">472,031<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes</a></td>
        <td class="nump">$ 319,278<span></span></td>
        <td class="nump">$ 77,712<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_CashPaidDuringPeriodForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_CashPaidDuringPeriodForAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of warrants and stock options in connection with equity offerings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_IssuanceOfEquityWarrantsInConnectionWithEquityOfferings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_LossOnEarlyDebtExtinguishment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Noncash unamortized portion of deferred financing costs related to the debt represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_LossOnEarlyDebtExtinguishment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_SupplementalGrossCashPaidForAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental - Gross cash paid for acquisition</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_SupplementalGrossCashPaidForAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 8<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4542-108314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 4<br><br> -Section 7<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 6<br><br> -Paragraph 86<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWriteDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherOperatingActivitiesCashFlowStatement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Accounting Standards Codification<br><br> -Publisher FASB<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -Subparagraph c<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from cash and cash items that are not available for withdrawal or usage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedStockExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockOptionPlanExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">1,468,750<span></span></td>
        <td class="nump">1,468,750<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, issued</a></td>
        <td class="nump">73,332<span></span></td>
        <td class="nump">284,844<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
        <td class="nump">73,332<span></span></td>
        <td class="nump">284,844<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_PreferredStockLiquidationPreferenceValue', window );">Convertible preferred stock, liquidation preference</a></td>
        <td class="nump">$ 3,222,368<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">18,750,000<span></span></td>
        <td class="nump">18,750,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
        <td class="nump">10,577,632<span></span></td>
        <td class="nump">6,563,076<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
        <td class="nump">10,577,632<span></span></td>
        <td class="nump">6,563,076<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-term Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0px"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.5in"><b>10.</b></td>
<td><b>Long-term Debt</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
All borrowings under the term debt agreements were fully repaid in
2011. During 2011 payments of $5,851 were made under capital lease
obligations. In 2010 payments of $3,500,000 were made under a term
note (fully repaid in February 2010 resulting in a $114, 072 loss
on debt extinguishment), $500,000 were made on a promissory note
and $59,185 were made on capital lease obligations.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 26, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">DSCI<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">DERMA SCIENCES, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000892160<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,630,865<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 55,127,459<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
        <td class="text"><div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.5in; text-align: left"><b>11.</b></td>
<td><b>Shareholders&#x2019; Equity</b></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Preferred Stock</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
There are 18,598 shares of series A convertible preferred stock
outstanding at December 31, 2011. The series A preferred stock is
convertible into common stock on a one-for-one basis, bears no
dividend, has a liquidation preference of $32.00 per share, votes
as a class on matters affecting the series A preferred stock and
has voting rights identical to the common stock on all other
matters.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
There are 54,734 shares of series B convertible preferred stock
outstanding at December 31, 2011. The series B preferred stock is
convertible into common stock on a one-for-one basis, bears no
dividend, has a liquidation preference of $48.00 per share, votes
as a class on matters affecting the series B preferred stock and
has voting rights identical to the common stock on all other
matters.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Common Stock</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In June 2011, the Company received net cash proceeds of $26,357,075
(after $2,717,872 in commission and other cash basis offering
expenses) from the sale of 3,524,239 shares of common stock at
$8.25 per share, together with 1,762,118 five-year series R
warrants to purchase common stock at $9.90 per share. Additionally,
the placement agents received 70,484 five-year Series R warrants to
purchase common stock at $9.90 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
During 2011, the Company received $618,119 (net of $68,204 in
expenses) and issued 257,805 shares of common stock upon the
exercise of stock purchase warrants and options. In addition,
during 2011 the Company issued 211,512 shares of common stock upon
the conversion of series B, C and D preferred stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In February 2010, the Company received net proceeds of $4,474,452
(after $1,114,548 in commission and other cash basis offering
expenses) from the sale of 1,117,800 shares of common stock at
$5.00 per share, together with 372,600 five-year Series D warrants
to purchase common stock at $5.50 per share. In addition, the
placement agent received 29,160 five-year Series P warrants to
purchase common stock at $6.25 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In February 2010, the Company issued 400,000 shares of its common
stock together with 133,333 Series Q warrants to purchase its
common stock at an exercise price of $5.50 per share and 100,000
Series N warrants to purchase its common stock at an exercise price
of $6.25 per share in connection with the purchase of the
world-wide Medihoney license rights. See Note 15 for further
discussion of license rights.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
During 2010, the Company received $16,278 and issued 5,601 common
stock shares upon the exercise of stock options. In addition,
during 2010 the Company issued 207 shares of common stock upon the
conversion of series A and B preferred stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Stock Purchase Warrants</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
At December 31, 2011, the Company had warrants outstanding to
purchase 3,065,702 shares of the Company&#x2019;s common stock
consisting of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" align="center" style="width: 70%">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Series</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Number of Warrants</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Exercise Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify; border-bottom: Black 1pt solid">
Expiration Date</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 20%; font-size: 10pt; text-align: center">J</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 20%; font-size: 10pt; text-align: right">
267,858</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: center">$</td>
<td style="width: 20%; font-size: 10pt; text-align: center">
6.16</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 30%; font-size: 10pt; text-align: justify">May
31, 2013</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: center">K</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">389,064</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">9.60</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify">April 1, 2013</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: center">L</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">6,250</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">3.12</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify">March 31,
2014</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: center">N</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">100,000</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">6.25</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify">February 22,
2015</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: center">O</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">331,900</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">5.50</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify">February 22,
2015</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: center">P</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">4,695</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">6.25</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify">February 16,
2015</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: center">Q</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">133,333</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">5.50</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify">February 22,
2015</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">R</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
1,832,602</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">$</td>
<td style="font-size: 10pt; text-align: center">9.90</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">June
22, 2016</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">
Total</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
3,065,702</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In 2011, 224,063 series H, 94,351 series I, 10,000 series K, 40,700
series O and 24,465 series P warrants were exercised either on a
for cash or cashless basis. A total of 179,304 shares of common
stock were issued upon exercise of those warrants. Also in 2011,
107,852 series H warrants expired and 1,832,602 series R warrants
were issued in connection with the June 2011 stock sale.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0; padding: 0; text-indent: 0"></td>
<td style="width: 0.5in; padding: 0; text-indent: 0"></td>
<td style="text-align: left; padding: 0; text-indent: 0"><b>Stock
Options</b></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company has a stock option plan under which options to purchase
a maximum of 2,500,000 shares of common stock may be issued. The
plan permits the granting of both incentive stock options and
nonqualified stock options to employees and directors of the
Company and certain outside consultants and advisors to the
Company. The option exercise price may not be less than the fair
market value of the stock on the date of the grant of the option.
The duration of each option may not exceed 10 years from the date
of grant. As of December 31, 2011, options to purchase 1,477,308
shares of the Company&#x2019;s common stock were issued and
outstanding under the plan and 991,691 shares were available for
grant.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company has previously granted nonqualified stock options to
officers, directors, agents and employees outside of the stock
option plan (&#x201C;non-plan options&#x201D;). All non-plan options
were granted at the fair market value at the date of grant. As of
December 31, 2011, non-plan options to purchase 105,375 shares of
the Company&#x2019;s common stock were issued and outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
For the years ended December 31, 2011 and 2010, the fair value of
each option award was estimated at the date of grant using the
Black-Scholes option-pricing model. The weighted-average
assumptions for the years ended December 31, 2011 and 2010 were as
follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" align="center" style="width: 70%">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 72%; font-size: 10pt; text-align: justify">
Risk-free interest rate</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
1.72</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
2.53</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Volatility
factor</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">76</td>
<td style="font-size: 10pt; text-align: left">%</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">80</td>
<td style="font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">Dividend
yield</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">0</td>
<td style="font-size: 10pt; text-align: left">%</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">0</td>
<td style="font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Expected option
life (years)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">6.25</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">6.25</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The risk-free rate utilized represents the U.S. treasury yield
curve rate for the expected option life at the time of grant. The
volatility factor was calculated based on the Company&#x2019;s
historical stock price volatility equal to the expected life of the
option at the grant date. The dividend yield is 0% since the
Company does not anticipate paying dividends in the near future.
Based on the Company&#x2019;s historical experience of options that
were forfeited before becoming fully vested, the Company has
assumed an annualized forfeiture rate of 1.0% for all options. The
Company will record additional expense if the actual forfeiture
rate is lower than estimated, and will record a recovery of prior
expense if the actual forfeiture rate is higher than estimated.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
A summary of the Company&#x2019;s stock option activity and related
information for the years ended December 31, 2011 and 2010
follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Weighted Average <u style="text-decoration: none">Exercise
Price</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Weighted Average <u style="text-decoration: none">Exercise
Price</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 44%; font-size: 10pt; text-align: justify">
Outstanding &#x2013; beginning of year</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
1,203,600</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
5.07</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
1,066,328</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
5.08</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Granted</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">463,085</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">7.30</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">246,625</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">5.09</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Forfeited</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(5,501</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">4.41</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(79,999</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">4.99</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Expired</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(23,753</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">6.00</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">
Exercised</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(78,501</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">3.21</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(5,601</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">2.91</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Outstanding &#x2013; end of year</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,582,683</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5.82</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,203,600</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5.07</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Expected to vest &#x2013; end of year</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,566,856</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5.82</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,191,564</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5.07</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Exercisable at end of year</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,118,152</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5.43</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
990,374</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5.17</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
During 2011, service based options of 320,585 and performance based
options of 142,500 were granted to Company officers, directors,
employees, and consultants. The weighted average fair value per
share of options granted during the year ended December 31, 2011
was $5.31. The intrinsic value of options exercised in 2011 was
$408,195.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The following table summarizes information related to stock options
outstanding and exercisable at December 31, 2011:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="10" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Options Outstanding</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Options Exercisable</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Range of <u style="text-decoration: none">Exercise Prices</u></td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Number<br />
<u style="text-decoration: none">Outstanding</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Weighted-Average Remaining <u style="text-decoration: none"><br />
Contractual Life</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Weighted-Average <u style="text-decoration: none">Exercise
Price</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Number <u style="text-decoration: none">Exercisable</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Weighted-Average <u style="text-decoration: none">Exercise
Price</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 15%; font-size: 10pt; text-align: justify">$2.88
- $4.00</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
363,842</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
4.90</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
3.41</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
332,534</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
3.45</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">$4.01 - $6.00</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">630,438</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">6.08</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">5.03</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">460,284</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">5.04</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">$6.01 -
$10.00</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">498,210</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">7.36</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">7.53</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">277,641</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">7.18</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">$10.01
- $13.60</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
90,193</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">5.80</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">11.59</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
47,693</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">12.78</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,582,683</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">6.20</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">5.82</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,118,152</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">5.43</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
During the year ended December 31, 2011 and 2010, stock option
compensation expense was recorded as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 66%; font-size: 10pt; text-align: justify">Cost
of sales</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
81,725</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
40,985</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">
Selling, general and administrative expenses</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
1,217,950</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
576,752</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">
Total stock option compensation expense</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
1,299,675</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
617,737</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
As of December 31, 2011, there was $968,699 of unrecognized
compensation cost related to non-vested service based awards and
$154,955 nonvested performance based awards granted under the plan.
These costs are expected to be recognized over the options&#x2019;
remaining weighted average vesting period of 1.68 years for service
based awards and 0.67 years for the performance based awards.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Restricted Common Stock</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company has a restricted common stock plan under which 312,500
shares of common stock are reserved for issuance. There are 218,125
shares available for issuance under the plan at December 31,
2011.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In September 2011, 1,000 shares of restricted common stock were
granted under the plan to a Company employee which vest one year
from date of grant. The fair market value at the date of grant
determined by the quoted market price was $7,810, or $7.81 per
share. For the year ended December 31, 2011, $2,604 of compensation
expense was recorded for these grants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In May 2011, 21,000 shares of restricted common stock were granted
under the plan to non-employee members of the Company&#x2019;s board
of directors; 20,000 shares will vest one year from date of grant,
and 1,000 shares vested immediately. The fair market value at the
date of grant determined by the quoted market price was $215,460,
or $10.26 per share. For the year ended December 31, 2011, $147,060
of compensation expense was recorded for these grants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In January 2011, 30,500 shares of restricted common stock were
granted under the plan to Company employees on a performance basis
which vest one year from date of grant if the performance
conditions are met. The fair market value at the date of grant
determined by the quoted market price was $150,975, or $4.95 per
share. For the year ended December 31, 2011, $150,975 was recorded
for these grants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
In May 2010, 20,000 shares of restricted common stock were granted
under the plan to non-employee members of the Company&#x2019;s board
of directors that will vest one year from date of grant. The fair
market value at the date of grant determined by the quoted market
price was $102,400, or $5.12 per share. For the year ended December
31, 2011 and 2010, $34,133 and $68,267, respectively, was recorded
for these grants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
During the year ended December 31, 2011 and 2010, restricted stock
compensation expense was recorded as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 66%; font-size: 10pt; text-align: justify">Cost
of sales</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
22,275</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">-</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">
Selling, general and administrative expenses</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
312,497</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
68,267</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">
Total restricted stock compensation expense</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
334,772</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
68,267</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
As of December 31, 2011, the intrinsic value of the non-vested
awards was $80,215 and there was $73,606 of unrecognized costs
related to the restricted common stock awards.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Shares Reserved for Future Issuance</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
At December 31, 2011, the Company had reserved the following shares
of common stock for future issuance:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 83%; font-size: 10pt; text-align: justify">
Convertible preferred shares (series A &#x2013; B)</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
73,332</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Common stock
options outstanding</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,582,683</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">Common stock
options available for grant</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">991,691</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Common stock
warrants outstanding</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">3,065,702</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">Restricted common
stock grants</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">51,500</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">
Restricted common stock available for grant</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
218,125</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.12in">
Total common stock shares reserved</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
5,983,033</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
<b>Securities Registration Obligations</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company consummated private syndications of its securities on
April 18, 2006, November 8, 2007 and April 2, 2008. In connection
with each such syndication, the Company agreed with purchasers both
to register the securities for public sale and to use its best
efforts to maintain the effectiveness of such registration
statements until the subject securities are sold or may be sold
without registration. The Company has satisfied its obligations to
register the securities issued in each of the aforementioned
syndications.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The registration statements relative to the April 2006 and November
2007 syndications have expired. Although the securities sold in
these syndications are eligible for sale under Rule 144(b)(1)(i),
the Company has accorded &#x201C;piggyback&#x201D; registration
rights to the subject purchasers for an indefinite period. The
registration statement relative to the April 2008 syndication is
currently effective and there has been no lapse in its
effectiveness.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The securities registration provisions applicable to the April 2008
syndication require that if the Securities and Exchange Commission
suspends the effectiveness of the subject registration statement
prior to all registered securities either having been sold or
becoming eligible for unrestricted sale pursuant to Rule
144(b)(1)(i) under the Securities Act of 1933, an event not now
anticipated, the Company must pay purchasers one thirtieth of one
percent of the purchase price of the securities for each day the
subject registration statement is not effective up to a maximum of
ten percent of the purchase price.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The securities purchased in the April 2008 syndication are all
eligible for unrestricted sale under Rule 144(b)(1)(i) with the
exception of securities purchased by a single institutional
investor in the total amount of $2,000,000. The Company&#x2019;s
maximum potential liability to the subject investor under the
foregoing registration provisions would be $200,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company consummated a public offering of its securities on
February 22, 2010. A portion of the underwriter&#x2019;s
compensation in this offering consisted of warrants to purchase the
Company&#x2019;s common stock. The Company agreed to accord the
underwriter a single demand registration right and thereafter
&#x201C;piggyback&#x201D; registration rights as to the common stock
issuable upon exercise of the underwriter&#x2019;s stock purchase
warrants. However, the Company, in lieu of providing the foregoing
registration rights, has the absolute right, in its discretion and
without penalty, to satisfy the exercise of the underwriter&#x2019;s
warrants with unregistered shares of common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
On June 23, 2011, the Company completed a private placement of its
common stock and warrants to purchase the Company&#x2019;s common
stock. In connection with such private placement, the Company
agreed with the purchasers to register the common stock and the
common stock underlying the warrants for public sale and to use its
best efforts to maintain the effectiveness of such registration
statement until such securities are sold or may be sold without
registration. The Company has filed a registration statement with
respect to the common stock and the common stock underlying the
warrants, which was declared effective on July 21, 2011.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2QAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net Sales</a></td>
        <td class="nump">$ 62,630,247<span></span></td>
        <td class="nump">$ 56,474,056<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
        <td class="nump">44,218,300<span></span></td>
        <td class="nump">39,946,724<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
        <td class="nump">18,411,947<span></span></td>
        <td class="nump">16,527,332<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">21,173,884<span></span></td>
        <td class="nump">17,905,097<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">1,057,094<span></span></td>
        <td class="nump">292,660<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">22,230,978<span></span></td>
        <td class="nump">18,197,757<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(3,819,031)<span></span></td>
        <td class="num">(1,670,425)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense, net:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump">263,059<span></span></td>
        <td class="nump">580,622<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
        <td class="nump">176,101<span></span></td>
        <td class="nump">114,072<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
        <td class="nump">12,682<span></span></td>
        <td class="num">(340,216)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
        <td class="nump">451,842<span></span></td>
        <td class="nump">354,478<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
        <td class="num">(4,270,873)<span></span></td>
        <td class="num">(2,024,903)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
        <td class="nump">69,538<span></span></td>
        <td class="nump">423,961<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (4,340,411)<span></span></td>
        <td class="num">$ (2,448,864)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
        <td class="num">$ (0.49)<span></span></td>
        <td class="num">$ (0.39)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">Shares used in computing loss per common share - basic and diluted</a></td>
        <td class="nump">8,780,981<span></span></td>
        <td class="nump">6,335,798<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_WeightedAverageNumberBasicDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 26<br><br> -Paragraph 20, 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1(i)<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 4<br><br> -Paragraph 5A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
</td>
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>5.</b></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>Inventories</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
Inventories include the following:</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt">
Finished goods</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
7,625,009</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
8,727,822</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Work in
process</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">664,272</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">598,486</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Packaging
materials</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">985,600</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">778,900</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">Raw
materials</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
1,255,840</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
2,393,311</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
Total inventory</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
10,530,721</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
12,498,519</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Receivable, net<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable, net</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0px"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.5in"><b>4.</b></td>
<td><b>Accounts Receivable, net</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
Accounts receivable, net include the following:</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">December 31,</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt">
Accounts receivable</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
6,606,896</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
5,809,056</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Less:
&#xA0;Allowance for doubtful accounts</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">(79,216</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">)</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">(89,736</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">)</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt">
Allowance for trade rebates</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">(128,875</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">)</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">(163,789</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">)</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt">
Allowance for cash discounts and returns</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(130,966</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(114,020</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.36in; FONT-SIZE: 10pt">
Accounts receivable, net</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
6,267,839</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
5,441,511</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5066-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5162-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3,4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5074-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0px"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.5in"><b>16.</b></td>
<td><b>Subsequent Event</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
On March 27, 2012, the Company entered into a definitive agreement
to acquire the stock of Medefficiency, Inc.
(&#x201C;Medefficiency&#x201D;) for $14,500,000 in cash.
Medefficiency is a privately held company that sells a proprietary
line of total contact cast products for the treatment of diabetic
foot ulcers. Since 2008, the Company has been a distributor of
Medefficiency&#x2019;s products. In 2011, the Company represented
approximately 25% of Medefficiency&#x2019;s annual revenues of
$5,300,000. The acquisition is subject to customary closing
conditions and is anticipated to be completed by April 30,
2012.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Operating Segments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Operating Segments</a></td>
        <td class="text"><div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.5in; text-align: left"><font style="text-underline-style: none"><b>12.</b></font></td>
<td><font style="text-underline-style: none"><b>Operating
Segments</b></font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In 2011, the Company changed its segment reporting to reflect the
current and foreseeable nature of its business operations. The
former wound care, wound closure and specialty securement devices
and skin care segments no longer reflect how the Company operates
its business. The previously reported wound care segment reflected
the combined operating activities of the advanced and traditional
wound care products. Under the new reporting format they are
separately identified and form the basis for two new reporting
segments. The previously reported wound closure and specialty
securement devices and skin care operating segments are now
combined into the traditional wound care segment. A new segment was
created to reflect the Company&#x2019;s significant investment in
pharmaceutical products. Operating results for 2010 have been
restated to conform to the new segment reporting.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The Company currently operates in three segments: advanced wound
care, traditional wound care and pharmaceutical wound care
products. They are and will be managed separately because each
segment requires different technology, marketing and sales
strategies. Advanced wound care products principally consist of
both novel and otherwise differentiated dressings, bandages and
ointments designed to promote wound healing and/or prevent
infection. Traditional wound care products principally consist of
commodity related dressings, ointments, gauze bandages, adhesive
bandages, wound closer strips, catheter fasteners and skin care
products. Pharmaceutical wound care products consist of DSC127, a
novel product for the treatment of diabetic foot ulcers which is
presently under development having recently completed its Phase 2
trial.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Advanced and traditional wound care products are marketed globally
to acute care, extended care, home health care, wound and burn care
clinics and physician offices. The Company utilizes a broad network
of well-established distributors to deploy its products to end
users. Only a small portion of the Company&#x2019;s sales are sold
directly to end users. The advanced and traditional wound care
products are both manufactured internally and sourced from third
party suppliers. The majority of marketing expenses are deployed in
support of advanced wound care products with traditional wound care
products requiring limited support. The Company utilizes direct
sales representatives, distributor relationships and contractual
relationships with buying groups and wound care service providers
to sell its products. Direct sales representatives are used solely
in support of advanced wound care sales in the U.S. and U.K. for
both advanced and traditional wound care products in Canada.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The pharmaceutical wound care segment is presently limited to the
development of DSC127. All expenses associated with this activity
are being recorded as research and development expense.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Each operating segment is managed at the segment contribution level
consisting of gross profit minus direct expense consisting of
distribution, marketing, sales and research and development
expenses. Expenses are allocated directly by segment to the extent
possible. Expenses common to all three operating segments are
allocated consistently using activity based assumptions. The
aggregation or allocation of indirect expenses by segment is not
practical.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Operating segment sales, gross profit, segment contribution and
other related information for 2011 and 2010 are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="vertical-align: bottom">
<td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center"><u>Year
ended December 31, 2011</u></td>
</tr>
<tr style="vertical-align: bottom">
<td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: center">&#xA0;</td>
<td style="font-size: 10pt; font-style: italic; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center; border-bottom: Black 1pt solid">
<font style="font-weight: normal; font-style: normal">Advanced
Wound Care</font></td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-style: italic; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; font-style: italic; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; font-style: italic; text-align: center; border-bottom: Black 1pt solid">
<font style="font-weight: normal; font-style: normal">Traditional
Wound Care</font></td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-style: italic; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; font-style: normal; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; font-style: normal; border-bottom: Black 1pt solid; text-align: center">
<font style="font-style: normal">Pharmaceutical <u style="text-decoration: none">Wound Care</u></font></td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-style: normal; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; font-style: normal; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; font-style: normal; border-bottom: Black 1pt solid; text-align: center">
Other</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-style: normal; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt; text-align: center">
&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
<font style="font-size: 10pt">Total</font> <u style="text-decoration: none">Company</u></td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 30%; font-size: 10pt; text-align: justify">Net
sales</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
15,927,920</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
46,702,327</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">-</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">-</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
62,630,247</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Gross profit</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">7,312,953</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">11,098,994</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">18,411,947</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Direct
expense</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(8,778,797</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(3,611,558</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(1,057,094</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(13,447,449</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Segment contribution</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(1,465,844</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
7,487,436</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(1,057,094</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">4,964,498</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Indirect expenses</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(9,304,909</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(9,304,909</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net
loss</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(4,340,411</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="vertical-align: bottom">
<td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center"><u>Year
ended December 31, 2010</u></td>
</tr>
<tr style="vertical-align: bottom">
<td colspan="21" style="font-size: 10pt; font-weight: bold; text-align: center">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 30%; font-size: 10pt; text-align: justify">Net
sales</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
11,597,373</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
44,876,683</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">-</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">-</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
56,474,056</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Gross profit</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">4,689,410</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">11,837,922</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">16,527,332</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Direct
expense</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(6,649,457</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(3,651,508</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(292,660</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(10,593,625</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Segment contribution</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(1,960,047</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
8,186,414</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
($</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(292,660</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">5,933,707</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Indirect expenses</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(8,382,571</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(8,382,571</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net
loss</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(2,448,864</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
A geographical breakdown of the Company&#x2019;s sales, gross profit
and equipment and improvements, net is as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
United States</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Canada</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Other</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
Total</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify"><u>2011</u></td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: justify">
&#xA0;</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 44%; font-size: 10pt; text-align: left">Net
sales</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
41,502,059</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
15,387,066</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
5,741,122</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
62,630,247</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Gross profit</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">13,216,794</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">2,772,647</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">2,422,506</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">18,411,947</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Equipment and
improvements, net</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">292,914</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">2,745,779</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">450,501</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">3,489,194</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-decoration: underline; text-align: left">
2010</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-decoration: underline; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Net sales</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">38,338,581</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">14,443,742</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">3,691,733</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">56,474,056</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Gross profit</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">11,765,478</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">3,393,376</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">1,368,478</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">16,527,332</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Equipment and
improvements, net</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">415,116</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">2,642,165</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">550,961</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">3,608,242</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
For the years ended December 31, 2011 and 2010, the Company had a
major Canadian customer comprising 24% and 25% of consolidated net
sales, respectively. Due to outstanding rebate obligations, the
Company was in a net liability position to this customer at
December 31, 2011 (see Note 9 and 15).</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 131<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Line of Credit Borrowings<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Line of Credit Borrowings</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0px"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.5in"><b>8.</b></td>
<td><b>Line of Credit Borrowings</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
On September 30, 2011, the Company terminated its five-year
revolving credit agreement with its lender. In connection with the
termination the Company recorded a loss on debt extinguishment of
$176,101, representing the then unamortized portion of deferred
financing costs of $112,336 and related fees of $63,765.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equipment and Improvements, net<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Equipment and Improvements, net</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0px"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.5in"><b>6.</b></td>
<td><b>Equipment and Improvements, net</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
Equipment and improvements, net include the following:</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt">
Machinery and equipment</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
6,522,941</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
5,981,946</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Furniture and
fixtures</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">682,545</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">648,460</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
Leasehold improvements</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
2,174,121</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
2,086,956</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">9,379,607</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">8,717,362</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
Less:&#xA0;&#xA0; accumulated depreciation</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(5,890,413</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(5,109,120</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
Total equipment and improvements, net</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
3,489,194</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
3,608,242</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Identifiable Intangible Assets, net<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets, net</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
</td>
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>7.</b></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>Identifiable Intangible Assets, net</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
Identifiable intangible assets, net include the following:</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 62%; FONT-SIZE: 10pt">
Medihoney license rights</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%; FONT-SIZE: 10pt">
5,667,126</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%; FONT-SIZE: 10pt">
4,667,126</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">Other
identifiable intangible assets</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
3,300,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
7,500,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">8,967,126</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">12,167,126</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">Less
accumulated amortization</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(2,564,082</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
(5,195,500</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
)</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
Total identifiable intangible assets, net</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
6,403,044</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
6,971,626</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
</table>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
In connection with the acquisition of the Medihoney worldwide
license rights (note 15) the Company capitalized the consideration
paid as an identifiable intangible asset. The cost will be
amortized over 10 years, and the expense is included as a component
of cost of sales in the Consolidated Statement of Operations.</p>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Other identifiable intangible assets result from acquisitions
completed in 2006 and 2007 and consist of the following:</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">December 31, 2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt">
Amortization Period</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 62%; FONT-SIZE: 10pt">
Customer list</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%; FONT-SIZE: 10pt">
1,500,000</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; WIDTH: 15%; FONT-SIZE: 10pt">10
years</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Trademarks and
trade names</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">1,600,000</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-SIZE: 10pt">10-13 years</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
Certification and product designs</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
200,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;5
years</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
3,300,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
</table>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
In 2011, $4,200,000 of fully amortized identifiable intangible
assets were written-off.</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Amortization expense of the other identifiable intangible assets is
included in selling, general and administrative expenses in the
Consolidated Statement of Operations. The weighted average useful
life of identifiable intangible assets as of December 31, 2011 and
2010 is 7.0 and 3.9 years, respectively. Amortization expense for
2011 and 2010 and estimated amounts thereafter by year is as
follows:</p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;</p>
<table style="WIDTH: 90%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Medihoney License Rights</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Other Identifiable <u style="TEXT-DECORATION: none"><br />
Intangible Assets</u></td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Total</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 58%; FONT-SIZE: 10pt">
Amortization expense for&#xA0; year ended December 31, 2011</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 2%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">
519,200</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 2%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">
1,049,382</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 2%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">
1,568,582</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Amortization
expense for&#xA0; year ended December 31, 2010</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
375,750</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
1,314,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
1,689,750</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Estimated
amortization expense for&#xA0; years ending December 31,</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt">
2012</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">584,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">323,993</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">908,293</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt">
2013</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">584,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">285,000</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">869,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt">
2014</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">584,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">285,000</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">869,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt">
2015</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">584,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">285,000</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">869,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt">
2016</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">584,300</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">136,250</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">720,550</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 1.32in; FONT-SIZE: 10pt">
Thereafter</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
1,850,676</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
315,625</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
2,166,301</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
4,772,176</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
1,630,868</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
6,403,044</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 44, 45, 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
</td>
<td style="PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 0.5in; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>9.</b></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px">
<b>Accrued Expenses and Other Current Liabilities</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
Accrued expenses and other current liabilities include the
following:</p>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt">
Accrued Canadian sales rebate, net (see note 15)</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
316,280</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
409,842</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Accrued
compensation and related taxes</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">575,710</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">265,334</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Accrued sales
incentives and other fees</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">416,215</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">461,944</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Accrued
royalties</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">425,796</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">220,232</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
Other</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
643,633</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
793,269</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
Total accrued expenses and other current liabilities</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
2,377,634</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
2,150,621</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
At December 31, 2011 and 2010, the amount of the Canadian accrued
sales rebate and other reserves exceeded the amount of the
underlying trade receivables outstanding. The net credit balance in
trade receivables was reclassified for financial reporting purposes
to accrued expense to recognize it as a net liability.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Liabilities And Other Current Liabilities Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Retirement Benefits<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
        <td class="text"><div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td>
<td style="width: 0.5in; text-align: left"><b>14.</b></td>
<td><b>Retirement Benefits</b></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company maintains a profit sharing/401(k) plan for eligible
full-time United States employees. Participants may contribute a
fixed percentage of their salary to the plan, subject to IRS
limitations. The Company makes a matching contribution of 50% on
the first 6% of each participant&#x2019;s annual earnings
contributed to the plan. Company contributions to the plan for the
years ended December 31, 2011 and 2010 were $75,324 and $66,442,
respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The Company&#x2019;s Canadian subsidiary maintains a group
retirement savings plan (Registered Retirement Savings Plan) for
eligible full time Canadian employees. The Canadian subsidiary
makes a matching contribution of 50% of an employee&#x2019;s
contribution to a maximum of 3% of annual gross earnings. Employee
contribution limits to the group retirement savings plan are set by
the Canada Customs and Revenue Agency. The Company&#x2019;s Canadian
subsidiary&#x2019;s contributions to the plan for the year ended
December 31, 2011 and 2010 were $75,186 and $64,855,
respectively.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUCDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Preferred Stock</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Income</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2009</a></td>
        <td class="nump">$ 21,231,100<span></span></td>
        <td class="nump">$ 2,851<span></span></td>
        <td class="nump">$ 50,395<span></span></td>
        <td class="nump">$ 41,221,613<span></span></td>
        <td class="nump">$ 1,303,293<span></span></td>
        <td class="num">$ (21,347,052)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">285,051<span></span></td>
        <td class="nump">5,039,468<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(2,448,864)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,448,864)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Foreign currency translation adjustment</a></td>
        <td class="nump">301,647<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">301,647<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(2,147,217)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,117,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
        <td class="nump">4,474,452<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,178<span></span></td>
        <td class="nump">4,463,274<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_IssuanceOfCommonStockAndWarrantsShares', window );">Issuance of common stock and warrants for license rights (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_IssuanceOfCommonStockAndWarrantsValue', window );">Issuance of common stock and warrants for license rights</a></td>
        <td class="nump">2,417,126<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000<span></span></td>
        <td class="nump">2,413,126<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,601<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
        <td class="nump">16,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">55<span></span></td>
        <td class="nump">16,223<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock conversion (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(207)<span></span></td>
        <td class="nump">207<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Preferred stock conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3)<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">688,974<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">688,974<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2010</a></td>
        <td class="nump">26,680,713<span></span></td>
        <td class="nump">2,848<span></span></td>
        <td class="nump">65,631<span></span></td>
        <td class="nump">48,803,210<span></span></td>
        <td class="nump">1,604,940<span></span></td>
        <td class="num">(23,795,916)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">284,844<span></span></td>
        <td class="nump">6,563,076<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(4,340,411)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,340,411)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Foreign currency translation adjustment</a></td>
        <td class="num">(102,409)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(102,409)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(4,442,820)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,524,239<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
        <td class="nump">26,357,075<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35,242<span></span></td>
        <td class="nump">26,321,833<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrants, net of costs of $68,204 (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">179,304<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrants, net of costs of $68,204</a></td>
        <td class="nump">366,465<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,793<span></span></td>
        <td class="nump">364,672<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">78,501<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
        <td class="nump">251,654<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">785<span></span></td>
        <td class="nump">250,869<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock conversion (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(211,512)<span></span></td>
        <td class="nump">211,512<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Preferred stock conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,115)<span></span></td>
        <td class="nump">2,115<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_VestingOfIssuedRestrictedStock', window );">Vesting of restricted stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsci_VestingOfIssuedRestrictedStockValue', window );">Vesting of restricted stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">210<span></span></td>
        <td class="num">(210)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">1,634,447<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,634,447<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 50,847,534<span></span></td>
        <td class="nump">$ 733<span></span></td>
        <td class="nump">$ 105,776<span></span></td>
        <td class="nump">$ 77,374,821<span></span></td>
        <td class="nump">$ 1,502,531<span></span></td>
        <td class="num">$ (28,136,327)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73,332<span></span></td>
        <td class="nump">10,577,632<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_IssuanceOfCommonStockAndWarrantsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Warrants, Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_IssuanceOfCommonStockAndWarrantsShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_IssuanceOfCommonStockAndWarrantsValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of issuance of common stock and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_IssuanceOfCommonStockAndWarrantsValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_StockIssuedDuringPeriodSharesStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_StockIssuedDuringPeriodValueStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_StockIssuedDuringPeriodValueStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_VestingOfIssuedRestrictedStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the vesting of restricted stock units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_VestingOfIssuedRestrictedStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsci_VestingOfIssuedRestrictedStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Vesting of Issued Restricted Stock, value</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dsci_VestingOfIssuedRestrictedStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dsci_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 14, 17, 19, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 13, 20, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash and Cash Equivalents and Investments</a></td>
        <td class="text"><div>
<table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0px"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.5in"><b>3.</b></td>
<td><b>Cash and Cash Equivalents and Investments</b></td>
</tr>
</table>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
The Company considers cash and cash equivalents as amounts on hand,
on deposit in financial institutions and highly liquid investments
purchased with an original maturity of three months or less. The
Company considers highly liquid investments purchased with an
original maturity greater than three months as investments.</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Cash and cash equivalents and investments at December 31, 2011 and
2010 consisted of the following:</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 66%; FONT-SIZE: 10pt">
Cash</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
4,986,234</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
404,216</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">Money market
accounts</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">2,706,863</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">-</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">Money
market mutual funds</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
9,417,253</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">Cash
and cash equivalents</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">17,110,350</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">404,216</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
Investments</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
5,474,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
Total cash and cash equivalents and investments</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
22,584,350</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
404,216</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
</table>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
The Company maintains cash with various domestic and foreign
financial institutions within the ordinary course of business,
which at times may exceed jurisdictional insurance limits. The
money market accounts are deposited in various U.S. financial
institutions and are fully insured by the Federal Deposit Insurance
Corporation. Cash equivalents consist of funds deposited into
mutual funds investing in U.S. government obligations that are
fully secured by the U.S. government. Investments consist of
certificates of deposits in various U.S. financial institutions and
are fully insured by the Federal Deposit Insurance Corporation. The
Company intends to hold its investments to maturity and accordingly
these investments are carried at amortized costs.</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
The following table provides fair value information as of December
31, 2011:</p>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 90%; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="14">Fair Value Measurements, Using</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Total carrying value as of December 31, 2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Quoted prices in active markets (Level 1)</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Significant other observable inputs (Level 2)</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Significant unobservable inputs (Level 3)</td>
<td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt" colspan="2">
&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; WIDTH: 34%; FONT-SIZE: 10pt">Cash
and cash equivalents</td>
<td style="WIDTH: 2%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
17,110,350</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 1%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
17,110,350</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 1%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">
&#xA0;&#xA0;&#xA0;&#xA0;-</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="WIDTH: 1%; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%; FONT-SIZE: 10pt">
&#xA0;&#xA0;&#xA0;&#xA0;-</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
Investments</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
5,474,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
5,453,429</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.24in; FONT-SIZE: 10pt">
&#xA0;Total</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
22,584,350</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
22,563,779</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">
&#xA0;</td>
</tr>
</table>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Level 1 inputs are quoted prices (unadjusted) in active markets for
identical assets. Level 2 inputs are quoted prices for similar
assets in active markets or inputs that are observable for the
asset, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument. Level
3 inputs are unobservable inputs based on management&#x2019;s own
assumptions used to measure assets at fair value. A financial
asset&#x2019;s classification is determined based on the lowest
level input that is significant to the fair value measurement.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>32</ContextCount>
  <ElementCount>140</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>5</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations</Role>
      <ShortName>Description of Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCashCashEquivalentsAndShortTermInvestmentsTextBlock</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Accounts Receivable, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock</Role>
      <ShortName>Accounts Receivable, net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>Inventories</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Equipment and Improvements, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Equipment and Improvements, net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Identifiable Intangible Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>Identifiable Intangible Assets, net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Line of Credit Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Line of Credit Borrowings</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock</Role>
      <ShortName>Long-term Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Shareholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock</Role>
      <ShortName>Operating Segments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Retirement Benefits</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock</Role>
      <ShortName>Commitments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dermasciences.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Event</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 108 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>dsci-20111231.xml</File>
    <File>dsci-20111231.xsd</File>
    <File>dsci-20111231_cal.xml</File>
    <File>dsci-20111231_def.xml</File>
    <File>dsci-20111231_lab.xml</File>
    <File>dsci-20111231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0; padding: 0; text-indent: 0"></td>
<td style="width: 0.5in; padding: 0; text-indent: 0">
<b>13.</b></td>
<td style="text-align: left; padding: 0; text-indent: 0"><b>Income
Taxes</b></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
Loss before income taxes for the year ended December 31 consists of
the following components:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 66%; font-size: 10pt; text-align: justify">
Domestic</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
(3,483,103</td>
<td style="width: 1%; font-size: 10pt; text-align: left">)</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
(2,329,148</td>
<td style="width: 1%; font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">
Foreign</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(787,770</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
304,245</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Loss
before income taxes</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(4,270,873</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(2,024,903</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">
The components of income taxes (benefit) for the year ended
December 31 are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">Current:</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Federal</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
State</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">_</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 66%; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">
Foreign</td>
<td style="width: 2%; font-size: 10pt; padding-bottom: 1pt">
&#xA0;</td>
<td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 13%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(13,570</td>
<td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="width: 2%; font-size: 10pt; padding-bottom: 1pt">
&#xA0;</td>
<td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 13%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
268,072</td>
<td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">
Total current</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(13,570</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
268,072</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">Deferred:</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Federal</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">144,399</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">144,399</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
State</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">30,742</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">30,742</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">
Foreign</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(92,033</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(19,252</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">
Total deferred</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
83,108</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
155,889</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in">
Total income taxes</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
69,538</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
423,961</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The reconciliation of income tax computed at the United States
federal statutory tax rates to income tax expense along with
percentage of loss before income taxes for the year ended December
31, 2011 and 2010 is as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="14" style="font-size: 10pt; text-align: center"></td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 40%; font-size: 10pt; text-align: justify">Tax
benefit at federal statutory rate</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 11%; font-size: 10pt; text-align: right">
(1,452,097</td>
<td style="width: 1%; font-size: 10pt; text-align: left">)</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 11%; font-size: 10pt; text-align: right">
34.0</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 11%; font-size: 10pt; text-align: right">
(688,467</td>
<td style="width: 1%; font-size: 10pt; text-align: left">)</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 11%; font-size: 10pt; text-align: right">
34.0</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">State tax, net of
federal benefit</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(113,482</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">2.7</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(84,530</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">4.2</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">Nondeductible
expenses</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">370,516</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(8.7</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">168,389</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(8.3</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Other</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">68,865</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(1.6</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(1,383</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Change
in valuation allowance</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
1,195,736</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(28.0</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
1,029,952</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(50.8</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">
Income taxes</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
69,538</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(1.6</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
423,961</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(20.9</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
Significant components of the Company&#x2019;s deferred tax assets
and liabilities are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 80%; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
December 31,</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
2010</td>
<td style="padding-bottom: 1pt; font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td colspan="2" style="font-size: 10pt; text-align: center">
&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt; text-align: justify">Deferred tax
assets:</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 66%; font-size: 10pt; text-align: justify; padding-left: 0.12in">
Net operating loss carryforwards</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
4,812,975</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 13%; font-size: 10pt; text-align: right">
4,207,947</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">Equity
based compensation</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">312,675</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">236,232</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Allowance for sales deductions</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">134,826</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">144,931</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Amortization of identified intangibles</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,753,702</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,519,140</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Inventory adjustments</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">992,113</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">656,338</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">
Other</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
169,198</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
178,599</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">
Deferred tax assets</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
8,175,489</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
6,943,187</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify">Deferred tax
liabilities:</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Prepaid expenses</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(81,800</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(22,226</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Goodwill</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(890,238</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(715,098</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.12in">
Depreciation</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(123,625</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(244,856</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.12in">
Other</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(576</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(626</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-left: 0.24in">
Deferred tax liabilities</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(1,096,239</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(982,806</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0.24in">
Valuation allowance</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(8,220,710</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">
(7,024,974</td>
<td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: justify">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Net
deferred tax liabilities</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(1,141,460</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">
(1,064,593</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The net deferred tax liability of $1,141,460 consists of a deferred
tax asset of $4,587 and a net deferred tax liability of $1,146,047
as of December 31, 2011. The net deferred tax liability consists of
a deferred tax liability of $890,238 related to the differences in
the basis of goodwill for financial reporting and tax purposes
coupled with a $251,222 net deferred tax liability ($255,809
deferred tax liability and a deferred tax asset of $4,587) related
to the Company&#x2019;s Canadian operations. The deferred tax asset
is included in prepaid expenses and other current assets in the
Consolidated Balance Sheet.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
The amount by which the Company can utilize its United States
federal net operating loss carryforwards in any year or in total
may be limited under the Internal Revenue Code Section 382
regarding changes in ownership of corporations. Due to
uncertainties surrounding the Company&#x2019;s ability to use its
net operating loss carryforwards and to realize the other net
deferred tax assets, a full valuation allowance has been provided
as of December 31, 2011 and 2010 for the deferred tax assets for
the United States and United Kingdom.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">
At December 31, 2011, the Company has net operating loss
carryforwards of approximately $12,603,000 for United States
federal income tax purposes that begin to expire in 2012. For state
income tax purposes, the Company has net operating loss
carryforwards in a number of jurisdictions in varying amounts and
with varying expiration dates.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
